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Background:Proximal humeral fractures account for 5–6% of al fractures in adults. There is considerable
variation in whether or not surgery is used in the management of displaced fractures involving the
surgical neck.
Objective:To evaluate the clinical efectiveness and cost-efectiveness of surgical compared with
non-surgical treatment of the majority of displaced fractures of the proximal humerus involving the surgical
neck in adults.
Design:A pragmatic paralel-group multicentre randomised controled trial with an economic evaluation.
Folow-up was for 2 years.
Setting:Recruitment was undertaken in the orthopaedic departments of 33 acute NHS hospitals in the
UK. Patient care pathways included outpatient and community-based rehabilitation.
Participants:Adults (aged≥16 years) presenting within 3 weeks of their injury with a displaced fracture
of the proximal humerus involving the surgical neck.
Interventions:The choice of surgical intervention was left to the treating surgeons, who used techniques
with which they were experienced. Non-surgical treatment was initial sling immobilisation folowed by
active rehabilitation. Provision of rehabilitation was comparable in both groups.
Main outcome measures:The primary outcome was the Oxford Shoulder Score (OSS) assessed at
6, 12 and 24 months. Secondary outcomes were the 12-item Short Form health survey, surgical and
other shoulder fracture-related complications, secondary surgery to the shoulder or increased/new
shoulder-related therapy, medical complications during inpatient stay and mortality. European Quality
of Life-5 Dimensions data and treatment costs were also colected.
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Results:The mean age of the 250 trial participants was 66 years and 192 (77%) were female.
Independent assessment using the Neer classification identified 18 one-part fractures, 128 two-part
fractures and 104 three- or four-part fractures. OSS data were available for 215 participants at 2 years.
We found no statisticaly or clinicaly significant diferences in OSS scores between the two treatment
groups (scale 0–48, with a higher score indicating a beter outcome) over the 2-year period [diference of
0.75 points in favour of the surgery group, 95% confidence interval (CI)–1.33 to 2.84;p=0.479; data
from 114 surgery and 117 non-surgery participants] or at individual time points. We found no statisticaly
significant diferences between surgical and non-surgical group participants in SF-12 physical or mental
component summary scores; surgical or shoulder fracture-related complications (30 vs. 23 respectively);
those undergoing further shoulder-related therapy, either surgery (11 vs. 11 respectively) or other therapy
(seven vs. four respectively); or mortality (nine vs. five respectively). The base-case economic analysis
showed that, at 2 years, the cost of surgical intervention was, on average, £1780.73 more per patient
(95% CI £1152.71 to £2408.75) than the cost of non-surgical intervention. It was also slightly less
beneficial in terms of utilities, although this diference was not statisticaly significant. The net monetary
benefit associated with surgery is negative. There was only a 5% probability of surgery achieving the
criterion of costing<£20,000 to gain a quality-adjusted life-year, which was confirmed by extensive
sensitivity analyses.
Conclusions:Curent surgical practice does not result in a beter outcome for most patients with
displaced fractures of the proximal humerus involving the surgical neck and is not cost-efective in the UK
seting. Two areas for future work are the seting up of a national database of these fractures, including
the colection of patient-reported outcomes, and research on the best ways of informing patients with
these and other upper limb fractures about initial self-care.
Trial registration:Curent Controled Trials ISRCTN50850043.
Funding:This project was funded by the NIHR Health Technology Assessment programme and wil be
published in ful inHealth Technology Assessment; Vol. 19, No. 24. See the NIHR Journals Library website
for further project information.
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Plain English summary
Fracture of the proximal humerus (the top part of the upper arm bone) is common, particularly in olderadults. Generaly, less serious fractures are successfuly treated by supporting the injured arm in a sling
while the fracture mends. More serious fractures, in which two or more bony fragments are displaced, are
often treated surgicaly. This usualy involves puting the fracture fragments back in place and fixing them
with plates and screws. In more complex fractures, the humeral head is sometimes replaced by an artificial
joint. However, we identified a need for evidence to clarify whether surgery or non-surgical treatment is
best for the more common types of displaced fracture.
We conducted a randomised controled trial in 35 NHS hospitals that compared surgery with non-surgical
treatment for these fractures. Of the 250 patients who enroled into the trial, 125 were randomised to
‘surgery’and 125 to‘not surgery’. Questionnaires, which colected data on patients’shoulder function and
general health at 6, 12 and 24 months, were received back from 215 participants at 24 months’folow-up.
Analysis of these questionnaires and the forms from hospitals showed that there were no important
diferences in shoulder function, general health, complications or treatment for complications between
patients in the surgery group and those in the non-surgery group. Analysis of the treatment costs incured
over the 2 years showed that surgery also costs more. In summary, the evidence from this trial shows that
curent methods of surgery do not result in a beter outcome for these patients and are more costly.
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Scientific summary
Background
Proximal humeral fractures occur mainly in older adults and account for 5–6% of al fractures in adults.
It is estimated that the substantial costs associated with these fractures are about one-fifth of those of hip
fracture in the first year. Approximately 40% of these fractures are displaced fractures involving the
surgical neck. As reflected in the variation in practice, the role of surgery for this group of fractures is
unclear but its use is increasing.
Objectives
The primary objective was to evaluate the clinical efectiveness and cost-efectiveness of surgery compared
with non-surgical treatment of the majority of displaced fractures of the proximal humerus involving the
surgical neck in adults.
Secondary objectives included:
l to describe the study population in terms of key characteristics and in particular to categorise the trial
fractures according to the Neer classification
l to ensure that both groups of patients received comparable and good standards of care
l to explore the efect of age (<65 years vs.≥65 years), type of fracture (involving none vs. one or both
tuberosities) and patients’treatment preference on the primary outcome [Oxford Shoulder Score (OSS)].
Design
The PROximal Fracture of the Humerus: Evaluation by Randomisation (ProFHER) trial was a pragmatic
paralel-group multicentre randomised controled trial (RCT) with an economic evaluation. Patients were
randomised on an equal basis to receive surgical or non-surgical treatment via a remote randomisation service.
Randomisation was stratified by tuberosity involvement (yes or no) with alocation using random block sizes.
Folow-up was for 2 years. Data colection, which included copies of baseline radiographs for al randomised
patients, was by means of hospital and physiotherapy forms, and patient questionnaires. There was no
blinding of outcome assessment. However, the independent classification of the baseline radiographs and al
coding of data, which involved at least two independent raters, was caried out blind to treatment alocation.
Throughout the conduct of the trial we emphasised the importance of good practice from clinical and
research perspectives; standardised protocols and care pathways; and comparable and suficient expertise
of care providers in the two groups. As far as possible we adopted procedures that reflected and were
compatible with usual practice and that did not delay treatment, add unnecessarily to the clinical workload
or place burden on participants.
Setting
Trial recruitment was undertaken in the orthopaedic departments of 33 of the 35 participating acute NHS
hospitals; 33 participating hospitals were based in England and one each was based in Scotland and
Wales. Patient care pathways included outpatient and community-based rehabilitation. Patients were
recruited from fracture clinics or orthopaedic wards from 17 September 2008 up to 13 April 2011.
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Participants
Adults (aged≥16 years) presenting to the participating hospital within 3 weeks of their injury with a
radiographicaly confirmed displaced fracture of the proximal humerus involving the surgical neck were
considered for inclusion. Fractures that were displaced enough for the treating surgeon to consider surgical
intervention were considered for inclusion, even if the degree of displacement did not meet the exact
displacement criteria of the Neer classification (1 cm and/or 45° angulation of displaced parts). (We refer to
fractures not meeting these criteria as‘one-part’fractures.) Exclusion criteria were associated dislocation of
the injured shoulder joint; open fracture; lack of mental capacity to understand the trial or instructions
for rehabilitation; comorbidities precluding surgery/anaesthesia; clear indication for surgery such as severe
soft-tissue compromise; multiple injuries (upper limb fractures); pathological fractures (other than osteoporotic)
and terminal ilness; and participant not resident in thehospital catchment area. Patients were provided with an
ethicaly approved information sheet and writen consent was obtained before randomisation.
Interventions
The choice of surgical intervention was left to the treating surgeons, who used techniques that they
were fuly experienced with to avoid learning curve problems. Non-surgical treatment was initial sling
immobilisation folowed by active rehabilitation. Measures taken to ensure comparable delivery of care
and rehabilitation for both groups of patients included the development and provision of an information
leaflet on personal care during initial sling immobilisation, a physiotherapy protocol to promote standard
rehabilitation care and promotion of the need for patients to perform home exercises.
Main outcome measures
The primary outcome measure was the OSS (scale 0–48, with higher scores indicating a beter outcome)
assessed at 6, 12 and 24 months. The trial was powered to detect a clinicaly important diference in the
OSS of 5 points (equivalent to an efect size of 0.4).
Secondary outcomes were the 12-item Short Form health survey (SF-12) [physical and mental component
summary scores (PCS; MCS) scale 0–100, with higher scores indicating beter health], surgical and other
shoulder fracture-related complications, secondary surgery to the shoulder or increased/new shoulder-related
therapy, medical complications during the inpatient stay and mortality. European Quality of Life-5 Dimensions
(EQ-5D) data and treatment costs incured in hospital and subsequently were also colected.
Statistical analysis
Both the clinical efectiveness and economic analyses were conducted to a prespecified and externaly
endorsed analysis plan. Intention-to-treat analysis was conducted throughout.
The primary clinical efectiveness analysis compared the results of the two groups over al three folow-up
assessments. A random slope multilevel model was fited to the data with time points nested in patients to
alow for clustering of data within each patient. This model adjusted for the fixed efects of treatment
group, time (6, 12 or 24 months), the interaction between treatment and time, tuberosity involvement at
baseline (yes or no), age (<65 years or≥65 years), gender and health status at baseline (EQ-5D). Diferent
covariance paterns for the repeated measurements were explored and the most appropriate patern
selected for the final model. Estimates of the diference in OSS between treatment groups were assessed
overal and at individual time points. Al main analyses were performed using two-sided significance tests
at the 5% significance level.
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Two subgroup analyses, whose expected direction of efect was specified a priori, were planned for the
OSS only. These were based on age (<65 years or≥65 years), with younger patients expected to benefit
more from surgery, and tuberosity involvement (yes or no) recorded by the surgeon who assessed patient
eligibility at baseline, with patients expected to benefit from surgery over non-surgical treatment when
one or both tuberosities were involved. A sensitivity analysis of tuberosity involvement in terms of
Neer one- and two-part fractures compared with Neer three- and four-part fractures was undertaken.
This was based on the classification of the fractures by two independent experts using baseline radiographs.
The primary analysis model was extended for each of these subgroup analyses by including, in turn, an
interaction of treatment group with age group, tuberosity involvement or Neer parts. The diferences in
2-log likelihood model fit between these and the base model were assessed using the chi-squared test
atp<0.10.
Reflecting a chance baseline imbalance, smoking status was added to the primary model as a sensitivity
analysis. To ascertain the impact of prior beliefs, an interaction of treatment group with patient treatment
preference was added to the base model. The variability in the OSS across recruitment sites was
analysed descriptively.
The SF-12 PCS and MCS scores were analysed by multilevel modeling using the same predictors as in the
OSS primary model. Frequencies of shoulder surgery- and fracture-related complications and any treatments
for these were compared between treatment groups using the chi-squared test. Mortality rates were
reported and compared between treatment groups using the chi-squared test.
Economic analysis
The economic analysis was caried out from the UK NHS and Personal Social Services perspective. Data on
health utilities, obtained from the EQ-5D data colected from patient questionnaires, were converted into
quality-adjusted life-years (QALYs) for each patient using the area under the curve method. Costs were
expressed in UK pounds sterling at a 2012 price base.
Diferences in mean costs and QALYs at 2 years were used to derive an estimate of the cost-efectiveness
of surgery and non-surgical treatment. Multiple imputation was used to derive the data set for the
base-case analysis. An additional analysis was conducted for complete cases (in which patients with
any missing data are excluded). We used sensitivity analyses to explore the impact of incorporating
both types of resource use (shoulder and non-shoulder related) and using diferent data sources.
Cost-efectiveness acceptability curves (CEACs) were used to express the probability of whether or not
surgery is cost-efective at the wilingness-to-pay threshold.
Clinical effectiveness results
Of 1250 patients screened, 563 were considered eligible, of whom 250 were recruited. The mean age
of the trial participants was 66 years and 192 (77%) were female. Independent characterisation of
radiographs confirmed that the patients included in the ProFHER trial had sustained injuries that are
typicaly considered for surgical intervention in contemporaneous practice. The assessment, based on
the Neer classification, identified 18 one-part fractures, 128 two-part fractures and 104 three- or
four-part fractures.
Of the 125 patients alocated to surgery, 109 received surgery. Consultant surgeons were predominantly
involved in the management of these fractures and usualy performed the operations. The choice of
implants, with the majority being locking plates and a minority receiving hemiarthroplasty, is compatible
with expectations of curent practice. Of the 125 patients alocated non-surgical treatment, 123 received
conservative care. Good and comparable non-surgical care in the two groups was achieved as evidenced
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by (1) the provision of the ProFHER trial sling information leaflet to nearly al trial patients; (2) the
equivalent provision of physiotherapy in terms of timing, numbers of sessions and interventions applied;
and (3) comprehensive recording by physiotherapists showing that the majority of patients were doing
their home exercises.
The treatment groups were balanced for al baseline characteristics, including Neer categories, except for
smoking status. These profiles also applied to the baseline characteristics of the 215 patients (106 surgery
patients vs. 109 non-surgery patients) with OSS data at 2 years.
The primary analysis included data from 231 patients (114 surgery patients vs. 117 non-surgery patients)
with valid OSS data for at least one folow-up time point and complete baseline covariates. We found that
there were no statisticaly significant diferences in OSS between the two treatment groups over the 2-year
period [diference of 0.75 points in favour of the surgery group, 95% confidence interval (CI)–1.33 to
2.84;p=0.479] or at individual time points. Al 95% CIs excluded the prespecified diference in OSS of
5 points, thus indicating that any observed diference was not of‘clinical significance’.
There was no statisticaly significant efect of treatment group when including interactions with age
[comparison with base model:χ2(1)=1.24,p=0.265] or fracture type [assessed by tuberosity involvement
at baseline;χ2(1)<0.01,p=0.954] and Neer classification [χ2(1)=0.05,p=0.823] in the two planned
subgroup analyses. Thus, our prior expectations of directions of efect (subgroup diferences) were not
supported by these results and strengthen the case for not diferentiating treatment (use of surgery) on the
basis of these characteristics. Similarly, the efect of treatment group remained not statisticaly significant
when accounting for smoking status and patient treatment preference.
We found no statisticaly significant diferences between treatment groups in the SF-12 PCS score. The
PCS score was on average 1.8 score points higher in the surgical group than in the non-surgical group
(95% CI–0.84 to 4.39,p=0.184). The same lack of significance applied for the SF-12 MCS score.
The MCS score was on average 1.3 points lower in the surgical group than in the non-surgical group
(95% CI–3.80 to 1.23,p=0.317).
Al 10 early medical complications occured in surgery group participants. Slightly more patients in the
surgery group than in the non-surgery group experienced a surgical or shoulder fracture-related
complication [30 (24%) vs. 23 (18%)]. Although the same number in each group (n=11; 9%) had
secondary surgery to the shoulder within the 2-year folow-up period, slightly more in the surgery group
than in the non-surgery group had increased or new shoulder-related therapy [seven (5.6%) vs. four
(3.2%)]. Neither of these diferences were statisticaly significant (patients with complicationsp=0.279;
patients undergoing further surgery or therapyp=0.575). The same finding applied to mortality, with
slightly more deaths in the surgery group than in the non-surgery group [nine (7.2%) vs. five (4.0%),
p=0.271]. In total, 28 patients in each group experienced at least one serious adverse event (SAE). Nine
patients experienced at least one non-SAE, of whom four were in the surgery group and five were in the
non-surgery group.
Cost-effectiveness results
The base-case economic analysis showed that, at 2 years, the cost of surgical intervention was, on average,
£1780.73 more per patient (95% CI £1152.71 to £2408.75) than the cost of non-surgical intervention.
It was also slightly less beneficial in terms of utilities, although this diference was not statisticaly
significant (diference of–0.0158, 95% CI–0.13 to 0.10 when adjusted for baseline utility;–0.0101,
95% CI–0.13 to 0.11 when adjusted for covariates). The net monetary benefit associated with surgery is
negative, indicating that the resources to be displaced would be greater than the benefit to be gained if
surgery were implemented in the NHS. Furthermore, the CEAC showed that surgery had only a 5%
probability of achieving the criterion of costing<£20,000 to gain a QALY. Therefore, surgery appears to
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be a dominated treatment option and not a cost-efective use of health-care resources. These findings
were robust to the three sensitivity analyses that were undertaken. Although surgery did not result in a
dominated alternative for the base-case analysis or the sensitivity analyses that included both shoulder and
non-shoulder-related resource use, the incremental cost-efectiveness ratios were stil above National
Institute for Health and Care Excelence cost-efectiveness thresholds (£20,000–30,000 per QALY gained).
Conclusion
The ProFHER trial has provided robust clinicaly relevant evidence showing that curent surgical practice
does not result in a beter outcome for most patients with a displaced fracture of the proximal humerus
involving the surgical neck and that, in addition, it is not cost-efective in the UK seting.
It is important that non-surgical care should be of a good standard, including the availability of a leaflet
about sling immobilisation, timely access to physiotherapy and promotion of home exercises. The potential
need for remedial surgery for severe symptomatic complications in around 5–10% of these patients should
be factored into forecasts for hospital budgets.
Recommendations for research
Given the above findings and the existence of five ongoing trials, initiating further RCTs on this question
is not appropriate. The seting up of a national database of these fractures, with the systematic and
prospective colection of data on epidemiology, management and outcome, including of patient-reported
outcomes, should be considered. In addition, research is required to establish the best approach to
providing patient information on the early treatment of these fractures.
Trial registration
This trial is registered as ISRCTN50850043.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
DOI: 10.3310/hta19240 HEALTH TECHNOLOGY ASSESSMENT 2015VOL. 19 NO. 24
© Queen’s Printer and Controler of HMSO 2015. This work was produced by Handolet al.under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the ful report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxxii

Chapter 1Introduction
Proximal humeral fractures
Fractures of the proximal humerus are those occuring at the top end of the humerus or upper arm bone.
An estimated 706,000 proximal humeral fractures occured worldwide in 2000.1In the same year,
an incidence of 63 proximal humeral fractures per 100,000 adults was reported for the population
(534,715 adults) served by the Edinburgh Royal Infirmary,2and an incidence of 79 humeral fractures,
of which 61 were likely to be proximal humeral fractures based on fracture distribution statistics,2
per 100,000 adults aged>20 years was reported in England and Wales.3Based on 2001 UK census data,
this amounted to an estimated 23,788 proximal humeral fractures in England and Wales (population
38,997,087 aged>20 years).4These fractures accounted for 5–6% of al adult fractures in studies
conducted in Scotland2and Denmark.5Their incidence increases rapidly with age, with the majority
occuring in people aged>65 years.2,5Women are afected between two and three times as often as
men.2,5,6Most of these fractures result from low-energy trauma, predominantly a fal from standing
height.5,7The primary injury mechanism, the gender ratio and the age distribution point to underlying
osteoporosis.7,8Similar to other primarily osteoporotic fractures, the incidence and age-specific incidence of
these fractures are increasing.8
The immediate and long-term consequences of proximal humeral fractures are substantial. Especialy in
the elderly, who wil often have other comorbidities, these fractures can result in lengthy inpatient
rehabilitation and, for some, a loss of independence such as a permanent move to a nursing home.9
Hospital Episode Statistics (HES) data for England10over a 9-year period (2003–12) consistently show a
mean inpatient stay of>1 week and that just over half of these episodes relate to patients aged
≥75 years (seeAppendix 1). The outcome folowing treatment of these fractures is frequently
unsatisfactory. Poor shoulder function and pain are common long-term outcomes, with a substantial
proportion of patients, even those with less severe injuries, continuing to report some or severe disability
at 2 years.11These injuries are also associated with an increase in mortality.12
Although dwarfed by the costs of hip (proximal femur) fracture, for which the bulk of specific economic
cost data on osteoporotic fractures are available, the costs of proximal humeral fractures are stil
considerable and rising. One study reporting data colected from 1989 to 1991 on residents of Olmsted
County, MN, USA, reported a 0.21 cost ratio of treating a humeral fracture compared with a hip
fracture in the first year.13Again in the USA, a retrospective study of fracture-related direct medical costs
in 2000 found that the cost per fracture per year for a humeral fracture was 21% that of a hip fracture
(US$5567 vs. US$26,856 at 2003 Medicare fee schedule payment levels).14Given the 3.2% increase in the
surgical management of proximal humeral fractures (most hip fractures are managed surgicaly) between
1999–2000 and 2004–5, it is likely that the relative cost of these fractures has increased in the USA.15
A report providing direct health-care costs of injuries to the shoulder, arm and wrist in the Netherlands,
adjusted to 2007 prices, reported that upper arm fractures (annual average of 9038 proximal humeral and
humeral shaft fractures) were the most expensive injuries per case (€4440) and that their overal annual cost
was approximately€40M out of an estimated€290M cost for upper extremity injuries.16It was suggested
that the increase in the cost of fracture care in‘elderly women’from a previous report of costs in the
Netherlands was partly because of a higher number of patients receiving operations for these fractures.16
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Fracture morphology, classification and epidemiology
Over 99% of proximal humeral fractures are closed fractures in which the overlying skin remains intact.17
The most commonly used classification of these fractures is that of Neer.18Neer based his 16-category
classification primarily on the relative positions of the four main segments of the proximal humerus:
the humeral head, the greater tuberosity, the lesser tuberosity and the humeral shaft (seeFigure 1).
Although these may be delineated by fracture lines, a segment is only considered a‘part’if there is
displacement of>1 cm or 45° angulation. A‘minimaly displaced’or‘undisplaced’fracture occurs when the
displacement criteria are not met for any of the four segments. For ease of description and to avoid the
misinterpretation that these are al ‘undisplaced’or‘minimaly displaced’fractures, in common with other
researchers,19we generaly refer to such fractures as one-part fractures in this report. The other categories–
two-part, three-part and four-part fractures–involve the relative displacement of two, three or al four
segments respectively. Additional Neer categories involve fractures associated with an anterior or posterior
humeral head dislocation and fractures involving the articular surface of the humeral head.Appendix 2
shows the Neer classification system, with numbering of the categories by Sidoret al.19
The doted lines inFigure 1represent lines of epiphyseal scar where the four segments that ossify
separately fuse at skeletal maturity. Codman made a key observation that fractures tend to generaly occur
along lines of these epiphyseal scars in the proximal humerus.20
A large prospective epidemiological study involving 1027 fractures found that around half (51%) of
proximal humeral fractures are displaced according to Neer’s criteria.7Of these, the largest groups involved
two-part surgical neck fractures (28% of the whole population) and three-part greater tuberosity and
surgical neck fractures (9%). Three-part lesser tuberosity and surgical neck fractures were rare (0.3%).
Four-part fractures without fracture dislocation comprised 2% of the total. Overal, approximately 40% of
proximal humeral fractures involve a displaced surgical neck.Figure 2shows an example of a two-part
fracture of the surgical neck and subsequent internal fixation.
Limitations of the Neer classification include the arbitrary thresholds for displacement; the absence of key
potentialy prognostic fracture paterns, particularly those relating to the relative positions of the shaft and
the humeral head (varus and valgus displacement); and the findings of only fair to moderate interobserver
and intraobserver agreement for classification.21,22
2 3
4
1
FIGURE 1Proximal humerus anatomy and the four segments. (1) Shaft, (2) greater tuberosity, (3) lesser tuberosity
and (4) head.
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Treatment: care pathways
People with these injuries typicaly present with a very painful and swolen shoulder to an accident and
emergency (A&E) department soon after their injury. As wel as having severely limited movement of the
shoulder, there is often deformity and bruising. On radiographic (generaly plain radiography) confirmation
of their fracture, patients are either sent home with their arm in a sling and given analgesics or admited
to hospital for social or other health-related reasons. (In rare instances there are serious complications,
such as an open fracture or major vascular injury, necessitating emergency surgery.) Subsequently, patients
are seen by an orthopaedic specialist in the next fracture clinic at the hospital. A second set of radiographs
may be taken to further characterise the fracture. These are likely to be at least two views from the
standard shoulder trauma series: anteroposterior in the scapular plane, scapular Y-lateral and axilary or
modified axilary.23,24
The majority of these fractures, including al undisplaced fractures, are treated non-surgicaly. Closed
reduction of displaced fractures to reposition the fractured parts is generaly not caried out. Non-surgical
treatment generaly involves‘immobilisation’and support of the injured arm in a sling for around 3 weeks25
to facilitate initial fracture healing before alowing shoulder movement. Surgical treatment, which is often
undertaken for more complex displaced fractures, usualy involves either closed or open reduction of the
fracture and internal fixation using various devices or replacing the humeral head with a hemiarthroplasty.
In some cases, total joint replacement (including reverse polarity shoulder arthroplasty in which the bal
part is uppermost, fixed to the socket, and the cup is fixed to the upper end of the humerus) may be
performed. Common methods of internal fixation are plating, in which a metal plate is placed alongside
the repositioned bone and secured using screws (seeFigure 2b); intramedulary nailing, in which a nail
is inserted into and along the medulary canal and usualy‘locked’into place, such as with screws;
and percutaneous fixation using pins, screws and/or wires after closed reduction. Bone grafts or substitutes
may be used to fil bony voids. Typicaly, patients are placed on the next available list of a specialist surgeon
and operated on within 3 weeks of their injury. Post-operative treatment generaly involves a period of
immobilisation. Whether treated surgicaly or non-surgicaly, rehabilitation, comprising a mixture of advice,
instruction, physiotherapy and home exercises, is required, with the aim of restoring shoulder function and
achieving functional independence.25
(a) (b)
FIGURE 2Two-part fracture of the (a) surgical neck with (b) subsequent internal fixation with plate and screws.
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Evidence underpinning practice
Historicaly, there has been a paucity of evidence from randomised controled trials (RCTs) to inform the
management of these fractures. In 2007, at the time of developing the PROximal Fracture of the Humerus:
Evaluation by Randomisation (ProFHER) trial protocol, the Cochrane review (search date September 2006)
on this topic included just 12 smal trials (578 participants).26Of these, three heterogeneous and
methodologicaly flawed trials (102 participants in total) compared surgery with non-surgical treatment.27–29
The review concluded that there was‘insuficient evidence from RCTs to determine which interventions are
the most appropriate for the management of diferent types of proximal humeral fractures’.26More
specificaly, it concluded that‘It is unclear whether operative intervention, even for specific fracture types,
wil produce consistently beter long term outcomes’.26The review noted that dificulties in patient
recruitment seemed a key problem in this area, particularly in trials involving surgery, as shown by the
abandonment of three trials and the slow rates of recruitment and lower than planned recruitment rates in
other trials.
Subsequent updates of the Cochrane review have noted a continuing inadequacy of the evidence.
The update published in 2012 (search date January 2012) included six trials (270 participants) comparing
surgery with non-surgical treatment but noted also six ongoing trials that aim to recruit 1052 patients in
al.30Al three of the more recent trials31–33recorded validated patient-reported outcome measures of upper
limb function. Such measures, which include the Disabilities of the Arm, Shoulder and Hand questionnaire34
and the Oxford Shoulder Score (OSS),35were unavailable previously.
As wel as a lack of evidence to inform on al aspects of management of these fractures (including optimal
conservative or surgical treatment), there is evidence of substantial variation in practice. This includes the
length of immobilisation and the timing and provision of physiotherapy for less severe fractures25and the
use of surgery.15,36,37Additionaly, technology is changing al the time and there are various pressures for
early implementation of new fixation devices15,37and surgical techniques, for example.38
Rationale for a trial comparing surgical with non-surgical
treatment
Surgery is rarely essential for these fractures and there is a clinical consensus that it is not needed for the
majority of non-displaced or minimaly displaced fractures. As shown by the large variation in practice,
there is uncertainty about the role of surgery for the majority of displaced fractures, most of which involve
the surgical neck. The commonly perceived advantages of surgery are restoration of anatomy, the potential
avoidance of symptomatic nonunion and malunion, and improved functional outcome. In particular,
this last presumption is unproven.30Moreover, surgery involves additional trauma and risks in terms of
anaesthesia and complications (such as wound infection) and sometimes surgical erors.39There is a need
also to justify the greater initial costs associated with surgery, including the potentialy increased inpatient
stay. Later surgery for failed non-surgical treatment or major revision surgery for surgical complications is
usualy technicaly more dificult and less successful. There is some limited evidence indicating that initial
surgery is associated with a higher risk of subsequent surgery.15,30
Aim of the ProFHER trial
This key treatment uncertainty formed the rationale for the ProFHER trial. This was a pragmatic multicentre
RCT whose primary objective was to evaluate the clinical efectiveness and cost-efectiveness of surgical
compared with non-surgical treatment of the majority of displaced fractures of the proximal humerus
involving the surgical neck in adults.
INTRODUCTION
NIHR Journals Librarywww.journalslibrary.nihr.ac.uk
4
This objective was supported and supplemented by the folowing secondary objectives:
l To describe the study population in terms of key characteristics and in particular to categorise, using
optimised methods including training, the trial fractures according to the Neer classification through an
independent assessment of baseline radiographs of al randomised patients in the ProFHER trial.
l To ensure that both groups of patients receive comparable and good standards of care. This included
remedying identified‘gaps’such as through the development of a leaflet to advise patients on self-care
during sling immobilisation and a physiotherapy protocol in consultation with specialist shoulder
physiotherapists and promoting the need to encourage home exercise.
l To explore the efect of age (<65 years vs.≥65 years), type of fracture (involving none vs. one or both
tuberosities) and patients’treatment preference on the primary outcome (OSS).
l To explore surgeon treatment preferences, including the relationships between surgeons’decisions to
exclude patients because of a lack of equipoise, and patient age (<65 years vs.≥65 years) and
fracture type (involving none or one or both tuberosities).
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Chapter 2Methods
Summary of trial design
The ProFHER trial was a pragmatic UK-based multicentre RCT, with a concomitant economic evaluation,
of surgical compared with non-surgical treatment of acute displaced proximal humeral fractures involving
the surgical neck in adults.40The choice of surgical intervention was the decision of the surgeons, who had
to use techniques with which they were experienced and fuly familiar. Good standards of non-surgical
care, including care-provider competence, and a comparable provision of rehabilitation for both groups of
patients were expected. The later was facilitated through the provision to patients of an information
leaflet on personal care during initial sling immobilisation and the development of a writen physiotherapy
protocol. We aimed to recruit and randomise 250 patients with these fractures and folow them up for
2 years. Our primary outcome was the OSS,35,41colected at 6, 12 and 24 months via a postal questionnaire.
There was no blinding of outcome assessment. However, coding, including the independent categorisation
of baseline fractures, was caried out blind to alocation. Al analyses were based on intention to treat (ITT).
The final version of the study protocol (version 7), shown inAppendix 3, was published in 2009.40
Appendix 4summarises the changes to the protocol.
Randomisation: sequence generation and alocation
concealment
Patients were randomised on an equal basis to surgery or non-surgical treatment by the remote
randomisation service (telephone or web based) provided by the York Trials Unit (YTU), University of York.
Throughout, randomisation was stratified by tuberosity involvement (yes or no) with alocation using
random block sizes (these were four, eight and 12). The original intention, after a specified time, to use
minimisation based on the minimisation factors of tuberosity involvement (yes or no) and study centre
was not implemented (seeAppendix 4). These measures were taken to avoid the risk of prediction of
alocation. As fewer patients than expected were being recruited at centres, the initial concern about an
imbalance leading to an excess in the alocation to surgery at a centre, with the associated cost and
logistics of performing this surgery, no longer applied. Alocation concealment was assured by the
treatment being assigned only after obtaining patient identifiers and key baseline data.
Participant eligibility
Only adults with an acute displaced unilateral fracture of the proximal humerus involving the surgical neck
were eligible for inclusion. Alowance was made for surgical neck displacement that did not meet the exact
displacement criteria of the Neer classification (1 cm and/or 45° angulation of displaced parts) when this
reflected an individual surgeon’s equipoise (e.g. whether or not the surgical neck fracture was displaced
enough to be considered for surgical treatment). Fractures involving dislocation of the humeral head
out of the glenohumeral joint were explicitly excluded. Although fractures involving the articular surface
(head-spliting fractures) were not explicitly excluded, it was anticipated that these rare fractures would not
be considered eligible.
The folowing inclusion and exclusion criteria, which were applied throughout patient recruitment, were
summarised on the study eligibility form (seeAppendix 5). (The order of the exclusion criteria was adjusted
for presentational reasons.)
DOI: 10.3310/hta19240 HEALTH TECHNOLOGY ASSESSMENT 2015VOL. 19 NO. 24
© Queen’s Printer and Controler of HMSO 2015. This work was produced by Handolet al.under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the ful report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
Inclusion criteria
Adults (aged≥16 years) presenting to the participating hospital within 3 weeks of their injury with a
radiographicaly confirmed displaced fracture of the proximal humerus involving the surgical neck were
eligible for inclusion. This included al two-part surgical neck fractures and three-part (including surgical
neck) and four-part fractures of the proximal humerus (according to the Neer classification). Also included
were displaced surgical neck fractures that did not meet the exact displacement criteria of the
Neer classification.
Exclusion criteria
l Associated dislocation of the injured shoulder joint.
l Open fracture.
l Lack of mental capacity: unable to understand the trial procedure or instructions for rehabilitation;
significant mental impairment that would preclude compliance with rehabilitation and
treatment advice.
l Comorbidities precluding surgery/anaesthesia.
l A clear indication for surgery such as severe soft-tissue compromise requiring surgery/emergency
treatment (nerve injury/dysfunction).
l Multiple injuries: same limb fractures; other upper limb fractures.
l Pathological fractures (other than osteoporotic) and terminal ilness.
l Participant not resident in the hospital catchment area.
Also listed on the study eligibility form was‘Other reason to exclude the patient’, with an open text box
to record the reason.
Sample population
Al patients meeting the main inclusion criteria (age≥16 years, presenting within 3 weeks of injury, with a
displaced fracture of the proximal humerus involving the surgical neck) were considered potentialy eligible.
Ineligible patients were defined as those who were excluded for one or more reasons given in the list of
exclusion criteria or for another reason, such as a surgeon’s preference for one of the treatment options,
reflecting lack of surgical equipoise, stated by the surgeon. Some eligible patients were not included
because of a lack of patient consent (non-consenting patients), reflecting a strong preference for a specific
treatment option or refusal of randomisation.
Study setting
Trial recruitment was undertaken in the orthopaedic departments of 33 of the 35 participating acute NHS
hospitals; 33 participating hospitals were based in England and one each was based in Scotland and
Wales. Patient care pathways including outpatient and community-based rehabilitation were as per
routine practice. Patient recruitment, which was from fracture clinics or orthopaedic wards, lasted from
17 September 2008 until 13 April 2011, when the last patient was recruited. Folow-up was for 2 years.
Interventions
Each centre in the trial had to agree to forgo the introduction of radicaly novel and experimental
interventions for these fractures during the recruitment period. The centres were also responsible for
identifying surgeons with suficient expertise for participation in the trial. We emphasised to the
participating centres that central to obtaining reliable evidence was that good standard care, both surgical
and non-surgical, was provided throughout the trial. It was expected that, as part of good standard care,
METHODS
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surgery for these types of fractures would usualy be caried out by specialist surgeons, who were
experienced in operating on these fractures. When possible, decisions about the method of surgery, when
alocated, and non-surgical treatment were left to the clinical judgement of the participating clinicians.
Participating surgeons were advised that they must, however, use surgical interventions and procedures
with which they were familiar (and thus experienced with). This was to avoid learning curve problems.42,43
Similarly, other clinicians, including physiotherapists, were advised that they should use procedures
with which they were familiar. Additionaly, prescribed deviations from the planned surgery and the
physiotherapy protocol for rehabilitation provided for the trial had to be documented and reasons given.
Surgery
We anticipated that plate fixation or intramedulary nailing were likely to be chosen for displaced
(two-part) surgical neck fractures. For three-part (including displaced surgical neck) or four-part fractures,
we anticipated that surgical interventions were likely to include internal fixation such as nails, plates or
other methods that preserved the humeral head, or humeral head replacement (hemiarthroplasty).
We stipulated that peri- and post-operative management, including anaesthesia and analgesia, antibiotic
and thromboembolism prophylaxis and dressing policies, should folow local guidelines and that similar
mobilisation protocols should be provided for al interventions.
Non-surgical intervention (control)
We recommended that conservatively treated patients should be given sling immobilisation for about
3 weeks or for as long as the treating clinician deemed necessary and active early rehabilitation.
We stressed the need for competence in conservative methods, including rehabilitation.
Rehabilitation
We stipulated that al trial participants who were assessed as eligible for the trial should be provided
with writen advice on personal care during sling immobilisation. We stressed that similar access to
physiotherapy should be provided for surgical and non-surgical participants. A basic treatment protocol for
physiotherapy was provided. This emphasised that, although the protocol acted as a guide, variation in
practice was accepted and anticipated. However, electrotherapy, other than transcutaneous electrical
nerve stimulation (TENS), was discouraged. (As there is no evidence in support of TENS for treating these
fractures,30its exclusion served to avoid potential confounding given its stil albeit unproven efect on
fracture healing.44) We promoted strongly the need to encourage patients to perform home exercises and
that they should receive information sheets ilustrating how to cary out the exercises.
Outcome measures
Primary outcome measure: the Oxford Shoulder Score
The primary outcome measure was the OSS,35assessed at 6, 12 and 24 months. We purposefuly did not
stipulate a primary time point as we considered that none of these three was of primary interest; thus, the
primary analysis compared the results of the two groups over al three folow-up assessments. The OSS is a
condition-specific questionnaire providing a total score based on the patient’s subjective assessment of
pain and impairment of activities of daily living (ADL). The OSS contains 12 items, each with five categories
of response. It has been shown to corelate wel with both the professionaly endorsed Constant–Murley
shoulder score45and the 36-item Short Form health survey (SF-36)46and to be sensitive to clinical change
at 6 months after surgical intervention.47It has been demonstrated to be consistent, reproducible and valid
in a UK population.35Based on the revised scoring algorithm used in our analyses, the range of available
scores was from 0 (worst) to 48 (best).41OSS data were colected by participant-completed questionnaires
that were posted to participants at 6, 12 and 24 months. OSS data were not colected at baseline because
questions refer to functioning during the past month and baseline assessments usualy took place within a
week of injury.
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Secondary outcomes
The folowing secondary outcomes were colected:
l health status/patient-reported quality of life data measured by:
¢ the 12-item Short Form health survey (SF-12)48at 6, 12 and 24 months
¢ the European Quality of Life-5 Dimensions (EQ-5D)49at 3, 6, 12 and 24 months (also colected
at baseline)
l surgical and other shoulder fracture-related complications
l secondary surgery to the shoulder or increased/new shoulder-related therapy
l medical complications during the inpatient stay
l mortality.
12-item Short Form health survey
The SF-12 is a generic health status measure and a short form of the SF-36 health survey. It consists of
12 questions measuring eight domains (physical, role physical, bodily pain, general health, vitality, social
functioning, role emotional and mental health) rated over the past month. Questions have three or five
response categories and responses are summarised into a physical component summary (PCS) score and a
mental component summary (MCS) score. Outcomes range from 0 (lowest level of health) to 100 (highest
level of health). SF-12 data were colected by patient-completed questionnaires at 6, 12 and 24 months.
(The SF-12 PCS and MCS scores are presented here.)
European Quality of Life-5 Dimensions
The EQ-5D is a standardised measure of curent health status developed by the EuroQol Group for clinical
and economic appraisals. We used the EQ-5D-3L version. This consists of five questions assessing five
dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension is
rated on three levels: no problems, some problems and extreme problems. Scores are converted to a single
summary index ranging from 0 (death) to 1 (perfect health), although a score of<0 (worse than death) is
possible too. EQ-5D data were colected by patient-completed questionnaires at baseline and 3, 6, 12 and
24 months. (The EQ-5D data are analysed as part of the economic evaluation and are not presented
separately in clinical efectiveness analysis.)
Surgical and other shoulder fracture-related complications, secondary surgery
to the shoulder and increased/new shoulder-related therapy
These outcomes were extracted from hospital records by hospital staf, and centres were required to
complete relevant case report forms (CRFs) at the end of the inpatient stay, when applicable, and again
at 1 and 2 years’folow-up. Listed categories were surgical site infection, haematoma formation at the
surgical site, nerve injury, implant-related complication/failure, dislocation/instability, metalwork problems,
avascular necrosis (AVN), nonunion/malunion and‘other’.
Medical complications during the inpatient stay
Early medical complications were documented by centre staf on a CRF for recording episodes during
the inpatient stay. Listed categories were myocardial infarction (MI), stroke, chest infection, other
hospital-acquired infection, deep-vein thrombosis (DVT), pulmonary embolism, admission to the intensive
care unit, admission to the high-dependency unit and other serious event.
Mortality
Mortality at any time was reported by centre staf to the YTU using a CRF.
Data colection schedule
An overview of the time points at which trial data were colected is presented inTable 1.
METHODS
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Data for the economic evaluation
Health utility data were obtained from the EQ-5D data colected at baseline and 3, 6, 12 and 24 months
from patient questionnaires. Prospective cost data for trial participants were colected from the hospital
forms and patient questionnaires. These included costs incured in hospital (surgery, inpatient stay
and physiotherapy) and subsequently [outpatient physiotherapy, visits to a general practitioner (GP) and
other NHS costs]. We colected surgical data on the actual procedures caried out, including anaesthesia,
and the interventions provided and the experience of operators/care providers (according to grade).
Data were colected to alow some estimation of other‘societal’costs to the patients, specificaly private
health care, days of paid work or days unable to perform normal activities; but, as indicated in the
protocol, these data were not used in the analyses presented in this report.
Classification of study fractures
Copies of al baseline radiographs for al randomised patients were colected. These were processed to
facilitate an independent and blinded classification of the study fractures based on the Neer classification
system at the end of study recruitment by two orthopaedic specialist shoulder surgeons experienced in
assessing and operating on proximal humeral fractures. This was preceded by a training session on the
Neer classification, which has been shown to improve inter-rater agreement.22
Sample size
The primary outcome for the trial is diferences in patients’subjective assessments of pain and ADL as
measured by the OSS. To justify both the increased cost of surgery and the exposure to the hazards
of surgery, there need to be greater improvements in patients’subjective assessments of pain and ADL in the
surgery group than in the conservative treatment group. There continues to be a lack of data to inform on
the minimum clinicaly important diference for any validated patient-reported outcome measure for these
fractures. Observational data colected by the chief investigator and his coleagues found that those patients
who had surgery without subsequent complications [1- to 5-year data from 50 patients treated with a
PHILOS®plate (Synthes Ltd, Welwyn Garden City, UK) between 2001 and 2005] had a 5-point diferential
TABLE 1Data colection schedule
Outcome Baseline
End of inpatient
episode 3 months 6 months 12 months 24 months
Demographics and fracture data ✗
OSS (primary outcome) ✗ ✗  ✗
SF-12 ✗ ✗  ✗
EQ-5D ✗ ✗a ✗ ✗  ✗
Surgical and other shoulder
fracture-related complications
✗ ✗ ✗
Medical complications ✗
Secondary surgery to the shoulder ✗ ✗ ✗
Increased/new therapy for
shoulder-related complications
✗ ✗ ✗
a Colection of data at 3 months was restricted purposefuly to those required for the economic analysis. Six months was
considered the earliest time point that was appropriate to colect OSS and SF-12 data in terms of the typical recovery
patern and treatment regimens of patients with these fractures. It was expected that many patients would stil be
undergoing rehabilitation, primarily physiotherapy, at 3 months.
DOI: 10.3310/hta19240 HEALTH TECHNOLOGY ASSESSMENT 2015VOL. 19 NO. 24
© Queen’s Printer and Controler of HMSO 2015. This work was produced by Handolet al.under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the ful report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11
improvement in OSS compared with patients treated conservatively (3- to 12-month data from 103 patients
treated between April 2000 and July 2003).50This 5-point diference was judged to be of clinical importance.
Given a standard deviation (SD) of 12 this equated to an efect size of 0.42. It was calculated that to detect a
minimum efect size of 0.4 with 80% power and a two-sided 5% significance level 100 patients in each
treatment group would be required. After alowing for a potential loss to folow-up of 20%, we proposed to
recruit and randomise 250 patients (125 in the surgery group and 125 in the control group). (This did not take
account of any potential cluster efect, such as from similarities between surgeons within centres, as we did
not expect there to be many patients treated by individual surgeons.51)
Estimating the numbers of patients and centres needed
to recruit
There were insuficient good-quality prospectively colected data to inform our estimates of the number of
trial centres and duration of recruitment needed to achieve our target of 250 trial participants. Although
data from the epidemiological study conducted in Edinburgh7were used, particularly in terms of the
relative proportions of Neer categories in our intended fracture population, using these as a basis for
estimating the sample populations in individual hospitals was hampered by the unavailability of accurate
data on the catchment populations of individual hospitals. There is also the unknown but expected
variation in risk factors in these populations. Another approach of directly asking putative principal
investigators when developing the study proposal yielded rough estimates without reliable data on how
many proximal humeral fractures were treated at a centre and what proportion of these might be treated
surgicaly. In December 2006 we sent each of the six putative principal investigators a form requesting
information that would inform on the recruitment potential of the site. This included estimates of the
numbers of people presenting with proximal humeral fractures at individual centres each year, how many
of these had surgery and how many would be eligible for inclusion. We received two completed forms,
one provided by the chief investigator. This lack of information on centre activity relating to proximal
humeral fractures was mirored throughout the trial. Furthermore, we used HES data to obtain a general
impression of overal activity at a hospital (taken as a proxy for catchment population) and specific proximal
humeral fracture activity, while recognising that patients with less serious (minimaly displaced) fractures
may not have been admited.Appendix 6gives details of the calculations used to estimate the size of our
population sample using the HES data.
Proposed recruitment rate
From the outset we anticipated that recruitment to this trial would be chalenging and thus we set very
conservative recruitment targets. We set our recruitment period at 18 months and aimed to recruit
between 18–20 centres. We estimated that across 18 centres there would be 6132 patients (corected
from the protocol) with a proximal humeral fracture over the 18 months of recruitment. Based on data
from Court-Brownet al.,7we calculated that 2391 patients would have the fracture types suitable for
inclusion in the trial. Thus, to achieve our sample size we needed to recruit only 11% of these patients.
We established an expectation that each participating centre would recruit at least one participant
per month.
Because of the uncertainty in terms of recruitment we proposed a feasibility study in which there was an
assessment point after 10 months of recruitment to determine if recruitment into the trial was suficient
(set at 88 patients) to justify its continuation after 18 months. Subsequently, we successfuly argued for the
cancelation of this and the associated stopping rule at 12 months (seeAppendix 4).
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Governance
Ethical arrangements
Multicentre Research Ethics Commitee (MREC) (now the National Research Ethics Service Commitee
Yorkshire and the Humber–Leeds West) approval was obtained from the York Research Ethics Commitee
(reference number 08/H1311/12; date of favourable ethical opinion 11 March 2008). This was preceded by
approval from the School of Health and Social Care Research Governance and Ethics Commitee, Teesside
University (sponsor) via the Chair’s action (date of favourable ethical opinion 10 December 2007).
Separate approval was also sought from local research ethics commitees for each centre up until this
became the responsibility of NHS research and development (R&D) ofices from 1 April 2009. Approval
was obtained from al R&D ofices of participating hospitals. In some cases R&D approval was required also
for primary care trusts to alow for data colection by physiotherapists delivering care in the community
such as in general practices or other local hospitals.
Appendix 7lists the six minor and seven substantial amendments to the protocol approved by the MREC.
The R&D ofice of each participating hospital was notified of al amendments after approval was received
from the MREC. The last three amendments, dating from September 2010, apply to the extension to
folow-up to enable patient questionnaires to be colected at 3, 4 and 5 years. The long-term folow-up
study wil be reported separately in 2016.
The MREC was notified within 15 days of the YTU being notified of any serious adverse events (SAEs) that
were judged to be both unexpected and related to trial participation. Reports to the MREC were submited
on an annual basis.
Trial governance
Independent supervision
Independent and non-executive members of the Trial Steering Commitee (TSC), including the independent
chairperson, two other independent members (a shoulder specialist and a statistician), two service users and
the sponsor representative provided independent supervision and advice on the trial. Up to the final TSC
meeting, whole-population data on accrual, recruitment and folow-up, as wel as‘housekeeping’statistics,
were disseminated to TSC members on a regular basis. The TSC, which convened at the discretion of the
independent chairperson, met formaly with members of the extended Trial Management Group (TMG) a
total of seven times.
A separate Data Monitoring and Ethics Commitee (DMEC), comprising an independent statistician,
a shoulder specialist and a consultant rheumatologist, met a total of eight times, generaly via
audioconference. An analysis of major complications was provided to the DMEC on a regular basis
folowing the commencement of trial recruitment.
Appendix 8lists the membership of the TMG and these two commitees.
Good Clinical Practice
Throughout the trial we adhered to the good clinical research practice guidelines.52Research governance
approval was obtained from participating trusts. This included local modifications of the Clinical Trial
Agreement (or contract) between the trial sponsor and local trusts and agreeing on which hospital staf
needed Good Clinical Practice (GCP) training.
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Patient consent and information
Writen informed consent was obtained from al participants. A participant information sheet for the trial,
which was produced with the involvement of service users, was provided to al potential participants
(seeAppendix 9). This gave a balanced and easily understandable account of the possible benefits and
known risks of the interventions under test and stated explicitly that quality of care would not be
compromised if the participant decided to (1) not enter the trial or (2) withdraw their consent. We alowed
patients suficient time to make an informed decision without unduly delaying their care. (Although we
intended, when possible, to provide translations of the participant information sheet for non-English
speakers, none was requested throughout the trial.)
Blinding and data management
There was no blinding of trial participants, care providers or outcome assessments. Data entry, processing
and analysis were caried out independently. Aside from accrual and whole-population baseline statistics,
interim results were not made available to the trial investigators, including the chief investigator, or
associates in the participant centres. Al data, including baseline radiographs, were anonymised before
distribution using study IDs, which were unique to each participant. Coding, which always involved at least
two independent coders, was caried out blind to alocation. To enable appropriate data checking, the trial
statistician conducting the analyses was unblinded to treatment group. However, the primary analyses
were repeated by a second blinded statistician using diferent statistical software and the results were
in agreement.
The anonymity of al treatment providers, including surgeons and physiotherapists, and centres is preserved
for al analyses.
Retention of al relevant trial documentation is set for a minimum of 20 years from the date of
trial completion.
Data handling
The patient questionnaires and hospital forms (i.e. CRFs) were designed using TeleForm software (version 10;
Cardif Software, Cambridge, UK). The CRFs were marked up in TeleForm with variable names and
appropriate scoring. When the CRFs were completed and returned to the YTU they were prepared for
scanning by a data entry clerk using the TeleForm software. When a form would not scan, the data were
manualy entered. When a form was scanned, the data were then verified depending on what TeleForm had
identified as requiring corection. The verified data were then downloaded into the study database and were
available for second checking. This involved each hard copy of the CRF being compared against the entry
stored in the study database and corecting the electronic data as necessary. Al data that had been scanned,
downloaded and second checked were then ready for validating. The data validation was undertaken by
the data manager who applied predetermined rules to check that the data recorded for the variables on the
CRF, such as whether or not the dates when the patient injured his or her shoulder and was assessed for
eligibility fel within the 3-week time frame for being eligible for the trial. Data that had been validated were
then available to the trial statistician and health economist.
Data checks, cleaning and processing
The MREC did not alow any return to patients for missing data. Data checks, including those conducted
by the data manager, alerted us to recurent problems with completion of hospital forms during
trial recruitment.
METHODS
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Data‘cleaning’, before the staged closure of the data set according to pre-established time points, was
caried out in a systematic manner with consultation on and discussion of any amendments.
Categorisation and interpretation of text comments that were recorded on the various data colection
forms was generaly performed by two independent and blinded members of the TMG, who then
discussed disagreements to reach a consensus. The criteria for assessment were documented, often
beforehand. When categorisation was performed by one rater, a second rater was asked to check the
results and criteria.
Clinical effectiveness analysis
Al analyses pertaining to clinical efectiveness were conducted to a prespecified analysis plan, endorsed by
the DMEC. Signatures of approval of the final version (version 19; August 2013) were obtained from the
chief investigator (AR), trial manager (SB) and‘co-applicant’(HH) before release of results by the statistician
(AK). ITT analysis, including al randomised patients in the groups to which they were randomised, was
conducted throughout. Al main analyses were performed using Stata 12 (StataCorp LP, Colege Station,
TX, USA) using two-sided significance tests at the 5% significance level.
Primary outcome analyses
The primary outcome (OSS) was summarised descriptively by treatment group at each time point
(6, 12 and 24 months post randomisation), including the extent of missing data. Baseline characteristics
predicting non-response were determined by logistic regression. As no specific assessment time was
considered to be of primary interest, the primary analysis compared the surgical and non-surgical
treatment groups over al folow-up assessments. A random-slope multilevel model was fited to the data
with time points nested in patients to alow for clustering of data within each patient. This model adjusted
for the fixed efects of time (6, 12 or 24 months), tuberosity involvement at baseline (yes or no), age
(<65 years or≥65 years), gender, health status at baseline (EQ-5D), treatment group and the interaction
between treatment and time (to assess whether or not any diference between treatment groups changed
over time). Diferent covariance paterns for the repeated measurements were explored and the most
appropriate patern was used for the final model. Estimates of the diference in OSS between treatment
groups were assessed overal and at individual time points (significance set atp<0.05). The trial was
powered to detect an efect size of approximately 5 points.
Subgroup and sensitivity analyses
Two subgroup analyses, the second with an associated sensitivity analysis, were set up a priori; these were
for the primary outcome only (OSS):
l age (≥65 years vs.<65 years)53
l surgical neck fractures involving one or both tuberosities (no vs. yes) as per initial surgeon classification
(Neer one- and two-part fractures vs. Neer three- and four-part fractures based on classification by two
independent experts from radiographs was used as a sensitivity analysis).
To strengthen our choice of subgroups, we made the folowing a priori specification of
subgroup direction:54
l the benefit of surgery over non-surgical treatment wil be larger in patients aged<65 years
l the benefit of surgery over non-surgical treatment wil be larger in patients with a surgical neck fracture
with displacement of one or both tuberosities (Neer three- and four-part fractures).
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The primary analysis model was extended for each of these subgroup analyses by including in turn an
interaction of treatment group with age group, tuberosity involvement or Neer parts. The diferences in
model fit between these and the base model were assessed atp<0.10. The statistical significance level of
10% was chosen as the study had not been powered to detect interactions.
Smoking status was added to the primary model as a sensitivity analysis (seeAppendix 4). To ascertain the
impact of prior beliefs, a treatment group × patient treatment preference interaction was added to
the base model. The variability in OSS across recruitment sites was analysed descriptively.
Secondary outcomes
The SF-12 PCS and MCS scores were analysed by multilevel modeling using the same predictors as for the
OSS primary model.
The numbers of surgical and shoulder fracture-related complications as wel as treatments for these were
reported by treatment group and time point. The frequencies of shoulder surgery and fracture-related
complications and any treatments for these were compared between treatment groups using the chi-squared
test. Mortality rates were reported and compared between treatment groups using the chi-squared test.
The use of the chi-squared test was determined by prespecified criteria.
Other outcomes
The numbers of other admissions and treatments for serious newly diagnosed medical complications
and fractures reported over the 2-year folow-up period were listed by treatment arm. Selected baseline
characteristics were inspected for patients with or without these complications. Adverse events were
summarised for each arm by type and expectedness/relatedness to treatment. Complications reported
within the physiotherapy treatment logs were reported descriptively if they were identified via the inpatient
episode or hospital folow-up forms.
Lack of surgeon equipoise
A separate analysis of lack of equipoise across centres and individual surgeons was undertaken. A lack
of equipoise occured when the sole reason why a patient was found to be ineligible was because the
surgeon’s response to the question about‘other reason to exclude the patient’when completing the study
eligibility form was that he or she had a treatment preference. To determine whether or not the reason for
exclusion was the result of a lack of equipoise, the reasons given were checked by two independent raters
(AR and HH), who resolved any disagreements through discussion. The impact of lack of surgeon equipoise
on study generalisability was explored by comparing participants’age, gender, time since injury and
tuberosity involvement between those ineligible because of a lack of equipoise and al eligible participants
using at-test or chi-squared test depending on the type of outcome. The relationship between age and
fracture type (the prespecified subgroup analyses) and surgeon treatment preference was explored for
those participants excluded because of a lack of equipoise. Age and fracture type were compared between
the surgeon treatment preference groups using a chi-squared test.
The Neer classification of baseline radiographs
Baseline fracture radiographs were evaluated during eligibility assessment and used later for an independent
classification using Neer’s proforma. A separate analysis explored the quality of available baseline fracture
radiographs, the agreement between raters and the agreement between the two assessments in terms
of the involvement/displacement of relevant anatomical structures. The kappa statistic was used
when appropriate.
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Economic analysis
Economic analysis was likewise conducted to a prespecified analysis plan shared with the DMEC.
Key diferences from the protocol are described inAppendix 4. The analysis was caried out from the
perspective of the UK NHS and Personal Social Services.55Data on health utilities, obtained from the EQ-5D
data colected from patient questionnaires, were converted into quality-adjusted life-years (QALYs) for
each patient using the area under the curve (AUC) method. Costs were expressed in UK pounds sterling at
a 2012 price base.
Diferences in mean costs and QALYs at 2 years were used to derive an estimate of the cost-efectiveness
of surgery and non-surgical treatment. Multiple imputation56,57instead of the method of Linet al.58was
used to derive the data set for the base-case analysis. ITT analysis was conducted throughout. An
additional analysis was conducted for complete cases (in which patients with any missing data are
excluded). Al analysis and modeling were undertaken in Stata 12. The ful methods used are detailed in
Chapter 7.
DOI: 10.3310/hta19240 HEALTH TECHNOLOGY ASSESSMENT 2015VOL. 19 NO. 24
© Queen’s Printer and Controler of HMSO 2015. This work was produced by Handolet al.under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the ful report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17

Chapter 3Further methods: standardisation
of trial procedures and care programmes, patient
recruitment and data colection and processing
This chapter gives a detailed account of various aspects of trial design and conduct that colectivelycontributed to the successful meeting of the primary objective of the trial. It begins by describing
specific measures taken to ensure standardisation of trial procedures and care programmes. These include
processes for seting up trial centres for recruitment and actions taken to meet our secondary objective of
ensuring that both groups of patients received comparable and good standards of care. It then describes
typical processes involved in patient recruitment and systematic approaches undertaken for data colection
and processing. It ends by covering the methods undertaken to meet another secondary objective, that
of obtaining a reliable characterisation of al of the fractures included in the trial according to the
Neer classification.
Standardisation of trial procedures and care programmes
Throughout the conduct of the trial we emphasised the importance of good practice from clinical and
research perspectives; standardised protocols and care pathways; and comparable and suficient expertise
of care providers in the two groups. As far as possible we adopted procedures that reflected and were
compatible with usual practice and that did not delay treatment, add unnecessarily to the clinical workload
or place a burden on participants. Specific areas of focus are described in the folowing sections.
Site visits and information
Where possible, a site visit was aranged before submission for local R&D approval of the study to meet
al of the key people who would be involved in conducting the trial at that site. In addition to discussion of
the rationale and design of the trial, this helped to establish the practical arangements of trial management
at that site and facilitate obtaining approvals for these at the relevant departments (e.g. orthopaedics,
physiotherapy and radiology). At this stage or subsequently, the designated person, most often a research
nurse, was identified and agreements were reached on which hospital staf needed Good Clinical Practice
training and the required modifications to the Clinical Trial Agreement (or contract) between the trust and
the trial sponsor. The Clinical Trial Agreement made clear the obligations of the trust to the sponsor and
vice versa. The later included reimbursement according to a payment schedule for data colection by the
hospital (seeAppendix 10). Because several months often elapsed between this site visit and the submission
for local R&D approval of the study and subsequent approval, we also undertook a second site visit after
R&D approval was obtained to meet with the key people involved in the study. The purpose of this visit was
to ensure that al of the practical arangements were established to enable recruitment to begin on an
agreed start date. The site was also provided with its investigator site file, which included al of the essential
documentation required to conduct the study and the packs of materials to begin screening and recruiting
patients into the trial.
The trial manual, which was developed from the trial protocol to facilitate the conduct of the trial at the
hospital sites, reinforced the information on trial governance, patient recruitment, data colection procedures
and expectations about trial conduct. It contained copies of al data colection forms, the protocol, information
sheets, the physiotherapy protocol and the Clinical Trial Agreement. The designated person completed a
staf delegation log, which acted as a record of who was involved in the trial at that site, and a participant log,
for documenting actions relating to trial patients. At al times we ensured that consistent messages were
given on eligibility criteria and trial procedures.
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Radiographs
Initialy, we strongly recommended the use of the ful shoulder trauma series (three perpendicular views)
for assessing fracture eligibility.59Documentation including a PowerPoint (Microsoft Corporation,
Redmond, WA, USA) presentation ilustrating the ful trauma series was made available as part of the trial
materials (seeAppendix 11). We adjusted this expectation after feedback from sites on diferences from
local practice and anticipated dificulties with implementation. On guidance from independent members of
the TSC who emphasised the need to keep a pragmatic approach, we instead promoted the need to
adhere to local guidelines for radiographic assessment. We thus stipulated that a minimum of two
radiographic views/projections were required for the assessment of study eligibility. Anonymised baseline
radiographs were colected for al randomised patients. The radiographic views were recorded on the study
eligibility form (seeAppendix 5).
Assessment of fractures
An introduction to the Neer classification was included in the trial manual that was provided to al hospital
sites. In the trial manual and other information for the trial, the study eligibility criteria were expressed in
terms of the Neer classification and the displacement criteria stated. However, training in the Neer
classification was not provided22and, in keeping with normal practice in busy A&E departments and
fracture clinics, there was no expectation that the recruiting surgeons would classify the fractures. Thus,
rather than request that surgeons judge whether or not displaced parts met the Neer criteria, they were
asked to indicate on the eligibility form if the fractureinvolvedeither of the tuberosities (seeAppendix 5).
Provision of written patient information on personal care during initial
sling immobilisation
The initial care of these fractures generaly includes immobilisation of the injured arm in a sling, colar and
cuf or similar. When working through the processes for patient recruitment in the context of the clinical
pathway, we discovered that there was a lack of writen patient information on personal care during‘sling
immobilisation’at al centres involved in the funding application. This discovery prompted the development
of an ilustrated information sheet by two physiotherapists, with input and feedback from the TMG and
the two service users (both former proximal humeral fracture patients) (seeAppendix 12). Items covered
in the information sheet were the rationale for the sling; sling use and care; advice on keeping mobile;
hand and wrist exercises; washing and hygiene; geting comfortable; sleeping position; pain relief,
including breathing; important‘don’ts’; warning signs; and a reminder to seek further advice in case of
problems. The information sheet was included in the trial recruitment materials to be given to potentialy
eligible patients. Centres were advised that the ProFHER trial sling immobilisation leaflet could be replaced
by a local hospital leaflet if available.
Physiotherapy protocol
The need for equivalent provision of physiotherapy to both treatment groups was emphasised. The
absence of a physiotherapy protocol to guide and promote standard care for these fractures was similarly
noted at al centres involved in the funding application. With the absence of evidence on which to base
practice,26we aimed to develop a physiotherapy protocol, giving basic treatment guidelines, that was
representative of accepted good practice. This process comprised several stages.
Informed by an initial review of curent physiotherapy practice at the lead site, a draft protocol structured
to reflect successive phases of rehabilitation was drawn up by four specialist physiotherapists based at
diferent sites. The independent TSC advised of the need to seek feedback on the draft protocol and obtain
further insights on the curent management of these fractures from specialist shoulder physiotherapists
and other experts in the field. Additional advice from the TSC pertained to the importance of keeping to
routine practice and avoiding unusual interventions, including electrotherapy (other than TENS).
We prepared a short questionnaire (seeAppendix 13) that asked for feedback on the draft protocol in
terms of its acceptability as a guide to basic treatment for these fractures and on whether or not the
specialists themselves would adopt the approach given in the protocol. Additionaly, the specialists were
FURTHER METHODS
NIHR Journals Librarywww.journalslibrary.nihr.ac.uk
20
asked to list other interventions that they applied routinely for people with these fractures and any
interventions available in a NHS seting that they would discourage. In June 2008, the questionnaire and
draft protocol were circulated for feedback in two ways: electronicaly via the hub contacts for the National
Physiotherapy Research Network (NPRN)60and in person at the British Elbow and Shoulder Society (BESS)
annual scientific meeting in Liverpool.
We received 29 completed questionnaires, predominantly from specialist physiotherapists curently
involved in treating these fractures and other shoulder injuries. Fourteen responses were from the 50 alied
health professionals atending the BESS meeting, 12 were from the NPRN mailshot (it is unknown how
many relevant people received the request for participation) and three were from members of a local
shoulder guideline development group.
The results from the questionnaire survey were colated and assessed in terms of the acceptability of
the draft protocol and any changes that were needed. Responses to al comments were documented.
We found that 27 respondents agreed that the protocol was acceptable as a basis for treatment, and,
moreover, were‘happy’with the approach given in the protocol. We made two main modifications to the
protocol in response to feedback. The first involved additional text stressing that the protocol was only
a guideline and that variation in practice was anticipated and acceptable, with the proviso that any
substantive diference was recorded using the hospital proforma. The second was a corection to some
contradictory instructions. Al of the other interventions listed as being used routinely for people with these
fractures were recorded for future reference. None of these interventions was considered unexpected
or inappropriate. Notably, there was a strong discouragement of electrotherapy except for the use
of TENS for pain relief: 12 of the 14 responses on what interventions should be discouraged specified
electrotherapy (including ultrasound), with three excluding TENS from this category.
Subsequent feedback from the TMG and coleagues from the United Kingdom Rotator Cuf Trial on
rotator cuf repair61on the modified protocol pointed to a greater emphasis on the non-surgical aspects of
treatment and rehabilitation and that the protocol applied to both surgicaly and non-surgicaly treated
patients. The final version of the physiotherapy protocol (seeAppendix 14) was included in the trial
documentation provided to trial sites. The substantial endorsement from other specialist physiotherapists
experienced in treating these fractures was stressed in the trial manual.
Home exercises
We promoted the need for physiotherapists to encourage patients to do home exercises and emphasised
this in the trial manual and physiotherapy protocol. Home exercises tend to reflect patient ability and to be
adapted as the patient recovers, which contradicted the provision of standardised material. Our agreed
approach was to check that physiotherapists either provided information leaflets ilustrating exercises for
home use already or would access a standard web-based facility to generate‘bespoke’exercise sheets.
The recording by physiotherapists of whether or not patients had done their home exercises was
completed for each session of physiotherapy.
Delivery of physiotherapy
Patients with these fractures often receive physiotherapy at one or more diferent localities after leaving
hospital. This added considerable complexity to the delivery and recording of physiotherapy and outcome.
R&D approval for primary care trusts (now disbanded) was sometimes required in addition to that obtained
for the acute hospital trusts, to alow for data colection by physiotherapists delivering care in the community,
such as in general practices or other local hospitals. For practical purposes, only the main primary care trusts
were generaly targeted; thus, patients expected to use venues outside their catchment area were ineligible
for the trial. Ultimately, additional R&D approval was obtained for 16 primary care trusts.
Contacts for physiotherapy were identified at each trial site to facilitate delivery of physiotherapy and
data colection. The contact physiotherapists usualy atended the multidisciplinary team meeting at site
set-up visits and were named in the local site R&D approval. They were responsible for organising the
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physiotherapy including dissemination of trial methods and materials, the provision of advice, the
distribution and colection of physiotherapy folow-up forms and often the return of these forms
to the YTU. Al 32 centres that recruited patients had named contacts for physiotherapy; in 10 centres,
the physiotherapy contact was also the designated contact for the centre.
Patient recruitment
This section describes the typical processes involved in the identification of potential participants and trial
recruitment. Trial recruitment packs, which included al relevant forms and materials for potentialy eligible
patients (thus those meeting the trial inclusion criteria), were provided by the YTU. Each potentialy
eligible patient had a unique four-digit identification number that was prerecorded on the individual forms
in the individual recruitment packs. Freepost envelopes were provided. To assist centres further in keeping
track of form returns, a participant log listing the various forms and materials for return to the YTU was
provided for the designated person to record the dates when individual forms were returned to the YTU.
Identification of potential participants
The designated person at each centre was requested to inform A&E staf about the trial and to distribute
specific leaflets about the trial to them. It was important that A&E staf were aware of the trial and also
that they took care not to jeopardise patient consent by biasing patients’atitudes to treatment. As per
local arangements, which may have been adjusted specificaly for the trial, patients with a radiologicaly
confirmed fracture of the proximal humerus were often refered by A&E to specific fracture clinics. As
described earlier, the requirement for a minimum of two perpendicular radiographic views to assess
patient eligibility for the trial had been established at site set-up. When feasible, the radiography
department flagged up potentialy eligible patients for the trial to the orthopaedic department.
In some cases, patients were admited into hospital from A&E. When this occured a patient was assessed
by the orthopaedic surgeon for eligibility and approached for recruitment into the trial using the same
procedures as established for the fracture clinic, as described in the folowing paragraphs.
At the fracture clinic, the designated person would identify a potentialy suitable patient and the orthopaedic
surgeon would assess whether or not the inclusion criteria were met as presented in the study eligibility
form (seeAppendix 5). Only when these criteria were met did the surgeon, often with the assistance of the
designated person, complete the study eligibility form to confirm whether or not the patient was eligible to
take part in the trial (thus, none of the exclusion criteria applied). When the patient was eligible, the surgeon
invited the patient to talk to the designated person about obtaining consent to take part in the trial. If the
patient was not eligible, the surgeon was required to complete the form by stating what treatment they
would advise for the patient. The form was then returned by the designated person to the YTU. For both
categories of patient, either the surgeon or the designated person gave the patient the sling immobilisation
leaflet supplied in the recruitment pack (seeAppendix 12) or the hospital equivalent leaflet.
Obtaining informed consent and randomisation
The designated person provided the patient with the patient information leaflet (seeAppendix 9) and
answered their questions before asking for their consent to participate in the trial. Although the patient
could decide immediately, it was made clear that he or she could defer the decision for up to 24 hours to
think about it further and/or discuss it with family or friends. The result of the decision was recorded by
the designated person on the consent status form (seeAppendix 15). When the patient did not consent,
the designated person requested that the orthopaedic surgeon answer the questions on the consent status
form on their advised treatment for the patient, the patient’s prefered treatment if it had been expressed
and the agreed treatment. This form and the study eligibility form were then returned by the designated
person to the YTU.
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When the patient consented to take part, he or she signed the consent form (seeAppendix 16) and
completed the baseline information form (seeAppendix 17) before randomisation. Of note is that the
baseline information form specificaly gave advice about the desirability of stopping smoking for those
who admited they smoked. The designated person then contacted the YTU either by a free telephone
service during weekday working hours or via the internet at any time to access a password-protected
randomisation service. When randomising the patient, the designated person provided key identification
information (e.g. name and date of birth) and basic descriptive details about the patient (gender, fracture
tuberosity involvement, location of recruitment: ward or fracture clinic) and answered a series of questions
in relation to study eligibility. On receipt of these details and confirmation of study eligibility and patient
consent, the random alocation (surgery or not surgery) was given. This was recorded on the baseline
information form in addition to informing the patient about the treatment that he or she was to receive.
On randomising an eligible patient, the designated person returned the study eligibility form, consent status
form, a copy of the consent form, the baseline information form and copies of the baseline radiographs to
the YTU in the Freepost envelope provided. A copy of the consent form was also given to the patient, the
original being kept in the medical notes. A leter was sent from the YTU to each trial participant to thank
them for agreeing to take part in the trial. Additionaly, each patient’s GP was notified of the patient’s
enrolment into the ProFHER trial and provided with a copy of the patient information sheet.
A flow chart showing the patient recruitment and hospital data colection processes is shown inFigure 3.
Data colection
Data handling and record keeping
Each trial participant had a unique four-digit identification number, which was prerecorded on al routine
data colection forms. A central database at the YTU was developed to prompt the sending out of patient
questionnaires and the 1- and 2-year hospital forms, usualy by the trial secretary, and to record the return
of al forms and facilitate the management of data.
Baseline data
Baseline data were sourced from the study eligibility form, baseline information form and data obtained at
randomisation (Table 2) and baseline radiographs used for classification of the fracture according to the
Neer classification.
Baseline radiographs
In each centre the designated person liaised with the radiography department to arange for the dispatch
to the YTU of copies of the radiographs used in the assessment of trial eligibility for each randomised
patient. Before sending the radiographs, either as films or electronicaly [on compact disc; Joint
Photographic Expert Groups (JPEG) files, preferably with a resolution of 300 dpi, were requested], they
were identified using a patient’s unique four-digit number but were otherwise anonymised, with the
removal of patient details such as name.
Patient questionnaires
Postal questionnaires were sent by the YTU to al patients promptly at 3, 6, 12 and 24 months’folow-up
after recruitment into the trial. Reply-paid envelopes were included at al times. The questionnaires included
the EQ-5D (at al times), the OSS and SF-12 (at 6, 12 and 24 months) and brief questions on the number of
consultations with NHS care providers (GPs, physiotherapists, district nurses, etc.), the number of hospital
atendances, use of private health care and days lost from work or other normal activities. Copies of the
3-month questionnaire and the 2-year questionnaire are provided inAppendices 18and19respectively. The
content of these questionnaires was commented on by the service users and al versions were approved by
the MREC (see, for example, substantial amendment 28 July 2010 inAppendix 7). Particular focus revolved
around the practicality and ease to the patient of answering questions on health care (care from the NHS,
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Patients with proximal humerus fractures wil be flagged up by radiology/screened
by designated person as potentialy eligible
Patients with proximal humerus fractures are assesseda by
orthopaedic surgeon for eligibility in fracture clinic trauma ward
Not eligible Eligible – obtain consentb
Patient must meet the folowing inclusion criterion before completing any forms:
‘Aged 16 or above, presenting within 3 weeks of their injury with a radiologicaly confirmed
displaced fracture of the proximal humerus with involvement of the surgical neck’
Consent No consentComplete and post to YTU:
• Study eligibility form
Complete folowing forms:
• Study eligibility form
• Consent status form
• Consent form
• Baseline form
Complete and post to YTU:
• Study eligibility form
• Consent status form
Surgical treatment Non-surgical treatment
Contact randomisation service (online or telephone) to randomise patient and post above forms to YTU
Complete forms and post to YTU:
• Inpatient episode formd 
• Physiotherapy treatment forms
Complete forms and post to YTU within 1 month from randomisation:
• Surgical formc 
• Treatment confirmation form 
• Copies of radiographs
Complete forms and post to YTU:
• 1-year folow-up form and 2-year folow-up form
Complete and post to YTU as necessary during the trial:
• Adverse event form and trial exit form
FIGURE 3Flow chart of patient recruitment and hospital data colection. a, The series of radiographs used to
confirm the fracture should be, for example, anteroposterior, axilary (or modified axilary) and scapular Y lateral
views; b, after assessing eligibility, patients may need at least 24 hours to decide whether or not to consent to take
part; c, the surgical form was also to be completed for any patient randomised to non-surgical treatment who then
underwent surgery; and d, the inpatient episode form for a patient not randomised to surgery was not required if
the patient was not admitted to hospital.
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private treatments) and impact on usual activities. To improve compliance, 2-week and 4-week reminders
were sent. Patients were also ofered by the trial manager the option of completing a shortened questionnaire
(OSS, EQ-5D and information on hospital readmissions) by telephone at 6 weeks. We also sent pre-notification
leters at al time points and used unconditional incentives of £5 at 12 and 24 months’folow-up; both
approaches are efective at improving response rates.62
The sending out of reminders was recorded as was the timing of questionnaire return. Additionaly,
patients were asked to add in‘today’s date’near the beginning of each questionnaire to record the date
when it was completed.
Hospital forms
Seven hospital forms covering various aspects of routine data colection for randomised patients were
completed by the designated person or others, as appropriate. These and two other forms for non-routine
data colection are described in the folowing section.Figure 3shows the hospital data colection process.
Treatment confirmation form
The (1-month) treatment confirmation form (seeAppendix 20) was completed at 1 month from the date
of randomisation. This multipurpose data colection and‘housekeeping’form was used (1) to establish
what treatment the patient received, including prescribed non-surgical treatment, record inpatient
TABLE 2Sources of baseline characteristics data
Characteristic Eligibility form Baseline form Randomisation
Gender ✗ (✗)
Age (date of birth) ✗ (✗)
Ethnicity ✗
Education (highest qualification) ✗
Employment ✗
Diabetes ✗
Smoking status ✗
Steroid use ✗
Health status (EQ-5D) ✗
Time since injury (date of injury) ✗
Afected shoulder ✗
Tuberosity involvement ✗ (✗)
Radiographs used ✗
Previous fractures ✗
Previous surgery for fractures ✗
Shoulder dominance ✗
Injury mechanism ✗
Previous treatment preference (✗)
Location at randomisation (fracture clinic/ward) ✗
Treatment alocation ✗ ✗
Date of randomisation ✗
(✗), data not used for presenting baseline characteristics.
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admission and determine the intended or actual start date of physiotherapy and (2) to prompt the dispatch
of the baseline radiographs and, when appropriate, the completion and return of the surgical form
(seeAppendix 21) and the inpatient episode form (seeAppendix 22) to the YTU. The questions on
non-surgical treatment and the use of other imaging investigations to determine patient eligibility, added
very shortly after the start of the trial, were prompted by feedback from a site visit to one centre and an
early TSC meeting respectively.
Surgical form
It was anticipated that the surgical form (seeAppendix 21) for the patient would be completed by a
member of theatre staf. This form colected basic data on the type of surgery performed and key details
relating to stafing and costs. Details on surgical techniques, such as surgical approach, were purposefuly
not colected. It was requested that the implant label was stuck on the back of the form. Also colected
was information on unexpected procedures that occured during the operation.
Inpatient episode form
The inpatient episode form (seeAppendix 22) was completed at the conclusion of the patient’s inpatient
episode in the orthopaedic department. This form was important for colecting data on secondary
outcomes such as mortality, surgical complications and treatment for shoulder-related complications and
was the only source for colecting medical complications prior to discharge. It also provided a record of
where the patient was discharged to and whether or not they had treatment for a serious newly
diagnosed medical complication.
Physiotherapy treatment forms
The physiotherapy treatment log (seeAppendix 23) was completed for each session of physiotherapy
by the physiotherapist providing treatment to the patient. In designing this form, consideration was given
to the normal record keeping of physiotherapists so that the completion of the form would require litle
additional efort. This included tick boxes for registering the use of basic categories of interventions, with
space for recording other interventions, including whether or not there was any substantial diference
from the ProFHER physiotherapy protocol. As indicated earlier, there was a question on whether or not
the patient had performed their home exercises plus a text box for any comments. Key data on the
physiotherapist’s grade, the location of the session and session duration were colected for inclusion in
the cost-efectiveness analysis. Piloting of draft data colection forms was undertaken at the lead centre
by the lead physiotherapist (LG) to identify and resolve any problems before the start of the trial.
At the end of treatment, the physiotherapy treatment log–completion of treatment (‘end of treatment’)
form (seeAppendix 24) was usualy completed by the physiotherapy contact at the centre in charge of
co-ordinating data colection. This form captured the reasons for discharging a patient when treatment was
and was not completed. The set of physiotherapy logs and the end of treatment form were then sent to
the YTU.
One-year and 2-year folow-up forms
The designated person was responsible for the completion of the 1-year folow-up form (seeAppendix 25)
and the 2-year folow-up form (seeAppendix 26) at the appropriate times for each patient. These forms
were designed to colect information on complications, treatments and admissions that the patients
may have had after their initial treatment and, for the 1-year form, their inpatient episode. Hospital
admission for another fracture was recorded on both forms.
Adverse event reporting
Hospitals were provided with adverse event (reporting) forms (seeAppendix 27) to record adverse events
and to guide them in determining whether an event was a serious or a non-serious event. For a SAE,
the form had to be completed and faxed to the trial manager within 24 hours of the local investigator
becoming aware of the SAE. When the adverse event was not serious, the form had to be faxed within
5 days. Adverse events were judged also in terms of whether they were related or not to the patient
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taking part in the trial (research procedures) and whether they were‘expected’or‘unexpected’. Unless
the patient had died, the trial manager contacted the designated person 1 month after the original
notification to request a completed review of adverse event form (seeAppendix 28).
Al adverse event and review forms were circulated to the chief investigator (AR) and two members of the
TMG (HH and DT) for their feedback and consideration of whether or not any action should be taken,
including reporting to the MREC. As per protocol, reports of al related and unexpected SAEs were
submited by the chief investigator to the MREC within 15 days of becoming aware of the event.
The sponsor representative was also informed as these events arose. Details of al adverse events by
treatment group were provided for review at DMEC meetings. The DMEC also reviewed adverse events
after scrutiny by the TMG on a case-by-case basis. Count data of al adverse events, divided into
non-serious and serious, were provided in the annual reports to the MREC. The funder (the National
Institute for Health Research) was notified in the 6-monthly progress reports of the number of adverse
events reportable to a regulatory body occuring in the last reporting period.
Trial exit form and withdrawal from folow-up
The trial exit form (seeAppendix 29) was provided to facilitate notification and documentation when a trial
participant did not want to continue with the trial or was no longer able to continue taking part in the
trial. The key role of this form was to ensure that the trial participant or his or her family were not
approached again. When appropriate, the trial manager checked with the participant whether or not he or
she was happy for the colection of hospital folow-up data to continue.
Questionnaire on use of the ProFHER trial sling immobilisation
leaflet and immobilisation
At the end of trial recruitment, a two-page questionnaire on sling use was sent to the designated person
at each participating centre (seeAppendix 30). The questions on the first page were aimed at gathering
evidence on the implementation of a key standard of care by obtaining feedback on the use of the sling
leaflet provided for the ProFHER trial or alternative leaflets on care during immobilisation provided to
patients eligible for participation in the trial. The second page asked about immobilisation (type and
duration) typicaly provided to non-surgical patients and to surgical patients after surgery who would have
been eligible for the ProFHER trial. This was to obtain additional insights on this aspect of care, in
particular on post-surgical immobilisation, for which we had not colected patient data.
Analysis of the questionnaire
The contents of the two pages of this questionnaire were processed and analysed separately. For the first
page, draft analysis tables and criteria for assessment and interpretation of responses and alternative
leaflets were generated by one TMG member (HH), who remained blinded to the completed
questionnaires. These tables were completed by the trial manager (SB). Copies of any alternative leaflets
were provided to HH, who summarised their contents.
For the second page, al of the responses were colated into a Microsoft Excel 2010 database (Microsoft
Corporation, Redmond, WA, USA), which was then summarised by one person (HH). Feedback on the
categorisation and reporting of the findings was obtained from the physiotherapy lead (LG).
Data checks and‘cleaning’: specific actions
Data checks alerted us to recurent problems with completion of two hospital forms during trial
recruitment. Early on, missing data for the consent status form in terms of which treatment surgeons
would advise for non-consenting patients was remedied by adding in a box to alow for uncertainty
(seeAppendix 15). The surgical form (seeAppendix 21) proved troublesome in terms of data entry for
DOI: 10.3310/hta19240 HEALTH TECHNOLOGY ASSESSMENT 2015VOL. 19 NO. 24
© Queen’s Printer and Controler of HMSO 2015. This work was produced by Handolet al.under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the ful report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27
numbers of personnel involved, which were important data for the economic analysis. A folow-up visit to
centres by the trial manager and advice in a monthly newsleter were strategies used to address this.
During data‘cleaning’, two sources of problems were identified and corective measures taken. A scrutiny
of‘other reasons to exclude the patient’in the study eligibility forms revealed a very few cases in which
lack of patient consent was recorded rather than non-eligibility. There were also some sequence and
duplication problems in the recording of dates of physiotherapy sessions in the physiotherapy treatment
logs (seeAppendix 23).
Processing of data on complications and new therapy
including surgery
A file of blinded data for each trial patient from the relevant fields in three forms [inpatient episode form
(seeAppendix 22), 1-year folow-up form (seeAppendix 25) and 2-year folow-up form (seeAppendix 26)]
was compiled by the trial statistician (AK) to facilitate the independent screening and coding of
complications and new therapy by two raters (HH and AR). Any disagreement on the processing, coding
and categorisation of these items was resolved by discussion.
In the first stage, the complications and associated treatments were grouped into seven categories:
complications related to the proximal humeral fracture and/or its treatment, gastrointestinal events, cardiac
and peripheral vascular events, malignancy, fals and other fractures, respiratory events and‘other’.
Processing of the first of these categories is described in the folowing section.
Surgical and other shoulder fracture-related complications, increased/new
shoulder-related therapy and secondary surgery to the shoulder
A secondary file containing information on these complications and their treatment was generated to link
each complication with the recorded treatment on the hospital form, when available, and to give information
on the‘outcome’of each complication or treatment. This facilitated coding of the complications and the
summarisation of treatment. It also facilitated the identification and coding of complications in which
only treatment had been reported; each instance of this resulted in a new entry in the trial database by
the statistician.
The categories used to code the complications were based primarily on the descriptions presented in the
folow-up forms, with the decision taken to distinguish, when possible, between nonunion and malunion
(Table 3). Additional categories were added, most notably‘post-traumatic stifness’, which included
reported reference to‘frozen shoulder’. Rather than speculate, we coded al instances in which there was
insuficient information as‘unclear’. Each complication was reported separately; thus, new entries in the
definitive database were generated in the few cases in which two complications were described together.
Brief descriptions were generated for increased/new therapy for shoulder-related complications, types of
shoulder surgery (based on categorisation by AR) and information on‘outcome’. Our interpretation was
purposefuly cautious. We did not complete missing entries for treatment but noted mention of treatment
or atendance of folow-up clinics under‘outcome’.
We discarded entries for complications and treatment subsequent to definitive treatment for a
complication. The information on these was instead summarised under‘outcome’, which was categorised
according to the definitions listed inTable 4.
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TABLE 3Descriptions of complications
Complications as described on forms
Complications as described in
coding and presentation
Surgical site infection requiring treatment with antibiotics/further surgery Surgical site infection
Haematoma formation at surgical site Haematoma formation (not used)
Nerve injury Nerve injury
Implant-related complication/failure Implant-related complication/failure
Dislocation/instability Dislocation/instability
Metalwork problems requiring further surgery Metalwork problems
AVN of the humeral head AVN
Nonunion/malunion requiring further treatment Nonunion
Malunion
Other Post-traumatic stifness
Rotator cuf tear
Complex regional pain syndrome
Pain/severe pain
Impingement
Unclear
TABLE 4Coding scheme for‘outcome’of a complication or treatment for a complication
‘Outcome’category Definition
No information No information on outcome; however, other information on treatment and
rehabilitation may be available. Although resolution of some complications would be
very likely (e.g. metalwork impingement by metalwork removal; no reference to
subsequent treatment for unresolved surgical site infection), explicit mention of this
was required
Not treated Clear indication that complication (usualy malunion) was not treated nor is‘under
review’
Resolved Explicit statement that complication resolved. This includes cases in which
physiotherapy was required to resolve initial problems after secondary surgery
Resolving Explicit statement that complication was resolving (final resolution was not assumed)
Under review Clear indication that original (primary) complication was being monitored/investigated,
with or without reference to future new treatment/surgery
Unresolved Consequence of definitive treatment (mainly surgery) in which either the original
problem persisted or a new problem arose
Unresolved–further surgery As above, but further surgery reported
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Medical complications prior to discharge
Data for this secondary outcome were colected from the inpatient episode form only (seeAppendix 22).
These were grouped in the categories described on this form, with any appearing in the two‘other’
categories (‘other hospital-acquired infection’and‘other serious event’) being placed into one of
six groups: gastrointestinal events, cardiac and peripheral vascular events, malignancy, fals and other
fractures, respiratory events and others.
Treatment for serious newly diagnosed medical complications
Data on these complications were colected only when they were first recorded, with any subsequent
reports of recurence discarded. Each newly diagnosed complication was placed into one of the six
aforementioned groups.
Further fractures
Data on subsequent fractures were colected on a most appropriate mention basis, with other reports
relating to the same fracture discarded. A secondary table with the descriptions of the fractures and source
key information was compiled and the fractures were independently grouped by the two raters into the
same four categories used for grouping fractures reported as adverse events (see folowing section):
shoulder, wrist, hip and other.
Adjusting the database for complications and treatment
After screening and coding, the database was amended to reflect the decisions made and coding of the
various complications and treatments. One rater (HH) coded the discarded entries, which for reporting
purposes were honed down to four categories by AK: repeat information, subsequent/additional
information on treatment for a complication, irelevant content and, for further fracture data, routine
folow-up.
Adverse events classification
A protocol was developed to inform the reporting and classification of adverse events. This established
the folowing:
l Appraisal of adverse events would be based only on the adverse event reporting forms and thus
would be independent of information on complications from hospital forms such as the 1-year
folow-up form.
l Events reported after 2 years’folow-up would not be included.
l We would present separate results, divided by treatment group, for SAEs and non-SAEs. In these two
categories, we would report the number of participants who had an adverse event and, as some
participants had multiple events, also the number of adverse events.
l We would report the classification of the adverse event based on the judgement of the principal
investigator at the centre reporting the adverse event of whether or not the event was (a) related and
(b) expected.
l Two reviewers (HH and AR) would independently group, without knowledge of treatment alocation,
the adverse events based on the categories used on the hospital forms. Facilitated by the trial manager
(SB), consensus would be reached through discussion when there was disagreement on the categories
and on the brief descriptions of the events added to the data file by the reviewers.Box 1presents the
agreed categories.
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Baseline radiographs: processing and quality assessment
Initial processing of the radiographic images, al of which were in digital format, involved checks on
blinding (removal of patient and hospital details), labeling with the corect patient identifier and ensuring
that the images could be accessed and transfered to a YTU computer and CD. The designated person
and/or the contact in the radiography department was contacted to resolve dificulties at individual
centres. For blinding purposes, before sending out for quality checks (see folowing paragraph) and
eventual classification, the sets of radiographs were renumbered using a three-digit code (e.g. 039), with
leters used to label each of the radiographs within a set (e.g. 039a, 039b).
At various times during trial recruitment, and subsequently to complete the process, there was a review of
the quality of the copies of the radiographic images for each trial participant provided by trial centres. This
aimed to facilitate the Neer classification of the study fractures by two independent assessors by ensuring
that such images were available and of suficient quality for this purpose. We undertook a two-phased
assessment for each centre whereby the quality of the radiographs for the first five participants at each
centre was independently assessed by two orthopaedic surgeons, one of whom was the chief investigator
(AR) and other of whom was a principal investigator (JC); the assessment of the radiographs of subsequent
participants from each centre was caried out by AR only. When there were concerns about the quality
of the radiographs being provided, this was to be raised by AR with the principal investigator of the
participating centre to see whether or not beter copies could be obtained. The criteria that were used to
judge the quality of the radiographs were:
l Are there at least two projections in planes perpendicular to each other? (yes/no)
l Are the proximal humerus and glenohumeral joint seen on each projection? (yes/no)
l Is it possible on the two views to clearly identify the shaft, greater tuberosity, lesser tuberosity, head of
the humerus and the glenohumeral joint? (yes/no).
BOX 1Categories for coding adverse events
1. Shoulder-related complications (e.g. infection, implant complication, frozen shoulder),awhich are
subgrouped according to whether or not there is:
i. surgery to the shoulder (if there is any mention of surgery to the shoulder)
i. non-surgical treatment/investigation of the shoulder.
2. Medical complications/conditions that do not involve the shoulder, which are subgrouped according to
whether or not it is:
i. non-serious
i. serious: non-fatal
ii. serious: fatal.
3. Any other fractures, which are subgrouped according to whether or not they involve the:
i. shoulder
i. wrist
ii. hip
iv. other.
a This should exclude a second shoulder fracture as this is not a complication that is related to the
original injury.
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The review also included monitoring for a clear breach of the main inclusion criterion; thus, fractures
should involve the surgical neck. The trial manual alerted centres to this intention to‘monitor the eligibility
of patients entering the trial’, stating also that any findings from the interim review would‘not be refered
back to individuals but applied generaly’. However, there was the potential to report to the TSC for
consideration of discontinuation of recruitment at a site where there were ongoing problems with
poor-quality images and serious concerns about patient eligibility.
On discussion with the TSC of the interim findings on radiograph quality, the independent orthopaedic
surgeon member of the TSC (Professor Andrew Car) volunteered to act as a third rater for resolving
disagreements in the final stage of the quality audit. This staged audit identified 46 radiograph sets in
which at least one out of the three quality criteria had not been met, as judged either by AR alone (n=28)
or, after arbitration by AC, by two independent raters (n=18). This meant that 18% of the baseline
radiograph sets were likely to present future dificulties for the independent Neer classification of fractures.
Post-recruitment survey of hospital radiographers
On consideration of the interim findings on radiograph quality, which showed that, at that stage, over
one-quarter of the radiographic sets did not meet our quality criteria, the TSC advised that we contact the
participating centres to obtain feedback on this aspect of the trial. We did this by sending out a survey in
December 2011 to the named radiographers of the individual sites (seeAppendix 31). As stated in our
covering leter, this survey aimed to obtain their specialist feedback on a key part of the care pathway for
people with proximal humeral fractures. Thus, we had extended the scope of the questionnaire to obtain
a beter understanding of the issues relating to imaging for these patients, including the routine use of
computerised tomography (CT) scans. The results of this survey are reported inAppendix 32.
In connection with the issues relating to assessing radiograph quality for suitability for the Neer
classification, the survey feedback prompted two actions. First, the wording of the second two criteria was
revised to make clearer what was required; these were piloted subsequently, with the final versions
appearing in the proforma used for the Neer classification. Second, based on suggestions for other quality
criteria, another question was included in the proforma that asked about overal image quality, taking into
consideration exposure and patient positioning.
Preparations for the independent assessment and classification
of radiographs based on the Neer classification
Key to the Neer classification of the radiographs is the facility to assess whether or not there is
≥1 cm displacement of parts, with clear delineation of the edge of the bones. (The assessment of angular
displacement is fortunately not size or scale independent.) Hence, to measure this displacement, a life-sized
image or a scale is required. In retrospect it was discovered that, for some Picture Archiving and
Communications Systems (PACS), the scale as wel as patient details were removed when the images were
anonymised. On investigating this, we discovered that it could be remedied by saving the radiograph image
as a picture and then removing the patient details manualy. However, this may not be an acceptable
procedure at some hospitals and is stil subject to scaling erors. We learnt, through discussions with a
radiographer (Brian Cox) at James Cook University Hospital, Middlesbrough, that a calibration object such
as a scaling bal, placed in an appropriate location, is required at image acquisition to enable the accurate
measurement of scale. We identified two albeit suboptimal approaches of limited applicability to assist the
assessment of linear displacement in our study sample:
l For a limited number of radiographs for which standard left/right markers are used, the stems of
the‘L’and‘R’are 9 mm. It was therefore possible to measure the stem of the‘L’or‘R’marker on the
image to adjust for the scale when measuring for displacement.
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l Software such as Microsoft Ofice Picture Manager (Microsoft Corporation, Redmond, WA, USA) could
be used to alow a JPEG file to be opened and viewed at the original size that it was saved at. (This stil
may not be a true result if the image was manipulated in some way before it was saved.)
In addition to being able to present the best-quality images available with the right scale to accurately
assess displacement, we also considered what training was necessary for the two raters who would be
reviewing the radiographs. We therefore revisited a systematic review22and various individual reports of
studies investigating inter-rater and intra-rater reliability for classifying proximal humeral fractures using the
Neer system, noting in particular the approaches taken for assessing displacement and training.19,63–65
We also approached Stig Brorson (Herlev University Hospital, Herlev, Denmark) for details of the training
programme used in his RCT, which showed that interobserver agreement is improved with training.65
Brorson reported that the authors of the RCT had chosen to include only material from Neer’s original
articles (22 and 29 March 2012, personal communication).18,66Eighteen ilustrations from the first article
and two from the second article were reproduced and incorporated into two 45-minute teaching sessions.
We decided against adopting this approach as we considered that using actual ProFHER trial images was
more relevant for facilitating the training of the two raters. This decision was consistent with our aim to
have continuity in the images available for the decision-making process–from those seen by the recruiting
surgeon to those seen by the independent assessor.
When considering which of the baseline radiographic images should be available for the two raters to
review for the Neer classification we decided that it would be in excess to have more than four images
per set of radiographs. This is because we expected that some images were poorer-quality duplicates
of standard views or uninformative radiographs that would not contribute to the Neer classification.
On provision of the baseline radiographs and a table listing al of the radiograph image sets, AR selected
the best-quality projection (based on prespecified criteria) in each perpendicular plane. The duplicates in
these planes that were of poorer quality were removed, with the reasons for exclusion being recorded.
The decisions that AR made were checked by two others (SB and HH), who sought clarification
when necessary.
We developed a protocol, training presentation and data colection tool (proforma) to aid in the
description and assessment of the quality of each set of radiographs and the Neer classification of the
study fractures. Throughout, the purpose of quality assessment was to establish if the sets of radiographs
were adequate to permit their classification and not if they were adequate for use in clinical practice.
As wel as colecting data on the displacement of structures according to the Neer classification, the
proforma facilitated the recording of‘involvement’(any indication of a fracture), a fuly displaced surgical
neck fracture (bone parts/fragments do not overlap), whether or not the head segment was in varus or
valgus and whether or not the fracture was impacted.
The training presentation and data colection process were piloted with the help of two senior orthopaedic
registrars at the James Cook University Hospital, Middlesbrough, on 6 August 2012. For this pilot, AR
selected 10 sets of patient radiographs based on the folowing criteria: with and without adequate markers
(i.e. with markers that were added to the cassete at the time of image acquisition and with markers that
were added using PACS); a selection of two, three and four views (which for the last should include a
couple with similar anteroposterior views); and a choice of two- compared with three- and four-part
fractures so that some would have tuberosity involvement. After AR had delivered the presentation, which
described the objectives of the Neer classification study and provided training in the interpretation and
classification of radiographs, he and the two registrars independently classified 10 sets of radiographs
according to the Neer classification using the proforma. A ruler and goniometer were made available to
the raters, who were advised to use these. The trial manager (SB) acted as a general facilitator, including
timing the various processes and documenting the proceedings, including the inter-rater diferences after
each of the two batches of five assessments. This enabled the three raters to discuss their diferences
and decide on the Neer classification for each fracture. The insights from the pilot led to some adjustment
of the proforma (seeAppendix 33for the final version), clarification of the advice on interpretation,
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development of a briefing document on the Neer classification of radiographs and a form to record
discrepancies between the two raters and their resolution and development of a realistic timetable for the
main assessment of the baseline radiographs and classification of the study fractures according to Neer.
The main Neer classification of the radiographs was undertaken by two independent consultant
orthopaedic surgeons (from the UK) who were experienced in treating proximal humeral fractures and
who had comparable experience to that of surgeons in the ProFHER trial. This difered from our original
intention to use an independent panel of musculoskeletal radiologists or orthopaedic surgeons with
specific expertise in the Neer classification. However, it was in keeping with the pragmatic design of
the trial and, from our experience of the audit described earlier and the literature, it was clear that
involving more raters does not improve agreement. When agreeing to perform this role, both surgeons
confirmed that they had the writen support of their clinical director to commit to the requirements for
participation. This comprised atendance at the training day (held on 17 January 2013), protected clinic
time (five sessions: 20 hours) to undertake assessment of the radiographs and up to a day to achieve
consensus when required. They also confirmed that they would‘complete the assessment of radiographs
for the whole study population according to the agreed procedures and undertake to deliver a definitive
categorisation of the fractures, if necessary via an adequately-documented consensus process, within
the timeline for this study’(leter from AR to the two orthopaedic surgeons seting out the terms,
6 November 2012).
The same format and number of sets of radiographs were used for the main study training day as in the
pilot. Thus, after the presentation by AR with examples, the two independent surgeons looked at the first
five sets of radiographs and reviewed discrepancies; this was folowed by assessment of the second five
sets of radiographs, with a review of discrepancies. Subsequently, the surgeons returned copies of their
completed data colection forms to SB, who colated the results and returned a table indicating where
there were diferences in the Neer classification for individual fractures. The two surgeons then met up to
resolve these diferences and document the decisions behind each of the final verdicts.
FURTHER METHODS
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Chapter 4Results: baseline characteristics of
patients, delivery of interventions and return
of questionnaires and other data
Patient recruitment
The first patient was recruited on 17 September 2008, which was during the short 3-month pilot phase,
and the 250th patient was recruited on 13 April 2011. Thus, patients were recruited over a 31-month
period; the trial stopped when the recruitment target was met.Figure 4shows the monthly recruitment
and accrual set in the context of the revised projections submited with our successful application for an
extension to recruitment from the original 18 months (from the oficial start time of the main trial
recruitment of 1 October 2008) to 36 months.
Ultimately, 32 out of 35 UK-based centres that had been set up to recruit after approvals had been
received recruited a patient. One of the three centres that did not recruit had started screening but
identified only ineligible patients. A list of the participating centres, and the primary care trusts for which
R&D approval for folow-up was obtained, is given inAppendix 34. A ful list of health-care colaborators at
the participating centres is presented inAppendix 35.
The 35 participating centres recruited a median of five patients [interquartile range (IQR) 2–9 patients].
The lead centre, James Cook University Hospital, Middlesbrough, recruited 43 patients and achieved the
original centre recruitment target of one patient per month.Figure 5shows the distribution of number of
patients recruited by centre, ordered by when each site was set up to recruit.
Location in hospital of patients at recruitment
The location (fracture clinic or ward) at which each patient was recruited from was recorded at the time
of randomisation. These data showed that 36 (14%) patients had been admited and the rest were
outpatients atending a fracture clinic. Of these 36, 15 were randomised to‘surgery’(12% of the
125 patients randomised to surgery) and 21 were randomised to‘not surgery’(17% of the 125 patients
randomised to‘not surgery’).
Population sample
Based on the return of corectly completed study eligibility forms and consent status forms, 1250 patients
with a suitable fracture were identified, of whom 563 (45%) were considered eligible; of these 563
patients, 250 (44%) consented to take part in the study. Thus, of 1250 patients identified with a suitable
fracture, 250, or 20%, were enroled into the study. This figure compared favourably with our original
expectation to recruit only 11% of patients with fracture types suitable for inclusion in the trial.
Reasons for exclusion
The reasons for excluding patients (790 reasons for 687 ineligible patients), as listed on the study eligibility
form (seeAppendix 5), are shown inTable 5.
The numbers of ineligible patients and the reasons for exclusion at individual centres and overal during the
recruitment period were monitored on a regular basis by the TMG. In particular, there was an ongoing
review of‘other’reasons for exclusion (option j), which might indicate potential problems at centres,
including lack of surgeon equipoise (‘protocol violation’). These were folowed up when deemed necessary.
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FIGURE 5Patient recruitment by centre listed in order of when the centre was set up to recruit.
TABLE 5Reasons listed for exclusion
Reason for exclusion (more than one reason may apply) Number excluded
Associated dislocation of the injured shoulder joint 101
Open fracture 2
Other upper limb fractures 72
Clear indication of surgery 87
Comorbidities that preclude surgery or anaesthetic 179
Pathological fracture 5
Terminal ilness 5
Patient not resident in hospital catchment area 28
Lack of mental capacity 116
‘Other’reason 195a
a For 159 of these no other reason was given.
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Exclusions because of a patient’s lack of mental capacity to understand the trial and comply with trial
procedures (option i) were selected for special focus by the TSC, which was provided with regular reports
of the percentage of overal exclusions for this item. There was a consistent rate of between 14% and
18% of the total reasons given at each monitoring period and the initial concern regarding inappropriate
exclusion based on an excess of people excluded for mental incapacity was alayed.
At the end of recruitment and colection of al trial eligibility forms, two raters (AR and HH), who were
blind to centre, independently assessed the‘other’reasons listed for excluding patients (option j; see
Appendix 5). They concluded that 117 patients (17% of a total of 687 ineligible patients) were excluded
because of a lack of equipoise. As these 117 patients were otherwise eligible for the trial, a more
appropriate statistic is that 17% of 680 (563+117) patients who were actualy‘eligible’for the trial were
not approached for consent because of a lack of surgeon equipoise. This is examined in more detail in
Chapter 6.
Patient consent
The percentage of eligible patients who consented to take part in the trial varied substantialy in the
32 centres that recruited a patient, from 20% to 100% (Figure 6). Patient treatment preference data were
colected but otherwise, patients were purposefuly not asked for their reasons for not consenting. It is
likely that there are various reasons for this variation in the rate of consent. It should be noted that al of
the designated persons involved in consenting were provided with advice and training on the process
involved but stil had variable skils and experience in recruiting patients into a trial.
Participant flow
The flow of patients from screening to the 2-year folow-up as wel as the data used for the primary
analysis are summarised in a Consolidated Standards of Reporting Trials (CONSORT) flow diagram in
Figure 7. Of the 250 patients randomised in equal numbers to surgery or not surgery, 215 (86%) were
available for analysis at 2 years’folow-up (85% in the surgical arm, 87% in the non-surgical arm).
The trial was designed to alow for a 20% dropout rate.
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FIGURE 6Non-consenting and consenting patients by centre.
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Assessed for eligibility
(N = 1250)
Eligible
(n = 563)
Patient non-consent (n = 313)
Randomised
(n = 250)
Ineligible (n = 687)
Reason(s) for exclusion:
• Associated dislocation, n = 101
• Open fracture, n = 2
• Other upper-limb fracture, n = 72
• Clear indication for surgery, n = 87
• Comorbidities that preclude surgery, n = 179
• Pathological fracture, n = 5
• Terminal ilness, n = 5
• Not resident in trauma centre area, n = 28
• Lack of mental capacity, n = 116
• Other, n = 195
Alocated to surgery
(n = 125)
Alocated conservative treatment
(n = 125)
Received surgery (n = 109)
Did not receive surgery (n = 16)
  Difference in surgeon opinion, n = 2
  Patient changed mind, n = 8
  Patient unfit for surgery, n = 6
Withdrew from questionnaires (n = 1)
Died (n = 1)
Withdrew from questionnaires (n = 0)
Died (n = 2)
Withdrew from questionnaires (n = 2)
Died (n = 4)
Withdrew from questionnaires (n = 1)
Died (n = 2)
Withdrew from questionnaires (n = 1)
Died (n = 0)
Withdrew from questionnaires (n = 0)
Died (n = 1)
Withdrew from questionnaires (n = 1)
Died (n = 1)
Withdrew from questionnaires (n = 1)
Died (n = 3, one had already withdrawn)
Received conservative treatment (n = 123)
Received surgery (n = 2)
  Patient changed mind, n = 1
  Surgeon changed mind, n = 1
(Surgery was reported for four further patients later
in the trial folowing unsuccessful conservative
treatment; these were not considered crossovers)
Centres providing conservative treatment (n = 27)
  Number of patients for each centre
  [median = 4 (IQR: 2–6), min. = 1, max. = 22]
Surgeons (n = 2)
  Number of patients for each surgeon
  [median = 1 (IQR: 1–1), min. = 1, max. = 1]
Physiotherapists (n = 163)
  Number of sessions for each physiotherapist
  [median = 4 (IQR: 2–8), min. = 1, max. = 41]
Centres performing surgery (n = 30)
  Number of patients for each centre
  [median = 3 (IQR: 1–5), min. = 1, max. = 21]
Surgeons (n = 66)
  Number of patients for each surgeon
  [median = 1 (IQR: 1–2), min. = 1, max. = 9]
Physiotherapists (n = 165)
  Number of sessions for each physiotherapist
  [median = 5 (IQR: 2–8), min. = 1, max. = 78]
3-month questionnaire
  Received (n = 111)
  No response (n = 13)
   3-month questionnaire
Received (n = 114)
No response (n = 9)
   6-month questionnaire
Analysed (n = 113)
Excluded from analysis (n = 0)
No response (n = 8)
   6-month questionnaire
Analysed (n = 119)
Excluded from analysis (n = 0)
No response (n = 4)
   12-month questionnaire
Analysed (n = 111)
Excluded from analysis (n = 0)
No response (n = 4)
   12-month questionnaire
Analysed (n = 114)
Excluded from analysis (n = 1)
  Insufficient data, n = 1
No response (n = 6)
   24-month questionnaire
Analysed (n = 106)
Excluded from analysis (n = 3)
   Insufficient data, n = 3
No response (n = 3)
   24-month questionnaire
Analysed (n = 109)
Excluded from analysis (n = 0)
No response (n = 9)
FIGURE 7Participant flow through the trial. Max., maximum; min., minimum.
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Baseline characteristics: al screened patients
The characteristics of the screened, ineligible, eligible consenting and eligible non-consenting patients at
baseline are presented inTable 6. Eligible patients tended to be younger, presenting slightly later folowing
injury, and were more likely to have fractures that involved tuberosities than ineligible patients. There were
no marked diferences between consenting and non-consenting patients.
Baseline characteristics of randomised patients
Consenting patients were stratified by tuberosity involvement (yes or no) at randomisation. Their baseline
demographics and fracture details by treatment group are given inTables 7–9. The treatment groups
appeared to be balanced for these characteristics, including Neer category, with the exception of smoking
status. Patients in the non-surgical group were more likely to be smokers (smoking status was included in a
sensitivity analysis for the primary outcome; seeChapter 5). The same observations applied to the baseline
characteristics of the 215 patients with OSS data at 24 months (seeTables 7and8).
TABLE 6Baseline characteristics (different populations)
Characteristic
Screened
(n=1250)
Ineligible
(n=687)
Eligible (n=563)
Non-consenting
(n=313)
Consenting
(n=250)
Gender,n(%)
Male 318 (25.4) 185 (26.9) 75 (24.0) 58 (23.2)
Female 924 (73.9) 496 (72.2) 236 (75. 4) 192 (76.8)
Missing 8 (0.6) 6 (0.9) 2 (0.6) –
Age (years)
n 1192 644 298 250
Mean (SD) 69.03 (14.85) 70.45 (16.41) 68.48 (13.04) 66.01 (11.94)
Median (min., max.) 71.12
(16.09, 106.19)
73.61
(16.09,106.19)
70.56
(18.42, 98.39)
66.88
(24.63, 92.04)
Time since injury (days)a
n 1250 687 313 250
Mean (SD) 5.21 (4.92) 5.03 (5.01) 5.19 (4.72) 5.74 (4.89)
Median (min., max.) 3 (0, 21) 3 (0, 21) 4 (0, 21) 4 (0, 21)
Tuberosity involvement,n(%)
Tuberosity not involved
(or missing data)
417 (33.4) 276 (40.2) 84 (26.8) 57 (22.8)
Greater tuberosity 536 (42.9) 255 (37.1) 162 (51.8) 119 (47.6)
Lesser tuberosity 62 (5.0) 36 (5.2) 16 (5.1) 10 (4.0)
Greater and lesser tuberosity 235 (18.8) 120 (17.5) 51 (16.3) 64 (25.6)
Max., maximum; min., minimum.
a This is consistent with the inclusion criterion for presentation of patients within 3 weeks of their injury.
RESULTS: RECRUITMENT, INTERVENTIONS AND DATA RETURN
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TABLE 7Baseline characteristics (demographics) at randomisation and 24 months’folow-up
Characteristic
Al randomised
Those with primary outcome (OSS)
data at 24 months
Surgery
(n=125)
Not surgery
(n=125)
Surgery
(n=106)
Not surgery
(n=109)
Gender,n(%)
Male 28 (22.4) 30 (24.0) 26 (24.5) 25 (22.9)
Female 97 (77.6) 95 (76.0) 80 (75.5) 84 (77.1)
Age (years)
n 125 125 106 109
Mean (SD) 66.60 (11.80) 65.43 (12.09) 66.18 (11.1) 65.79 (11.97)
Median (min., max.) 67.42
(27.04, 92.04)
66.12
(24.63, 89.02)
66.67
(37.09, 87.76)
66.77
(31.33, 89.02)
Age (group),n(%)
<65 years 51 (40.8) 57 (45.6) 45 (42.5) 50 (45.9)
≥65 years,n(%) 74 (59.2) 68 (54.4) 61 (57.5) 59 (54.1)
Ethnicity,n(%)
White 124 (99.2) 125 (100.0) 105 (99.1) 109 (100.0)
Black 1 (0.8) 0 (0.0) 1 (0.9) 0 (0.0)
Asian 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Chinese 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Education,n(%)
No formal qualifications 66 (52.8) 68 (54.4) 53 (50.0) 57 (52.3)
Some qualifications/no degree 47 (37.6) 43 (34.4) 43 (40.6) 38 (34.9)
Degree or higher 12 (9.6) 14 (11.2) 10 (9.4) 14 (12.8)
Employment,n(%)
Part-time 12 (9.6) 7 (5.6) 12 (11.3) 7 (6.4)
Ful-time 17 (13.6) 22 (17.6) 16 (15.1) 19 (17.4)
Self-employed 1 (0.8) 3 (2.4) 1 (0.9) 3 (2.8)
Retired 78 (62.4) 82 (65.6) 64 (60.4) 72 (66.1)
Not employed but seeking work 3 (2.4) 1 (0.8) 3 (2.8) 1 (0.9)
Other 12 (9.6) 9 (7.2) 9 (8.5) 6 (5.5)
Missing 2 (1.6) 1 (0.8) 1 (0.9) 1 (0.9)
Diabetes,n(%)
Yes 18 (14.4) 13 (10.4) 15 (14.2) 11 (10.1)
No 106 (84.8) 111 (88.8) 90 (84.9) 97 (89.0)
Missing 1 (0.8) 1 (0.8) 1 (0.9) 1 (0.9)
continued
DOI: 10.3310/hta19240 HEALTH TECHNOLOGY ASSESSMENT 2015VOL. 19 NO. 24
© Queen’s Printer and Controler of HMSO 2015. This work was produced by Handolet al.under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the ful report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
TABLE 7Baseline characteristics (demographics) at randomisation and 24 months’folow-up (continued)
Characteristic
Al randomised
Those with primary outcome (OSS)
data at 24 months
Surgery
(n=125)
Not surgery
(n=125)
Surgery
(n=106)
Not surgery
(n=109)
Smoking status,n(%)
Yes 24 (19.2) 40 (32.0) 20 (18.9) 33 (30.3)
No 96 (76.8) 81 (64.8) 82 (77.4) 72 (66.1)
Missing 5 (4.0) 4 (3.2) 4 (3.8) 4 (3.7)
Steroid use,n(%)
Yes 6 (4.8) 7 (5.6) 6 (5.7) 6 (5.5)
No 118 (94.4) 116 (92.8) 100 (94.3) 102 (93.6)
Missing 1 (0.8) 2 (1.6) 0 (0.0) 1 (0.9)
Health Status (EQ-5D index)
n 123 121 104 106
Mean (SD) 0.43 (0.37) 0.38 (0.37) 0.43 (0.35) 0.35 (0.36)
Median (min., max.) 0.59 (–0.36, 1)a 0.26 (–0.35, 1)a 0.59 (–0.35, 1)a 0.26 (–0.35, 1)a
Max., maximum; min., minimum.
a An EQ-5D score of 1 (perfect health) was reported for 11 surgery group patients and 13 non-surgery group patients.
It is possible that this applied to their pre-fracture status.
TABLE 8Baseline characteristics (fracture data) at randomisation and 24 months’folow-up
Characteristic
Al randomised
Those with primary outcome (OSS)
data at 24 months
Surgery
(n=125)
Not surgery
(n=125)
Surgery
(n=106)
Not surgery
(n=109)
Time since injury (days)
n 125 125 106 109
Mean (SD) 5.78 (4.90) 5.69 (4.89) 5.81 (5.00) 5.69 (4.82)
Median (min., max.) 4.00 (0.00, 19.00) 4.00 (0.00, 21.00) 4.00 (0.00, 19.00) 4.00 (0.00, 21.00)
Afected shoulder,n(%)
Left 57 (45.6) 68 (54.4) 46 (43.4) 58 (53.2)
Right 68 (54.4) 57 (45.6) 60 (56.6) 51 (46.8)
Tuberosity involvement,n(%)
Yes 99 (79.2) 94 (75.2) 85 (80.2) 83 (76.1)
No 26 (20.8) 31 (24.8) 21 (19.8) 26 (23.9)
Tuberosity involvement,n(%)
Tuberosity not involved or missing 26 (20.8) 31 (24.8) 21 (19.8) 26 (23.9)
Greater tuberosity 58 (46.4) 61 (48.8) 51 (48.1) 56 (51.4)
Lesser tuberosity 7 (5.6) 3 (2.4) 5 (4.7) 2 (1.8)
Greater and lesser tuberosity 34 (27.2) 30 (24.0) 29 (27.4) 25 (22.9)
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TABLE 8Baseline characteristics (fracture data) at randomisation and 24 months’folow-up (continued)
Characteristic
Al randomised
Those with primary outcome (OSS)
data at 24 months
Surgery
(n=125)
Not surgery
(n=125)
Surgery
(n=106)
Not surgery
(n=109)
Radiographs used,n(%)
Anteroposterior view only 5 (4.0) 17 (13.6) 3 (2.8) 15 (13.8)
Axilary view only 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Scapular Y-lateral view only 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Anteroposterior and axilary view 42 (33.6) 43 (34.4) 33 (31.1) 39 (35.8)
Anteroposterior view and
scapular Y-lateral view
35 (28.0) 26 (20.8) 31 (29.2) 22 (20.2)
Axilary view and scapular
Y-lateral view
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Anteroposterior and axilary view
and scapular Y-lateral view
40 (32.0) 36 (28.8) 36 (34.0) 30 (27.5)
Missing 3 (2.4) 3 (2.4) 3 (2.8) 3 (2.8)
Previous fractures,n(%)
Yes 33 (26.4) 33 (26.4) 27 (25.5) 30 (27.5)
No 92 (73.6) 90 (72.0) 79 (74.5) 77 (70.6)
Missing 0 (0.0) 2 (1.6) 0 (0.0) 2 (1.8)
Previous surgery for fractures,n(%)
Yes 8 (6.4) 12 (9.6) 6 (5.7) 10 (9.2)
No 23 (18.4) 21 (16.8) 19 (17.9) 20 (18.3)
Missing 2 (1.6) 0 (0.0) 2 (1.9) 0 (0.0)
No previous fractures 92 (73.6) 92 (73.6) 79 (74.5) 79 (72.5)
Shoulder dominance,n(%)
Yes 67 (53.6) 61 (48.8) 57 (53.8) 55 (50.5)
No 56 (44.8) 62 (49.6) 48 (45.3) 52 (47.7)
Missing 2 (1.6) 2 (1.6) 1 (0.9) 2 (1.8)
Injury mechanism,n(%)
Fal/trip from standing height
or less
90 (72.0) 96 (76.8) 77 (72.6) 84 (77.1)
Fal downstairs/steps or from
a height
18 (14.4) 17 (13.6) 15 (14.2) 15 (13.8)
Other 15 (12.0) 9 (7.2) 12 (11.3) 7 (6.4)
Missing 2 (1.6) 3 (2.4) 2 (1.9) 3 (2.8)
Max., maximum; min., minimum.
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Table 9shows the results of the independent classification of the fractures according to Neer (seeChapter 3).
The categories in bold (categories 3, 8, 9 and 12) are those that fuly meet the ProFHER inclusion
criteria, accounting for 221 of the 250 participants (88%). Consistent with the pragmatic study design,
there were other fractures involving the surgical neck that did not meet the Neer criteria but which were
suficiently displaced for inclusion of these patients into the trial because of their potential suitability for
surgery. The two surgeons undertaking the classification confirmed that al 250 fractures met the main
study criterion, that is, that the fracture involved the surgical neck. Only category 10, involving humeral
head dislocation, is a protocol violation. It was noteworthy that both fracture dislocations were categorised
at the consensus meeting; before this, the two independent surgeons had assigned each of these fractures
to category 8. This indicates some uncertainty and dificulty in the classification of these two fractures.
For the purposes of the sensitivity analysis, secondary to a subgroup analysis of tuberosity involvement,
categories 1 and 3–5 were combined to form the one- or two-part fractures group, with the other four
categories forming the three- or four-part fractures group (seeChapter 5). More detailed results and
analysis of the baseline radiographs and the Neer classification results are presented inChapter 6.
Interventions: surgery
Of the 125 patients alocated to surgery, 109 received surgery and 16 (13%) were treated non-surgicaly
for the folowing reasons: diference in opinion of surgeon (n=2), patient changed mind (n=8) and
patient unfit for surgery (n=6).
Surgery took place on average 4.8 days (median 4 days; range 0–21 days) from randomisation and an
average of 10.4 days (median 9 days; range 1–33 days) from the date of injury.
Operating surgeon
It was expected that, as part of good standard care, surgery for these types of fractures would usualy be
caried out by a consultant who was experienced in operating on such fractures. The 109 operations in
the surgery group were caried out by 66 diferent surgeons (operations: median 1, IQR 1–2, range 1–9).
The grade of the operating surgeons is summarised inTable 10.
TABLE 9Baseline characteristics: types of fractures according to the Neer classification
Final Neer classification categories (seeAppendix 2)a
Alocation,n(%)
Surgery
(n=125)
Not surgery
(n=125)
1b Neer one part: undisplacedcsurgical neck 9 (7.2) 9 (7.2)
3 Neer two part: surgical neck 60 (48.0) 59 (47.2)
4b Neer two part: greater tuberosity 5 (4.0) 3 (2.4)
5b Neer two part: lesser tuberosity 0 (0.0) 1 (0.8)
8 Neer three part: surgical neck+greater tuberosity 45 (36.0) 45 (36.0)
9 Neer three part: surgical neck+lesser tuberosity 1 (0.8) 0 (0.0)
10b Neer three part: anterior dislocation+greater tuberosity 0 (0.0) 2 (1.6)
12 Neer four part: surgical neck+greater tuberosity+lesser tuberosity 5 (4.0) 6 (4.8)
a The categories in bold (categories 3, 8, 9 and 12) are those that fuly meet the ProFHER trial inclusion criteria.
b These categories are outside the expected categories for the trial.
c Although these fractures were rated as‘undisplaced’for the purposes of the Neer classification, they were al displaced
fractures in which the degree of displacement was insuficient for categorisation as a‘part’.
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The standard short curicula vitae (CVs) that surgeons provided for the purposes of obtaining site R&D
approval were scrutinised to ascertain specialty (how the surgeon described him- or herself) and
appointment history (appointments within the previous 5 years). These CVs provided very litle insight on
specialty (most stated‘orthopaedics’or‘orthopaedics and trauma’). Of the 89 operations caried out by
consultants, 46 were conducted by surgeons who had been consultants for at least 5 years, 18 were
conducted by surgeons who had become consultants within the past 5 years and 25 were conducted by
consultant surgeons for whom CVs were not available.
As expected in our protocol, the majority (n=89; 82%) of operations were performed by consultant
surgeons, with a further 13 (12%) operations being caried out by a registrar aided by a consultant or vice
versa. In the few cases in which a registrar was listed without a consultant in theatre (n=7; 6%), al
operating surgeons were identified as a senior registrar or specialist felow and the availability of a
consultant was confirmed in al cases.
Summary of surgery data
A summary of the surgery details from the surgical forms (seeAppendix 21) is provided inTable 11. Details
of the seven unexpected procedures listed are presented inBox 2.
Type of surgery/implant
Brief details of the actual types of implant provided to the 109 patients alocated to surgery were
colected under four categories (nail, plate and screws, hemiarthroplasty and other). These are presented
inTable 12.
The majority of fractures (82.6%) were fixed using a plate and screws, with the PHILOS plate being used in
66 (60.6%) cases. Hemiarthroplasty was used in 10 patients (9.2%); it is likely that cemented prostheses
were used in at least eight of these.
Additional details on the implants, such as the specific type of PHILOS plate and number of screws used,
were available from implant labels stuck, as requested, on the back of 12 surgery forms and writen notes,
recording various details such as the manufacturer’s code for the device, on the back of a further 11
surgery forms. Two other forms noted the absence of implant labels to comply with this request. Although
the general absence of implant labels was disappointing, the requests to centres for further key
information to inform the cost analysis were generaly successful (seeChapter 7).
TABLE 10Staff grade of operating surgeons (n=109 participants)
Operating surgeon n(%) Notes
Consultant 89 (82)
Consultant or registrar 8 (7) Both were present in the theatre but we were unable to determine the
status of the named surgeon
Registrar (consultant present
in theatre)
5 (5) Both were present in the theatre–the registrar was the operating surgeon
Registrar or felow 7 (6) Al were confirmed to be senior registrars/specialist felows. The availability of
the consultant was confirmed in al cases
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TABLE 11Treatment details: surgical methods used in the surgery group
Treatment n(%)
Number randomised 125 (100)
Number receiving surgerya 109 (87.2)
Operation timeb
Time (minutes) in theatre, mean (SD) 113.14 (34.68)
Type of surgery (as listed)
Nail 4 (3.7)
Plate and screwsc 90 (82.6)
Hemiarthroplasty 10 (9.2)
Other 5 (4.6)
Unexpected procedures 7 (6.4)
Conversion ORIF to hemiarthroplasty 2 (1.8)
Rotator cuf repair 2 (1.8)
Other 3 (2.8)
Type of anaesthesia
Generald 107 (98.2)
Locale 21 (19.3)
Regionalf 41 (37.6)
Otherg 3 (2.8)
Antibiotics used
Yes 100 (91.7)
No 1 (0.9)
Missing 8 (7.3)
Radiographic imaging
Image intensifier 99 (90.8)
Filmsh 3 (2.8)
ORIF, open reduction and internal fixation.
a Data in table apply only to the patients who received surgery.
b Data missing for six patients.
c One patient also received a bone graft (Tutobone®; Wescot Medical, Chester-le-Street, UK) and another patient received
two additional Kirschner (K) wires.
d The two patients not receiving general anaesthesia had regional anaesthesia.
e Al patients received general anaesthesia as wel.
f Al but two patients received general anaesthesia as wel.
g Al three were in addition to either general or regional anaesthesia or both.
h Both image intensifier and films were used for one patient.
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Interventions: non-surgical care
Brief details of the prescribed non-surgical treatment for these patients, exemplified by‘sling
immobilisation’, were colected using the treatment confirmation form. These details are summarised in
Table 13. Of the 125 patients alocated to non-surgery, 78 (62.4%) were prescribed sling immobilisation,
35 (28.0%) were prescribed a colar and cuf; four (3.2%) were prescribed a polysling or equivalent
and three (2.4%) were prescribed a hanging cast folowed by a colar and cuf in one case and sling
immobilisation in a second case. Data were missing for five patients. There was reference made to early
mobilisation in six cases, to exercises in three cases and to physiotherapy in 18 cases. The prescribed
duration of immobilisation was stated in four cases: 2 weeks, 2–3 weeks, 3 weeks and 6 weeks.
BOX 2Unexpected surgical procedures
l Originaly planned for ORIF–changed intraoperatively to Global hemiarthroplasty as graft tissue atachment
did not alow fracture reduction.
l Atempted ORIF but reduction failed and therefore proceeded to hemiarthroplasty.
l Rotator cuf tear repair.
l Rotator cuf tear (pre-existing)–subacromial decompression and cuf closure.
l Fixation of a greater tuberosity fracture using FiberWire®sutures (Arthrex Ltd, Shefield, UK).
l Femoral head used as a bone graft because of large defect.
l Fracture had united; take down thought hazardous and therefore no fixation was caried out.
ORIF, open reduction and internal fixation.
TABLE 12Types of implant (n=109)
Implant n(%) Implant types,n
Nail 4 (3.7) Polarus®(Acumed, Andover, UK) (n=3); Expert®(DePuy Synthes UK Ltd, Leeds, UK) (n=1)
Plate and screws 90 (82.6) PHILOS®(DePuy Synthes UK Ltd) (n=66); AxSOS (Stryker UK Ltd, Newbury, UK) (n=11);
Acumed®plate (Acumed) (n=3); NCB®humeral plate (Zimmer Inc., Warsaw, IN, USA)
(n=2); S3™ plate (DePuy Synthes UK Ltd) (n=2); unnamed plates (n=6)
Hemiarthroplasty 10 (9.2) Global®(DePuy Synthes) (n=6); Anatomical™ (Zimmer Inc.)a(n=2); Biomet Bio-Modular®
(Biomet UK Ltd, Swindon, UK) (n=1); Epoca®(DePuy Synthes UK Ltd) (n=1)
Other 5 (4.6) Suture fixation (n=1); titanium screws (n=1); only screws (n=1); fracture united–
no fixation (n=2)
NCB, non-contact bridging.
a It is not known whether these were cemented or uncemented.
TABLE 13Prescribed non-surgical care (sling immobilisation) received by non-surgery patients
Description n(%)
Colar and cuf 35 (28.0)
Hanging cast 3 (2.4)
Polysling (or equivalent) 4 (3.2)
Sling 78 (62.4)
Missing 5 (4.0)
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Information on sling immobilisation after surgery was not colected for individual patients. To gain further
insights about this and the use of the ProFHER sling immobilisation information leaflet (seeAppendix 12),
we sent a survey to hospitals asking about curent practice.
Findings from the questionnaire survey on sling immobilisation
Al 35 participating sites completed the post-recruitment survey (seeAppendix 30) on the provision of sling
care information leaflets and sling immobilisation to patients eligible for participation in the ProFHER trial.
Use of the ProFHER trial sling immobilisation care leaflet
This was covered in the first page of the survey. The survey results show that 28 (85%) of the
33 centres that had identified eligible patients had routinely provided the ProFHER sling immobilisation
care leaflet to eligible patients, whether or not they had consented to take part in the trial. Two sites
‘never’used the leaflet, one of which provided an alternative. Three other sites‘rarely’used the leaflet.
The reasons for not providing the leaflets were to not confuse the patient or complicate maters in terms
of trial participation and because of administrative problems.
Inspection of the only alternative leaflet showed that it was a text-only leaflet providing general advice on
sling use during conservative management of people with a proximal humeral fracture. It covered fewer
items than the ProFHER leaflet; the only additional information being the advice that‘it may be more
comfortable to wear the sling under your clothes for the first week’.
Al 32 sites that had recruited patients into the trial routinely provided the ProFHER trial sling information
leaflet. These results confirm the delivery of a standard of care, in particular for consenting patients,
thereby ensuring comparability between the two randomised groups.
Type and duration of sling immobilisation typicaly provided to patients
who would have been eligible for the ProFHER trial
This was covered in the second page of the survey. A distinction was made between the 32 centres that
recruited patients and the three that did not.
Type of immobilisation for non-surgical patients
Twenty-two (69%) of the 32 centres that recruited patients reported routinely/typicaly using one method
of immobilisation for non-surgicaly treated patients who would have been eligible for the ProFHER trial.
The others reported either two (25%) or three (6%) methods. Comments provided by centres in which
two or three devices were reported indicated that the choice of method was dependent on patient
comfort in one centre, patient ability to cope in another centre and consultant preference in a third centre.
Table 14summarises the type of immobilisation routinely/typicaly used for non-surgicaly treated patients
in recruiting centres.
TABLE 14Non-surgical treatments routinely/typicaly used by recruiting centres (n=32)
Description n(%)
Colar and cuf 14 (44)
Polysling (and equivalent) 8 (25)
Colar and cuf or polysling 7 (22)
Broad arm sling or polysling 1 (3)
Colar and cuf, broad arm sling or polysling 2 (6)
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A colar and cuf was the main method used in 14 centres (44%) and was one of two or three methods
used in a further nine centres (28%). A polysling or equivalent was the main method used in eight centres
(25%) and one of two or three methods used in 10 centres (31%). Aside from those described under
the generic label, we included the folowing devices in this category: coton polysling, high arm sling
(Chaneco, Chris Hanley & Partners, Northampton, UK), Lancaster sling (Promedics Orthopaedics Ltd, Port
Glasgow, UK), body sling, shoulder immobiliser and Seaton sling. There was a general lack of information
on the extent of immobilisation (i.e. use of the waist belt of the polysling). A broad arm sling was one of
two or three methods of immobilisation in three centres. The occasional use of a hanging cast was noted
in one centre. (The single methods described by the three centres that did not recruit patients were colar
and cuf, polysling, and colar and hanging cast.) In principle, al of these slings work similarly, that is, to
rest the arm comfortably adducted and internaly rotated, with the arm by the side of the body, elbow
flexed and the forearm resting in front of the body.
Type of immobilisation for post-surgical patients
Twenty-three (72%) of the 32 centres that recruited patients reported routinely/typicaly using one method
of immobilisation for surgicaly treated patients who would have been eligible for the ProFHER trial.
Six centres (19%) reported two methods, two (6%) reported three methods and one (3%) reported that
immobilisation was a consultant-led decision based on the stability of fixation and extent of soft-tissue
injury. Comments provided by centres in which two devices were reported indicated that the choice of
immobilisation was dependent on the comfort and quality of fixation in one centre, on the presence or not
of a cuf tear in one centre and on ADL and ability to cope in a third centre.Table 15summarises the
types of immobilisation routinely/typicaly used post surgery in recruiting centres.
A polysling or equivalent was the main method in 17 centres (53%) and one of two or three methods in
eight centres (25%). Aside from those described under the generic label, we included the folowing
devices in this category: high arm sling (Chaneco), Lancaster sling, body sling, shoulder immobiliser,
neoprene immobiliser and Seaton sling. There was a general lack of information on the extent of
immobilisation (i.e. use of the body belt of the polysling), but the use of the immobiliser was specificaly
described in two cases. A colar and cuf was the main method in three centres (9%) and was one of two
or three methods in a further seven centres (22%). A broad arm sling was the main method in two centres
(6%) and was one of two or three methods of immobilisation in three other centres (9%). One centre
described the use of a‘sling’only and another described policy rather than devices. (Information was
missing from one of the three centres that did not recruit. Of the other two centres, the main method
used was a polysling in one centre and a polysling without a waist belt in the other centre.)
In al, 14 centres used the same method or combination of methods for non-surgical and post-surgical
immobilisation, as summarised inTable 16.
TABLE 15Post-surgical immobilisation routinely/typicaly used by recruiting centres (n=32)
Description n(%)
Colar and cuf 3 (9)
Polysling 17 (53)
Broad arm sling 2 (6)
Not a defined sling 1 (3)
Colar and cuf or polysling 5 (16)
Broad arm sling or polysling 1 (3)
Colar and cuf, broad arm sling or polysling 2 (6)
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Duration of sling immobilisation for non-surgical patients
The recommended duration of arm immobilisation for non-surgicaly treated patients ranged from 2 to
6 weeks. Of the 32 recruiting centres, 29 (91%) recommended immobilisation of≥3 weeks. This is
consistent with our expectations and guidance. Commentary on this indicated that exercises often started
during sling use: two centres refered to pendular exercises and six centres to exercises starting at around
2–3 weeks, with some reduction in the wearing of the sling. In five of these six centres, the treatment
period was 6 weeks; in the other centre it was 4 weeks. In terms of sling immobilisation there was also
reference made to fracture healing and dependency on type of fracture, pain, age and comorbidities and
also, in four centres, to consultant preference.
Duration of sling immobilisation for post-surgical patients
The recommended duration of arm immobilisation after surgery was more variable, ranging from none
(early mobilisation in one recruiting centre) to 8 weeks. Of the 32 recruiting sites, 23 (72%) recommended
immobilisation of≥3 weeks. This is consistent with our expectations but we gave no guidance on this.
Commentary on this again indicated that exercises often started during sling use. In two centres, exercises
started almost immediately, yet the recommended period of immobilisation was 6 weeks in both. In three
other centres that reported immobilisation of 6 weeks, exercises/physiotherapy were reported to start at
around 2–3 weeks. In one centre, sling use was for pain and comfort only, with no time given for the
period of immobilisation. There was some mention of variation according to the method of surgery
(four cases) but this was not in consistent directions for the two centres providing times (in one centre
fixation involved longer immobilisation than hemiarthroplasty and in another centre the reverse was true).
Reference was again made to fracture healing and dependency on the type of fracture and pain, with the
additional consideration of the quality of surgical fixation in one centre. Four centres specificaly reported
that the decision depended on the surgeon.
In al, 19 (18 recruiting) centres reported the same recommended period of arm immobilisation for
non-surgical treatment and post-surgical treatment.
Physiotherapy
Details of the physiotherapy provided to each treatment group, colected from the physiotherapy logs
(seeAppendix 23), are provided inTable 17. This demonstrates equivalence between the treatment groups
in access to and implementation of physiotherapy, including advice given for home exercises and
performance of home exercises by patients.
TABLE 16Recruiting centres listing the same methods for non-surgical and post-surgical immobilisation
Description n
Colar and cuf 3
Polysling 7a
Colar and cuf or polysling 3
Colar and cuf, broad arm sling or polysling 1
a One centre used diferent but similar polyslings in the two groups.
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TABLE 17Physiotherapy treatment
Description Surgery (n=125) Not surgery (n=125)
Number (%) receiving physiotherapy 118 (94.4) 117 (93.6)
Days to first session
Mean (SD) 23.1 (24.07) 25.5 (18.60)
Median (min., max.) 16 (1, 120) 22 (–1, 122)
Duration of physiotherapy
(days from first to last session)
Mean (SD) 116.7 (75.75) 113.0 (67.46)
Median (min., max.) 111.5 (0, 510) 104 (0, 395)
Number of sessions
Mean (SD) 9.6 (6.22) 9.6 (6.59)
Median (min., max.) 8 (1, 36) 8 (1, 43)
Alocated time per session (minutes)
Mean (SD) 28.3 (9.57) 29.2 (10.49)
Median (min., max.) 30 (0, 60) 30 (0, 60)
Session detailsa,b
Advice and/or education
n(%) 115 (92.0) 113 (90.4)
Mean (SD) 7.1 (5.13) 7.3 (5.61)
Exercise
n(%) 118 (94.4) 114 (91.2)
Mean (SD) 8.6 (5.37) 8.4 (6.08)
TENS
n(%) 1 (0.8) 8 (6.4)
Mean (SD) 0.0 (0.09) 0.1 (0.34)
Soft-tissue techniques
n(%) 49 (39.2) 49 (39.2)
Mean (SD) 1.3 (2.13) 1.9 (3.52)
Joint mobilisations
n(%) 55 (44.0) 71 (56.8)
Mean (SD) 2.1 (3.11) 2.5 (3.40)
Stretching techniques
n(%) 83 (66.4) 84 (67.2)
Mean (SD) 3.0 (3.16) 3.7 (4.11)
continued
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Reasons for not starting physiotherapy
Based on the receipt of the physiotherapy logs and information from the physiotherapy end-of-treatment
logs, 119 patients (95%) in the surgery group and 118 patients (94%) in the non-surgery group started
physiotherapy. Thus, physiotherapy logs were missing for one patient in each group who started
physiotherapy according to their end-of-treatment log. Of the six patients in the surgery group who
were reported as not starting physiotherapy within the ProFHER trial, the reasons, when given, were
non-atendance or patient unavailability in three cases and the separate provision of physiotherapy at the
nursing home for one patient. Of the five patients in the non-surgery group who were reported as not
starting physiotherapy, this was recorded as resulting from non-atendance or a change in health status or
circumstances in four patients. Both types of physiotherapy forms were missing for two patients alocated
to non-surgery. Overal, these data indicate that our eforts to ensure equivalent access to and delivery of
physiotherapy were met for the two groups.
‘Other’physiotherapy interventions
Twenty-two patients in each group received one or more‘other’physiotherapy interventions that were
distinctly diferent from those listed in the physiotherapy logs or protocol. These do not include typical
devices used for exercising, such as a Thera-Band (Paterson Medical Ltd, Suton-in-Ashfield, UK) and
puleys, reports of which were excluded on screening of the data entries by two raters.‘Other’
interventions reported were ice, heat, general mobility exercises, acupuncture, proprioceptive
neuromuscular facilitations and ADL/functional training and advice.
TABLE 17Physiotherapy treatment (continued)
Description Surgery (n=125) Not surgery (n=125)
Relaxation techniques
n(%) 31 (24.8) 31 (24.8)
Mean (SD) 0.5 (1.11) 1.0 (2.95)
Hydrotherapy
n(%) 5 (4.0) 10 (8.0)
Mean (SD) 0.2 (1.17) 0.5 (1.74)
Other,n(%) 22 (17.6) 22 (17.6)
Home exercisea,b
Reported (yes or no) 112 (89.6) 106 (84.8)
Yes 109 (87.2) 103 (82.4)
Mean (SD) 6.9 (5.21) 7.0 (6.01)
No 38 (30.4) 44 (35.2)
Mean (SD) 0.6 (1.24) 0.5 (0.85)
Referal to other specialty,n(%)a 9 (7.2) 12 (9.6)
Occupational therapy,n(%) 1 (0.8) 2 (1.6)
Other,n(%) 8 (6.4) 10 (8.0)
Deviation from protocol,n(%) 0 (0.0) 0 (0.0)
Max., maximum; min., minimum.
a Frequency of patients if reported at least once in session logs.
b Means and SDs are based on the number of sessions for patients with available data.
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Home exercises
Of the 118 patients in the surgery group for whom there was at least one completed physiotherapy log,
109 patients (92%) were recorded as having performed their home exercises in one or more logs.
This applied to only slightly fewer patients, 103 (88%) of the 117 patients with completed physiotherapy
logs, in the non-surgery group. The majority of patients were recorded as having performed their home
exercises in most of their sessions. Just three patients in each group were recorded as never having caried
out their home exercises.
Referrals to other specialties
When screening the entries for referals to occupational therapy and other specialties in the physiotherapy
logs, we discounted referals to further physiotherapy for the shoulder, routine reviews with an orthopaedic
consultant and referals to a GP. Referals to a GP were predominantly for patients to seek advice for
pain medication and were considered as being for information only rather than a referal for a specific
episode of care. Of the 18 referals of individual patients to other specialties for‘problems’, 12 were to an
orthopaedic consultant and the others were single referals to community care, neurology, radiology, a
hand therapist, an oncologist and for physiotherapy aimed at balance and fal prevention.
Reasons for any substantial differences from the ProFHER trial
physiotherapy protocol
The physiotherapy treatment log alowed a physiotherapist to record the reasons why the care delivered to
a patient was substantialy diferent from that in the physiotherapy protocol. Some variation from protocol
was expected and permited and, thus, referal to and description of adjustments to accommodate clinical
need or instruction from the consultant were not considered as‘protocol violations’. One of us (HH)
reviewed 486 treatment log comment entries and found no mention of electrotherapy, which would have
been a‘protocol violation’. Reference was made to acupuncture, which was an accepted intervention.
Lack of knowledge of/access to the physiotherapy protocol was identified from the comments made for
two surgical group patients. In one case the physiotherapist providing treatment noted that they had
no knowledge of the trial and in the second case a physiotherapist from an externaly based clinic
categoricaly stated that they did not know‘what the ProFHER physiotherapy protocol is’.
Provision of information leaflets ilustrating home exercises
The trial protocol and trial manual indicated that physiotherapists involved in the treatment of trial patients
should provide an information leaflet ilustrating the home exercises. We did not assess compliance
with this expectation. However, in discussions between the lead physiotherapy contact (LG) and the
physiotherapists acting as the named contacts for physiotherapy at the participating hospital sites, we
recorded that advice on home exercises was often adjusted to accommodate home exercises that were
predominantly based on daily functional tasks (such as reaching up to the top of a cupboard). Writen
instructions for these were considered unhelpful and the emphasis was shifted to the monitoring and
reinforcement of these and related functional activities at subsequent physiotherapy.
Completion of physiotherapy
Physiotherapy end-of-treatment logs were obtained for 245 patients. Similar reasons for formal discharge
were provided for both treatment groups (Table 18). Although the time to formal discharge was on
average 2 weeks later in the surgery group than in the non-surgery group, this is likely to have been
administrative rather than reflecting outcome.
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Return of data colection forms
Patient questionnaires
In total, folow-up patient questionnaires were returned for 225 (90%), 232 (93%), 226 (90%) and 218
(87%) of the 250 recruited patients at 3, 6, 12 and 24 months’folow-up respectively. Thus, we achieved
a response rate above the 80% target stated in our protocol. These statistics include the abridged
questionnaire data (including the OSS) colected by telephone as a last resort in 19 instances: nine
(four surgery vs. five non-surgery) at 6 months, seven (three surgery vs. four non-surgery) at 12 months
and three (two surgery vs. one non-surgery) at 24 months. The return of questionnaires by treatment
group is shown inTable 19.
Patient questionnaires were dispatched promptly from the YTU on the date that the folow-up assessment
was due; a leter informing patients to expect the questionnaire was sent a fortnight beforehand. The
number of days from questionnaire dispatch by the YTU to the completion of the questionnaire as
recorded by the patient (‘Days to completion’) and the number of days from questionnaire dispatch by the
YTU to the returned questionnaire being logged by the YTU (‘Days to return’) are presented inTable 20.
Medians and interquartile statistics are presented given the right-skewed distribution, as the majority of
TABLE 18Completion of physiotherapy
Description
Surgery (n=125),
n(%)
Not surgery (n=125),
n(%)
Treatment completed (formal discharge) 93 (74.4) 96 (76.8)
Independent shoulder function achieved 66 (52.8) 72 (57.6)
No improvement noted over several sessions 19 (15.2) 18 (14.4)
Other 8 (6.4) 6 (4.8)
Treatment not completed (formal discharge) 23 (18.4) 22 (17.6)
Patient stopped atending 17 (13.6) 14 (11.2)
Another problem intervened 3 (2.4) 2 (1.6)
Other 3 (2.4) 5 (4.0)
Unknown 0 (0) 1 (0.8)
Treatment never started (patient never atended) 6 (4.8) 5 (4.0)
Days to discharge since start of therapy, mean (SD)
Overal 137.5 (83.6) 123.0 (71.6)
Formal discharge (treatment completed) 141.3 (80.5) 127.5 (68.9)
Formal discharge (treatment not completed) 121.7 (96.0) 102.7 (81.2)
TABLE 19Return of patient questionnaires
Questionnaire Surgery,n(%) Not surgery,n(%)
Baseline 125 125
3 months’folow-up 114 (91) 111 (89)
6 months’folow-up 113 (90) 119 (95)
12 months’folow-up 111 (89) 115 (92)
24 months’folow-up 109 (87) 109 (87)
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patients completed and returned their forms promptly. As expected, the time to completion was shorter
than the time to return. There was no obvious diference between the two groups in the time to
completion or the time to return.
Return of hospital data colection forms
The return of the hospital forms is summarised inTable 21. Treatment confirmation forms, which were
colected 1 month after treatment, were colected for al patients. This provided confirmation that
the surgical forms for the 109 participants who had their alocated surgery had been returned, as had the
inpatient episode forms for al 130 participants who had been admited to hospital. Overal, 235 of
250 (94.0%) physiotherapy treatment logs and 245 of 250 (98.0%) physiotherapy end-of-treatment forms
were returned. In addition, 249 of 250 (99.6%) 1-year folow-up forms and 234 of 250 (93.6%) 2-year
folow-up forms were returned.
TABLE 20Days from due folow-up date to completion (date recorded on the patient questionnaire) and return
(logged by the YTU) of the questionnaires
Folow-up
Surgery Not surgery
Days to completiona Days to return Days to completiona Days to return
3 months,n, median (IQR) 93, 7 (4–16) 114, 12 (8–22) 99, 8 (4–12) 111, 11 (8–18)
6 months,n, median (IQR) 97, 6 (3–13) 113, 11 (8–22) 106, 7 (4–12) 119, 12 (8–18)
12 months,n, median (IQR) 93, 6 (4–11) 111, 12 (8–18) 101, 7 (4–12) 115, 13 (8–20)
24 months,n, median (IQR) 89, 7 (4–15) 109, 13 (10–21) 95, 7 (4–13) 109, 11 (8–19)
a The lower numbers of patients in the days–completion columns than in the days to return columns reflect the fact that
some patients at each time period did not record the date on which they completed the questionnaire.
TABLE 21Return of hospital forms
Hospital form Surgery (n=125),n(%) Not surgery (n=125),n(%)
Treatment confirmation form 125 (100) 125 (100)
Surgical form 109 (100a) [6b]
Inpatient episode form 109 (100a)[2b] 22 (100a)[1b]
Physiotherapy treatment log (any received for patient) 118 (99c) 117 (98c)
Physiotherapy end-of-treatment log 122 (98) 123 (98)
1-year folow-up form 124 (99) 125 (100)
2-year folow-up formd 113 (90) 121 (97)
a Percentage based on the number expected from reports in the treatment confirmation forms.
b Additional forms received.
c Percentage based on number expected from accounts in the physiotherapy end-of-treatment logs (forms not received for
one surgery and two not surgery patients who started physiotherapy; two not surgery physiotherapy end-of-treatment
logs missing).
d Forms were not requested for those known to have died within 1 year.
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Other returns
Baseline radiographs
Anonymised copies of baseline radiographs were obtained for al 250 patients. Although provision had
been alowed for copies of radiographs to be sent as films, al copies of baseline radiographs were
returned in digital format. This was consistent with the completion in December 2007 of the national
rol-out of PACS to al acute trusts across England as part of the NHS Connecting for Health initiative.67,68
There were, however, greater than anticipated dificulties in obtaining copies of images that met the
criteria for blinding and transferability (electronic portability). Hospitals used diferent PACS packages and
diferent setings for permission of access for saving images as JPEG files. Al images were under the
requested 300 dpi resolution. When checked, the majority of images were at 96 dpi resolution, which
appears to be the accepted resolution for images that would be viewed by surgeons in everyday practice.
Ultimately, JPEG files were available for al baseline radiographs; in 26 sets of radiographs these were
screen shots because of unresolved dificulties with saving images from the various PACS packages used.
Monitoring of the radiographs confirmed that al fractures met the main inclusion criterion that fractures
should involve the surgical neck. No site was contacted with specific concerns relating to this issue. Aside
from basic checks regarding blinding and requests for additional views when two views were not received,
we did not ask for‘beter quality radiographs’because it seemed safe to assume that we had been sent
the best quality baseline radiographs available.
Adverse events
The 88 adverse event (reporting) forms (seeAppendix 27) returned reported adverse events for 61 patients
occuring within the 2-year folow-up period. Seventy-eight SAEs were reported for 56 patients and
10 non-SAEs were reported for nine patients. As judged by the sites, five SAEs met the criteria for
informing the MREC. On checks made by two reviewers (HH and AR) of these and al SAEs, and in
consultation with the DMEC, three of these and one other adverse event were reported separately to the
MREC. No further action was required for any of these four events. For al 1-month review of adverse
event forms (seeAppendix 28), both reviewers agreed that there was no cause for further action to be
taken by sites to address the adverse events and progress made by the patients involved.
Patient withdrawals
Two patients alocated to surgery explicitly withdrew from their treatment but agreed to complete the
patient questionnaires. Six patients withdrew from completing the questionnaires at diferent stages of
folow-up; al six confirmed that we could continue to colect data from their hospital records. No patient
withdrew entirely from the trial.
RESULTS: RECRUITMENT, INTERVENTIONS AND DATA RETURN
NIHR Journals Librarywww.journalslibrary.nihr.ac.uk
56
Chapter 5Primary outcome (Oxford Shoulder
Score) analysis
The OSS [0 (worst score) to 48 (best score)] was assessed at 6, 12 and 24 months. When a maximum oftwo of the 12 OSS items were missing, these were replaced with the mean of the remaining items.41
An efect size of 0.4 (assuming a SD of 12) was sought between treatment groups; this is equivalent to an
OSS diference of approximately 5 points.
Missing data
The multilevel model analysis used assumed any missing data to be missing at random (MAR). The extent
of and reasons for missing OSS data at each time point are detailed inTable 22. Complete response is
defined here as suficient data (maximum of two missing OSS items) to alow the calculation of the OSS
total score.
Overal, 209 patients (84%) had complete OSS responses at al folow-up time points (surgery: 103 patients;
not surgery: 106 patients), whereas 41 patients (16%) did not respond or only partialy responded at
one or more time points (surgery: 22 patients; not surgery: 19 patients). The later group are defined as
non-responders in the folowing tables and analysis.
Demographic and fracture characteristics at baseline for responders and non-responders are presented in
Tables 23and24respectively. Each baseline variable was entered into a logistic regression model
predicting non-response, none of which reached statistical significance (p<0.10). Consequently, no
additional variables were included in the primary analysis.
TABLE 22Missing primary outcome data over time
Folow-up Response type Surgery (n=125),n(%) Not surgery (n=125),n(%)
6 months Complete response 113 (90.4) 119 (95.2)
No or partial response 12 (9.6) 6 (4.8)
No response 8 (6.4) 4 (3.2)
Withdrawn from questionnaires 1 (0.8) 1 (0.8)
Died 3 (2.4) 1 (0.8)
12 months Complete response 111 (88.8) 114 (91.2)
No or partial response 14 (11.2) 11 (8.8)
Insuficient data for calculation of OSS 0 (0.0) 1 (0.8)
No response 4 (3.2) 6 (4.8)
Withdrawn from questionnaires 3 (2.4) 2 (1.6)
Died 7 (5.6) 2 (1.6)
24 months Complete response 106 (84.8) 109 (87.2)
No or partial response 19 (15.2) 16 (12.8)
Insuficient data for calculation of OSS 3 (2.4) 0 (0.0)
No response 3 (2.4) 9 (7.2)
Withdrawn from questionnaires 4 (3.2) 2 (1.6)
Died 9 (7.2) 5 (4.0)
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TABLE 23Predictors of non-response: demographics
Characteristic
Complete response
(n=209)
No/partial response
(n=41)
p-value (prediction of
non-response)
Gender,n(%) 0.836
Male 49 (23.4) 9 (22.0)
Female 160 (76.6) 32 (78.0)
Age (years) 0.763
n 209 41
Mean (SD) 66.1 (11.50) 66.5 (14.10)
Median (min., max.) 66.8 (31.3, 89.0) 67.4 (24.6, 92.0)
Ethnicity,n(%) NA
White 208 (99.5) 41 (100.0)
Black 1 (0.5) 0 (0.0)
Education,n(%) 0.233
No formal qualifications 107 (51.2) 27 (65.9)
Some qualifications/no degree 79 (37.8) 11 (26.8)
Degree or higher 23 (11.0) 3 (7.3)
Employment,n(%) 0.436
Part-time 19 (9.1) 0 (0.0)
Ful-time 32 (15.3) 7 (17.1)
Self-employed 4 (1.9) 0 (0.0)
Retired 133 (63.6) 27 (65.9)
Not employed but seeking work 4 (1.9) 0 (0.0)
Other 15 (7.2) 6 (14.6)
Missing 2 (1.0) 1 (2.4)
Diabetes,n(%) 0.336
Yes 24 (11.5) 7 (17.1)
No 183 (87.6) 34 (82.9)
Missing 2 (1.0) 0 (0.0)
Smoking status,n(%) 0.188
Yes 50 (23.9) 14 (34.1)
No 151 (72.2) 26 (63.4)
Missing 8 (3.8) 1 (2.4)
Steroid use,n(%) 0.424
Yes 12 (5.7) 1 (2.4)
No 196 (93.8) 38 (92.7)
Missing 1 (0.5) 2 (4.9)
Health status (EQ-5D index) 0.136
n 204 40
Mean (SD) 0.39 (0.36) 0.48 (0.40)
Median (min., max.) 0.29 (–0.35, 1) 0.62 (–0.36, 1)
Max., maximum; min., minimum; NA, not applicable.
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Table 25provides the descriptive OSS total scores for complete responders and those non-responders for
whom data were available at some of the time points. Complete responders had beter OSS outcomes
than non-responders at al time points. OSS scores were entered into a logistic regression model predicting
non-response and the observed diferences were statisticaly significant at 12 months’folow-up
(p=0.025) but not at 6 or 24 months’folow-up. Although this is a clear indication that data were not
MAR, this is not anticipated to be a substantial problem given the relatively smal number of
non-responders.
TABLE 24Predictors of non-response: fracture data
Characteristic
Complete response
(n=209)
No/partial response
(n=41)
p-value (prediction of
non-response)
Time since injury (days) 0.784
n 209 41
Mean (SD) 5.7 (4.89) 5.9 (4.92)
Median (min., max.) 4 (0, 21) 4 (1, 18)
Afected shoulder,n(%) 0.394
Left 102 (48.8) 23 (56.1)
Right 107 (51.2) 18 (43.9)
Tuberosity involvement,n(%) 0.332
Tuberosity not involved or missing 45 (21.5) 12 (29.3)
Greater tuberosity 104 (49.8) 15 (36.6)
Lesser tuberosity 7 (3.3) 3 (7.3)
Greater and lesser tuberosity 53 (25.4) 11 (26.8)
Previous fractures,n(%) 0.674
Yes 54 (25.8) 12 (29.3)
No 153 (73.2) 29 (70.7)
Missing 2 (1.0) 0 (0.0)
Previous surgery for fractures,n(%) 0.391
Yes 15 (7.2) 5 (12.2)
No 37 (17.7) 7 (17.1)
Missing 2 (1.0) 0 (0.0)
No previous fractures 155 (74.2) 29 (70.7)
Shoulder dominance,n(%) 0.948
Yes 107 (51.2) 21 (51.2)
No 99 (47.4) 19 (46.3)
Missing 3 (1.4) 1 (2.4)
Injury mechanism,n(%) 0.510
Fal/trip from standing height or less 156 (74.6) 30 (73.2)
Fal downstairs/steps or from a height 30 (14.4) 5 (12.2)
Other 18 (8.6) 6 (14.6)
Missing 5 (2.4) 0 (0.0)
Max., maximum; min., minimum.
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Descriptive Oxford Shoulder Score statistics
Descriptive OSS statistics at 6, 12 and 24 months are presented inTable 26and ilustrated inFigure 8.
Mean scores improved over time for both treatment groups. At 6 months, the surgery group showed
beter scores than the non-surgery group (a mean diference of 3.0 points), although the 95% confidence
interval (CIs) overlapped. This diference was smaler than the sought efect size of 5 points. Mean scores
at 12 and 24 months were very similar between the groups.
TABLE 25Predictors of non-response: OSS total score
Characteristic
Complete response
(n=209)
No/partial response
(n=41)
p-value (prediction
of non-response)
OSS at 6 months 0.193
n 209 23
Mean (SD) 34.83 (10.38) 31.78 (12.39)
Median (min., max.) 38 (3, 48) 36 (3, 48)
OSS at 12 months 0.025
n 209 16
Mean (SD) 37.13 (10.55) 30.63 (12.59)
Median (min., max.) 41 (1, 48) 30.5 (4, 46)
OSS at 24 months 0.167
n 209 6
Mean (SD) 38.49 (10.41) 32.33 (10.27)
Median (min., max.) 42 (1, 48) 30.5 (23, 46)
Max., maximum; min., minimum.
TABLE 26Unadjusted descriptive OSS statistics over time by treatment group
Folow-up Surgery (n=125) Not surgery (n=125) Total (n=250)
6 months
n(%) 113 (90.4) 119 (95.2) 232 (92.8)
Mean (SD) score 36.07 (9.99) 33.07 (11.00) 34.53 (10.61)
Median (min., max.) score 39 (11, 48) 35 (3, 48) 37 (3, 48)
12 months
n(%) 111 (88.8) 114 (91.2) 225 (90.0)
Mean (SD) score 36.89 (10.78) 36.45 (10.86) 36.67 (10.80)
Median (min., max.) score 41 (1, 48) 41 (4, 48) 41 (1, 48)
24 months
n(%) 106 (84.8) 109 (87.2) 215 (86.0)
Mean (SD) score 38.25 (9.91) 38.39 (10.96) 38.32 (10.43)
Median (min., max.) score 42 (16, 48) 42 (1, 48) 42 (1, 48)
Max., maximum; min., minimum.
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As suggested by the discrepancy between the means and the medians, the distribution of OSS scores was
found to be left skewed (Figure 9), that is, a greater number of participants reported higher (beter)
shoulder function.
Primary analysis
The primary outcome was analysed using a multilevel model. Patients were treated as a random efect and
time (6, 12 and 24 months) was nested within patients. The efect of treatment group was assessed while
adjusting for time, group × time interaction, baseline EQ-5D index, gender, age group and tuberosity
involvement at baseline. As no baseline characteristics were found to predict non-response, no further
covariates were added.
Diferent covariance structures were applied to this model. An unstructured patern that models al
variances and covariances separately was judged to be the most intuitive. The more restrictive paterns of
independent and exchangeable structures were tried and resulted in a worse model fit. Therefore, the
unstructured covariance patern was selected.
Diagnostics of model fit revealed non-normal standard residuals that were not uniform against predicted
model values. This was likely to be a result of the left-skewed distribution of OSS scores. Therefore, al
analyses were caried out on squared OSS values, which reduced skew and resulted in acceptable fit
diagnostics. Al group means and diferences reported here were back transformed to the original
OSS scores.
Adjusted OSS means and group diferences for the model as specified above are presented inTable 27.
The primary analysis (and subgroup analyses) included data from 231 patients (114 surgery, 117 not
surgery) with a valid OSS score for at least one folow-up time point and complete baseline covariates. The
analysis showed no significant diferences between treatment groups at any time point, although the
diference of 2.25 score points in favour of the surgery group at 6 months approached significance
(p=0.058). There was no overal efect of treatment group (diference of 0.75 score points in favour of
the surgery group;p=0.479).
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FIGURE 8Mean OSS scores (with 95% confidence intervals) over time by treatment group.
DOI: 10.3310/hta19240 HEALTH TECHNOLOGY ASSESSMENT 2015VOL. 19 NO. 24
© Queen’s Printer and Controler of HMSO 2015. This work was produced by Handolet al.under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the ful report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
61
Fre
qu
en
cy
50
40
30
20
10
0
0 10 20 30 40 50
OSS scores
(a)
0 10 20 30 40 50
OSS scores
Fre
qu
en
cy
50
40
30
20
10
0
(b)
0 10 20 30 40 50
OSS scores
Fre
qu
en
cy
50
40
30
20
10
0
(c)
FIGURE 9Distribution of OSS scores over time. (a) 6 months; (b) 12 months; and (c) 24 months.
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Subgroup analyses
Age
The first subgroup analysis was undertaken to test the hypothesis that younger patients (aged<65 years)
would benefit more from surgical treatment than older patients. The relationship between age and
treatment group in terms of OSS is ilustrated inTable 28andFigure 10. Older patients generaly had
lower OSS scores (including poorer shoulder functioning), and scores in the surgery group were higher
than those in the non-surgery group at al time points for this age group, although the CIs overlapped in
each case. There was a trend for younger patients in the non-surgery group to improve more rapidly than
those in the surgery group and older patients.
The same multilevel model as for the primary analysis was applied but an additional treatment group × age
group interaction was included. Adjusted OSS means and group diferences for this model are presented
inTable 29. Similar to the primary analysis, there was no significant overal efect of treatment group over
the 2-year folow-up period and no significant efect of treatment group at individual time points. A 2-log
likelihood comparison with the primary analysis model was not significant [χ2(1)=1.24,p=0.265];
therefore, inclusion of the interaction did not significantly improve the model.
Fracture type
The second subgroup analysis was undertaken to test the hypothesis that patients with more complex
fractures would benefit more from surgical treatment than patients with less complex fractures. Baseline
radiographs were initialy assessed by surgeons at the time of assessing patient eligibility in terms of
tuberosity involvement (primary subgroup analysis) and were later categorised by the two independent
surgeons using the Neer classification (sensitivity subgroup analysis).
Tuberosity involvement at baseline
Surgeons indicated at baseline whether a fracture involved the greater tuberosity, the lesser tuberosity or
both in addition to the surgical neck. This information was summarised as tuberosity involvement (yes or
no). The relationship between tuberosity involvement and treatment group in terms of OSS scores is
ilustrated inTable 30andFigure 11. Patients with fractures that involved one or both tuberosities
generaly had lower OSS scores (poorer shoulder functioning). Again, the scores in the surgery group were
noticeably higher than those in the non-surgery group at 6 months, although the CIs overlapped. The
diferences between the two groups were greater for patients with fractures that involved neither
tuberosity than for those with fractures with tuberosity involvement.
TABLE 27Difference in mean OSS scores over time by treatment group: primary analysis using a multilevel modela,b
Folow-up
Surgery (n=125),
mean (95% CI),n
Not surgery (n=125),
mean (95% CI),n
Difference (95% CI),
standard errorc p-value
Overal 39.07 (37.30 to 40.76), 114 38.32 (36.57 to 39.99), 117 0.75 (–1.33 to 2.84), 1.0638 0.479
6 months 37.84 (35.93 to 39.65), 111 35.59 (33.62 to 37.45), 115 2.25 (–0.07 to 4.57), 1.1837 0.058
12 months 39.23 (37.38 to 40.99), 109 38.80 (36.99 to 40.53), 110 0.42 (–1.78 to 2.63), 1.1250 0.706
24 months 40.11 (38.24 to 41.90), 104 40.40 (38.59 to 42.13), 106 –0.29 (–2.53 to 1.95), 1.1429 0.800
a Multilevel model adjusted for treatment group, time (6, 12 and 24 months), group × time interaction, baseline EQ-5D
index, gender, age group (<65 years/≥65 years) and tuberosity involvement at baseline (yes/no).
b The model included data from 114 surgery and 117 not surgery patients with valid OSS data for at least one folow-up
time point and complete baseline covariates. Thenvalues at the individual time points, which are presented for
information only, are the numbers with valid OSS data and complete baseline covariates at that time point.
c Standard erors are the more appropriate measure of variability for these data than SDs.
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TABLE 28Descriptive OSS statistics over time by treatment group and age group
Folow-up Surgery (n=125) Not surgery (n=125) Total (n=250)
Age:<65 years (n=108)
6 months
n 46 53 99
Mean (SD) 35.5 (10.87) 33.9 (10.11) 34.7 (10.45)
Median (min., max.) 39 (11, 48) 35 (3, 48) 38 (3, 48)
12 months
n 48 53 101
Mean (SD) 37.0 (11.6) 37.8 (10.53) 37.4 (11.01)
Median (min., max.) 42 (5, 48) 42 (4, 48) 42 (4, 48)
24 months
n 45 50 95
Mean (SD) 38.7 (9.95) 41.0 (8.36) 39.9 (9.17)
Median (min., max.) 43 (16, 48) 43 (14, 48) 43 (14, 48)
Age:≥65 years (n=142)
6 months
n 67 66 133
Mean (SD) 36.4 (9.40) 32.4 (11.72) 34.4 (10.76)
Median (min., max.) 39 (14, 48) 34.5 (3, 48) 37 (3, 48)
12 months
n 63 61 124
Mean (SD) 36.8 (10.20) 35.2 (11.09) 36.0 (10.63)
Median (min., max.) 40 (1, 48) 39 (7, 48) 40 (1, 48)
24 months
n 61 59 120
Mean (SD) 37.9 (9.94) 36.2 (12.41) 37.1 (11.21)
Median (min., max.) 41 (16, 48) 39 (1, 48) 40.5 (1, 48)
Max., maximum; min., minimum.
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FIGURE 10Mean OSS scores (with 95% CIs) over time by treatment group and age group. (a)<65 years and
(b)≥65 years.
TABLE 29Difference in mean OSS scores over time by treatment group: subgroup analysis 1–age
(<65 years/≥65 years)a
Folow-up
Surgery (n=125;n=114
in analysis), mean (95% CI)
Not surgery (n=125;n=117
in analysis), mean (95% CI) Difference (95% CI) p-value
Overal 38.98 (37.21 to 40.68) 38.40 (36.66 to 40.07) 0.58 (–1.52 to 2.68) 0.590
6 months 37.74 (35.83 to 39.56) 35.69 (33.72 to 37.55) 2.06 (–0.28 to 4.40) 0.085
12 months 39.14 (37.29 to 40.91) 38.89 (37.08 to 40.62) 0.26 (–1.96 to 2.47) 0.822
24 months 40.03 (38.15 to 41.82) 40.48 (38.68 to 42.21) –0.46 (–2.71 to 1.79) 0.690
a Multilevel model adjusted for treatment group, time (6, 12 and 24 months), group × time interaction, baseline EQ-5D
index, gender, age (<65 years/≥65 years), group × age interaction and tuberosity involvement at baseline (yes/no).
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TABLE 30Descriptive OSS statistics over time by treatment group and tuberosity involvement
Folow-up Surgery (n=125) Not surgery (n=125) Total (n=250)
Neither tuberosity involved (n=57)
6 months
n 24 29 53
Mean (SD) 37.6 (9.81) 33.6 (11.89) 35.4 (11.09)
Median (min., max.) 41.5 (18, 48) 36 (3, 48) 38 (3, 48)
12 months
n 22 28 50
Mean (SD) 38.7 (10.58) 36.6 (11.92) 37.5 (11.29)
Median (min., max.) 44 (14, 48) 43 (7, 48) 43 (7, 48)
24 months
n 21 26 47
Mean (SD) 39.0 (9.86) 40.0 (12.34) 39.6 (11.19)
Median (min., max.) 43 (16, 48) 45.5 (1, 48) 44 (1, 48)
Greater and/or lesser tuberosity involved (n=193)
6 months
n 89 90 179
Mean (SD) 35.7 (10.05) 32.9 (10.78) 34.3 (10.48)
Median (min., max.) 39 (11, 48) 33.5 (3, 48) 37 (3, 48)
12 months
n 89 86 175
Mean (SD) 36.4 (10.84) 36.4 (10.57) 36.4 (10.68)
Median (min., max.) 40 (1, 48) 40 (4, 48) 40 (1, 48)
24 months
n 85 83 168
Mean (SD) 38.1 (9.97) 37.9 (10.53) 38.0 (10.23)
Median (min., max.) 41 (16, 48) 42 (3, 48) 41.5 (3, 48)
Max., maximum; min., minimum.
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The same multilevel model as for the primary analysis was applied but an additional treatment group by
tuberosity involvement interaction was included. Adjusted OSS means and group diferences for this model
are presented inTable 31. Similar to the primary analysis, there was no significant overal efect of
treatment group over the 2-year folow-up period and no significant efect of treatment group at individual
time points. A 2-log likelihood comparison with the primary analysis model was not significant [χ2(1)<0.01,
p=0.954]; therefore, inclusion of the interaction did not significantly improve the model.
Independent Neer classification (sensitivity analysis)
The Neer classification categories were grouped into one- or two-part fractures and three- or four-part
fractures. The relationship between Neer grouping and treatment group in terms of OSS scores is
ilustrated inTable 32andFigure 12. Patients with Neer three- or four-part fractures had lower OSS scores
(poorer shoulder functioning), and scores in the surgery group were higher than those in the non-surgery
group at al time points, although CIs overlapped. Patients with Neer one- or two-part fractures seemed to
improve shoulder functioning at a slower rate over time in the surgery group than in the non-surgery group.
SurgeryNot surgeryMe
an 
OSS
45
40
35
30
35
20
(a)
6 12
Folow-up times (months)
24
Treatment group
SurgeryNot surgery
Me
an 
OSS
45
40
35
30
35
20
(b)
6 12
Folow-up times (months)
24
Treatment group
FIGURE 11Mean OSS scores (with 95% CIs) over time by treatment group and tuberosity involvement. (a) Neither
tuberosity involved and (b) greater and/or lesser tuberosity involved.
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TABLE 31Difference in mean OSS scores over time by treatment group: subgroup analysis 2–tuberosity
involvement (yes/no)a
Folow-up
Surgery (n=125;n=114
in analysis), mean (95% CI)
Not surgery (n=125;n=117
in analysis), mean (95% CI) Difference (95% CI) p-value
Overal 39.05 (37.10 to 40.90) 38.33 (36.48 to 40.10) 0.71 (–1.79 to 3.22) 0.577
6 months 37.81 (35.73 to 39.79) 35.61 (33.53 to 37.57) 2.20 (–0.54 to 4.94) 0.115
12 months 39.20 (37.18 to 41.12) 38.82 (36.91 to 40.64) 0.38 (–2.22 to 2.98) 0.772
24 months 40.09 (38.05 to 42.02) 40.42 (38.52 to 42.23) –0.33 (–2.94 to 2.28) 0.804
a Multilevel model adjusted for treatment group, time (6, 12 and 24 months), group × time interaction, baseline EQ-5D
index, gender, age (<65 years/≥65 years), tuberosity involvement at baseline (yes/no) and group × tuberosity
involvement interaction.
TABLE 32Descriptive OSS statistics over time by treatment group and Neer classification
Folow-up Surgery (n=125) Not surgery (n=125) Total (n=250)
Neer one- and two-part fractures (n=146)
6 months
n 69 67 136
Mean (SD) 37.4 (9.69) 34.6 (10.59) 36.0 (10.20)
Median (min., max.) 41 (12, 48) 37 (3, 48) 39 (3, 48)
12 months
n 66 62 128
Mean (SD) 38.2 (10.51) 38.4 (10.62) 38.3 (10.52)
Median (min., max.) 42.5 (5, 48) 43 (4, 48) 43 (4, 48)
24 months
n 63 58 121
Mean (SD) 39.0 (10.40) 40.8 (10.34) 39.9 (10.37)
Median (min., max.) 43 (16, 48) 45 (1, 48) 44 (1, 48)
Neer three- and four-part fractures (n=104)
6 months
n 44 52 96
Mean (SD) 34.0 (10.21) 31.1 (11.30) 32.4 (10.86)
Median (min., max.) 36.5 (11, 48) 32 (7, 48) 33 (7, 48)
12 months
n 45 52 97
Mean (SD) 35.0 (11.03) 34.1 (10.80) 34.5 (10.86)
Median (min., max.) 37 (1, 48) 36 (10, 48) 37 (1, 48)
24 months
n 43 51 94
Mean (SD) 37.2 (9.16) 35.6 (11.08) 36.3 (10.23)
Median (min., max.) 39 (16, 48) 39 (3, 48) 39 (3, 48)
Max., maximum; min., minimum.
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A similar multilevel model to the primary analysis was applied but the Neer grouping term replaced the
tuberosity involvement term and the model additionaly included a treatment group × Neer grouping
interaction. Adjusted OSS means and group diferences for this model are presented inTable 33. Similar to
the primary analysis, there was no significant overal efect of treatment group over the 2-year folow-up
period and no significant efect of treatment group at individual time points. A 2-log likelihood comparison
with an adjusted primary analysis model (including Neer grouping instead of tuberosity involvement) was
not significant [χ2(1)=0.05,p=0.823]; therefore, inclusion of the interaction did not significantly improve
the model.
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FIGURE 12Mean OSS scores (with 95% CIs) over time by treatment group and Neer grouping. (a) Neer one- and
two-part fractures and (b) Neer three- and four-part fractures.
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Sensitivity analysis: smoking
A sensitivity analysis was undertaken for the primary outcome model to explore whether or not outcomes
were robust when smoking status was taken into account. Smoking is associated with a number of
complications and additionaly was found to be imbalanced at baseline (surgery group: 19% smokers; not
surgery group: 32% smokers).
Descriptive OSS statistics by treatment group and smoking status at 6, 12 and 24 months are provided in
Table 34and ilustrated inFigure 13.
The OSS scores improved for both smokers and non-smokers over the trial period. Because of the relatively
smaler number of participants who were smokers, the variability of scores around the mean was greater
for this group. Although scores at 6 and 12 months’folow-up were comparable between smokers and
non-smokers, at 24 months the mean OSS score was around 2 score points higher for non-smokers.
Again, surgical group scores were noticeably higher than those for the non-surgery group at 6 months,
although CIs substantialy overlapped.
The same multilevel model as for the primary analysis was applied but an additional smoking status was
included as a covariate. Adjusted OSS means and group diferences for this model are presented inTable 35.
Similar to the primary analysis, there was no significant overal efect of treatment group over the 2-year
folow-up period and no significant efect of treatment group at individual time points. Therefore, the results
of the primary analysis are robust.
TABLE 33Difference in mean OSS scores over time by treatment group: subgroup analysis 2–Neer grouping
(one- and two-part fractures/three- and four-part fractures)a
Folow-up
Surgery (n=125;n=114 in
analysis), mean (95% CI)
Not surgery (n=125;n=117 in
analysis), mean (95% CI) Difference (95% CI) p-value
Overal 38.20 (36.50 to 39.82) 37.65 (36.00 to 39.23) 0.55 (–1.58 to 2.68) 0.613
6 months 36.93 (35.09 to 38.69) 34.86 (32.98 to 36.64) 2.08 (–0.29 to 4.45) 0.086
12 months 38.36 (36.58 to 40.06) 38.15 (36.42 to 39.80) 0.21 (–2.03 to 2.46) 0.853
24 months 39.26 (37.46 to 40.99) 39.77 (38.05 to 41.43) –0.51 (–2.79 to 1.77) 0.661
a Multilevel model adjusted for treatment group, time (6, 12 and 24 months), treatment group × time interaction, baseline
EQ-5D index, gender, age (<65 years/≥65 years), Neer grouping (one- and two-part fractures/three- and four-part
fractures) and treatment group × Neer grouping interaction.
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TABLE 34Descriptive OSS statistics over time by treatment group and smoking status
Folow-up Surgery (n=125) Not surgery (n=125) Total (n=250)
Smoking status: smoker (n=64)
6 months
n 22 37 59
Mean (SD) 34.7 (11.99) 31.7 (10.61) 32.8 (11.14)
Median (min., max.) 39 (11, 48) 33 (8, 48) 34 (8, 48)
12 months
n 22 33 55
Mean (SD) 37.4 (11.68) 36.1 (10.76) 36.6 (11.05)
Median (min., max.) 42 (14, 48) 40 (13, 48) 42 (13, 48)
24 months
n 20 (16.0) 33 53 (21.2)
Mean (SD) 36.8 (11.04) 37.0 (11.41) 36.9 (11.17)
Median (min., max.) 42 (16, 48) 41 (3, 48) 41 (3, 48)
Smoking status: non-smoker (n=177)
6 months
n 86 78 164
Mean (SD) 36.3 (9.55) 33.4 (11.21) 34.9 (10.44)
Median (min., max.) 39 (14, 48) 36 (3, 48) 37 (3, 48)
12 months
n 85 77 162
Mean (SD) 36.6 (10.77) 36.3 (11.01) 36.4 (10.85)
Median (min., max.) 40 (1, 48) 41 (4, 48) 41 (1, 48)
24 months
n 82 72 154
Mean (SD) 38.7 (9.59) 38.7 (10.95) 38.7 (10.21)
Median (min., max.) 42 (16, 48) 42.5 (1, 48) 42 (1, 48)
Max., maximum; min., minimum.
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FIGURE 13Mean OSS scores (with 95% CIs) over time by treatment group and smoking status. (a) Smoker and
(b) non-smoker.
TABLE 35Difference in mean OSS scores over time by treatment group: sensitivity analysis–smokinga
Folow-up
Surgery (n=125;n=109
in analysis), mean (95% CI)
Not surgery (n=125;n=114
in analysis), mean (95% CI) Difference (95% CI) p-value
Overal 38.65 (36.74 to 40.48) 38.05 (36.24 to 39.79) 0.60 (–1.57 to 2.77) 0.588
6 months 37.40 (35.34 to 39.35) 35.31 (33.26 to 37.24) 2.09 (–0.32 to 4.50) 0.089
12 months 38.76 (36.76 to 40.66) 38.53 (36.65 to 40.33) 0.23 (–2.06 to 2.51) 0.847
24 months 39.77 (37.75 to 41.69) 40.16 (38.29 to 41.96) –0.40 (–2.72 to 1.93) 0.739
a Multilevel model adjusted for treatment group, time (6, 12 and 24 months), group × time interaction, smoking status
(yes/no), baseline EQ-5D index, gender, age group (<65 years/≥65 years) and tuberosity involvement at baseline
(yes/no).
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Patients’baseline treatment preferences
Treatment preference was recorded for al eligible patients. Surgeons recorded treatment preference for
non-consenting patients, and consenting patients recorded whether or not they had any treatment
preference at baseline, before randomisation.
Patient preferences at baseline are shown inTable 36. The majority of non-consenting patients (72%)
expressed a preference for non-surgical treatment, whereas this applied to only 24% of consenters. Of the
consenters, just under half (46%) had no treatment preference and the remainder were split slightly in
favour of surgical treatment (29% vs. 24% for non-surgical treatment). Patients in the surgery group
showed a greater preference for surgical treatment (33% vs. 25% in the non-surgery group), whereas
patients in the non-surgery group were more likely to have no preference (50% vs. 42% in the
surgery group).
Descriptive OSS statistics by treatment group and patient preference at 6, 12 and 24 months are detailed
inTable 37and ilustrated inFigure 14. Although OSS scores improved for al groups over time, patients
who expressed a preference for surgery generaly reported the lowest OSS scores folowed by patients who
had no preference; patients who expressed a preference for no surgery had the highest OSS scores. The
diference between treatment groups in favour of surgery at 6 months’folow-up was most pronounced
for patients who had no preference for either treatment.
Patients who prefered surgery tended to be older (by 3 years on average) and presented earlier (by 2 days)
with more complex fractures (7% more factures involving one or both tuberosities) than patients who
prefered not to have surgery; this gives an indication why these patients had poorer OSS outcomes.
The same multilevel model as for the primary analysis was applied but additionaly patient preference at
baseline and its interaction with alocated treatment group were included as covariates. Adjusted OSS
means and group diferences are presented inTable 38. Again, there was no significant overal efect of
treatment group over the 2-year folow-up period or at individual time points.
Of al the analyses adding further terms to the primary model (age, fracture type, smoking status, patient
preference), this model reduced the magnitude of the treatment efect the most (from an overal group
diference of 0.75 score points to 0.50 score points), reflecting the additional variability in OSS scores
explained by patient preference, as seen inFigure 14. However, the interaction between patient preference
and alocated treatment was not statisticaly significant (F=0.29,p=0.751), even against a relaxed
significance level of 0.1.
TABLE 36Treatment preference of eligible patients at baseline
Preference Non-consenters (n=313),n(%)
Consenters,n(%)
Surgery (n=125) Not surgery (n=125) Total (n=250)
Surgery 55 (17.6) 41 (32.8) 31 (24.8) 72 (28.8)
Not surgery 226 (72.2) 32 (25.6) 28 (22.4) 60 (24.0)
No preference 23 (7.3) 52 (41.6) 63 (50.4) 115 (46.0)
Missing data 9 (2.9) 0 (0.0) 3 (2.4) 3 (1.2)
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TABLE 37Descriptive OSS statistics over time by treatment group and patient preference
Folow-up Surgery (n=125) Not surgery (n=125) Total (n=250)
Preference surgery (n=72)
6 months
n 39 31 70
Mean (SD) 32.9 (11.38) 31.7 (12.80) 32.4 (11.96)
Median (min., max.) 33 (11, 48) 32 (3, 48) 33 (3, 48)
12 months
n 38 30 68
Mean (SD) 34.1 (11.50) 34.4 (12.10) 34.2 (11.68)
Median (min., max.) 36 (1, 48) 37.5 (4, 48) 37 (1, 48)
24 months
n 37 27 64
Mean (SD) 36.2 (11.61) 36.0 (11.92) 36.1 (11.65)
Median (min., max.) 41 (16, 48) 39 (1, 48) 39.5 (1, 48)
Preference not surgery (n=60)
6 months
n 28 27 55
Mean (SD) 39.6 (8.09) 37.0 (7.29) 38.3 (7.75)
Median (min., max.) 42.5 (20, 48) 39 (20, 48) 39 (20, 48)
12 months
n 27 27 54
Mean (SD) 39.6 (8.67) 39.7 (7.14) 39.6 (7.86)
Median (min., max.) 41 (19, 48) 42 (23, 48) 41.5 (19, 48)
24 months
n 25 27 52
Mean (SD) 41.5 (7.07) 42.2 (6.16) 41.9 (6.55)
Median (min., max.) 44 (23, 48) 44 (25, 48) 44 (213, 48)
No preference (n=115)
6 months
n 46 58 104
Mean (SD) 36.6 (9.11) 31.9 (11.28) 34.0 (10.60)
Median (min., max.) 39 (17, 48) 34.5 (7, 48) 37 (7, 48)
12 months
n 46 54 100
Mean (SD) 37.7 (10.98) 36.2 (11.23) 36.9 (11.08)
Median (min., max.) 42 (5, 48) 42 (10, 48) 42 (5, 48)
24 months
n 44 52 96
Mean (SD) 38.1 (9.44) 37.5 (12.18) 37.8 (10.96)
Median (min., max.) 41.5 (16, 48) 42 (3, 48) 42 (3, 48)
Max., maximum; min., minimum.
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FIGURE 14Mean OSS scores (with 95% CIs) over time by treatment group and patient preference. (a) Preference
surgery; (b) preference not surgery; and (c) no preference.
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Exploration of centre variability
In our analysis plan we revised our intention to explore the potential for clustering, from individual
surgeons to the level of the centre, in essence quantifying the performance of the surgical team(s) rather
than that of an individual surgeon within the centre. This was because of the low numbers of patients
treated by an individual surgeon. Among the 33 centres that screened patients, around 60% (n=148) of
the 250 participants were recruited by eight sites (12–43 patients each, 18.5 patients on average) and
around 40% (n=102) were recruited by the remaining 25 centres (0–9 patients each, 4.1 patients
on average).
Mean OSS scores and 95% CIs for randomised patients in each centre at each folow-up time point
are ilustrated inFigure 15. These ranged from 22 to 48 score points, but no centre appeared to be
substantialy outlying. When CIs were either exceptionaly wide or did not include the overal mean, this
was predominantly because of the smal number of patients in those centres. Extreme CI limits are not
displayed in ful here. When no CIs are displayed, the sample size was equal to 1, except in one case in
which there were two patients with identical scores.
The distribution of scores is further examined using box plots of OSS scores (Figure 16). These show a wide
spread of scores within each centre, again afected by smal sample sizes in some centres, and highlight a
smal number of outliers.
Summary of the Oxford Shoulder Score multilevel
modeling results
Table 39summarises the OSS estimates for each treatment group as wel as group diferences folowing
multilevel analysis. These are generated using a mixed-efect model with a random slope of time within
patients. The outcome is the squared OSS (estimates are back transformed in the table). Fixed efects for
each model are given in the footnotes.
TABLE 38Difference in mean OSS scores over time by treatment group: including patient preferences at baselinea
Folow-up
Surgery (n=125;n=114
in analysis), mean (95% CI)
Not surgery (n=125;n=115
in analysis), mean (95% CI) Difference (95% CI) p-value
Overal 39.14 (37.38 to 40.83) 38.65 (36.85 to 40.37) 0.50 (–1.64 to 2.63) 0.649
6 months 37.91 (36.01 to 39.72) 35.91 (33.89 to 37.83) 2.00 (–0.37 to 4.36) 0.098
12 months 39.30 (37.46 to 41.06) 39.22 (37.36 to 40.99) 0.86 (–2.16 to 2.33) 0.940
24 months 40.19 (38.32 to 41.98) 40.66 (38.80 to 42.44) –0.47 (–2.76 to 1.82) 0.687
a Multilevel model adjusted for treatment group, time (6, 12 and 24 months), group × time interaction, patient preference,
group × patient preference interaction, baseline EQ-5D index, gender, age group (<65 years/≥65 years) and tuberosity
involvement at baseline (yes/no).
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TABLE 39Difference in mean OSS scores over time by treatment group
Folow-up
Surgery (n=125),a
mean (95% CI)
Not surgery (n=125),a
mean (95% CI) Difference (95% CI) p-value
Primary analysisb
Overal 39.07 (37.30 to 40.76) 38.32 (36.57 to 39.99) 0.75 (–1.33 to 2.84) 0.479
6 months 37.84 (35.93 to 39.65) 35.59 (33.62 to 37.45) 2.25 (–0.07 to 4.57) 0.058
12 months 39.23 (37.38 to 40.99) 38.80 (36.99 to 40.53) 0.42 (–1.78 to 2.63) 0.706
24 months 40.11 (38.24 to 41.90) 40.40 (38.59 to 42.13) –0.29 (–2.53 to 1.95) 0.800
Subgroup analysis 1: age (<65 years/≥65 years)c
Overal 38.98 (37.21 to 40.68) 38.40 (36.66 to 40.07) 0.58 (–1.52 to 2.68) 0.590
6 months 37.74 (35.83 to 39.56) 35.69 (33.72 to 37.55) 2.06 (–0.28 to 4.40) 0.085
12 months 39.14 (37.29 to 40.91) 38.89 (37.08 to 40.62) 0.26 (–1.96 to 2.47) 0.822
24 months 40.03 (38.15 to 41.82) 40.48 (38.68 to 42.21) –0.46 (–2.71 to 1.79) 0.690
Subgroup analysis 2: tuberosity involvement (yes/no)d
Overal 39.05 (37.10 to 40.90) 38.33 (36.48 to 40.10) 0.71 (–1.79 to 3.22) 0.577
6 months 37.81 (35.73 to 39.79) 35.61 (33.53 to 37.57) 2.20 (–0.54 to 4.94) 0.115
12 months 39.20 (37.18 to 41.12) 38.82 (36.91 to 40.64) 0.38 (–2.22 to 2.98) 0.772
24 months 40.09 (38.05 to 42.02) 40.42 (38.52 to 42.23) –0.33 (–2.94 to 2.28) 0.804
Subgroup analysis 2 (sensitivity analysis): Neer grouping (one- and two-part fractures/three- and four-part fractures)e
Overal 38.20 (36.50 to 39.82) 37.65 (36.00 to 39.23) 0.55 (–1.58 to 2.68) 0.613
6 months 36.93 (35.09 to 38.69) 34.86 (32.98 to 36.64) 2.08 (–0.29 to 4.45) 0.086
12 months 38.36 (36.58 to 40.06) 38.15 (36.42 to 39.80) 0.21 (–2.03 to 2.46) 0.853
24 months 39.26 (37.46 to 40.99) 39.77 (38.05 to 41.43) –0.51 (–2.79 to 1.77) 0.661
Sensitivity analysis: smoking status (yes/no)f
Overal 38.65 (36.74 to 40.48) 38.05 (36.24 to 39.79) 0.60 (–1.57 to 2.77) 0.588
6 months 37.40 (35.34 to 39.35) 35.31 (33.26 to 37.24) 2.09 (–0.32 to 4.50) 0.089
12 months 38.76 (36.76 to 40.66) 38.53 (36.65 to 40.33) 0.23 (–2.06 to 2.51) 0.847
24 months 39.77 (37.75 to 41.69) 40.16 (38.29 to 41.96) –0.40 (–2.72 to 1.93) 0.739
continued
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TABLE 39Difference in mean OSS scores over time by treatment group (continued)
Folow-up
Surgery (n=125),a
mean (95% CI)
Not surgery (n=125),a
mean (95% CI) Difference (95% CI) p-value
Patient preference analysis (surgery/not surgery/no preference)g
Overal 39.14 (37.38 to 40.83) 38.65 (36.85 to 40.37) 0.50 (–1.64 to 2.63) 0.649
6 months 37.91 (36.01 to 39.72) 35.91 (33.89 to 37.83) 2.00 (–0.37 to 4.36) 0.098
12 months 39.30 (37.46 to 41.06) 39.22 (37.36 to 40.99) 0.86 (–2.16 to 2.33) 0.940
24 months 40.19 (38.32 to 41.98) 40.66 (38.80 to 42.44) –0.47 (–2.76 to 1.82) 0.687
a Numbers given are those randomised. The numbers of patients included in each analysis are stated in the footnotes.
These are the numbers of patients with valid OSS data for at least one folow-up time point and complete
baseline covariates.
b Fixed efects: group, time (6, 12 and 24 months), group × time interaction, baseline EQ-5D index, gender, age
(<65 years/≥65 years), tuberosity involvement at baseline (yes/no). Included in the analysis: 114 surgery group,
117 not surgery group.
c Fixed efects: group, time (6, 12 and 24 months), group × time interaction, baseline EQ-5D index, gender, age group
(<65 years/≥65 years), group × age group interaction, tuberosity involvement at baseline (yes/no). Included in the
analysis: 114 surgery group, 117 not surgery group.
d Fixed efects: group, time (6, 12 and 24 months), group × time interaction, baseline EQ-5D index, gender, age group
(<65 years/≥65 years), tuberosity involvement at baseline (yes/no), group × tuberosity involvement interaction. Included
in the analysis: 114 surgery group, 117 not surgery group.
e Fixed efects: group, time (6, 12 and 24 months), group × time interaction, baseline EQ-5D index, gender, age group
(<65 years/≥65 years), Neer grouping (one- and two-part fractures/three- and four-part fractures), group × Neer
grouping interaction. Included in the analysis: 114 surgery group, 117 not surgery group.
f Additional fixed efects: group, time (6, 12 and 24 months), group × time interaction, baseline EQ-5D index, gender, age
group (<65 years/≥65 years), smoking status (yes/no), tuberosity involvement at baseline (yes/no). Included in the
analysis: 109 surgery group, 114 not surgery group.
g Additional fixed efects: group, time (6, 12 and 24 months), group × time interaction, baseline EQ-5D index, gender, age
group (<65 years/≥65 years), patient preference, group × patient preference interaction, tuberosity involvement at
baseline (yes/no). Included in the analysis: 114 surgery group, 115 not surgery group.
PRIMARY OUTCOME (OXFORD SHOULDER SCORE) ANALYSIS
NIHR Journals Librarywww.journalslibrary.nihr.ac.uk
80
Chapter 6Results: analyses of secondary and
other outcomes and supplementary analyses
12-item Short Form health survey
The 12 SF-12 questions were summarised into eight domain scores, each based on one or two
questionnaire items. If at least one question had been completed for a domain, any missing items were
replaced with the available score for that domain. Weighted estimates of the eight SF-12 domains were
then used to calculate the PCS score and MCS score, each ranging from 0 to 100 score points, with higher
scores representing a beter health status. Al domain scores needed to be available for the calculation of
the PCS and MCS scores. Scores were standardised against the general US population (mean 50, SD 10).69
Using standard efect sizes, diferences of 2, 5 and 8 score points would corespond to smal, medium and
large diferences respectively.
Physical component summary score
Descriptive SF-12 PCS score statistics at 6, 12 and 24 months are shown inTable 40and ilustrated in
Figure 17. The distribution of scores is presented inFigure 18.
Overal, physical functioning remained largely unchanged over the trial period. The distribution of scores
was approximately normal at al time points. Mean PCS scores were slightly higher for the surgery group at
al time points, with group diferences being largest at 6 months. There was substantial overlap in the CIs
between groups.
A similar multilevel model to that in the OSS analysis was applied, using SF-12 PCS score as the outcome
(no transformation was found to be necessary) and including the same predictors. Adjusted SF-12 PCS
score means and group diferences for this model are presented inTable 41. The results mirored those of
the OSS analysis, with slightly beter functioning in the surgery group by an average of between 1.3 and
2.6 score points over the 2-year folow-up period. None of the diferences between the two groups,
overal or at individual time points, was statisticaly significant. Similar to the OSS outcome, the largest
group diference was observed at 6 months’folow-up.
Mental component summary score
Descriptive SF-12 MCS score statistics at 6, 12 and 24 months are shown inTable 42and ilustrated in
Figure 19. The distribution of scores is presented inFigure 20.
Overal, mental functioning improved slightly over the trial period. The distribution of scores was slightly
left skewed at 6 and 12 months, which became more pronounced at 24 months. Unlike physical
functioning, as assessed by the OSS and PCS score, the mean MCS score was slightly higher for the
non-surgery group at al time points, with the group diference being greatest at 12 months. There was
substantial overlap of the 95% CIs of the two groups.
A similar multilevel model to the OSS analysis was applied, using SF-12 MCS score as the outcome
(no transformation was found to be necessary) and including the same predictors. Adjusted SF-12 MCS
score means and group diferences for this model are presented inTable 43. There were beter scores in
the non-surgery arm by an average of between 0.5 and 2.0 score points over the 2-year folow-up period.
This diference was not statisticaly significant over the 2-year folow-up period or at individual time points.
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FIGURE 17Mean SF-12 PCS scores (with 95% CIs) over time by treatment group.
TABLE 40Descriptive SF-12 PCS score statistics over time by treatment group
Folow-up Surgery (n=125) Not surgery (n=125) Total (N=250)
6 months
n(%) 106 (84.8) 110 (88.0) 216 (86.4)
Mean (SD) 45.3 (10.01) 42.7 (11.25) 43.9 (10.71)
Median (min., max.) 46.7 (15.4, 64.1) 43.6 (11.9, 62.4) 45.0 (11.9, 64.1)
12 months
n(%) 108 (86.4) 110 (88.0) 218 (87.2)
Mean (SD) 45.2 (10.98) 43.7 (10.98) 44.5 (10.93)
Median (min., max.) 45.2 (14.9, 63.7) 44.1 (17.6, 61.3) 44.7 (14.9, 63.7)
24 months
n(%) 105 (84.0) 105 (84.0) 210 (84.0)
Mean (SD) 45.2 (11.30) 44.1 (11.58) 44.6 (11.43)
Median (min., max.) 46.1 (14.9, 65.7) 45.2 (14.3, 60.7) 46.0 (14.3, 65.7)
Max., maximum; min., minimum.
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FIGURE 18Distribution of SF-12 PCS scores over time. (a) 6 months; (b) 12 months; and (c) 24 months.
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TABLE 41Difference in mean SF-12 PCS scores over time by treatment groupa
Folow-up
Surgery (n=125;n=111
in analysis), mean (95% CI)
Not surgery (n=125;n=115
in analysis), mean (95% CI) Difference (95% CI) p-value
Overal 45.64 (43.44 to 47.84) 43.87 (41.75 to 45.99) 1.77 (–0.84 to 4.39) 0.184
6 months 45.73 (43.44 to 48.02) 43.18 (40.97 to 45.39) 2.55 (–0.21 to 5.32) 0.070
12 months 45.51 (43.22 to 47.80) 44.22 (42.01 to 46.43) 1.29 (–1.48 to 4.06) 0.361
24 months 45.68 (43.28 to 48.08) 44.20 (41.87 to 46.54) 1.48 (–1.48 to 4.43) 0.327
a Multilevel model adjusted for treatment group, time (6, 12 and 24 months), group × time interaction, baseline EQ-5D
index, gender, age group (<65 years/≥65 years) and tuberosity involvement at baseline (yes/no).
TABLE 42Descriptive SF-12 MCS score statistics over time by treatment group
Folow-up Surgery (n=125) Not surgery (n=125) Total (N=250)
6 months
n(%) 106 (84.8) 110 (88.0) 216 (86.4)
Mean (SD) 49.2 (10.84) 49.8 (11.46) 49.5 (11.14)
Median (min., max.) 52.2 (20.3, 63.7) 52.1 (17.6, 68.4) 52.2 (17.6, 68.4)
12 months
n(%) 108 (86.4) 110 (88.0) 218 (87.2)
Mean (SD) 48.8 (10.51) 50.8 (10.67) 49.8 (10.61)
Median (min., max.) 51.2 (17.8, 66.2) 54.0 (15.8, 67.4) 52.6 (15.8, 67.4)
24 months
n(%) 105 (84.0) 105 (84.0) 210 (84.0)
Mean (SD) 50.1 (11.64) 51.5 (9.96) 50.8 (10.83)
Median (min., max.) 55.2 (8.8, 64.4) 54.2 (21.2, 66.1) 54.3 (8.8, 66.1)
Max., maximum; min., minimum.
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FIGURE 19Mean SF-12 MCS scores (with 95% CIs) over time by treatment group.
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FIGURE 20Distribution of SF-12 MCS scores over time. (a) 6 months; (b) 12 months; and (c) 24 months.
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Surgical and shoulder fracture-related complications
Surgical and other shoulder fracture-related complications were recorded at the end of patients’
orthopaedic inpatient episodes when applicable and at 1- and 2 years’folow-up. Clinic staf could select
from a list of predefined complication categories or indicate‘other’. For each, descriptions could be added
as free text and resulting treatments could be detailed in a further section on each form.
As described inChapter 3, to ensure the validity and interpretability of the entered complications, two
expert raters assessed each reported complication in the context of the information provided elsewhere on
the same form or previous/subsequent forms as wel as the other trial data available for that patient and
agreed on any changes. Using clinical judgement, some records were recategorised and entries under
‘other’were grouped when possible. Duplicate and irelevant information was removed and additional
complications were appended to the data if these were clearly reported elsewhere, for example when
included in the description of further treatment (seeAppendix 36).
The final data set consisted of 59 surgical and shoulder fracture-related complications reported for
53 patients (Table 44).
Apart from haematoma formation at the surgical site, al predefined complications were reported at least
once. In the surgery group, a total of 30 patients (24%) experienced at least one complication over the
2-year folow-up period. These included six patients with two complications, which were concurent for
three of these patients. The majority of complications were reported at the 1-year folow-up. The most
common complications in the surgery group were metalwork problems (n=10) and post-traumatic
stifness (n=6). It is noteworthy that three of the four reported malunions occured for crossover patients
who were alocated to surgery but who did not receive the intervention. In the non-surgery group, a total
of 23 patients (18%) experienced one complication each over the trial period. Al but four of these were
reported at the 1-year folow-up. The most common complications in this group were malunion (n=5),
nonunion (n=5) and post-traumatic stifness (n=5). Although marginaly more patients in the surgery
group experienced these complications, a chi-squared test revealed that there was no statisticaly
significant diference between the treatment groups [χ2(1)=1.17,p=0.279].
To ascertain whether or not certain atributes may predispose patients to experience a surgical or shoulder-
related complication, selected baseline characteristics for patients who sufered at least one complication
(n=53) and patients for whom no complications were reported (n=197) were compared (Table 45). No
marked between-group diferences were evident. [Although patients with complications appeared to be
marginaly younger (49% were aged<65 years compared with 42% of patients without complications),
the mean ages of the treatment groups were similar.]
TABLE 43Difference in mean SF-12 MCS scores over time by treatment groupa
Folow-up
Surgery (n=125;n=111
in analysis), mean (95% CI)
Not surgery (n=125;n=115
in analysis), mean (95% CI) Difference (95% CI) p-value
Overal 48.66 (46.55 to 50.77) 49.96 (47.92 to 52.00) –1.28 (–3.80 to 1.23) 0.317
6 months 48.43 (46.07 to 50.80) 48.95 (46.66 to 51.24) –0.52 (–3.44 to 2.41) 0.729
12 months 48.24 (45.96 to 50.53) 50.20 (47.98 to 52.41) –1.95 (–4.76 to 0.85) 0.172
24 months 49.30 (46.97 to 51.64) 50.69 (48.40 to 52.97) –1.38 (–4.27 to 1.51) 0.349
a Multilevel model adjusted for treatment group, time (6, 12 and 24 months), group × time interaction, baseline EQ-5D
index, gender, age group (<65 years/≥65 years) and tuberosity involvement at baseline (yes/no).
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TABLE 45Baseline characteristics by presence and absence of surgical and shoulder fracture-related
complications
Characteristic
Patients with at least one
complication (n=53)
Patients without
complications (n=197) Total (N=250)
Gender,n(%)
Male 12 (22.6) 46 (23.4) 58 (23.2)
Female 41 (77.4) 151 (76.6) 192 (76.8)
Age (years)
n 53 197 250
Mean (SD) 65.3 (13.33) 66.2 (11.56) 66.0 (11.94)
Median (min., max.) 65.2 (24.6, 89.0) 67.4 (31.3, 92.0) 66.9 (24.6, 92.0)
Age (group),n(%)
<65 years 26 (49.1) 82 (41.6) 108 (43.2)
≥65 years 27 (50.9) 115 (58.4) 142 (56.8)
Diabetes,n(%)
Yes 7 (13.2) 24 (12.2) 31 (12.4)
No 46 (86.8) 171 (86.8) 217 (86.8)
Missing 0 (0.0) 2 (1.0) 2 (0.8)
Smoking status,n(%)
Yes 15 (28.3) 49 (24.9) 64 (25.6)
No 37 (69.8) 140 (71.1) 177 (70.8)
Missing 1 (1.9) 8 (4.1) 9 (3.6)
Steroid use,n(%)
Yes 3 (5.7) 10 (5.1) 13 (5.2)
No 49 (92.5) 185 (93.9) 234 (93.6)
Missing 1 (1.9) 2 (1.0) 3 (1.2)
Health status (EQ-5D index)
n 51 193 244
Mean (SD) 0.40 (0.38) 0.41 (0.37) 0.40 (0.37)
Median (min., max.) 0.59 (–0.36, 1) 0.33 (–0.35, 1) 0.33 (–0.36, 1)
Tuberosity involvement,n(%)
Yes 40 (75.5) 153 (77.7) 193 (77.2)
No 13 (24.5) 44 (22.3) 57 (22.8)
Tuberosity involvement,n(%)
Tuberosity not involved
or missing
13 (24.5) 44 (22.3) 57 (22.8)
Greater tuberosity 22 (41.5) 97 (49.2) 119 (47.6)
Lesser tuberosity 3 (5.7) 7 (3.6) 10 (4.0)
Greater and lesser
tuberosity
15 (28.3) 49 (24.9) 64 (25.6)
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Treatments for surgical and shoulder fracture-related complications
Clinical staf were asked to detail any secondary surgery or increased/new therapy for these complications
at the end of the orthopaedic inpatient episodes and again at the 1- and 2-year folow-ups.
After processing there were 33 valid entries reported for 33 patients, al of whom had received the
treatment that they were randomised to. Each treatment coresponded to a surgical or shoulder
fracture-related complication as detailed in the previous section. A breakdown of reported treatments by
time and treatment group is presented inTable 46.
Secondary surgery to the shoulder was reported for 22 (9%) of the 250 participants, with 11 in each
treatment group. Increased/new shoulder-related therapy was reported for 11 (4%) of the 250 participants,
of whom seven were in the surgery group and four were in the non-surgery group. Although numbers
were too smal for formal testing, there appeared to be no marked group diferences for secondary surgery
or increased/new therapies. There was no statisticaly significant diference when combining secondary
surgery and increased/new therapies to compare the total number of treatments between groups
[χ2(1)=0.31,p=0.575].
Using al available patient information, the two expert raters assessed whether a reported surgical or
shoulder fracture-related complication was addressed by further surgery or increased/new therapy and
whether or not each complication was ultimately resolved (Table 47). Proportionaly more complications
were treated surgicaly in the non-surgery group (48% vs. 33% in the surgery group). The opposite was
true for increased or new therapy (21% in the surgery group vs. 13% in the non-surgery group).
TABLE 45Baseline characteristics by presence and absence of surgical and shoulder fracture-related
complications (continued)
Characteristic
Patients with at least one
complication (n=53)
Patients without
complications (n=197) Total (N=250)
Previous fractures,n(%)
Yes 14 (26.4) 52 (26.4) 66 (26.4)
No 39 (73.6) 143 (72.6) 182 (72.8)
Missing 0 (0.0) 2 (1.0) 2 (0.8)
Previous surgery for fractures,n(%)
Yes 3 (5.7) 17 (8.6) 20 (8.0)
No 10 (18.9) 34 (17.3) 44 (17.6)
Missing 1 (1.9) 1 (0.5) 2 (0.8)
No previous fractures 39 (73.6) 145 (73.6) 184 (73.6)
Injury to dominant shoulder,n(%)
Yes 30 (56.6) 98 (49.7) 128 (51.2)
No 23 (43.4) 95 (48.2) 118 (47.2)
Missing 0 (0.0) 4 (2.0) 4 (1.6)
Max., maximum; min., minimum.
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TABLE 47Shoulder fracture-related complications: treatments and outcomes by treatment group
Treatment for complications
and outcome
Surgery (n=33
complications)a
Not surgery (n=23
complications)
Total (N=56
complications)
Secondary surgery,n(%)
Yes 11 (33.3) 11 (47.8) 22 (39.3)
No 22 (66.7) 12 (52.2) 34 (60.7)
No information 0 (0.0) 0 (0.0) 0 (0.0)
Increased/new therapy,n(%)
Yes 7 (21.2) 3 (13.0) 10 (17.9)
No 25 (75.8) 19 (82.6) 44 (78.6)
No information 1 (3.0) 1 (4.4) 2 (3.6)
Complication outcome,n(%)
Resolved 2 (6.1) 1 (4.4) 3 (5.4)
Resolving 1 (3.0) 1 (4.4) 2 (3.6)
Under review 4 (12.1) 2 (8.7) 6 (10.7)
Unresolved 2 (6.1) 2 (8.7) 4 (7.1)
Unresolved–further surgery 1 (3.0) 2 (8.7) 3 (5.4)
Not treated 6 (18.2) 4 (17.4) 10 (17.9)
No information 17 (51.5) 11 (47.8) 28 (50.0)
a There were 36 complications in the surgery group; these included three pairs of concurent complications that are
combined here as any treatments addressed them together.
TABLE 46Number of secondary surgeries or increased/new therapies by treatment group
Treatment for complications Surgery (n=125) Not surgery (n=125) Total (N=250)
Secondary surgery to the shoulder
End of orthopaedic inpatient episode,n 0 0  0
Year 1,n 6 9  15
Year 2,n 5 2  7
Total patients,n(%)a 11 (8.8) 11 (8.8) 22 (8.8)
Increased/new shoulder-related therapy
End of orthopaedic inpatient episode,n 1 0  1
Year 1,n 3 3  6
Year 2,n 3 1  4
Total patients,n(%)a 7 (5.6) 4 (3.2) 11 (4.4)
Total patients,n(%)a 18 (14.4) 15 (12.0) 33 (13.2)
a As no multiple treatments were reported (or kept after data screening) for any patient, the number of treatments equals
the number of patients.
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Information regarding treatment outcome was ascertainable for only half (50%) of the recorded
observations, and only a smal number (9%) were categorised as being resolved or resolving. There were
no marked between-group diferences in outcome.
The treatments and outcomes associated with the listed complications are shown for surgery inTable 48
and for non-surgery inTable 49. Linking this information in this way shows, for example, that the three
malunions for cross-over patients in the surgery group were‘not treated’. One patient with malunion
died before further treatment could be discussed. Four of the five nonunions in non-surgical group had
secondary surgery; the fifth patient died before referal for orthopaedic assessment.
Medical complications during the inpatient stay
Clinical staf were asked to select from a list of medical complications or specify any other medical
complications that occured during the patients’orthopaedic inpatient stay when applicable. End of
orthopaedic inpatient episode forms were received for 111 patients in the surgery group and 23 patients
in the non-surgery group.
After processing (seeAppendix 36), there was a total of 10 medical complications for 10 patients (4% of
al patients) (Table 50). Al complications were reported for patients in the surgery group, although two
of these patients were crossovers and did not receive their randomised treatment. Medical complications
could be grouped into cardiac or peripheral vascular events (MI, cardiac arest), respiratory events (two
chest infections) and gastrointestinal events (norovirus, jaundice); the remainder were individual
complications summarised under‘other’(urinary retention, intensive care admission and two
blood transfusions).
The smal number of complications limits the validity of comparing the baseline characteristics of the 10
patients with medical complications with the baseline characteristics of the 240 patients without medical
complications. Nonetheless, consistent with expectations, patients experiencing an early medical
complication tended to be older [mean (SD) age 71.8 (10.08) years vs. 65 (11.96) years].
Details of medical complications that occured after the inpatient stay were colected as treatment for
newly diagnosed medical complications at 1 and 2 years’folow-up (see the folowing section).
TABLE 48Details of the treatments and outcomes associated with the 36 complications in the surgery group
Complication na Recorded treatment Outcome
Surgical site infection 2 (T: antibiotics)b Resolved
– No information
Nerve injury 2 T: electromyography/nerve conduction tests Resolved
– No information
AVN 4 – Under review
– Under review
S: revision of PHILOS implant to hemiarthroplasty No information
S: revision of PHILOS implant to hemiarthroplasty Unresolved–further
surgery
Implant-related complication/
failure
2 – Not treated
T: hydrotherapy Unresolved
continued
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TABLE 48Details of the treatments and outcomes associated with the 36 complications in the
surgery group (continued)
Complication na Recorded treatment Outcome
Metalwork problems 10 S: implant (screw) removal under general anaesthetic Unresolved
– Not treated
T: treated in a U-slab as implant was‘backing out’ No information
S: metalwork removal No information
– Not treated
S: PHILOS implant removal No information
S: PHILOS implant removal and rotator cuf repair No information
S: metalwork removal No information
S: removal of metalwork and rotator cuf repairc1,d1 No information
S: removal of metalwork No information
Malunion 4××× – Not treatede
– Not treated
– Not treated
–d2 No information
Other–post-traumatic stifness 6 T: manipulation under anaesthesia No information
–d2 No information
T: physiotherapy and hydrotherapyc2,d3 No information
S: manipulation under anaesthesia No information
S: manipulation under anaesthesia No information
– Under review
Other–rotator cuf tear 3 – No information
(S: rotator cuf repair)b,c1,d1 No information
(T: physiotherapy and hydrotherapy)b,c2,d3 No information
Other–complex regional pain
syndrome
1 (T: amitryptaline)b Resolving
Other–(severe) pain 1 T: pain clinic No information
Other–unclear 1 T: investigations including nerve conduction tests for
hand paraesthesia
Under review
S, surgery; T, therapy.
a Each × denotes that a crossover patient is included in the count, that is, the patient did not receive the
alocated treatment.
b (T) or (S) signifies that treatment was mentioned but was not counted in the analysis as it was not recorded in the
corect location on the form.
c Combined treatment (only counted once in analysis) for two separately reported complications: 1, metalwork problems
and rotator cuf tear; 2, post-traumatic stifness and rotator cuf tear.
d Concurent complications: 1, metalwork problems and rotator cuf tear; 2, malunion and post-traumatic stifness;
3, post-traumatic stifness and rotator cuf tear.
e Patient died before surgery was discussed.
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TABLE 49Details of the treatments and outcomes associated with the 23 complications in the non-surgery group
Complication na Recorded treatment Outcome
AVN 1 S: resurfacing hemiarthroplasty No information
Dislocation/instability 1× – Not treated
Malunion 5 – Not treated
S: reverse shoulder arthroplasty No information
S: subacromial decompression No information
– Not treated
– Under review
Nonunion 5 – Not treatedb
S: ORIF with PHILOS plate No information
S: intramedulary nailing and biocomposite bone
grafting
No information
S: intramedulary nailing and calcium phosphate bone
grafting
Unresolved–further surgery
S: ORIF plus bone grafting Unresolved
Other–post-traumatic
stifness
5 S: arthroscopic capsular release and subacromial
decompression
Resolved
T: physiotherapy No information
T: intensive physiotherapy Resolving
(T: physiotherapy)c Under review
– No information
Other–rotator cuf tear 1 S: arthroscopic subacromial decompression plus
mini-open cuf repair
Unresolved–further surgery
Other–(severe) pain 1 S: Epoca hemiarthroplasty Unresolved
Other–impingement 1 – No information
Other–unclear 3 T: further physiotherapy No information
T: no information No information
S: PHILOS plate fixation No information
ORIF, open reduction and internal fixation; S, surgery; T, therapy.
a Each × in this column denotes that a crossover patient is included in the count, that is, the patient did not receive the
alocated treatment.
b Patient died before referal for orthopaedic assessment.
c (T) signifies that treatment was mentioned but was not counted in the analysis as it was not recorded in the corect
location on the form.
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Other admissions and treatments: newly diagnosed medical
complications and fractures
Treatments for any serious newly diagnosed medical problems were recorded at the end of the patients’
inpatient episode when applicable and at the 1- and 2-year folow-ups. After processing (seeAppendix 36),
there were treatments recorded for 51 valid medical problems in 46 patients (Table 51).
Fifteen patients (12%) were treated for a newly diagnosed medical complication in the surgery group
(including two crossover patients who did not receive surgical treatment), whereas more than twice as
many patients in the non-surgery group (n=31, 25%) were treated for such medical complications.
However, medical complications reported for 10 patients in the surgery group during the inpatient stay
(seeTable 50) should also be taken into account.
For patients in the surgery group, the majority of treatments were recorded during the second year of
folow-up, whereas in the non-surgery group an equal number of treatments were recorded in year 1 and
year 2. Five patients, of whom one was in the surgery group and four were in the non-surgery group,
were treated for more than one medical complication, once during the first year and once during the
second year. Overal, the most common complications were‘other’(n=21), cardiac and peripheral
vascular events (n=13, 10 of which occured in the non-surgery group) and gastrointestinal events (n=8).
Admissions to hospital for another fracture as wel as any visits to the orthopaedic/fracture clinic post
discharge were recorded at the 1- and 2-year folow-ups. After data processing, there were 18 valid entries
for 18 patients, which are detailed inTable 51. Eight patients (6%) in the surgery group and 10 patients
(8%) in the non-surgery group were admited to hospital for another fracture. In addition, there was a
total of 26 valid visits to orthopaedic/fracture clinics for 25 patients (seeTable 51). Fewer patients in the
surgery group (n=10, 8%) than in the non-surgery group (n=15, 12%) visited an orthopaedic/fracture
clinic, and only one patient (non-surgery) had more than one visit for a shoulder fracture in the first year
and for another fracture in the second year.
Overal, a total of 28 additional fractures for 25 patients were reported as part of the hospital admissions
and clinic visits: 10 in the surgery group and 18 in the non-surgery group. More details are given inTable 52.
The most commonly reported fractures were those of the hip (n=10) and the wrist (n=8). Al three patients
for whom multiple fractures were reported were in the non-surgical group.
TABLE 50Number of medical complications during the inpatient stay by treatment group
Complication Surgery (n=125)a Not surgery (n=125) Total (N=250)
Cardiac or peripheral vascular event,n 2 0  2
Respiratory event,n 2× 0 2
Gastrointestinal event,n 2× 0 2
Other,n 4 0  4
Total complications,n 10 0 10
Total patients,n 10 0 10
Total patients, % 8.0 0.0 4.0
Mean complications per patient 0.08 0 0.04
a Each × denotes that a crossover patient is included in the count, that is, the patient did not receive the
alocated treatment.
RESULTS: ANALYSES OF SECONDARY AND OTHER OUTCOMES AND SUPPLEMENTARY ANALYSES
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Mortality
Of the 14 patients who died during the trial period, nine (7%) were in the surgery group and five (4%)
were in the non-surgery group. Causes of death by treatment group are presented inTable 53. One death
in the surgery group was judged as being trial related (venous thromboembolism). A chi-squared test
revealed that there was no statisticaly significant diference in mortality rate between treatment groups
[χ2(1)=1.21,p=0.271].
Adverse events
A total of 78 SAEs were reported for 56 patients and 10 non-SAEs were reported for nine patients.
Serious adverse events
Twenty-eight patients in each treatment group experienced at least one SAE, with one patient in the
non-surgery group experiencing seven SAEs (Table 54). The numbers of SAEs by category and treatment
group are given inTable 55. There were no obvious diferences between treatment groups except that
there were a greater number of serious non-fatal medical complications in the non-surgery group than in
the surgery group (27 vs. 11). In part, these reflect multiple recurences of related conditions in patients
TABLE 52Further fractures by treatment group
Fracture site Surgery (n=125) Not surgery (n=125) Total (N=250)
Shoulder,n 1 2  3
Wrist,n 3 5  8
Hip,n 3 7  10
Other,n 3 4  7
Total fractures,n 10 18 28
Total patients,n(%) 10 (8.0) 15 (12.0)a 25 (10.0)a
a Three patients in the non-surgery group had multiple additional fractures (two in each case): hip fracture+other fracture
in the first year; hip fracture+wrist fracture in the second year; shoulder fracture in the first year+other fracture in the
second year.
TABLE 53Mortality by treatment group
Cause of death Surgery (n=125) Not surgery (n=125) Total (N=250)
Lung cancer 2 1 3
Respiratory failure 2 1 3
Venous thromboembolism 1 0 1
Pneumonia 0 1 1
MI 1 1 2
Renal failure 1 0 1
Intracerebral haemorhage 0 1 1
Accidental death 1 0 1
Unknown cause 1 0 1
Total deaths,n(%) 9 (7.2) 5 (4.0) 14 (5.6)
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experiencing several events but there is also a paralel with the greater number of patients treated for
serious newly diagnosed medical problems in the non-surgery group, recorded on the hospital forms
(seeTable 51).
Non-serious adverse events
Nine patients experienced at least one non-SAE, of whom four were in the surgery group and five were in
the non-surgery group. The numbers of patients experiencing one or more non-SAE are presented by
treatment group inTable 56. The numbers of non-SAEs by category and treatment group are given in
Table 57. With so few non-SAEs reported there were no obvious diferences between treatment groups.
TABLE 54Numbers of patients experiencing one or more SAE by treatment group
Number of SAEs Surgery (n=125),n(%) Not surgery (n=125),n(%) Total (N=250),N(%)
1 23 (18.4) 20 (16.0) 43 (17.2)
2 3 (2.4) 6 (4.8) 9 (3.6)
3 2 (1.6) 0 (0.0) 2 (0.8)
4 0 (0.0) 1 (0.8) 1 (0.4)
7 0 (0.0) 1 (0.8) 1 (0.4)
Total patients 28 (22.4) 28 (22.4) 56 (22.4)
TABLE 55Numbers of SAEs by category and treatment groupa
SAE type
Surgery (n=125)
(35 events),n(%)
Not surgery (n=125)
(43 events),n(%)
Total (N=250)
(78 events),N(%)
Surgery to the shoulder
(any mention of surgery
to the shoulder)
8 (22.9) 7 (16.3) 15 (19.2)
Non-surgical treatment/
investigation of the
shoulder
1 (2.9) 1 (2.3) 2 (2.6)
Medical complication/
condition
Non-serious 1 (2.9) 0 (0.0) 1 (1.3)
Serious: non-fatal 11 (31.4) 27 (62.8) 38 (48.7)
Serious: fatal 9 (25.7) 5 (11.6) 14 (17.9)
Any fracture
Shoulder 0 (0.0) 1 (2.3) 1 (1.3)
Wrist 0 (0.0) 0 (0.0) 0 (0.0)
Hip 3 (8.6) 2 (4.7) 5 (6.4)
Other 2 (5.7) 0 (0.0) 2 (2.6)
a Percentages relate to the total number of SAEs in each treatment group and overal.
TABLE 56Numbers of patients experiencing one or more non-SAE by treatment group
Number of non-SAEs Surgery (n=125),n(%) Not surgery (n=125),n(%) Total (N=250),N(%)
1 4 (3.2) 4 (3.2) 8 (3.2)
2 0 (0.0) 1 (0.8) 1 (0.4)
Total 4 (3.2) 5 (4.0) 9 (3.6)
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Expected adverse events and relatedness of adverse events to taking part in
the trial
Expected adverse events and trial-related adverse events (serious and non-serious) as reported by local
investigators were more likely to occur in the surgery group than in the non-surgery group. This is likely to
reflect the fact that it is simpler to link adverse events to surgery in the surgery group than it is to link
them to the treatment received in the non-surgery group (Table 58).
TABLE 57Numbers of non-SAEs by category and treatment groupa
Non-SAE type
Surgery (n=125)
(four events),n(%)
Not surgery (n=125)
(six events),n(%)
Total (N=250)
(10 events),N(%)
Non-surgical treatment/
investigation of the shoulder
1 (25.0) 0 (0.0) 1 (10.0)
Medical complication/condition
Non-serious 1 (25.0) 5 (83.3) 6 (60.0)
Serious: non-fatal 1 (25.0) 0 (0.0) 1 (10.0)
Any fracture: wrist 1 (25.0) 1 (16.7) 2 (20.0)
a Percentages relate to the total number of SAEs in each treatment group and overal.
TABLE 58Expected adverse events and relatedness of adverse events to trial participation by treatment groupa
Type of adverse event
Surgery (n=125)
(39 events),n(%)
Not surgery (n=125)
(49 events),n(%)
Total (N=250)
(88 events),N(%)
Expected
Yes 11 (28.2) 5 (10.2) 16 (18.2)
No 28 (71.8) 44 (89.8) 72 (81.8)
Related to trial
Yes 9 (23.1) 2 (4.1) 11 (12.5)
No 30 (76.9) 47 (95.9) 77 (87.5)
Combinations
Unrelated to trial and expected 6 (15.4) 4 (8.2) 10 (11.4)
Unrelated to trial and unexpected 24 (61.5) 43 (87.8) 67 (76.1)
Related to trial and expected 5 (12.8) 1 (2.0) 6 (6.8)
Related to trial and unexpected 4 (10.3) 1 (2.0) 5 (5.7)
a Percentages relate to the total number of adverse events in each group and overal.
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‘Untoward events’documented in the physiotherapy
treatment logs
The screening by two independent raters (LG and HH) of comments and reasons for referal recorded in
the physiotherapy treatment logs resulted in the identification of 37‘untoward events’recorded for 32
patients. These were shoulder-related or medical events that impeded physiotherapy or were reasons for
non-atendance or for referal. Listed surgical or shoulder-related complications that were not identified by
the inpatient and two hospital folow-up forms are summarised inTables 59and60for the surgical group
and non-surgical group respectively. As in the coding for the hospital forms, frozen shoulder is termed
post-traumatic stifness. In screening of the‘untoward events’, precursors (e.g. severe pain) to a
complication recorded on the hospital form (e.g. AVN) and complications subsequent to treatment for a
complication were not included.
Given that the physiotherapy logs did not specificaly colect data on complications and considering the
difuseness and variability in the commentary, these results should be considered as ilustrative of what was
recorded. It is clear that a few early complications were not recorded on the hospital forms but, apart from
axilary nerve lesion, none of these complications was a named complication on the hospital forms.
TABLE 59Additional complications reported in the physiotherapy logs for surgical group patients
Patient IDa Complication
Physiotherapy logs: other
information
Hospital forms:
information
S01 Delayed union Protracted physiotherapy Healed eventualy
S02 Chronic pain and alodynia of the
shoulder
Problematic recovery because of pain No mention; developed
hand paraesthesia
S03 Complex regional pain syndrome
(elements of)
Advised to see GP to obtain amitriptyline
(for neuropathic pain); resolving
No mention
S04 Axilary nerve lesion Referal–orthopaedics; recovered
spontaneously
No mention
S05 Shoulder pain and sweling–
metalwork removal considered?
Referal–orthopaedics; underwent
CT scan
No mention
S06 Rotator cuf tear No mention No mention;
post-traumatic stifness
a Patient IDs are specific to this table.
TABLE 60Additional complications reported in the physiotherapy logs for non-surgical group patients
Patient IDa Complication
Physiotherapy logs: other
information
Hospital forms:
information
NS01 Humeral head subluxation Referal–orthopaedics No mention;
post-traumatic stifness
NS02 Post-operative stifness Advised to see GP to obtain pain relief No mention; developed
AVN
NS03 Patient felt a‘crack’and pain
whilst exercising
Given local anaesthesia injection No mention; eventual
nonunion
Post-traumatic stifness No mention No mention
NS04 Delayed union (shoulder pain) Referal–orthopaedics Healed eventualy
NS05 Rotator cuf tear developing No mention No mention
a Patient IDs are specific to this table.
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Discharge locations after inpatient stay
Only five of the 109 participants who were inpatients in the surgery group and one of the 22 participants
who were inpatients in the non-surgery group were discharged to locations other than back home. In the
surgery group, one patient was discharged to a nursing home, three were discharged to a rehabilitation
unit and one was discharged to a renal ward for dialysis. The patient in the non-surgery group was
discharged to another hospital.
Patient treatment preferences at the end of the 2-year
folow-up
Consenting patients were asked at baseline in advance of randomisation whether or not they had any
treatment preference before agreeing to randomisation. At the end of the 2-year folow-up period,
patients were again asked to indicate their treatment preference in the event of a similar shoulder injury
given their experience over the past 2 years.
Patient preferences at 2 years’folow-up are tabulated against baseline preferences inTable 61and
against the alocated treatment inTable 62. More patients expressed a preference for a treatment
(either surgery or not surgery) at 24 months (61.9%) than at baseline (53.4%). The slight preference for
surgical treatment over non-surgical treatment seen at baseline remained.
Fewer than half of the patients retained their original treatment preference (41.7% for surgery and 46.7%
for non-surgery) (seeTable 61). Around half of the patients expressed a preference for the treatment that
they were alocated to (51.2% in the surgery group and 44.0% in the non-surgery group) (seeTable 62).
In each case, patients’second most frequent choice was‘no preference’rather than the opposite treatment.
TABLE 61Treatment preferences of trial participants at baseline and 24 months
Patient preference at 24 months
Patient preference at baseline,n(%)
Surgery (n=72) Not surgery (n=60) No preference (n=115)
Surgery 30 (41.7) 15 (25.0) 39 (33.9)
Not surgery 16 (22.2) 28 (46.7) 25 (21.7)
No preference 16 (22.2) 9 (15.0) 29 (25.2)
Missing 10 (13.9) 8 (13.3) 22 (19.1)
TABLE 62Treatment preferences of trial participants at 24 months by treatment group
Patient preference at 24 months
Randomised group,n(%)
Surgery (n=125) Not surgery (n=125) Total (N=250)
Surgery 64 (51.2) 22 (17.6) 86 (34.4)
Not surgery 15 (12.0) 55 (44.0) 70 (28.0)
No preference 24 (19.2) 30 (24.0) 54 (21.6)
Missing 22 (17.6) 18 (14.4) 40 (16.0)
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Lack of surgeon equipoise
As reported inChapter 4, the independent assessment of the‘other’reasons given for non-eligibility on
the study eligibility form (option j; seeAppendix 5) resulted in the identification of 117 patients who were
judged to have been excluded because of a lack of equipoise. The two raters also recorded the treatment
preference stated for individual patients (surgery, conservative management, unclear) and deduced this
when not recorded in the appropriate box on the study eligibility form if other information was available.
Listed below is the categorisation of‘protocol violations’for the 159 study eligibility forms on which only
option j had been ticked:
l lack of clinical equipoise: 117 (74%) [surgeons’treatment decision/preference: surgery 45 (38%); not
surgery 63 (54%); unclear 9 (8%)]
l existing exclusion criteria: 18 (11%)
l local dificulties (e.g. research nurse not available): 11 (7%)
l new exclusion criteria: 8 (5%)
l other: 5 (3%).
Listed under‘new exclusion criteria’, which equated to when the two raters considered that the reason for
exclusion was justified, were the folowing:
l severely compromised social circumstances (n=1)
l repeat injury to previous fracture (n=1)
l extreme age and frailty (n=1)
l patient with compromised or exceptional use (e.g. wheelchair user) upper limb function (n=4)
l head-split fracture (n=1).
Between one and 23 patients were excluded because of a lack of equipoise in 22 centres; no patients
were excluded for this reason in the remaining 11 centres that returned study eligibility forms.Figure 21
shows the numbers of patients excluded because of a lack of equipoise together with the numbers
of ineligible patients for each of the 33 centres. Lack of equipoise is most notable in three centres,
two with high numbers of inappropriately excluded patients [23 (47% of ineligible patients) and
14 (67% of ineligible patients)] and one in which lack of equipoise was the reason for exclusion of al
seven ineligible patients.
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FIGURE 21Lack of surgeon equipoise and ineligible patients by centre.
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Lack of equipoise was recorded for 68 surgeons. In some centres only a smal proportion of surgeons
(e.g. one of 16 in one centre) listed on study eligibility forms excluded patients because of a lack of
equipoise, whereas in other centres this was more prevalent (e.g. 12 of 17 surgeons in one centre).
Several surgeons (n=12) who showed a lack of equipoise screened and excluded only one patient. Of
those who excluded more than one patient because of a lack of equipoise, a further 12 excluded half or
more of the patients who they screened.
Using thet-test or chi-squared test as applicable, selected baseline characteristics were compared between
al eligible patients and patients who were excluded because of a lack of equipoise to identify any
diferences between the two populations (Table 63). Patients who were excluded because of a lack of
equipoise tended to be slightly older (70 years vs. 67 years,p=0.062) and were more likely to have a
fracture not involving either tuberosity (41% vs. 25%,p<0.001) than the sample of al eligible patients.
The proportion of men and women as wel as time since injury did not appear to difer meaningfuly
between the two groups.
Age and tuberosity involvement were tabulated against surgeons’treatment preference (reported data
only) and assessed by chi-squared test for patients excluded because of a lack of equipoise to estimate the
direction and strength of any observed preference related to age and fracture type (Table 64). Patients
aged≥65 years were more likely to be advised to have non-surgical treatment (p=0.059) whereas
patients with fractures involving tuberosities were just as likely to be advised surgery or non-surgery
as patients with fractures involving no tuberosities (p=0.794).
TABLE 63Baseline characteristics by lack of equipoise exclusion
Characteristic
Total eligible
patients (n=563)
Patients excluded because of
a lack of equipoise (n=117)
Significance of group
difference
Test p-value
Age (years)
n 548 113 t(659)=–1.9 0.062
Mean (SD) 67.4 (12.60) 69.9 (14.63)
Median (min., max.) 69.1 (18.4, 98.4) 72.0 (16.1, 106.2)
Gender,n(%)
Male 133 (23.6) 25 (21.4) χ2(1)=0.3 0.586
Female 428 (76.0) 92 (78.6)
Missing 2 (0.4) 0
Time since injury (days)
n 563 117 t(678)=–0.3 0.741
Mean (SD) 5.4 (4.80) 5.6 (5.41)
Median (min., max.) 4 (0, 21) 3 (0, 19)
Tuberosity involvement,n(%)
Yes 422 (75.0) 69 (59.0) χ2(1)=12.3 0.000
No 141 (25.0) 48 (41.0)
Max., maximum; min., minimum.
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Surgeon preferences and agreed treatments for non-consenting
patients
Surgeon preferences
Preferences in terms of advised treatment as judged by the recruiting clinicians were recorded for al
patients who were ineligible or who did not consent to participate in the trial. The resulting frequencies in
Table 65show that, of the ineligible patients, 34% were advised to have surgical treatment and 56%
were advised to have non-surgical treatment. In contrast, only 21% of non-consenters were advised to
have surgical treatment, with 34% advised to have non-surgical treatment and clinicians uncertain what
treatment to advise in 38%.
Agreed treatment for non-consenting patients
Agreed treatments for patients who were eligible but who did not consent to partake in the trial are
presented inTable 66by patient and clinician preference. A total of 55 patients expressed a preference for
surgery and this treatment was agreed for 50 (91%); in two cases (4%) this was contrary to clinician
advice for the patient to undergo non-surgical treatment. A total of 226 patients expressed a preference
for non-surgery and this treatment was agreed for 221 (98%); in 26 cases (12%) this was contrary to
clinician advice for the patient to undergo surgical intervention. Of the 23 patients without a treatment
preference, surgery was agreed for seven (30%) and non-surgical treatment was agreed for 16 (70%).
TABLE 64Baseline characteristics by surgeon advice for patients excluded because of a lack of equipoise
Characteristic
Surgeon preference:
surgery (n=41)
Surgeon preference:
not surgery (n=58)
Significance of group difference
Test p-value
Age (years),n(%)
<65 16 (39.0) 12 (20.7) χ2(1)=3.6 0.059
≥65 25 (61.0) 44 (75.9)
Missing 0 2 (3.4)
Tuberosity involvement,n(%)
Yes 23 (56.1) 31 (53.4) χ2(1)=0.1 0.794
No 18 (43.9) 27 (46.6)
TABLE 65Treatment advice by clinicians for patients who were not entered into the trial
Clinician treatment advice Ineligible (n=687),n(%) Non-consent (n=313),n(%)
Surgery 232 (33.8) 66 (21.1)
Not surgery 384 (55.9) 105 (33.5)
Uncertaina – 118 (37.7)
Missing data 71 (10.3) 24 (7.7)
a There was no tick box for‘uncertain’on the study eligibility form. The box for‘uncertain’on the consent status form
was added in response to an early detected missing data issue.
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Availability of radiographic views in the study population
Clinicians completing a study eligibility form (seeAppendix 5) recorded whether or not the series of views used
to inform the assessment of the fracture included one or more of the folowing views: the anteroposterior
view, the axilary (or modified axilary) view and the scapular Y-lateral view. Our protocol stipulated that a
minimum of two radiographic views/projections were required for the assessment of study eligibility.Table 67
shows the breakdown of radiographic views recorded for al screened patients. This demonstrates that the
majority (88%) of the study eligibility forms indicated that the minimum requirement was achieved, with
the standard trauma series of three perpendicular views59being available for 18% of screened patients. The
anteroposterior view was recorded in 98% of patients, the axilary view in 57% and the scapular Y-lateral
view in 50%. Similar findings in terms of views recorded and meeting the minimum requirements of two
perpendicular views applied for ineligible (88%), eligible (89%) and randomised patients (89%).
TABLE 66Preferences and agreed treatments for eligible patients who did not consent
Clinician advice Agreed treatment
Patient preference,n(%)
Surgery
(n=55)
Not surgery
(n=226)
No preference
(n=23)
Missing
(n=9)
Surgery Surgery 27 (49.1) 3 (1.3) 6 (26.1) 0 (0.0)
No surgery 0 (0.0) 26 (11.5) 3 (13.0) 0 (0.0)
Missing 1 (1.8) 0 (0.0) 0 (0.0) 0 (0.0)
No surgery Surgery 2 (3.6) 0 (0.0) 0 (0.0) 0 (0.0)
No surgery 4 (7.3) 94 (41.6) 4 (17.4) 1 (11.1)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Uncertain Surgery 18 (32.7) 0 (0.0) 1 (4.3) 0 (0.0)
No surgery 0 (0.0) 87 (38.5) 9 (39.1) 0 (0.0)
Missing 0 (0.0) 2 (0.9) 0 (0.0) 1 (11.1)
Missing Surgery 3 (5.5) 0 (0.0) 0 (0.0) 0 (0.0)
No surgery 0 (0.0) 14 (6.2) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 7 (77.8)
TABLE 67Radiographic views recorded on the study eligibility forms
Radiographic views
Screened
(n=1250),n(%)
Ineligible
(n=687),n(%)
Eligible
(n=563),n(%)
Randomised
(n=250),n(%)
Anteroposterior view only 117 (9.4) 64 (9.3) 53 (9.4) 22 (8.8)
Axilary view only 2 (0.2) 1 (0.1) 1 (0.2) 0 (0.0)
Scapular Y-lateral view only 1 (0.1) 1 (0.1) 0 (0.0) 0 (0.0)
Anteroposterior+axilary viewsa 480 (38.4) 284 (41.3) 196 (34.8) 85 (34.0)
Anteroposterior+scapular Y-lateral
viewsa
398 (31.8) 220 (32.0) 178 (31.6) 61 (24.4)
Axilary+scapular Y-lateral viewsa 2 (0.2) 2 (0.3) 0 (0.0) 0 (0.0)
Anteroposterior+axilary+scapular
Y-lateral viewsa
224 (17.9) 98 (14.3) 126 (22.4) 76 (30.4)
Missing 26 (2.1) 17 (2.5) 9 (1.6) 6 (2.4)
a Two or three views complied with the requirements for assessing study eligibility.
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Use of other imaging investigations
Data on the use of other imaging modalities to determine study eligibility were colected only for
randomised patients (seeAppendix 20). In total, six patients (three in each treatment alocation group),
each from a diferent hospital, received a CT scan. This is consistent with the results of the post-recruitment
survey of radiography departments, which found that CT scanning was‘routinely/frequently used for these
fractures’in only one of the 26 responding hospitals (seeAppendix 31).
Independent assessment and classification of baseline
radiographs according to the Neer classification
Cul of radiographs in preparation for assessment
A minimum of two radiographs were available for each trial participant, with a maximum of seven being
received for two participants. In al, 664 radiographs were available for the 250 study participants.
Sixty-two views were excluded based on prespecified criteria, which aimed to retain the best-quality view(s)
in each perpendicular plane. Thus, the number of named views in each plane would not have been
afected by this cul. The results of the cul are ilustrated inFigure 22. For the majority of patients
(n=165), two radiographic views were available post cul, leaving 68 with three views and 17 with
four views.
Assessment of available radiographic views
The two independent surgeons (raters), using the Neer classification proforma (seeAppendix 33), were
asked to indicate which views were available to them (Table 68). Compared with the baseline assessment,
raters judged that there were a greater number of anteroposterior plus scapular Y-lateral views and fewer
anteroposterior only views and anteroposterior plus axilary plus scapular Y-lateral views. There was litle
diference in judgement between the two raters (91% agreement, kappa=0.87,p<0.001), whereas
agreement compared with baseline was weaker (rater 1: 56% agreement, kappa=0.39,p<0.001;
rater 2: 59% agreement, kappa=0.43,p<0.001). It is noteworthy that the 10 views for which
either rater indicated a single plane only (excluding any additional‘other’views) had al been rated to
show a minimum of two planes on the eligibility form.
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FIGURE 22Pre- and post-cul radiographic views per patient.
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Assessment of radiograph quality
As part of the completion of the Neer classification proforma, the two independent raters were asked
to evaluate the quality of the radiographs available for each patient in terms of their adequacy for
classification purposes. The questions asked are detailed inTable 69. A number of responses to questions
2 and 4 were missing for both raters but could be infered from the individual assessments of each
radiograph that were provided. For question 2, 14 responses were infered for rater 1 and 35 for rater 2.
For question 4, five responses were infered for rater 1 and six for rater 2.
TABLE 68Radiographic views available for study participants (eligibility forms and Neer classification proforma)
Radiographic view (eligibility forms and Neer
classification proforma)
Eligibility form
(n=250),n(%)
Rater 1
(n=250),nb(%)
Rater 2
(n=250),nb(%)
Anteroposterior onlya 22 (8.8) 101(4.0) 71(2.8)
Axilary only 0 (0.0) 11(0.4) 0 (0.0)
Scapular Y-lateral only 0 (0.0) 11(0.4) 0 (0.0)
Anteroposterior+axilary 85 (34.0) 874(34.8) 82 (32.8)
Anteroposterior+scapular Y-lateral 61 (24.4) 913(36.4) 95 (38.0)
Axilary+scapular Y-lateral 0 (0.0) 11(0.4) 1 (0.4)
Anteroposterior+axilary+scapular Y-lateral 76 (30.4) 581(23.2) 652(26.0)
Missing 6 (2.4) 1 (0.4) 0 (0.0)
a Combines scapular and coronal plane views (Neer classification only).
b Superscript numbers (1–4) indicate how many patients had the named radiographic view(s) plus one‘other’view
(Neer classification only).
TABLE 69Agreement on radiograph quality criteria between raters
Question (from the Neer classification
proforma) Response
Rater 1
(n=250),
n(%)
Rater 2
(n=250),
n(%)
Agreement between
ratersa
Q2. Are there at least two projections in planes
perpendicular to each other?
Yes 239 (95.6) 241 (96.4) 97.6% agreement
(kappa=0.69,p<0.001)No 11 (4.4) 9 (3.6)
Q4. Are the proximal humerus and glenohumeral
joint seen on each projection (of at least two
diferent views)?
Yes 245 (98.0) 241 (96.4) 95.2% agreement
(kappa=0.12,p=0.023)No 5 (2.0) 9 (3.6)
Q6. Considering al the available views together,
can you visualise the location of al five structures
(the humeral shaft, greater tuberosity, lesser
tuberosity, head of the humerus and glenohumeral
joint) suficiently to determine the position and
displacement of the fractured segments?
Yes 248 (99.2) 234 (93.6) 93.6% agreement
(kappa=0.10,p=0.006)No 2 (0.8) 16 (6.4)
Q7. Please give your overal assessment of quality
for this set of images (i.e. in terms of exposure and
patient positioning) based on the three grades
good, fair and poor
Good 219 (87.6) 168 (67.2) 71.4% agreement
(kappa=0.23,p<0.001)Fair 29 (11.6) 66 (26.4)
Poor 2 (0.8) 14 (5.6)
Missing 0 (0.0) 2 (0.8)
a Although, as planned, kappa statistic results are presented, these serve mainly to ilustrate that kappa statistics are
misleading when there is a lack of variability in the responses.
DOI: 10.3310/hta19240 HEALTH TECHNOLOGY ASSESSMENT 2015VOL. 19 NO. 24
© Queen’s Printer and Controler of HMSO 2015. This work was produced by Handolet al.under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the ful report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
Overal,Table 69shows that the sets of radiographs provided perpendicular views (for 96% of patients)
that were suficient to see the relevant anatomical structures (96–98%) and visualise the location of these
(94–99%). Agreement on these questions was high between raters (94–98%). Some of the associated
kappa values are low, which can be explained by the lack of variability in the responses, which results in a
high level of expected chance agreement against which the actual agreement is compared when using the
kappa statistic. Hence, the percentage agreement is the more representative statistic in this table.
Rater 2 judged the overal quality of the images (question 7) to be poorer than rater 1. Rater 1 estimated
that 88% of the radiograph sets were of good quality whereas rater 2 estimated that only 67% of the
radiograph sets were of good quality. Accordingly, the level of agreement between raters was lower for
this question (71% agreement, kappa=0.23,p<0.001).
Fracture types and characteristics: agreement between the two raters
Using assessments of individual anatomical features for each radiograph and ariving at a verdict for each
feature’s involvement/displacement, the two raters independently assigned a Neer category for each
patient (seeAppendix 2for the 16 possible categories). The classifications assigned in the first stage of the
classification process by each rater are listed inTable 70.
The majority of fractures were judged to be two-part surgical neck fractures (category 3, 51–52% of
patients) and three-part surgical neck plus greater tuberosity fractures (category 8, 32%). Rater 2 was
more likely to assign fractures to category 1 (single-part fractures) and category 4 (two-part greater
tuberosity fractures) whereas rater 1 was more likely to assign fractures to category 12 (four-part fractures
involving the surgical neck and both tuberosities). Agreement between the two raters was therefore only
moderate (68% agreement, kappa=0.48,p<0.001); overal, the two raters independently assigned
the same category in 169 cases.
The presence of other individual characteristics listed on the Neer classification proforma as judged by the
two raters is given inTable 71. In total, 9–11% of the fractures were judged to be no contact surgical
neck fractures and 24–30% were judged to be impacted surgical neck fractures. There was one dislocation
and 4% were articular surface fractures. The head segment was in varus in 20–25% of fractures and in
valgus in 28–31% of fractures. Diferences between raters applied to only a smal number of these
features, with a maximum magnitude of diference of 7%, which was for impaction.
TABLE 70Neer classification: initial assignments by the two raters acting independently
Neer classification
Rater 1
(n=250),n(%)
Rater 2
(n=250),n(%)
1 Neer one part: undisplacedasurgical neck 8 (3.2) 21 (8.4)
3 Neer two part: surgical neck 127 (50.8) 129 (51.6)
4 Neer two part: greater tuberosityb 2 (0.8) 14 (5.6)
5 Neer two part: lesser tuberosityb 1 (0.4) 0 (0.0)
8 Neer three part: surgical neck+greater tuberosity 81 (32.4) 81 (32.4)
9 Neer three part: surgical neck+lesser tuberosity 0 (0.0) 0 (0.0)
10 Neer three part: anterior dislocation+greater tuberosity 0 (0.0) 0 (0.0)
12 Neer four part: surgical neck+greater tuberosity+lesser tuberosity 30 (12.0) 4 (1.6)
13 Fracture–dislocation–anterior (four part) 1 (0.4) 0 (0.0)
15 Fracture–dislocation–anterior (articular surface) 0 (0.0) 1 (0.4)
a Fractures were rated as‘undisplaced’for the purposes of the Neer classification but were in reality displaced fractures in
which the degree of displacement was insuficient for categorisation as a‘part’.
b Surgical neck involved but not suficiently displaced to be a‘part’.
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Agreed Neer classification of baseline fractures
Consensus was reached between the two raters for the 81 fractures for which there had been discordance
in the initial assignment of Neer classification. The agreed classifications are provided inTable 72by trial
arm. The majority of patients were stil assigned to category 3 (48%) and category 8 (36%); however,
entries in categories 13 and 15 were removed from the individual assessments and added to categories 9
and 10 instead. Classifications were very wel balanced between the trial arms.
As highlighted inTable 72, some categories were‘unexpected’fractures (categories 1, 4, 5 and 10),
particularly those that were not associated with the displacement of the surgical neck (Neer criteria).
Tables 73and74provide further details for fractures assigned to these categories.
For al categories representing an‘undisplaced’surgical neck (category 1:n=18 undisplaced surgical neck
only; category 4:n=8 undisplaced surgical neck plus greater tuberosity; category 5:n=1 undisplaced
surgical neck plus lesser tuberosity), the surgical neck was assessed to be involved in al cases by both raters,
with the majority indicating displacement (Neer or unclear Neer: 74% rater 1, 95% rater 2). For most of the
category 1 and category 4 fractures (85–88%), the greater tuberosity was also involved, whereas both
tuberosities were estimated to be involved for the one category 5 fracture.Table 74shows that this agrees
with data from the study eligibility forms, confirming greater tuberosity involvement (either on its own or
together with lesser tuberosity involvement) for the majority of Neer category 1 (67%+14%) and category 4
(94%+6%) fractures and the involvement of both tuberosities for category 5 fractures (100%).
TABLE 71Separate fracture characteristics on the Neer classifications proforma: individual judgements of raters
Fracture characteristic Rater 1 (n=250),n(%) Rater 2 (n=250),n(%)
Surgical neck–no contact fracture 23 (9.2) 27 (10.8)
Surgical neck–impacted 59 (23.6) 76 (30.4)
Anterior fracture–dislocation 1 (0.4) 0 (0.0)
Posterior fracture–dislocation 0 (0.0) 0 (0.0)
Articular surface fracture 11 (4.4) 10 (4.0)
Head segment in varus 62 (24.8) 49 (19.6)
Head segment in valgus 69 (27.6) 77 (30.8)
TABLE 72Agreed Neer classification by treatment group
Final Neer classification categories (seeAppendix 2)a
Surgery
(n=125),n(%)
Not surgery
(n=125),n(%)
1b Neer one part: undisplacedcsurgical neck 9 (7.2) 9 (7.2)
3 Neer two part: surgical neck 60 (48.0) 59 (47.2)
4b Neer two part: greater tuberosity 5 (4.0) 3 (2.4)
5b Neer two part: lesser tuberosity 0 (0.0) 1 (0.8)
8 Neer three part: surgical neck+greater tuberosity 45 (36.0) 45 (36.0)
9 Neer three part: surgical neck+lesser tuberosity 1 (0.8) 0 (0.0)
10b Neer three part: anterior dislocation+greater tuberosity 0 (0.0) 2 (1.6)
12 Neer four part: surgical neck+greater tuberosity+lesser tuberosity 5 (4.0) 6 (4.8)
a The categories in bold (categories 3, 8, 9 and 12) are those that fuly meet the ProFHER trial inclusion criteria.
b These are categories outside the expected categories for the trial.
c Fractures were rated as‘undisplaced’for the purposes of the Neer classification but were in reality displaced fractures in
which the degree of displacement was insuficient for categorisation as a‘part’.
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The two fractures that were assigned to category 10 (anterior dislocation plus greater tuberosity
involvement) were judged to involve both the surgical neck and the greater tuberosity by both raters.
Raters also agreed that one of the fractures involved the lesser tuberosity. On the study eligibility forms
both fractures were assessed to involve the greater tuberosity only.
Agreement between the baseline assessment of tuberosity involvement and
the Neer classification
The agreed Neer classifications were compared against the radiography assessments at baseline on the
study eligibility forms.Table 75tabulates high-level groupings of the two assessments [Neer one- and
two-part fractures and Neer three- and four-part factures against tuberosity involvement at baseline
(yes/no)], used for subgroup and sensitivity analyses.
TABLE 74‘Unexpected’Neer categories: involvement of the tuberosities (Neer classification proforma plus
eligibility forms)
Neer classification (either rater)a Study eligibility form: tuberosity involvement
Category Tuberosity involvement None Greater Lesser Both
1 None 4 2 – 1
Greater – 19 – 5
Lesser – –  –  –
Both – 3 – 2
4 None – –  –  –
Greater – 11 – 4
Lesser – –  –  –
Both – 1 – –
5 None – –  –  –
Greater – –  –  –
Lesser – –  –  –
Both – –  – 2
10 None – –  –  –
Greater – 2 – –
Lesser – –  –  –
Both – 2 – –
a Totals for each category thus equal twice the number of fractures in that category.
TABLE 75Agreed Neer classification and tuberosity assessment at baseline: overview
Agreed Neer classification
Tuberosity involvement (study eligibility form),n(%)
None (n=57) Greater and/or lesser tuberosity (n=193)
Neer one- and two-part fractures 53 (93.0) 93 (48.2)
Neer three- and four-part fractures 4 (7.0) 100 (51.8)
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The majority of the baseline assessments indicating no tuberosity involvement (93%) were identified as
Neer one-part and two-part fractures. Conversely, half (48%) of the patients with an estimated
involvement of one or both tuberosities at baseline were associated with Neer one-part and two-part
fractures and the other half (52%) were associated with three-part and four-part fractures. Accordingly,
the agreement between the two assessments was only fair (61% agreement, kappa=0.29,p<0.001).
Table 76provides further details on how the assessment of tuberosity‘involvement’at baseline and the
Neer classification of‘displacement’related to each other. The focus here is on the main expected and
prevalent categories: 3 (n=119), 8 (n=90) and 12 (n=11). If we equate here the term‘involve’with
‘displacement meeting the Neer criteria’, then Neer category 3 fractures (two-part surgical neck fractures)
are not expected to‘involve’either tuberosity (the tuberosities are not displaced relative to the other
parts of the humerus). This was true for 43% (51/119) of category 3 fractures according to the baseline
assessment, with most of these fractures also being assessed to involve either the greater tuberosity only
at baseline (34%) or both tuberosities (16%). Neer category 8 fractures were expected to‘involve’the
surgical neck and greater tuberosity. This was true for the majority (54/90; 60%) of category 8 cases, with
many cases (36%) judged to additionaly‘involve’the lesser tuberosity at baseline. Neer category 12
(four-part) fractures were expected to‘involve’both tuberosities. This was true for 45% (5/11) of category
12 cases at baseline, with four fractures (36%) judged to‘involve’the greater tuberosity only at baseline.
TABLE 76Agreed Neer classification and tuberosity assessment at baseline: detail
Agreed Neer classification
Tuberosity involvement (baseline study
eligibility form),n(%)
None
(n=57)
Greater
tuberosity
(n=119)
Lesser
tuberosity
(n=10)
Both
(n=64)
1 Neer one part Undisplaced surgical neck 2 (3.5) 12 (10.1) 0 (0.0) 4 (6.3)
3 Neer two
part
Surgical neck 51 (89.5) 41 (34.5) 8 (80.0) 19 (29.7)
4 Greater tuberosity 0 (0.0) 6 (5.0) 0 (0.0) 2 (3.1)
5 Lesser tuberosity 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.6)
8 Neer three
part
Surgical neck+greater tuberosity 3 (5.3) 54 (45.4) 1 (10.0) 32 (50.0)
9 Surgical neck+lesser tuberosity 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.6)
10 Anterior dislocation+greater tuberosity 0 (0.0) 2 (1.7) 0 (0.0) 0 (0.0)
12 Neer four
part
Surgical neck+greater
tuberosity+lesser tuberosity
1 (1.8) 4 (3.4) 1 (10.0) 5 (7.8)
a Bold font indicates the expected categories as part of the trial.
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Chapter 7Economic evaluation
Objective
The objective of this economic evaluation was to assist decision-making in determining whether or not
surgery represents a cost-efective alternative within the UK NHS for the treatment of adults with an acute
closed displaced fracture of the proximal humerus with involvement of the surgical neck.
Overview
Economic evaluation supports decision-making when prioritising the alocation of limited health-care
resources.70Economic evaluation alongside clinical trials, as in the ProFHER trial, can therefore be a
valuable tool to help decide what interventions should be implemented based not only on efectiveness
but also on cost-efectiveness. Moreover, RCTs are often the best means for providing unbiased estimates
of both health efects and costs.71The pragmatic multicentre design of the ProFHER trial has the advantage
of reflecting actual practice; hence, the cost profile of the participants and the interventions is likely to
miror clinical practice in UK NHS hospitals.
Individual patient data colected alongside the ProFHER trial were used to perform a cost–utility analysis in
which health-related quality of life (HRQoL) was measured in terms of QALYs, which represent years lived
in perfect health. Diferences in mean costs and mean QALYs at 2 years were used to derive an estimate
of the cost-efectiveness of surgery and non-surgical treatment. Costs and QALYs were evaluated on the
basis of costs faling on the NHS and Personal Social Services (NHS perspective) and were expressed in
UK pounds sterling at 2012 prices. Costs and QALYs were discounted from year 1 using the recommended
discounting rates (3.5%) according to the curent available guidance.55The analysis was conducted on an
ITT basis; thus, the treatment groups were compared based on the initial random alocation of participants
irespective of protocol deviations or withdrawals.
Because of the magnitude of missing data throughout the trial folow-up, the base-case analysis was
conducted using the multiple imputed data set and a sensitivity analysis of complete cases was caried out
to test the impact of excluding patients with missing data on the final results.
Methods
Cost data sources
The data required for the analysis, both costs and health benefits (measured in terms of QALYs), were
colected from individual patients and through health professionals during the 2-year folow-up period of
the ProFHER trial.
Data on utilities were estimated by means of the EQ-5D questionnaire data elicited from patients at
baseline (seeAppendix 17) and 3 (seeAppendix 18), 6, 12 and 24 months (seeAppendix 19).
There are two main cost components in the analysis: (1) the cost of the surgical intervention and (2) the
cost of the health-care consultations at baseline and at the 3-, 6-, 12- and 24-month folow-ups:
l Data extracted from the surgical forms (seeAppendix 21), which include the main items of resource
use relating to each operation, were used to calculate the cost of the surgical intervention for
participants in the surgery group and that for six participants in the non-surgery group for whom
surgical forms had been completed.
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l The cost of the health-care consultation consists of al of the costs of visits to both primary and
secondary health-care professionals. Resource use from primary health-care consultations was colected
using patient questionnaires only. However, hospital outpatient visits, hospitalisations and
physiotherapy appointments were recorded by two sources (patient questionnaires and hospital forms).
Although physiotherapy treatment logs (seeAppendix 23), completed by physiotherapists providing
patient care, recorded information for only the first episode of care, these were a more complete
record of physiotherapy that included data on the timing of individual sessions. We used these as the
primary source for physiotherapy data. The other hospital data sources were the inpatient episode form
(seeAppendix 22) and the 1-year and 2-year folow-up forms (seeAppendices 25and26). The
inpatient episode form covered hospitalisation from initial surgery to discharge and hence non-surgical
patients had an inpatient episode form only if they were admited to hospital. The two hospital
folow-up forms recorded any hospitalisation from discharge after initial treatment to the end of the
second year because of surgical or medical complications. Both patients and health professionals were
asked to determine whether visits and hospitalisations reported were shoulder or non-shoulder related.
Our economic analysis plan indicated that, when data could be sourced from patient questionnaires and
hospital forms, hospital forms would be used as the main source for calculating resource use. This initial
decision was made because the hospital forms provided more detailed data on specific incidents and these
were completed by health-care professionals trained in the study and who were being paid for the return
of completed forms. This decision was justified by the extent of missing data on resource use in
patients’questionnaires.
Health-related quality of life and quality-adjusted life-years
Health-related quality of life was expressed in terms of utilities, which were obtained from trial patients
using EQ-5D scores at baseline, 3 months, 6 months, 1 year and 2 years.
The EQ-5D72is a standardised and validated generic instrument for the measurement of HRQoL that alows
the translation of patient utilities into QALYs. As wel as being one of the most used generic health status
measures, it is the instrument recommended in National Institute for Health and Care Excelence (NICE)
technology appraisal guidance.55This instrument considers health (functioning) in terms of five dimensions:
mobility, ability to self-care, ability to undertake usual activities, pain and discomfort, and anxiety and
depression. Each dimension has three possible levels: no problems, moderate problems or severe problems.
This five-domain and three-level system generates 245 mutualy exclusive health states, including
unconscious and death. According to the responses to the EQ-5D classification system, a health status
can be defined and a single index utility assigned. Each of these health states has been validated in a
large UK population sample using the time trade-of method, ranging from 1 for perfect health (thus the
maximum value possible) to–0.594 for severe problems; 0 coresponds to death.73
The validity of the EQ-5D has been evaluated within the context of a prospective study that tested its
ability to capture clinicaly important changes in patients with proximal humeral fractures.74This study
found that the EQ-5D displayed good internal and external responsiveness and recommended its use as a
quality of life measure in patients with these injuries.
We converted the utilities derived from the EQ-5D into QALYs for each patient using the AUC method,
folowing the trapezium rule, which assumes linear interpolation between folow-up points.75Incremental
mean QALYs between treatment groups were estimated with regression models according to treatment
alocation. Despite the randomisation process, which ensures that baseline variables are balanced between
the arms of the trial, in practice (regardless of sample size) it is normal to find an imbalance in mean
baseline utility. As baseline utility is likely to be corelated with QALYs gained over time, there are robust
reasons to control for baseline utility when estimating QALYs.76Therefore, we conducted two types of
analysis: (1) based on adjusted baseline utility scores and (2) adjusted for a number of covariates. We used
the same set of covariates as in the clinical efectiveness analysis, that is, age, gender, treatment group and
tuberosity involvement (yes/no) at baseline.
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Health-care resource use and costs
Surgery: data colection and cost estimates
On designing the surgical form (seeAppendix 21) we were mindful of its key role in colecting information
on resource use relating to surgery. The form colected information on operation times, the grade and
number of staf involved in the operation, the type of implant used, the disposables required and whether
or not there were any unexpected procedures during the intervention.
We received surgical forms for the 109 patients alocated to surgery who received surgery and six patients
alocated to non-surgery who received surgery. Two of these patients were considered crossovers; the
other four patients underwent surgery folowing unsuccessful conservative treatment.
Two key areas of missing data in the surgical forms for which data were imputed were operation time
and number of staf involved in the operation. After discussion it was agreed that the mean operation
time calculated from the rest of the data set should be used for the six patients with missing operation time.
As mentioned inChapter 3, data entry for numbers of personnel was problematic; frequently staf ticked
the relevant boxes instead of entering the number of staf. In these cases we assumed that there was one
surgeon or one anaesthetist in the theatre, as this was the typical (average) number of staf when provided.
Unit costs for surgery, together with their sources, are provided inTable 77. Aside from for implants, the
unit costs used in the analysis were obtained from published national averaged tarifs:Unit Costs of Health
and Social Care[Personal Social Services Research Unit (PSSRU)],77NHS Reference Costs78and theBritish
National Formulary(BNF).79
The staf cost per minute was estimated using PSSRU data77for each of the staf categories involved in the
surgical intervention. For those categories for which direct information about the cost per hour was not
provided, we used mean total earnings and total working times to infer the cost per minute. For example,
the mean total salary per ful-time equivalent for a senior house specialist is £41,100; based on a working
time of 42.8 weeks per annum and 37.5 hours per week, we estimated a unit cost of £0.43 per minute
for time spent in theatre. Radiographer time was costed for a patient’s time in theatre only when an image
intensifier was used.
Several of the hospitals involved in the ProFHER trial provided the prices (2012–13) that the hospital paid
for the implants used. These costs excluded value-added tax (VAT) and included any discount that might
have been agreed localy. Five diferent types of plates and screws provided by diferent manufacturers
were used in the trial: PHILOS, AxSOS, S3 plate, Polarus PHP and NCB plate. Costs were obtained from the
hospitals for three of the four hemiarthroplasties used–Epoca, Anatomical and Global FX/Advantage–
and for the two nailing systems, which were used in just four patients–Polarus and Expert. Screws used in
plates are costed individualy. We based our cost estimate on an average of nine screws per plate, six in
the humeral head fragment and three in the shaft. When the number of holes (three or five) was not
reported for a plate, we either assumed that the plate used was the most frequently used plate type in
that centre or, when this information was unavailable, used the average price from al hospitals to cost the
plate. The prices for the implants detailed inTable 77are based on the hospitals’average cost per implant
category. Hospitals provided detailed information about the specific costs involved in al eight (one in the
non-surgery group) unexpected surgical procedures, which assisted with costing.
We derived the costs of the drugs used in the operation based on the information provided by the lead centre
in the trial (James Cook University Hospital, Middlesbrough); we do not anticipate significant deviations from
these costs in other centres. The drugs used were propofol (200 mg), fentanyl (100 µg) and morphine (10 mg)
for induction; the antiemetics ondasetron (4 mg) and dexamethasone (8 mg), the muscle relaxant atracurium
(50 mg) and the reversal agents neostigmine (2.5 mg) and glycopyrolate (2.5 mg). Costs also included those
of two doses of antibiotics, typicaly a combination of cefuroxime (1.5 g) and co-amoxiclav (1 g).
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TABLE 77Unit costs (and sources) used to estimate the total cost for each individual patient: primary surgery
Resource use Unit cost (£) Source
Surgeon/anaesthetist consultant 2.86 (per minute) PSSRU77
Surgeon/anaesthetist registrar 1.43 (per minute) PSSRU77
Hospital radiographer 0.60 (per minute) PSSRU77
Nurse band 7 1 (per minute) PSSRU77
Nurse band 6 0.80 (per minute) PSSRU77
Nurse band 5 0.70 (per minute) PSSRU77
Nurse band 4 0.22 (per minute) PSSRU77
Nurse band 3 0.20 (per minute) PSSRU77
Nurse band 2 0.17 (per minute) PSSRU77
Senior house oficer 0.43 (per minute) PSSRU77
Associate specialist 0.94 (per minute) PSSRU77
Staf grade 0.74 (per minute) PSSRU77
Surgical assistant B5 0.50 (per minute) PSSRU77
Surgical assistant B6 0.64 (per minute) PSSRU77
Surgical ward per night 301 Department of Health78
General ward per night 261 Department of Health78
Plate and screws three hole 444.28 Manufacturer price 2012a
Plate and screws five hole 455.50 Manufacturer price 2012a
Lock screw 59.8 Manufacturer price 2012a
Cortical screw 17.14 Manufacturer price 2012a
Hemiarthroplasty 904.23 Manufacturer price 2012a
Nail 482.43 Manufacturer price 2012a
Propofol 200 mg 4.18 BNF79
Fentanyl 100 µmg 0.60 BNF79
Morphine 10 mg 15 BNF79
Ondansetron 4 mg 1 BNF79
Dexamethasone 8 mg 2.80 BNF79
Atracurium 50 mg 6 BNF79
Neostigmine 2.5 mg 0.50 BNF79
Glycopyrolate 2.5 mg 0.91 BNF79
Cefuroxime 1.5 g 5.05 BNF79
Co-amoxiclav 1 g 1.06 BNF79
a Al manufacturer prices were provided by hospitals.
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The cost of surgery therefore included the costs of the surgical team, implants, consumables and
unexpected surgical procedures and inpatient stay (data from inpatient episode forms).
Primary care, secondary care and physiotherapy: data colection and
cost estimates
Numerical information on primary care (visits to primary care professionals: GP, practice or community
nurse, occupational therapist or physiotherapist) and secondary care (hospital visits: as an outpatient, as an
inpatient or day admissions) was colected using the patient questionnaires at 3 months (seeAppendix 18),
6 months, 1 year and 2 years. As wel as being asked to record the number of times that they stayed in
hospital as an inpatient, patients were asked to record the total number of nights spent in hospital over al
visits. We assumed that, consistent with the format of the questionnaire, missing answers (boxes left
blank) to the second question when patients reported no hospital stay indicated no use of services, thus
no overnight stays.
As already mentioned, the number of hospital visits and complications reported on the hospital forms at
1 and 2 years were used as the primary sources of resource use. Similarly for physiotherapy, the primary
analysis is based on the number of sessions reported by physiotherapists rather than the number of visits
recorded by patients.Table 78details the unit costs for the aspects of patient care covered in this section.
TABLE 78Unit costs (and sources) used to estimate total cost for each individual patient: primary care, secondary
care and physiotherapy
Resource use Unit cost (£) Source
Primary care
Visit to GP 40 PSSRU77
Visit to practice nurse 11 PSSRU77
Visit to community nurse 13 PSSRU77
Visit to occupational therapist 44 PSSRU77
Secondary care
Shoulder hospital stay 3550 Department of Health78a
Shoulder excess hospital stay 301 Department of Health78b
Non-shoulder hospital stay 2724 Department of Health78c
Non-shoulder excess hospital stay 261 Department of Health78d
Outpatient visit 106 Department of Health78e
Day case 681 Department of Health78e
Physiotherapist
Physiotherapy session 34 PSSRU77f
a Averaged (elective and non-elective), weighted by activity levels across al trusts, using the relevant shoulder Healthcare
Resource Group (HRG) codes selected for the analysis: HA61B, HA61C, HA62Z, HA63Z, HB61B, HB61C, HB62B,
HB62C, HB63Z.
b Excess bed-day averaged (elective and non-elective) per activity across al trusts using the relevant shoulder HRG codes
selected for the analysis: HA61B, HA61C, HA62Z, HA63Z, HB61B, HB61C, HB62B, HB62C, HB63Z.
c Averaged (elective and non-elective), weighted by activity levels across al trusts and specialties.
d Excess bed-day averaged (elective and non-elective) per activity across al trusts and specialties.
e Outpatient visits and day cases averaged per activity across al trusts.
f The average duration for a physiotherapy session in the ProFHER trial was half an hour, whereas the unit cost provided
by the PSSRU is for a 1-hour session. The base-case analysis is based on a 1-hour session. When this unit cost was
halved in the model, as expected (as physiotherapy sessions are equal in both arms) it had no impact on the
incremental results.
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We calculated the cost for each patient in the trial by multiplying their use of health-care resources by the
associated unit costs (seeTables 77and78). The total cost for the base-case analysis included only
shoulder-related resource use. It comprised four main components: (1) visits to primary and community
health-care professionals (GP, practice or community nurse and occupational therapist); (2) hospital visits
(inpatient, outpatient and day cases); (3) physiotherapy sessions; and (4) the cost of the surgical
intervention. Other scenarios were tested as part of the sensitivity analysis, in which we explored the
impact of incorporating both types of resource use (shoulder and non-shoulder related) and using
the patient questionnaires as the primary source of resource use data for the analysis.
Multiple imputation
Missing data is a common and serious problem in most economic evaluations associated with clinical trials.
Not only missing forms but also incomplete forms reduce, often considerably, the quantity of data on
resource use that are available for analysis. The problem is amplified when there are frequent assessments,
as in the ProFHER trial, in which there were five assessments: at baseline and at 3, 6, 12 and 24 months.
Unfortunately, the loss of just one cost component or EQ-5D index result for a patient means that the
total costs or total QALYs for that patient are lost to the analysis.
Complete case assessment excludes al patients with any missing data; thus, only patients with an
observed total cost and QALY data are included in the analysis. As wel as the resulting sample usualy
being a much reduced sample of the original data, complete case analysis might be biased if the patients
included in the analysis are not a random subset of al study participants.80An alternative method to
address missing data in clinical trials is multiple imputation,81which has been recommended as the
appropriate method to reflect the uncertainty in the results of an economic evaluation because of
missing data.57
Multiple imputation resolves the missing data problem by substituting each missing value with a predicted
value. The multiple imputation process folows three consecutive steps. First, the imputed data set is
created, through the use of regression models to predict plausible values for the missing observations
from the observed values. The process includes al of the covariates that might be associated with the
‘missingness mechanism’(why the data are missing); these included sex, age, tuberosity involvement,
centre, costs (surgery, physiotherapy, primary care, inpatient and outpatient visits) and utilities (at baseline
and 3, 6, 12 and 24 months). Costs and utilities were simultaneously imputed in the model rather than
imputed separately. Therefore, the registered covariates were used for both costs and utilities, with a
regression model fited for each variable with missing values, with the previous variables as covariates.
Based on the resulting model, a new regression model is then estimated and used to impute the missing
values for each variable. A random component is included to reflect the uncertainty around the
predictions. Thus, multiple imputation reflects the uncertainty in the prediction of missing values while
preserving the distribution and corelations in the data.82These values are then used to fil in the gaps in
the data set. This process is repeated for a finitemnumber of times (mbeing the number of imputations),
creatingmnumber of imputed data sets. In the second stage, each data set is analysed independently
using complete case methods. Finaly, the estimates obtained from each imputed data set are pooled
together to generate mean estimates of costs and QALYs, variances and CIs using Rubin’s rules, in such a
way that the uncertainty around the predicted values is fuly taken into account.83As there were missing
data for both costs and EQ-5D scores, multiple imputation using chained equations was employed.82
This way, each variable is predicted with its own regression model. Each imputed data set is created by
running the regression models over several cycles, in which each variable informs the prediction of the
other variables.
The corect specification of the regression models is key to ensuring that the distribution of imputed values
does not difer from that of the observed values, thereby providing unbiased estimates. The specification
of the regression models depends on the type and distribution of the variable to be imputed. Costs and
QALYs (the variables to be predicted for this analysis) are both continuous and not normaly distributed.
Two alternative methods are proposed to deal with this dificulty when using multiple imputation with
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chained equations: data transformations and predictive mean matching.82As no transformation was
successful in the case of the ProFHER trial data, predictive mean matching was used. This method ensures
that observed data are used to estimate a predictive model (using the specified covariates) but, instead of
replacing missing values with the model-predicted values, the nearest observed value is used to fil the
missing value. This guarantees that the imputed values are sampled from values in the original data set
and therefore no imputed values wil lie outside the bounds of the original data distribution.
Given the extent of missing data in the ProFHER trial we decided to use the multiple imputation data set,
created using al available data and multiple imputation with chained equations, as the‘base case’.
Meanwhile, the use of the complete case data set was explored in the sensitivity analyses.
Incremental analysis
This cost-efectiveness analysis aims to guide decision-making. Given that total health-care expenditure
must be covered from a limited and fixed budget, the most informative estimate of cost for decision-makers
is the mean cost per patient. Also relevant is the mean utility per patient. Therefore, the focus of this
analysis was to estimate the diference in mean costs and mean QALYs between the two treatment groups
in the trial.
We used a bivariate modeling approach for the analysis. The incremental mean utility and the incremental
mean cost between the two treatments were estimated using seemingly unrelated regression equations
for data on costs and QALYs. This bivariate method brings eficiency gains over unrelated ordinary
least squares (OLS) regression83for three reasons: (1) it alows for explicit modeling of both costs and
efects while alowing the inclusion of a set of diferent covariates in the two equations; (2) it exploits the
existence of corelation between costs and efects; and (3) seemingly unrelated regression does not require
a new regression for every value of the cost-efectiveness threshold.84Again, the same set of covariates
as used in the clinical efectiveness analysis was used: treatment group, age, gender and tuberosity
involvement at baseline. The baseline EQ-5D utility was also included in the utility regression to adjust for
possible baseline imbalance.85
The incremental cost-efectiveness ratio (ICER) was estimated as the diference in mean total costs divided
by the diference in mean total QALYs from baseline to 2 years. According to standard cost-efectiveness
decision rules four diferent eventualities are plausible when comparing incremental costs and QALYs.86
If the new intervention provides a beter outcome (positive incremental QALYs) at a lower cost
(negative incremental costs) it is considered a dominant intervention and hence cost-efective. On the
contrary, if the new intervention achieves a poorer outcome (negative incremental QALYs) at a higher
cost (positive incremental costs) it is considered a dominated option and hence not cost-efective. Thus,
the ICER is considered only if either intervention does not dominate, that is, both incremental costs
and incremental QALYs are positive (or negative). In these last two situations, to determine whether or
not the incremental health gain is worth the incremental cost the ICER needs to be compared against a
threshold value. For positive incremental costs and QALYs (the most frequent situation in health technology
assessment), an intervention wil be considered cost-efective only if the ICER is lower than the threshold.
According to NICE,55the wilingness to pay (WTP) for an additional QALY ranges between £20,000 and
£30,000. Therefore, if the results of this cost–utility analysis–the estimated cost per QALY–are below this
threshold, surgery would be considered cost-efective and its use in the NHS would be recommended.
The ICER can be rearanged in terms of net benefit, a more intuitive way of expressing whether or not surgery’s
health benefits are worth the additional costs.87The net benefit can be estimated on the cost scale as the
incremental health gain expressed in terms of cost minus the incremental cost of the intervention. The health
benefits are translated into a monetary value using the cost-efectiveness threshold, that is, the incremental
QALYs are multiplied by the WTP threshold. Therefore, the net monetary benefit (NMB) provides an estimate of
the gain (or loss) in resources of investing in a particular intervention when those resources might be used
elsewhere.88Curent NICE guidance55recommends presenting the NMB using values of £20,000 and £30,000
per QALY for the WTP threshold. Thus, surgery would be considered cost-efective only if the NMB is positive.
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Uncertainty
The uncertainty around the cost-efectiveness results is explored by means of sensitivity analyses. As
already mentioned, the extent of missing data justified the use of the imputed data set as the base-case
scenario. Nevertheless, the complete case was tested as part of a sensitivity analysis and the results
presented and compared with the imputed results. Complete case analysis ofers unbiased estimates only
if the data are missing completely at random, that is, the probability of the data being missing is
independent of both observed and unobserved values, whereas multiple imputation provides unbiased
estimates only if the data are MAR, that is, the probability of the data being unobserved is dependent on
the observed but independent of the unobserved values. If the missing completely at random assumption
does not hold the results of the complete case analysis might be biased, but this would apply to the results
of the multiple imputation only if the MAR assumption also did not hold. Thus, multiple imputation has
the advantage over complete case analysis in that if data are MAR, multiple imputation wil produce
unbiased estimates.81
As stated, the base case was based on the imputed data set and included only shoulder-related visits and
hospitalisations; moreover, hospitalisations were estimated using the information reported on the hospital
forms. Two one-way sensitivity analyses were conducted to test the impact of (1) including al visits and
hospitalisations regardless of them being classified as shoulder or non-shoulder related and (2) using
patients’questionnaires as the main source for estimating hospital visits and overnight stays.
Finaly, we used probabilistic sensitivity analysis to investigate the uncertainty associated with the mean
diference in costs and QALYs between treatment groups using both the complete case and the multiple
imputation data sets. Non-parametric bootstrapping89was used to plot the joint distribution of costs
and efects (QALYs) on the cost-efectiveness plane and derive the cost-efectiveness acceptability curves
(CEACs) to express the (Bayesian) probability that surgery is cost-efective as a function of the threshold
WTP.90The bootstrap technique was used to sample with replacement from the original observed pairs of
costs and efects, maintaining the corelation structure, to create a new data set with 5000 observations.
For each bootstrapped resample, an estimate of the diferential costs and QALYs was calculated. The
95% CIs for the diferential estimates were estimated using bias-corected non-parametric bootstrapping.
Results
Patient population
Although the proportions of complete assessments during the trial were relatively high in both groups
(87% of patients in each group returned their questionnaires at 2 years), the number of patients with
complete folow-up assessments for al periods was much lower. A total of 173 (69%) patients–95 (76%)
alocated surgery and 78 (62%) alocated not surgery–comprised the complete case for utilities, that is,
information for al five EQ-5D dimensions was available for al five assessment points. A total of 118 (47%)
patients–58 (46%) alocated surgery and 60 (48%) alocated not surgery–had complete resource use
information for the whole folow-up period. However, when considering both utilities and resource use,
complete information was available only for 100 (40%) patients: 54 (43%) alocated surgery and 46 (37%)
alocated not surgery.
Fourteen patients died during the trial period, nine (7.2%) in the surgical arm and five (4.0%) in the
non-surgical arm. When there were missing data before their deaths, the multiple imputation process was
applied in the same way as for the rest of the patients in the trial. The questionnaires that should have
been received at the assessment points after their death were considered as part of the complete case,
with zero resource use and zero utilities.
Health-related quality of life and quality-adjusted life-years
To estimate QALYs, the EQ-5D responses were converted into utilities and then translated into QALYs
using the AUC approach. The EQ-5D is considered to be complete only if patients give a response to al
five dimensions.Table 79shows the number of questionnaires returned by patients (including
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questionnaires with any dimensions missing) and the number with complete EQ-5D data at each
assessment point. Generaly, the number of questionnaires returned decreased with time, as did the
number of complete cases. Exceptions to this trend were found at 6 months in the return of
questionnaires in the non-surgery group and in the number of complete cases in both groups. Of note
also is that there were several patients who did not return questionnaires at one folow-up point but
who returned completed questionnaires at subsequent folow-ups. The extent of incomplete EQ-5D data
because of missing data strengthened the justification for using the multiple imputation data set as the
base case.
Table 80summarises the mean EQ-5D scores reported at each folow-up point for al of the available
cases. The analysis of utilities shows that patients in the not surgery group started from a lower baseline
utility on average than those in the surgery group (0.38 vs. 0.43). However, at the end of the second year
there was litle diference in EQ-5D score between the treatment groups.
The overal distribution of EQ-5D scores (utilities) for the diferent folow-up points is ilustrated in
Figure 23. At baseline, the utilities ranged between–0.358 and 1.
The distribution of mean utilities over the 2 years for the two groups is shown inFigure 24. The surgery
patients reported beter HRQoL at baseline, at 3 months and notably at 6 months. However, the patients
in the non-surgery group reported beter HRQoL subsequently. Al of the diferences were smal and the
95% CIs overlap at each assessment point.
Total mean QALYs were estimated based on individual patient’s utilities.Table 81summarises the mean
QALYs and the diference between alocation arms for al available cases. At the end of the trial, patients
alocated to not surgery obtained on average a higher QALY gain than patients alocated surgery.
TABLE 79Health-related quality of life: numbers of questionnaires returned and completed EQ-5D scores and
corresponding proportions of missing data by alocation and folow-up
Folow-up
Questionnaires returned,n(%) Completed EQ-5D,n(%)
Missing EQ-5D (not
returned+incomplete),n(%)
Surgery
(n=125)
Not surgery
(n=125)
Surgery
(n=125)
Not surgery
(n=125)
Surgery
(n=125)
Not surgery
(n=125)
Baseline 125 (100) 125 (100) 123 (98) 121 (97) 2 (2) 4 (3)
3 months 114 (91) 111 (89) 106 (85) 98 (78) 19 (15) 27 (22)
6 months 113 (90) 119 (95) 111 (89) 114 (91) 14 (11) 11 (9)
12 months 111 (89) 115 (92) 109 (87) 109 (87) 16 (13) 16 (13)
24 months 109 (87) 109 (87) 108 (86) 103 (82) 17 (14) 22 (18)
TABLE 80Health-related quality of life: EQ-5D scores at baseline and at folow-up points up to 2 years
Folow-up
EQ-5D mean (SD) score Difference (surgery–not surgery)
(95% CI)Surgery Not surgery
Baseline 0.43 (0.37) 0.38 (0.37) 0.053 (–0.39 to 0.14)
3 months 0.64 (0.25) 0.63 (0.24) 0.013 (–0.06 to 0.06)
6 months 0.69 (0.24) 0.63 (0.28) 0.038 (–0.03 to 0.10)
12 months 0.65 (0.30) 0.68 (0.28) –0.034 (–0.11 to 0.04)
24 months 0.67 (0.30) 0.69 (0.31) –0.022 (–0.10 to 0.05)
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FIGURE 23Distribution of EQ-5D scores at baseline and folow-up points up to 2 years. (continued)
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Health-care resource use and costs
The mean levels of resource usage over the 2 years of folow-up based on al available data are shown for the
two treatment groups inTable 82. Although patients in the surgery group had on average fewer GP visits
than non-surgery patients over the duration of the trial, they had on average more visits to the practice nurse,
the community nurse and the occupational therapist. In terms of hospital resource use, patients in the surgery
group had on average more outpatient appointments but fewer inpatient admissions than non-surgery group
patients. The average number of inpatient days given inTable 82excludes the number of nights that surgery
patients spent in hospital as a result of their initial surgical intervention, as this was included in the cost of
surgery. Conversely, it does include hospital stay for non-surgery patients if they required hospitalisation.
The average number of day cases is similar for both arms. Likewise, the number of physiotherapy sessions
received did not difer between the treatment groups.
The resource use required for the surgical intervention was estimated in terms of the staf involved in the
operation, the type of implant and disposables used, and the length of stay. Based on data from al
115 surgical forms received, the mean operation time in the ProFHER trial was 144 minutes, including
anaesthesia time (114 minutes in theatre). The mean length of stay for surgery was 3.8 days.
The cost of surgery comprises the costs of the staf involved, the implants, the disposables (anaesthesia
and antibiotics) and the inpatient stay. The nights that patients stayed in hospital as a result of the surgical
intervention were costed at £301 per night using NHS Reference Costs for excess bed-days (average of the
appropriate shoulder Healthcare Resource Group (HRG) codes for both elective and non-elective setings).
The relevant HRG codes (relating to shoulder and upper arm procedures) in the NHS Reference Costs are
HA61B, HA61C, HA62Z, HA63Z, HB61B, HB61C, HB62B, HB62C and HB63Z. The mean average cost of
surgery in the trial was £3053 per patient (including elective and non-elective setings) for an average
length of stay in hospital of 3.8 nights. The average cost for the selected HRG codes using NHS Reference
Costs78is £2775 for the elective inpatient seting (average length of stay of 1.74 nights) and £3938 for the
non-elective inpatient seting (average length of stay 4.14 nights). HES data10related to surgery for a
primary diagnosis of fracture of the upper end of the humerus performed in the UK during the last 5 years
(from 2007/8 to 2011/12) show that the majority of patients are operated on as non-elective patients
(one-third elective vs. two-thirds non-elective). From NHS Reference Costs,78the average unit cost for
selected diagnosis codes weighted by activity levels and adjusted using the elective to non-elective ratio is
£3550 (average length of stay 3.81 nights). Accordingly, a unit cost of £3550 was used in the analysis to
cost the first 4 nights of the inpatient stay as a result of surgery to the shoulder and a unit cost of £301
was used for each of the remaining nights reported, that is, excess bed-days. To ilustrate this point,
consider a theoretical example of a patient who undergoes initial surgery requiring 3 days of hospitalisation
and who then is admited later for a complication related to the shoulder that requires 6 nights of
hospitalisation. The cost of the inpatient stay for this specific patient would be the sum of the inpatient stay
included in the cost of the surgical intervention–£903 (3 nights at £301 per night)–plus a later cost of the
inpatient stay as a result of the complication–£4152 (4 nights costing £3550 plus 2 excess bed-days at
£301 each). When interpreting the cost of a hospital stay as a result of surgery to the shoulder, it is
important to appreciate that the hospital stay as a result of the primary surgical intervention is included
TABLE 81Health-related quality of life: total QALYs for al available cases by alocation over the 2 years
of folow-up
Alocation Total Mean (SD) QALYs Min. QALYs Max. QALYs
Differencea(surgery–not surgery)
(95% CI)
Surgery 95 1.34 (0.43) 0.147 1.96 –0.066 (–0.186 to 0.054)
Not surgery 78 1.38 (0.37) –0.029 1.94
Max., maximum; min., minimum.
a Estimated using OLS regression and controling for baseline utility.
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TABLE 82Average resource use per arm of the trial over the 2 years of folow-up
Resource use Surgery Not surgery
Average number of GP visits
n 76 71
Mean (SD) 0.85 (1.33) 1.18 (1.98)
Median (min., max.) 0 (0, 6) 1 (0, 12)
Missing, % 39 43
Average number of practice nurse visits
n 74 75
Mean (SD) 0.78 (2.04) 0.28 (0.72)
Median (min., max.) 0 (0, 15) 0 (0, 4)
Missing, % 41 40
Average number of community nurse visits
n 87 82
Mean (SD) 0.56 (2.31) 0.17 (1.33)
Median (min., max.) 0 (0, 16) 0 (0, 12)
Missing, % 30 34
Average number of occupational therapist visits
n 86 81
Mean (SD) 0.66 (1.93) 0.59 (2.03)
Median (min., max.) 0 (0, 10) 0 (0, 12)
Missing, % 31 35
Average number of physiotherapy sessions
n 118 117
Mean (SD) 9.57 (6.22) 9.60 (6.59)
Median (min., max.) 8 (1, 36) 8 (1, 43)
Missing, % 5 6
Average number of outpatient appointments
n 106 112
Mean (SD) 0.41 (1.02) 0.34 (0.92)
Median (min., max.) 0 (0, 5) 0 (0, 5)
Missing, % 10 15
Average number of day case admissions
n 114 114
Mean (SD) 0.096 (0.32) 0.096 (0.032)
Median (min., max.) 0 (0, 2) 0 (0, 6)
Missing, % 9 9
Average number of inpatient nights
n 110 116
Mean (SD) 0.25 (1.23) 1.05 (3.15)
Median (min., max.) 0 (0, 16) 0 (0, 10)
Missing, % 12 7
Max., maximum; min., minimum.
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within the cost of surgery and is thus not included in the total for the inpatient stay, which thus applies to
subsequent shoulder complications.The same rationale was used to cost the number of nights in hospital
as a result of non-shoulder-related or medical complications. From NHS Reference Costs,78the average unit
cost across al inpatient setings is £2724 (average length of stay of 4 nights) and the average unit cost of
excess bed-days across al trusts and specialties is £261. Therefore, the first 4 nights in hospital reported by
patients as a result of medical complications were costed at £2724 and each subsequent night reported
was costed at £261.
Table 83summarises the mean cost by category of resource use and alocation based on al available
cases. Costs associated with surgery were the major cost driver for the surgery group whereas the cost of
hospital admissions was the cost driver for the non-surgical group.
Table 84ilustrates that patients in the surgical group experienced the largest proportion of the total cost
during the first 3 months, that is, during the period when they received surgical treatment of their
proximal humerus fracture.
TABLE 83Cost by category and treatment alocation
Category
Mean (SD) cost (£) Differencea(surgery–not surgery)
(95% CI)Surgery Not surgery
Surgery 2565.85 (1633.64) 234.96 (1224.26) 2330.88 (1971.25 to 2690.52)
GP 34.21 (53.34) 47.32 (79.27) –13.11 (–35.00 to 8.77)
Physiotherapy 325.56 (287.03) 326.63 (224.06) –1.03 (–57.03 to 54.95)
Practice nurse 8.62 (22.46) 3.08 (7.99) 5.54 (0.09 to 10.98)
Community nurse 7.32 (24.80) 2.21 (17.3) 5.10 (–2.41 to 12.62)
Occupational therapist 24.78 (101.91) 7.51 (58.58) 17.26 (–8.17 to 42.71)
Hospital outpatient 43.40 (107.66) 36.04 (96.03) 7.41 (–19.79 to 34.61)
Hospital day case 65.37 (19.60) 65.37 (19.60) 0 (–54.61 to 54.61)
Hospital inpatient 341.25 (1198.36) 921.82 (2222.07) –580.57 (–1052.18 to–108.96)
a Estimated using OLS regression.
TABLE 84Comparison of mean total costs per alocation during folow-up periods
Folow-up
Mean (SD) cost (£) Differencea(surgery–not surgery)
(95% CI)Surgery Not surgery
Month 3 2766.8 (1468.641) 694.00 (1868.78) 2072.79 (1595.84 to 2549.73)
Month 6b 11.80 (32.81) 29.93 (140.70) –18.13 (–46.78 to 10.52)
Month 12 183.42 (750.95) 231.21 (848.13) –47.79 (–294.15 to 198.57)
Month 24 58.28 (366.95) 180.12 (708.44) –121.83 (–288.72 to 45.05)
Physiotherapy 325.56 (287.03) 326.63 (224.06) –1.03 (–57.03 to 54.95)
a Estimated using OLS regression.
b Resource use data at 6 months were colected only in the patient questionnaires and thus are exclusively related to
primary care in the base-case analysis.
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Cost-effectiveness analysis and uncertainty
The base-case analysis shows that the participants randomised to surgery accumulated greater costs and
reported a lower HRQoL than participants randomised to non-surgery.Table 85shows the comparison of
total mean costs and total mean QALYs between the multiple imputation results and the complete case
data set. The similarity of both the mean and the CIs provides some reassurance of the validity of the
multiple imputation model. Using multiple imputation, the surgical intervention cost on average £1780.73
(95% CI £1152.71 to £2408.75) more per patient than non-surgical treatment when adjusted for baseline
utility. The incremental cost decreased very slightly when adjusted for the remaining covariates. Although
total QALYs for the surgical intervention were smaler than those for non-surgery, the diference between
treatment groups was not statisticaly significant either when adjusted for baseline utility (mean diference
–0.0158, 95% CI–0.13 to 0.10) or when adjusted for covariates (mean diference–0.0101, 95% CI
–0.13 to 0.11). The NMB associated with surgery was negative, indicating that this intervention is not
cost-efective as the resources to be displaced would be greater than the benefit to be gained if surgery
was implemented in the NHS.
As both the multiple imputation and complete case results indicate that surgery is dominated by the
non-surgery intervention, this indicates that surgery should not be adopted. However, the diferences in
QALYs are not statisticaly significant, indicating that there might be some uncertainty associated with this
conclusion. To analyse this uncertainty non-parametric bootstrapping was used.Figure 25shows the joint
distribution of costs and efects for the 5000 bootstrapped replicates on the cost-efectiveness plane. The
locations of the incremental cost pairs show that there is no uncertainty regarding the cost of surgery;
surgery wil be always be a more costly intervention as al replicates fal above the horizontal axis.
However, the position and spread of the QALY replicates indicate that there is uncertainty about the
existence of a health benefit associated with surgery. This is consistent with the non-significant diference
in QALYs between the two treatment groups. The outer elipse inFigure 26represents the 95% CI for
the true incremental cost-efectiveness for the compared alternatives. The inner elipse defines the 50%
confidence region. The point estimate represents the incremental cost (£1780.73) and incremental efect
(–0.0158 QALYs) per patient based on the ProFHER data.
TABLE 85Summary of the incremental analysis (ITT), cost-effectiveness results and uncertainty for the base case
Multiple imputation Complete case
Adjusted for
baseline utility
Adjusted for
covariatesa
Adjusted for
baseline utility
Adjusted for
covariatesa
Incremental mean cost (£)
(95% CI) (surgery–non
surgery)
1780.73
(1152.71 to 2408.75)
1757.65
(1126.29 to 2389.00)
1461.60
(527.10 to 2396.10)
1516.81
(614.94 to 2418.67)
Incremental mean QALYs
(95% CI) (surgery–non
surgery)
–0.0158
(–0.13 to 0.10)
–0.0101
(–0.13 to 0.11)
0.0004
(–0.16 to 0.16)
–0.0066
(–0.16 to 0.15)
ICER (£) Dominated Dominated 3,478,297.6 Dominated
NMB (£) –2098.39 –1959.88 –1453.19 –1650.79
Probability cost-efective at
WTP of £20,000 per QALY
0.05 0.06 0.20 0.16
Probability cost-efective at
WTP of £30,000 per QALY
0.13 0.15 0.28 0.23
a The covariates used to adjust for in the model were age, gender, treatment group and tuberosity involvement (yes/no)
at baseline.
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The CEAC derived from the joint distribution of costs and efects is represented inFigure 27. The curve was
constructed by ploting the proportion of the incremental cost-efectiveness pairs that are cost-efective
for a range of thresholds. They-axis, which presents the probability of surgery being cost-efective,
ranges between 0% and 100%, with the horizontal dashed line indicating a 50% probability of surgery
representing a value for money option for the NHS. As shown inFigure 27, the probability of surgery being
cost-efective is<10% (multiple imputation data set) given the curent NICE WTP threshold of £20,000 per
additional QALY. The probability is slightly higher for a threshold of £30,000 per additional QALY but is stil
too low for surgery to be considered as a cost-efective alternative by the NHS for fracture of the shoulder.
Both of the adjusted analyses give similar results.
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FIGURE 26Confidence elipses, controling for covariates: base-case analysis.
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Sensitivity analysis
The complete-case analysis, whose results have been shown to be consistent with the results of the multiple
imputation analysis, was tested as part of the sensitivity analysis.
The results of the one-way sensitivity analysis conducted to test the impact of including both shoulder- and
non-shoulder-related resource use are shown inTable 86. The complete case for this scenario comprises
64 (26%) patients: 32 (26%) alocated to surgery and 32 (26%) alocated to non-surgery. There is
litle change in the results when considering al resource use in the assessment. Surgery is stil not a
cost-efective intervention for the multiple imputation data set. Although surgery does not represent
a dominated option for the complete case, the ICERs for both adjusted scenarios are much higher than the
thresholds that NICE normaly consider for reimbursement decisions (£20,000–30,000 per QALY gained).
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FIGURE 27Cost-effectiveness acceptability curve, controling for covariates: base-case analysis.
TABLE 86Sensitivity analysis: summary of the incremental analysis (ITT), cost-effectiveness results and uncertainty
when considering al resource use
Multiple imputation Complete case
Adjusted for
baseline utility
Adjusted for
covariates
Adjusted for baseline
utility
Adjusted for
covariates
Incremental mean cost (£)
(95% CI) (surgery–non
surgery)
1759.43
(906.30 to 2613.55)
1738.81
(908.63 to 2568.98)
909.95
(–1000.07 to 2819.98)
1312.38
(–606.22 to 3230.99)
Incremental mean QALYs
(95% CI) (surgery–non
surgery)
–0.01758
(–0.14 to 0.10)
–0.011
(–0.13 to 0.11)
0.0201
(–0.15 to 0.19)
0.0338
(–0.14 to 0.21)
ICER (£) Dominated Dominated 45,050.66 38,783.19
NMB (£) –2111.19 –1970.41 –505.98 –635.60
Probability cost-efective at
WTP of £20,000 per QALY
0.05 0.06 0.40 0.37
Probability cost-efective at
WTP of £30,000 per QALY
0.13 0.15 0.42 0.41
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The results are similar when we investigate the impact of using patient questionnaires (rather than hospital
forms) as the main source for hospital data. The complete case for this scenario comprises 98 (40%)
patients, 52 (42%) alocated to surgery and 46 (37%) to non-surgery. As shown inTable 87, there is no
major impact on the results: surgery is always a dominated option, with a negative NMB and with a smal
probability of being cost-efective at the curent thresholds.
Conclusion
Patient-level data from the ProFHER trial provide robust evidence on whether or not surgery is cost-efective
in the treatment of adults with an acute closed displaced fracture of the proximal humerus with
involvement of the surgical neck.
The base-case analysis (multiple imputation data set) for the ITT approach suggests that surgery is expected
to be significantly more costly and to provide fewer health benefits than non-surgery for the treatment of
these patients. Similarly, the analysis of uncertainty confirmed that it is unlikely that surgery represents an
eficient intervention for the NHS, as the probability of surgery being cost-efective is≤0.15, regardless of
the covariates used for adjustments. The results were robust to the three sensitivity analyses: (1) using the
complete case data set; (2) considering patient questionnaires as the main source of hospital resource use;
and (3) including both shoulder and non-shoulder-related resource use in the analysis. Although surgery
was not a dominated alternative in the last scenario, the ICERs were stil above NICE cost-efectiveness
thresholds. In that sense, neither of these approaches (sensitivity analysis using patient questionnaires or
sensitivity analysis using al resources), assessed for both the complete case and the multiple imputation
data set, had any impact on the results.
TABLE 87Sensitivity analysis: summary of the incremental analysis (ITT), cost-effectiveness results and uncertainty
when considering patients’questionnaires
Multiple imputation Complete case
Adjusted for
baseline utility
Adjusted for
covariates
Adjusted for
baseline utility
Adjusted for
covariates
Incremental mean cost (£)
(95% CI) (surgery–non
surgery)
1609.44
(532.99 to 2685.88)
1563.10
(497.23 to 2628.98)
1740.65
(604.12 to 2877.19)
1792.93
(701.39 to 2884.47)
Incremental mean QALYs
(95% CI) (surgery–non
surgery)
–0.016
(–0.13 to 0.10)
–0.0103
(–0.13 to 0.11)
–0.0053
(–0.14 to 0.13)
–0.0120
(–0.15 to 0.12)
ICER (£) Dominated Dominated Dominated Dominated
NMB (£) –1929.60 –1769.69 –1847.50 –2034.36
Probability cost-efective
at WTP of £20,000 per
QALY
0.08 0.10 0.12 0.09
Probability cost-efective
at WTP of £30,000 per
QALY
0.16 0.18 0.21 0.18
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Chapter 8Discussion and conclusion
The ProFHER trial is the largest RCT to date to examine treatment options for proximal humeral fracture,which is an increasingly common fracture in an ageing population. More specificaly, it has efectively
more than doubled the previous evidence available on whether or not surgery is required for the majority
of displaced fractures of the proximal humerus. The ProFHER trial, with>200 participants folowed up at
2 years, is suficiently powered to draw strong conclusions about the absence of a significant diference
between the two groups in the primary outcome. Furthermore, using robust methods in the design of the
trial with good implementation ensures strong internal validity. The pragmatic multicentre design of
the ProFHER trial, including the constant emphasis on good standard practice, means that its results
have immediate applicability in the UK NHS and are likely to apply to other countries with similar
surgical practice.
In this discussion, we begin by summarising the main results, with guidance on their interpretation. We
then explore whether or not there are potential risks of bias that might chalenge the trial validity and
applicability. In terms of the later, we consider whether or not the trial population is representative of the
putative population for which the treatment question applied and examine related issues of treatment
preference and surgeon equipoise. The applicability of the findings to the NHS is discussed in the context
of the findings of the trial and hospital episode data on the volume of operations at a hospital trust level.
We provide a summary of the curently available evidence and pending RCTs examining this comparison
for these patients. We conclude by considering the application of the trial results in practice, including how
these findings can help the clinician make evidence-informed decisions in the clinical seting.
Summary of the main findings
Primary outcome
We found that there were no statisticaly significant diferences in OSS [scale 0–48 (best outcome)] between
the two treatment groups, either overal (diference of 0.75 score points in favour of the surgery group,
95% CI–1.33 to 2.84;p=0.479) or at individual time points. Although not statisticaly significant, there
was weak evidence to suggest a smal diference in OSS at 6 months’folow-up (diference of 2.25 OSS
points in favour of the surgery group, 95% CI–0.07 to 4.57,p=0.058). However, the coresponding
95% CI excluded the prespecified diference of 5 points, suggesting that any diference is not of‘clinical
significance’. The selection of the 5-point efect size is supported both for the general use of the OSS41and,
most recently, for its use in proximal humeral fractures.91The later study also reported an anchor-based
(relating to patient perception of change) minimal clinicaly important diference of 11.4 points. Thus, both
articles confirm that the diference between the two groups at 6 months is smal and not clinicaly important.
As the OSS could not be used for baseline assessment, we cannot report on the responsiveness of the OSS
in the period of greatest recovery. For example, a study of 20 patients with comparable characteristics
to those of our trial participants found a change score of 15.6 (SD 10.7) for the OSS between 6 and
12 weeks.91Nonetheless, the OSS improved over time in both treatment groups between 6 and 24 months,
and checks of individual patients with low scores, indicating poor shoulder functioning, generaly produced
coroborative evidence of shoulder-related and other complications. Additionaly, the smal between-group
divergence at 6 months was paraleled in the PCS domain of the SF-12 and the EQ-5D results. In the context
of the greater number of newly treated medical complications occuring in the first year in the non-surgery
group, it is plausible that the 6-month result is a reflection of greater morbidity, which impeded progress
with shoulder functioning.
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There was no statisticaly significant efect of treatment group for interactions with age or fracture type
(assessed by tuberosity involvement at baseline and Neer classification) in the two planned subgroup
analyses. Our prior expectations of directions of efect (subgroup diferences) were not supported by these
results but strengthen the case for not diferentiating treatment (use of surgery) on the basis of
these characteristics.
Similarly, the efect of treatment group remained not statisticaly significant when accounting for smoking
status and patient treatment preference. The proportion of smokers recorded at baseline was greater in
the non-surgery arm, puting these patients at greater risk of complications such as nonunion.92However,
this imbalance did not afect the results of the trial. Furthermore, a sensitivity analysis conducted after the
preparation of this report showed that the efect of treatment group remained not statisticaly significant
when accounting for clustering at centre level (seeAppendix 37).
Almost half of the patients in the trial had no treatment preference at baseline. Interestingly, for these
patients the diference between treatment groups in favour of surgery at 6 months’folow-up was the
most pronounced, but stil not statisticaly significant, compared with those patients who indicated a
treatment preference for either surgery or not surgery. Although there is scope for further investigation of
patient treatment preference, crucialy this did not significantly afect patients’treatment outcome with
regard to the main OSS findings.
Secondary outcomes
The use of a generic HRQoL measure such as the SF-12 in conjunction with the OSS is recommended
practice.41We found no evidence for statisticaly significant diferences between treatment groups in
physical functioning as measured by the PCS score of the SF-12 [scale 0–100 (best outcome); average 50]:
the PCS score was on average 1.8 score points beter in the surgical group than in the non-surgical group
(95% CI–0.84 to 4.39;p=0.184). The same lack of significance applied for mental functioning, as
measured by the MCS score of the SF-12 [scale 0–100 (best outcome); average 50]: the MCS score was on
average 1.3 points worse in the surgical group than in the non-surgical group (95% CI–3.80 to 1.23;
p=0.317). Although none of the diferences between the two groups at individual time points were
statisticaly significant for either of these outcomes, the results for the PCS mirored those of the OSS
analysis in that there was a slightly beter score (mean diference 2.55) in the surgery group at 6 months.
At most, this would equate to a smal diference in favour of the surgery group but more notable is the
similarity in the PCS scores over time in the two groups, with no additional improvement noted at 12 and
24 months for the surgery group.
Slightly more patients in the surgery group than in the non-surgery group experienced a surgical or
shoulder fracture-related complication [30 (24%) vs. 23 (18%)]. Although the same number (n=11; 9%)
in each group had secondary surgery to the shoulder within the 2-year folow-up period, slightly more in
the surgery group had increased or new shoulder-related therapy [seven (5.6%) vs. four (3.2%)]. None of
these diferences between groups (the number of patients with complications or the number undergoing
further surgery or therapy) was statisticaly significant. The same finding applied to mortality, with there
being slightly more deaths in the surgery group than in the non-surgery group [nine (7.2%) vs. five
(4.0%)]. One death in the surgery group was judged as being trial related.
Although our colection of data on complications and their treatment was active and systematic, with
specificaly designed forms, the retrospective completion of forms at 1 year and 2 years could stil be a
source of missing data. However, although these outcomes may be under-reported, it is unlikely that this is
a source of bias. This conjecture is supported by the findings of similar numbers in the two groups of
additional‘untoward events’detected in our scrutiny of the physiotherapy logs and of prospectively
colected adverse events, including those relating to the shoulder.
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We recognise also that the named complications on the forms were mainly surgery related. However,
the forms facilitated the colection of other‘complications’, especialy in relation to additional therapy or
surgery. We have described our processing and interpretation of these complex data inChapter 3,
including, when possible, comments on the reported‘outcomes’. With the addition of other complications,
notably post-traumatic stifness (sometimes reported as‘frozen shoulder’), we believe that we have given
an accurate account of the shoulder treatment and fracture-related complications incured by these patients.
Cost-effectiveness
The base-case analysis showed that the participants randomised to surgery accumulated greater costs and
reported a lower HRQoL than participants randomised to non-surgery. At 2 years, surgical intervention cost
on average £1780.73 (95% CI £1152.71 to £2408.75) more per patient than non-surgical treatment
(2012 prices). It was also slightly less beneficial, although this diference was not statisticaly significant
[diference in utility of–0.015 (95% CI–0.13 to 0.10) when adjusted for baseline utility and–0.0101
(95% CI–0.13 to 0.11) when adjusted for covariates]. The NMB associated with surgery is negative,
indicating that the resources to be displaced would be greater than the benefit to be gained if surgery was
implemented in the NHS. Furthermore, the CEAC showed that surgery had only a 5% probability of
costing<£20,000 to gain a QALY. Therefore, surgery appears to be a dominated treatment option and
not a cost-efective use of health-care resources. These findings were robust to the three sensitivity
analyses that were undertaken. Although surgery did not result in a dominated alternative for the
base-case analysis or the sensitivity analyses that included both shoulder and non-shoulder-related resource
use, the ICERs were stil above NICE cost-efectiveness thresholds. This finding could have been influenced
by an accurate account of the shoulder treatment and the greater number of newly treated medical
complications occuring in the first year in the non-surgery group.
Countering potential threats to internal validity
We took al of the necessary measures to ensure trial validity and thus minimise the risk of bias. Some of
these are discussed here.
Most importantly, these measures included a secure randomisation method, with a mid-recruitment
decision not to proceed to minimisation to avoid any risk of predictability of treatment alocation. The
comparability in the baseline characteristics of the two treatment groups atests to the success of this
measure. A sensitivity analysis examining the chance imbalance in the numbers of smokers showed no
efect on the primary outcome result.
We were proactive in establishing expectations for good standard clinical care, including clinicians using
techniques that they were experienced with. We took steps to remedy identified gaps in the care
programme for patients with these fractures, such as the absence of a patient information leaflet on sling
immobilisation and a basic physiotherapy protocol. We stressed the need for comparability in the care
provided to both treatment groups. Five key indicators of our success are listed here. First, at least two
radiographic views were available for the majority of patients. Second, the majority of operations were
conducted by consultant surgeons, with a consultant being in the theatre or available if needed for the
rest of the operations, which were caried out by senior registrars. The choice of implants used, with
the majority being locking plates (in particular PHILOS plates), is compatible with expectations of curent
practice. Third, the ProFHER trial sling information leaflet was provided, with very few exceptions, to al
trial patients and to most of the patients who were eligible for the trial. Fourth, equivalent provision of
physiotherapy was reported for the two treatment groups, as evidenced by comparability in the timing of
sessions, the number of sessions and the interventions listed. Finaly, physiotherapists recorded home
exercises for the majority of patients for both treatment groups. Encouragingly, this showed that the
majority of patients were performing their home exercises.
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The high return rate for patient questionnaires and the almost complete return of hospital forms reflect
the success of the measures taken to achieve high retention rates and as ful a data set as possible. As
described, particular efort, which was ultimately successful, was required to obtain portable copies of
baseline radiographs. The baseline characteristics of patients contributing OSS data at 24 months showed
no important diferences between the two groups, with the exception of the continued diference between
groups in the number of smokers. An analysis of the efect of missing data produced similar reassurance.
Missing data from incomplete forms was a relatively minor problem in the clinical efectiveness analysis but,
as explained inChapter 7, the accumulative efects of missing data over several assessments meant that it
was a serious problem in the economic analysis because of the strict criteria for complete case assessment,
which excludes al patients with any missing data. The a priori decision to use multiple imputation as the
base-case analysis to corect for missing data was thus corect.
An unavoidable limitation of trials such as the ProFHER trial that test sharply contrasting interventions is the
lack of blinding of the assessment of patient-reported outcomes. Although this limitation is inescapable,
measures to obtain as ful a data set as possible and obtaining information on patient preferences help to
assess the potential efect on the results of the lack of patient blinding. Altogether and separately, the similar
and high rate of return of patient questionnaires at each folow-up point, the lack of diferences between
the two groups in baseline characteristics of those patients with OSS data at 24 months, the minimal efect
of missing data on the analysis and the lack of a significant efect of baseline patient preferences on the
OSS results give reassurance that the lack of blinding did not importantly afect patient responses overal.
In addition, as described above, the diference between treatment groups in favour of surgery at 6 months
was most pronounced in the 46% of patients who had no baseline treatment preference.
Rigorous methods were used for data processing and analysis. Both the clinical efectiveness analysis and
the economic analysis were preceded by writen documents that set out the planned analyses in detail.
The former was overseen by the DMEC and, although the statistician was not blinded, the primary
analyses were repeated by a second blinded statistician using diferent statistical software and the results
were in agreement. ITT analysis, including al randomised patients in the groups to which they were
randomised, was conducted throughout. There were more crossovers in the surgery group than in the
non-surgery group [16 (13%) vs. two (1.6%], but this is likely to reflect clinical practice, in which a patient
can be found unsuitable for surgery subsequent to the fracture clinic consultation. Also, only a low
number of patients were operated on by any individual participating surgeon; thus, no one surgeon
dominated nor, indeed, any other clinician in providing treatment. Finaly, coding, which always involved at
least two independent raters, was caried out blind to alocation when this applied.
One commonly perceived threat to the validity of multicentre trials relates to the patern of recruitment,
including low recruitment from individual centres. Efective randomisation should counter any threat to
internal validity, but the applicability of the results needs to be checked in terms of the characteristics
of the actual trial population.
Applicability of the results
Characteristics of the trial population
The baseline characteristics of the trial participants and subsequent independent characterisation of
radiographs confirm that the patients included in the ProFHER trial had sustained injuries that are
typicaly considered for surgical intervention in contemporaneous practice. To emphasise this point a
selection of four fractures that are representative of those in the ProFHER trial is shown inFigure 28.
The results of this trial are therefore particularly relevant and important in guiding treatment decisions
for these displaced fractures.
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We aimed to include the majority of patients meeting the ProFHER trial’s inclusion criteria but also
established several exclusion criteria to avoid obstacles to appropriate (comorbidities precluding surgery or
anaesthesia) or efective (not resident in catchment area) trial participation. A comparison of four key
baseline characteristics revealed that patients who consented to participate in the trial tended to be on
average 4 years younger (mean age 66 years) and more likely to have tuberosity involvement than those
who were excluded. Although the higher age would also reflect exclusion because of comorbidities and
lack of mental capacity, both of these diferences were detected in the characteristics of the 117 patients
excluded because of a lack of surgeon equipoise. However, although the surgeons tended to advise
surgery in patients aged<65 years, patients with fractures involving tuberosities were just as likely to be
advised surgery or non-surgery as patients with fractures involving no tuberosities. This ilustrates that
these excluded fractures are stil within the area of treatment uncertainty. We found no marked
diferences between enroled and non-consenting patients. Overal, the age and gender characteristics of
the screened population and the RCT population are comparable with those reported from other
sources7,92,93as wel as HES data (seeAppendix 1).
The results of the carefuly prepared and performed independent classification of the fractures according to
Neer confirmed that the study fractures al had‘involvement’of the surgical neck and that the majority
met Neer displacement criteria. The formal classification fulfils the requirements for a description of the
study fractures using the most commonly used classification system for these fractures. We accepted
fractures that did not meet the Neer displacement criteria but which were nonetheless displaced fractures
that would have reflected an individual surgeon’s treatment uncertainty. The 18 one-part fractures, which
(a) (b)
(c) (d)
FIGURE 28Four representative fractures from the ProFHER trial. (a) and (b) Two-part fracture of the surgical neck
with an undisplaced greater tuberosity fracture; (c) and (d) three-part fracture with displacement of the surgical
neck and greater tuberosity. L, left; R, right.
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were distributed equaly in the two intervention groups, were evidently displaced enough for the treating
surgeon to have considered surgical intervention and hence they were included in the trial. The majority of
these had greater tuberosity involvement. We consider that the inclusion of these fractures is not a threat
to the internal or external validity of the trial. Ultimately, the Neer displacement criteria, although useful,
are arbitrary and Neer59himself, in a comprehensive article reflecting on the‘four-segment classification’,
advised that‘As displacement is a continuum, there wil always be some borderline lesions’(p. 392). It has
been revealed also that Neer’s criteria were devised in response to editorial instruction prior to publication
of the original classification and were therefore additional to the consideration of the main study.21
Other than these 18 one-part fractures, the distribution of the fractures in the trial tended to be more
towards the more complex fractures (i.e. three- and four-part fractures) than originaly anticipated based
on Court-Brownet al.’s epidemiological study.7Based on data from this study, we would have expected
179 two-part fractures and 71 three- and four-part fractures (ratio of 2.52 : 1). The actual data showed
146 one- and two-part fractures and 104 three- and four-part fractures (ratio of 1.40 : 1). This, together
with the other indications of severity (e.g. no contact surgical neck fractures) and the even smaler ratio of
fractures with no tuberosity involvement (57 fractures) to fractures with any tuberosity involvement
(193 fractures) as recorded on the study eligibility forms (0.30 : 1), points to the focus being on the more
complex fractures. Although the distribution is shifted towards more complex fractures, it is in keeping
with the aims of this pragmatic trial, which has addressed the treatment uncertainty that applied to the
majority of displaced fractures of the proximal humerus. Thus, whether based on assessment of the
fracture configuration (using radiography; CT scans were very rarely used) or a strict observation of
Neer’s displacement criteria, the study fractures are representative of the intended fracture population.
Additionaly, the absence of a significant efect on the study outcome in the subgroup analysis applied
whether based on tuberosity involvement assessed at baseline or on the independent Neer classification.
This indicates that the Neer classification is no more helpful than the assessment of tuberosity involvement/
displacement; indeed, the later, when exacting displacement criteria are not used, is more likely to be
used as the basis for a surgeon’s judgement in a busy clinic. Moreover, surgeons’inter-rater agreement on
treatment has been found to be higher than the poor agreement found for the Neer classification.94
Applicability to the UK NHS
The pragmatic design of the ProFHER trial lends itself for immediate application to the NHS seting. Our
requirements, such as for surgeons to perform operations with which they were familiar and for there to
be equivalent provision of physiotherapy, al came under the mantle of good standard practice in the NHS.
We showed that consultant surgeons were invariably involved in the management of these fractures, and
the majority of operations were caried out by these surgeons. Surgical fixation using locking plates
and hemiarthroplasty, as used in the ProFHER trial, is the most commonly used method in curent practice
in the UK and in many other countries. We also showed that the majority of these patients received
physiotherapy, with no distinction made between the treatment groups. The use of patient questionnaires
and patient-reported outcome measures meant that no clinic folow-up assessment was required.
Thirty-five NHS centres, 33 of which are based in England, participated in the trial. An examination of centre
variability by examining the OSS scores of patients in individual centres indicated greater variation within
centres than between centres because of the low numbers of patients generaly recruited. Although the
smal sample sizes for several individual centres hampers this sort of analysis, it gives support to considering
the centres as a group. This we did in our investigation (based on using HES data for NHS hospitals in
England) of the characteristics of the participating hospitals relative to those of non-participating acute
hospitals in England. To obtain consistent data sets it was necessary to perform our analyses at hospital
trust level, which is an overarching organisation providing particular NHS services in a particular region.
We compared the general characteristics and those relating to surgical activity of patients with proximal
humeral fracture in the 30 participating trusts (some centres belonged to the same trust) with those of the
other 118–122 (year dependent) non-participating‘acute/teaching’trusts over a 5-year period. This covered
the ProFHER trial recruitment period with an additional year at either end.
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This analysis showed that a significantly greater proportion of participating trusts than non-participating
trusts included teaching hospitals (0.33 vs. 0.14;p<0.0001). Based on finished consultant episode (FCE)
data, participating trusts in the ProFHER trial surgicaly treated, on average, significantly more patients with
these fractures than surgeons in non-participating trusts [overal mean per year: 31.62 (SD 17.02) vs. 22.72
(SD 13.49);p<0.0001]. These results are presented inFigure 29. The ratio of admissions to FCEs was
nearly identical (0.90 vs. 0.89), which is reflected in the data showing a similarly higher level of admissions
for episodes involving proximal humeral fracture surgery in the participating trusts (Figure 30).
These data show consistently higher surgical activity in relation to proximal humeral fractures in the
participating centres throughout the 5-year period (39% overal). Comparative patient-level statistics are
presented inTable 88. These show no important diferences between the two groups of trusts in the age
and gender of the patients undergoing surgery related to these fractures, nor in waiting time or length of
stay. [Length of stay for both groups of trusts (HES data) was on average 2 days greater than that found for
those treated surgicaly in the ProFHER trial (mean length of stay for surgery was 3.8 days).] The only
diference was that participating centres were more likely to admit emergency patients than elective patients.
Overal, the HES data for surgicaly treated patients showed that these patients were on average 5 years
younger than participants in the trial (mean 66.60 years). This is consistent with the general tendency to
operate on younger patients, as also detected in surgeon treatment preference data on lack of equipoise
and reflected in the increasing morbidity in older patients that would preclude surgery. Inspection of HES
data for patients aged<65 years and patients aged≥65 years (as per our subgroup analyses) provides
coroborative evidence. Summed over the 5-year period, in patients with a proximal humerus fracture who
were aged<65 years there were 9555 (43%) FCEs for operations out of the 22,084 FCEs for al possible
treatments. For patients aged≥65 years were 8821 (18.5%) FCEs for operations out of the 47,466 FCEs
for al possible treatments.
Nu
mb
er 
of 
FC
Es
40
35
30
25
20
15
10
5
0
2007–8 2008–9 2009–10
Reporting period (April to March of folowing year)
2010–11 2011–12
Trial
Rest of England
FIGURE 29Average number of FCEs in participating and non-participating trusts.
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Teaching hospitals and those with higher volumes of surgery are typicaly viewed as places that wil feature
more specialist surgeons who wil perform more surgery. Hence, the results of the ProFHER trial apply not
only to the participating centres but also to the rest of the acute hospitals in England and arguably to
other countries with similar acute hospital setings and provision.
Subsequent to the ProFHER trial there has been a reconfiguration of trauma care in the UK, resulting in the
establishment of major trauma centres. It is noteworthy that 11 of the 20 trauma centres for adults in
England are located in hospitals that participated in the ProFHER trial.
Summary review of the currently available evidence
The evidence from other RCTs on this topic has been under regular review, also as part of a Cochrane
review, and reports have been provided at TSC meetings. The curently published version of the Cochrane
review30(search date January 2012) includes evidence from six RCTs (including 270 participants) comparing
surgery with conservative (non-surgical) treatment plus details of six ongoing trials, including the ProFHER
trial. One author (HH) performed an interim update of the evidence for this comparison. The update of the
Cochrane review, which wil commence on publication of this report, wil folow the methods described in
the review; this wil include the independent reviewing of the ProFHER trial.
Using the search strategies listed in the Cochrane review, an interim search of the Cochrane Central
Register of Controled Trials (CENTRAL), MEDLINE and EMBASE was conducted on 9 September 2013 by
the Trial Search Co-ordinator of the Cochrane Bone, Joint and Muscle Trauma Group. HH also searched
the World Health Organization (WHO) International Clinical Trials Registry Platform Search Portal
(December 2012) and Curent Controled Trials (December 2012). HH screened a total of 219 records
from the folowing databases: CENTRAL (36 records), MEDLINE (46 records), EMBASE (115 records), WHO
Trials Registry (eight records registered from 2012) and Curent Controled Trials (14 records).
In total, HH identified one new single-centre RCT,95which compared hemiarthroplasty with non-surgical
treatment in 50 patients, and a published protocol for an ongoing trial [Treatment of Proximal Humeral
Fractures (TPHF)].96Brief details of the eight RCTs now available on this topic are provided inTable 89.
TABLE 88Patient characteristics in participating and non-participating trusts
Variable
Non-participating trusts Participating trusts
p-valueMean SD Mean SD
Age (years) 61.34 18.10 60.83 17.76 0.0923
Malea 0.34 0.47 0.34 0.48 0.6399
Emergencya 0.66 0.48 0.70 0.46 0.0000
Electivea 0.34 0.47 0.29 0.46 0.0000
Othera 0.01 0.09 0.01 0.10 0.1056
Day casea 0.01 0.08 0.01 0.09 0.0885
Waiting time (days) 7.73 19.86 7.67 15.22 0.9218
Length of stay (days) 5.73 8.91 6.00 8.59 0.0700
a Proportion of whole sample.
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Results
Three outcomes are presented for the purposes of this report: patient-reported functional scores;
additional or secondary surgery; and mortality. Pooled results for patient-reported functional scores at
6 months, 1 year and 2 years using Review Manager 5.2 (The Cochrane Colaboration, The Nordic
Cochrane Centre, Copenhagen, Denmark) are presented inFigure 31. These results, which are dominated
by those from the ProFHER trial, show no statisticaly significant diferences between the two groups at any
of the three folow-up times. Boonset al.95reported finding‘no between group diferences’in Simple
Shoulder Test scores at 12 months.
Pooled data from seven trials showed that significantly more surgical group patients than non-surgical
group patients had subsequent shoulder surgery (30/262 vs. 16/261; risk ratio 1.82, 95% CI 1.03 to 3.22;
p=0.04) (Figure 32). This is equivalent to an extra operation in one of every 20 surgicaly treated patients.
The equivalence between the two groups in the ProFHER trial in the incidence of subsequent shoulder
surgery is unusual and may partly reflect a more inclusive approach to treatment and fracture-related
complications. This is supported by evidence from a prospective 1-year study of 160 non-surgicaly treated
patients, which reported that nine patients subsequently received surgery: four underwent surgical fixation
and five had arthroscopic decompression.92It is also clear that the number of surgicaly treated complications
(11/109; 10%) in the ProFHER trial was not in excess. Further support for this conclusion comes from a
systematic review of 12 cohort studies reporting results for 791 patients treated with locking plates for
proximal fracture of the humerus; this found that 13.7% of these patients required a reoperation.97
As shown inFigure 33, pooled data from six trials showed no significant diference in mortality between
the two groups.
TABLE 89Characteristics of the eight RCTs comparing surgery with conservative treatment for proximal
humeral fractures
Study
Participants
(Neer classification) Surgery
Conservative
(starting with) Folow-up
ProFHER trial 250 patients with two-,
three- or four-part fractures,
al involving the surgical
neck (UK)
Surgeons’choice according
to expertise with implant:
plate (PHILOS mostly),
hemiarthroplasty, nails, other
Sling immobilisation 2 years
Boons 201295 50 patients with four-part
fractures (the Netherlands)
Hemiarthroplasty (Global) Shoulder immobiliser 1 year
Olerud 201132 60 patients with three-part
fractures (al with surgical
neck fracture) (Sweden)
Open reduction and fixation
with a PHILOS plate and
non-absorbable sutures
Sling immobilisation 2 years
Olerud 201133 55 participants with
four-part fractures (Sweden)
Humeral head replacement
with the Global FX prosthesis
Sling immobilisation 2 years
Fjalestad 201031 50 patients with three- or
four-part fractures (Norway)
Open reduction and fixation
with an interlocking plate
device and metal cerclages
Immobilisation of the
injured arm in a modified
Velpeau bandage. Closed
reduction in eight patients
1 year
so far
Zyto 199729 40 patients with three- or
four-part fractures (three
others excluded) (Sweden)
Internal fixation using a
surgical tension band or
cerclage wiring
Sling immobilisation 50 months
Kristiansen
198827
30 patients with 31 with
two-, three- or four-part
fractures (Denmark)
Percutaneous reduction
and external fixation
Closed manipulation and
sling immobilisation
2 years
Stableforth
198428
32 participants with
four-part fractures (UK)
Hemiarthroplasty Closed manipulation and
sling
6 months
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Pending and ongoing trials
A further five RCTs, based in four countries, are ongoing. Brief characteristics of these RCTs are presented
inTable 90. A check caried out in December 2014 of the trial registration documents for these trials
indicates that two are stil recruiting whereas the recruitment status of three is unknown. These five RCTs
plan to recruit a total of 802 patients aged≥60 years, the majority with a three- or four-part fracture.
Application of the trial results to practice
In the above, we have provided justification and support from various sources that the results of our trial
are reliable, are consistent with curent practice and apply to the patient population represented by
the trials inclusion and exclusion criteria. These criteria provide a preliminary guide to the patient
population to which the trial findings apply. Thus, for this population, our trial has provided strong
evidence that the majority of patients with displaced fractures involving the surgical neck, irespective of
age and involvement of tuberosity, are unlikely to benefit from surgery. Our results do not support the
trend towards increased surgery in this group, which partly resulted from the availability of locking plates.
Although we would not expect the trial results to completely alter surgical practice for these fractures,
they should at least slow, stop or even reverse the increase in surgical intervention in the NHS. As wel as
preventing inefective and thus unnecessary surgery, this would free up resources and operating time for
fractures that should be treated surgicaly.
TABLE 90Ongoing trials
Study
Location, start dateaand
recruitment statusb Participants Interventions
Brorson 200998 Sweden (five centres)
Start: April 2009
Recruiting status unknown
162 patients, age 60+years,
with four-part fractures
1. Hemiarthroplasty
2. Fixed-angle plate osteosynthesis
3. Non-surgical treatment
NCT0081898799 Canada
Start: November 2010
Recruiting status unknown
120 patients, age 70+years,
with three- or four-part
fractures
1. Open reduction and
internal fixation
2. Non-operative treatment
(reduction and immobilisation)
NCT00999193100 Finland
Start: November 2010
Recruiting verified
October 2014
150 patients, age 65+years,
with three- and four-part
fractures
1. PHILOS locking plate
2. Hemiarthroplasty (Global FX)
3. Conservative treatment
Den Hartog 2010101 Netherlands
Start: 15 June 2009
Recruiting status unknown
80 patients, age 65+years,
with a comminuted fracture
(Hertel classification)
1. Hemiarthroplasty (Afinis®;
Mathys Ltd, Betlach,
Switzerland)
2. Conservative treatment
Launonen 201296 Finland (four centres)
Start: January 2011
Recruiting verified
November 2014
290 patients, age 60+years,
with two-, three- and
four-part fractures
1. PHILOS locking plate
2. Hemiarthroplasty (Epoca)
3. Conservative management
a The start dates are the proposed start dates for patient recruitment at title registration.
b This is based on information available in the trial registration documentation (checked 22 December 2014).
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Crucialy, this evidence can help to inform discussions with patients, alowing surgeons to reassure patients
and perhaps themselves that surgery is not essential, thus avoiding some agonising decisions as wel as
unnecessary surgery. The majority of fractures in the ProFHER trial were complex but, although more
complex fractures were recruited than anticipated, the number of confirmed four-part fractures was smal
(n=11). These are rare fractures (2% of the population) and, although there is no evidence from the
ProFHER trial or another recent trial95that the results would difer for these fractures, we acknowledge that
there is uncertainty. The evidence from an ongoing multicentre trial98aimed at these fractures should help
resolve this issue in due course.
As discussed, the strength of the pragmatic design of the ProFHER trial is that it represents curent
practice. However, as pointed out inChapter 1, technology is changing al the time, with various pressures
for early implementation. This raises the question of how applicable these results are or can be when the
nature of surgical intervention has fundamentaly changed. For instance, for the more complex fractures
(including those outside the target population of the ProFHER trial) in older adults, there is a growing
trend towards the use of reverse total shoulder arthroplasty, both in the UK and in other countries
such as the USA.102Reverse total shoulder arthroplasty, which was used once in the ProFHER trial as a
revision procedure, is much more costly, more invasive and of unproven benefit for the patient population
covered by the ProFHER trial. Until reliable evidence of its superiority is available, including in relation
to hemiarthroplasty, the increasing use of the reverse prosthesis is questionable. Especialy when there
is a lack of evidence to inform the choice of surgical intervention, the pragmatic approach adopted
by the ProFHER trial in which experienced surgeons perform operations with which they are familiar is a
fundamental safeguard that underpins the continuing external validity of the trial results. The onus is on
surgeons who suggest that these results no longer apply to provide the evidence that the new techniques
are actualy superior to the old.
Conclusion
The ProFHER trial has provided robust clinicaly relevant evidence showing that curent surgical practice
does not result in a beter outcome for most patients with a displaced fracture of the proximal humerus
involving the surgical neck. It is also not cost-efective in the UK seting.
It is important that non-surgical care should be of a good standard including the availability of a leaflet
about sling immobilisation, timely access to physiotherapy and the promotion of home exercises. The
potential need for remedial surgery for severe symptomatic complications in around 5–10% of these
patients should be factored into forecasts for hospital budgets.
Recommendations for research
Given the findings of the ProFHER trial and the existence of five ongoing trials comparing surgical with
non-surgical treatment, the initiation of further trials investigating this comparison is not waranted.
The growing number and importance of these fractures merits a more systematic and prospective
colection of data on epidemiology, management and outcome; consideration is waranted as to the
feasibility and importance of seting up a national database of these fractures, which should include the
recording of patient-reported outcomes. This wil help to remedy the serious lack of data on these
fractures that hinders both practice and research in the UK. Although there are major diferences between
proximal humeral fractures and hip fractures in terms of the patient population, management, outcomes
and the evidence base, the usefulness of such a database as a clinical audit tool that could facilitate
improvements in the quality of care has been shown by the already established National Hip Fracture
Database (NHFD).103Given the processes already in place for the NHFD, it may be more practical to extend
the remit of this database to include proximal humeral fractures.
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One important question for future research is,‘What are the best ways of informing patients with proximal
humeral (and other upper limb) fractures about initial self-care?’People presenting to emergency
departments are routinely sent home with their arm in a sling but, as we found out when conducting the
ProFHER trial, no writen information is provided. As described, we developed a trial-specific information
leaflet on personal care during sling immobilisation. Research is required to establish the best approach to
providing patient information on the early treatment of these fractures. Patients are often distressed by
their injury and fail to ask questions or retain information; thus, the provision of writen information seems
appropriate but needs confirmation. The contents and format of such information needs input from
patients; this also presents an opportunity to gather beter information on curent practice and obtain
feedback from the patients on the practical considerations of (various types of) sling immobilisation.
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Appendix 1Hospital Episode Statistics for
England: inpatient statistics (2003/4 to 2011/12)–
totals and proximal humeral fracture
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Appendix 2Neer classification for proximal
humeral fractures
This figure shows the 16 categories of the Neer classification. A fracture is considered displaced if one or
more of the four segments are displaced>1 cm or angulated>45°. The figure is modified from Neer18
with permission from theJournal of Bone and Joint Surgeryand from Brorsonet al.104with permission.
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Appendix 3The ProFHER trial protocol
version 7.0 (19 May 2009)
Please note: the protocol published in this appendix is the final version of the protocol and is reproducedagain as is. Therefore, the appendices listed are not included and those cited do not corespond with
the appendices in the main report.
PROximal Fractures of the Humerus: Evaluation by
Randomisation–The PROFHER Trial
This protocol describes a UK multi-centre randomised controled trial of surgical versus non-surgical
treatment for the majority of displaced fractures of the proximal humerus in adults.
The NHS R&D Health Technology Assessment Programme (HTA) is the sole external funder of this trial.
This protocol is derived from the detailed project description of the HTA funding application entitled
‘Pragmatic multi-centre randomised trial of surgical versus non-surgical treatment for proximal fracture of
the humerus in adults’[HTA: 06/404/53].
The PROFHER trial is sponsored by the University of Teesside. Trial management is primarily by the York
Trials Unit (YTU), University of York. This trial has received endorsement by the British Elbow and
Shoulder Society.
Summary of planned investigation
Research objectives
Our primary aim is to obtain reliable evidence of efectiveness and cost-efectiveness of basic treatment
strategies for the majority of displaced fractures of the proximal humerus in adults. Hence, we plan to
undertake a pragmatic randomised clinical trial (RCT) of surgical versus non-surgical treatment of displaced
proximal humeral fractures involving the surgical neck in adults.
Study population
After a period of preparation and upon MREC (Multicentre Research Ethics Commitee) approval,
recruitment into the RCT wil be over an 18 month period from at least 18 NHS trauma centres; most of
which are either already commited or have expressed keen interest in contributing to the trial, and thus
identify with the study aims. We wil promote a minimum recruitment rate of one patient per centre per
month. Alowing for conservative estimate of recruitment success and for drop-outs we propose to recruit
and randomise 250 patients over an 18 month period. We anticipate data from 200 patients folowed up
for 2 years. The HTA have accepted our proposal for an assessment point after 10 months of recruitment
to determine if recruitment into the RCT is suficient (set at 88 patients) to justify its continuation after
18 months.
Integral to the trial, and to inform on trial recruitment and applicability of trial results as wel as to conform
to trial-reporting standards, we plan a systematic prospective colection of key patient data for those
meeting the main inclusion criteria (age 16 or over, presenting within 3 weeks of injury, with displaced
fractures of the proximal humerus involving the surgical neck) for the RCT but who were not included.
These wil consist of three categories of patients: those that were excluded because they met one or more
of the listed trial exclusion criteria, those who did not consent and those where there was a‘protocol
violation’(reflecting lack of surgeon equipoise). The information colected for these patients wil include
data on patient preference, surgeon’s advised treatment and the agreed treatment. In particular, we wil
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stress the importance of the systematic prospective colection of key patient data and reasons for exclusion
of otherwise eligible patients. At the end of the 10 month‘feasibility’study, we anticipate 1400 potentialy
eligible or eligible patients would not be included in the randomised trial; should recruitment continue, we
anticipate 2150 such patients.
Background
Proximal humeral fractures account for approximately 4–5% of al fractures. Their incidence rapidly
increases with age, and women are afected over twice as often as men. Similar to other primarily
osteoporotic fractures, the incidence of these fractures is increasing. Palvanenet al.2006 found a three
fold increase over a 33 year period in the incidence of proximal humeral fractures resulting from
low-energy trauma in people aged 60 and above.
A large prospective epidemiology study (Court-Brownet al.2001) found that around half of these
fractures (51%) are displaced, when assessed according to the criteria of Neer’s classification system
(Neer 1970): one or more parts of the fractured bone are displaced by more than one centimetre, or
angulated more than 45 degrees. Court-Brownet al.2001 found that the largest groups of displaced
fractures were 2 part surgical neck fractures (28% of the whole population), folowed by 3 part greater
tuberosity and surgical neck fractures (9%). Four part fractures without fracture dislocation were around
2% of the total. These figures are consistent with estimates from several members of the trial group.
Recent systematic reviews (Handolet al.2003; Misraet al.2001), one of which was updated in 2007
(Handolet al.2003), have found a lack of evidence from randomised controled trials (RCTs) to inform
management decisions for proximal humeral fractures. In particular, there were only three completed RCTs
comparing surgery with conservative treatment. Al were smal studies (numbers randomised: 30, 32, 40)
with flawed methodology. Both reviews (Handolet al.2003; Misraet al.2001) concluded that it was
unclear whether or not operative intervention, even for specific fracture types, would produce consistently
beter long-term outcomes.
It is also clear from the literature, confirmed by an informal survey of the treatment provided by several UK
centres, that there is great variation in the treatment of these fractures, both in basic (the use of surgery)
and specific (type of implants and surgical technique; non-surgical management (Hodgson 2006) and
rehabilitation packages) terms. Additionaly, technology is changing al the time with various pressures
towards early implementation.
The above findings point to a clear need to get reliable evidence to inform practice, and crucialy to
establish whether or not there is a role for operative intervention for the common types of acute displaced
fractures of the proximal humerus. This is the focus of this trial.
Research methods
As indicated, we intend to undertake a pragmatic randomised clinical trial evaluating the efectiveness and
cost-efectiveness of surgical intervention versus standard conservative therapy for the treatment of the
majority of displaced (al involving the surgical neck) proximal humeral fractures in adults. This RCT includes
the systematic colection of reasons for non-inclusion of eligible patients who were not recruited into the
trial, and their baseline characteristics, treatment preferences and intended treatment.
Underpinning our approach are two key issues:
l There is a general dearth of reliable evidence to inform on the use of surgery (definitive treatment) for
patients with these fractures.
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l There are known dificulties in recruitment and particularly patient (and surgeon) preferences. Based on
experience from previous studies, some abandoned, in this field it is anticipated that a large proportion
of eligible individuals are likely to refuse to be randomised because they (or their surgeons) wil have
a strong preference for one of the study interventions; generaly conservative in the case of patients.
On discussions with orthopaedic surgeons, lack of clinical equipoise, which is another important barier
to performing surgical RCTs (Solomonet al.1995), is anticipated to be less of an issue here. Because
of these strong preferences it is likely that patients recruited into any RCT wil be a highly selected
group, which may threaten the external validity of our study. Thus, colecting key data for al patients
eligible for the RCT wil alow us to set our randomised results within the context of the whole patient
population and give some pointers to the applicability of the results of the study.
How are the results of the trial to be used/interpreted?
The trial aims to establish whether or not surgery yields superior results to non-surgical treatment.
As detailed below, our protocol emphasises standardised protocols and care pathways throughout,
comparable and suficient expertise of care providers and that the surgeon uses established techniques
with which they are already familiar. Any questions over whether or not the use of other surgical methods,
perhaps new methods, would give diferent results are countered by two considerations. Firstly, there is an
absence of robust evidence to inform best surgical methods. Secondly, and arguably, the avoidance of
‘learning curves’and the reliance on surgeon’s competence is more representative of best surgical treatment.
Brief details of the proposed practical arrangements for trial recruitment
and alocating participants to trial groups
A detailed generic scheme of the recruitment process wil be devised for adoption according to local
circumstances in the participating centres. At radiological review by the surgeon or their nominated deputy,
a trial eligibility form (seeAppendix 1) wil be completed for any patient who meets the trial inclusion
criteria. For ineligible patients, the surgeon is asked to indicate what treatment they would advise for the
patient before the form is sent to the York Trials Unit. Those patients who the surgeon indicates as eligible
for the trial wil be invited to take part in the trial and the site-specific patient consent process is initiated.
For non-consenting patients, this fact wil be indicated on the Consent status form (seeAppendix 2), where
the surgeon or their deputy is asked to indicate their advised treatment, the patient’s prefered treatment
(if any) is completed.
Once patients have given consent (seeAppendix 3), the recruiting clinician wil complete the baseline data
form (seeAppendix 4) and then contact the York Trials Unit, either by telephone or via the internet, to
access a secure randomisation service. This wil ensure immediate and unbiased alocation of treatment.
Proposed methods for avoidance of bias and to ensure validity
Randomisation eliminates selection bias: there are, however, other forms of bias we wil guard against.
We wil also take measures to ensure the external validity of trial results. We wil undertake the folowing:
l Adherence to local guidelines for radiographic assessment wil be actively promoted. If not stipulated
already, we wil encourage the use of the ful shoulder trauma series (Neer 2002). Documentation
including a power point presentation ilustrating the ful trauma series wil be made available as part of
the trial materials. A minimum of two x-ray views/projections is required for the assessment of
study eligibility.
l At the end of the recruitment period, there wil be scrutiny and categorisation based on the Neer
classification system, using pre-prepared forms, of the baseline X-rays of al randomised patients. This
wil be done by an independent panel of musculoskeletal radiologists or orthopaedic surgeons who
have experience with the Neer classification (Neer 1970). Copies of X-rays wil be prepared beforehand
to ensure they are anonymised. On an on-going basis during trial recruitment there wil also be a
review of the quality of the copies of X-ray images for each trial participant provided by trial centres.
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This is to ensure that at the end of trial recruitment the images are of suficient quality for the
independent panel to assess and classify the fractures. For the X-rays of the first five participants at
each centre, independent assessment of the quality of images wil be done by three orthopaedic
surgeons, one of whom wil be the Chief Investigator. Assessment of the X-rays of subsequent
participants of each centre wil be done by one orthopaedic surgeon (the Chief Investigator), who if he
has concerns wil ask the two other independent surgeons for their comments.
l Clear entry criteria, including checks at randomisation, wil reduce inappropriate entry into the RCT.
l We wil endeavour to provide a consistent approach to recruitment and obtaining informed consent by
providing an unbiased account of the study to eligible participants using a specialy produced
information sheet. These materials wil be produced in colaboration with service users.
l Concealment of treatment alocation prior to trial entry wil be ensured by use of an independent
telephone randomisation service, as provided by the University of York’s Trials Unit. After an initial,
prespecified, period of randomisation, stratified by the presence or not of a tuberosity fracture and
with a prespecified block size, randomisation wil then be performed using a computer generated
minimisation programme. The minimisation factors wil be fractures involving either tuberosity
and centre.
l We wil emphasise good practice and standardised protocols and care pathways throughout, and
comparable and suficient expertise of care providers. Surgery for these types of fractures are usualy
caried out by consultants; this has been confirmed by an informal survey of the centres initialy
included in our study. We wil atempt to minimise‘learning curve’issues for the surgical interventions
by alowing the surgeon to use techniques with which they are familiar, but prohibiting the
introduction of radicaly new or experimental methods during the recruitment period.
l We wil encourage the prescription of comparable care, including rehabilitation programmes, such
that any substantive departures from the norm would reflect the special requirements of a specific
intervention. Consensus guidelines for non-surgical treatment and rehabilitation for both groups are
being prepared by rehabilitation specialists and wil be circulated for comment and input. These wil
form part of the trial materials and we wil request details of where the prescribed treatment difers
substantively from the standardised protocols. (See Notes added in clarification below.)
Notes added for clarification
1. Upon discussion, the proposed consensus guidelines for non-surgical treatment were considered
inappropriate in the context of a pragmatic trial and the lack of evidence to inform practice. It was
decided that the onus should be on the provision of good standard care and that our approach would
be to indicate both verbaly and in the site manual that we would anticipate initial care to comprise
sling immobilisation for about 3 weeks or for as long as the treating clinician deemed necessary and
active early rehabilitation. We considered that writen information to advise patients during sling
immobilisation was needed and should be provided to al eligible patients for the trial. We provide
a generic document to be adopted by the hospital should a suitable document not already be
available localy.
2. We stipulate that physiotherapy should be provided equaly to both treatment groups. A consensus
protocol giving basic treatment guidelines has been devised. Although, deviation from the protocol is
alowed and expected, we stipulate that electrotherapy (except TENS) is not used, and point to an
absence of evidence for these modalities as wel as endorsement via a consultation process with
specialist shoulder physiotherapists. We wil promote the need to encourage home exercises, but
decided not to provide generic information leaflets ilustrating exercises for home use by patients.
Instead we wil check that physiotherapists either provide these already or access a standard web-based
facilities to generate‘bespoke’exercise sheets.
3. We are prospectively colecting details of rehabilitation treatment which wil also alow the detection of
substantial diferences from the physiotherapy protocol.
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l We shal folow the CONSORT guidelines for considering and reporting RCTs (Moheret al. 2001).
l For instance, if eligible patients decline to be randomised, then this is refusal to consent (as per
CONSORT); if surgeons choose not to randomise an eligible patient then this is a break in protocol
(protocol violation) which must be recorded along with a reason.
l Intention to treat analyses wil be undertaken as the primary analysis in the RCT.
l Active and systematic folow-up of al randomised participants at 3, 6, 12 and 24 months is planned.
l This wil include pre-notification leters as wel as the use of reminders after 2 and 4 weeks. For 6, 12
and 24 month folow-ups, there wil be an option for completion of an abridged questionnaire via
telephone after 6 weeks. We wil also include an unconditional incentive payment of £5 to maximise
the 12 and 24 month folow-up.
l As far as possible, al participants wil be folowed up for any unplanned events. Their hospital notes
wil include a reminder to notify of relevant subsequent treatment/events and they wil be flagged for
mortality. With the participant’s permission, leters wil be sent to their General Practitioners to inform
of participation (seeAppendix 6). Participant’s permission wil also be sought to alow us to ask their
GP to provide the participant’s contact details should there be problems contacting them directly.
l There wil be independent data entry, processing and analysis. Aside from accrual and whole
populations baseline statistics, interim results wil not be made available to the trial investigators or
associates in the participant centres.
Data colection on al potentialy eligible patients
In addition to the systematic colection of basic baseline data for those eligible for the RCTs but who did
not consent or where there was a protocol violation (reflecting lack of surgeon equipoise) to satisfy the
requirements of CONSORT, we wil colect data on patient-prefered and intended management. To
complete the CONSORT flow diagram, we wil colect the baseline data and reasons for ineligibility for
ineligible adults presenting in the recruiting centres with the study fractures: see inclusion criteria.
Pilot study
The study wil initialy be set up in Teesside for training, and piloting materials and procedures.
Ethical arrangements
MREC (Multicentre Research Ethics Commitee) approval has been obtained from York Research Ethics
Commitee (reference number 08/H1311/12). Consequently, separate submissions of the protocol are
being submited to the ethical commitee of each centre. The approval of the HTA funding and MREC is
being raised in support of applications to preclude unsatisfactory local variation.
Risks and anticipated benefits for trial participants and society, including
how benefits justify risks
In the context of the lack of robust evidence to determine the best treatment for patients with these
fractures, the risks are not increased through trial and/or study participation. Measures, such as our
emphasis on good practice and standardised protocols/care pathways throughout, taken by us are indeed
likely to reduce risk and could bring additional benefits. We wil emphasise the importance of surgeons
performing operations with which they are familiar and undertake on a regular basis. We wil also stress
the importance of competence in conservative methods, principaly rehabilitation. We wil stipulate that
radicaly diferent novel devices or methods are not introduced at each centre for the duration of the trial;
any necessary training wil focus on already established methods. We wil adhere to the good clinical
research practice guidelines (MRC and Research Governance Framework). Though we wil perform active
and systematic folow-up, the timing of early folow-up paralels usual clinical practice and we wil not
place an undue burden on participants. Our adoption of the Oxford Shoulder Score, Euroqol (EQ-5D) and
SF12, al of which are self completion questionnaires, avoids the need for participants to specialy return
for clinical folow-up assessments at 6, 12 and 24 months.
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Ultimately, the RCT wil provide evidence that should make a major contribution to the future
management of these fractures. It is conceivable that the heightened awareness of and focus on these
fractures in each centre could directly benefit study and trial participants: for instance, there is some
evidence of improved outcomes of participants participating in RCTs.
Informing potential trial participants of possible benefits and known risks
A participant information sheet for the study has been compiled, with involvement of service users
(seeAppendix 5). This aims to give a balanced account of the possible benefits and known risks of the
interventions under test. It states explicitly that quality of care wil not be compromised if the participant
decides to a) not enter the trial or b) withdraw their consent. We believe that the information provided is
clear and easily understandable to the reader. Surgery is often performed the folowing day and therefore
the information leaflet wil be made available for the potential participant to alow them time to make an
informed decision. Where possible, translations of the participant information sheet wil be provided for
non-English speakers.
Obtaining informed consent from participants whenever possible or
proposed action where fuly informed consent is not possible
Writen informed consent wil be obtained from al participants. Where possible, provision of interpreters
wil be made on a local basis for non-English speaking participants. Where local interpreters are
unavailable, we wil consider using the National Interpreting Service. No participant wil be entered into the
RCT without informed consent.
Proposed time period for retention of relevant trial documentation
Minimum 20 years.
Participants: planned inclusion/exclusion criteria
Inclusion criteria
Adults (aged 16 or above) presenting to the participating trauma centre within 3 weeks of their injury with
a radiologicaly confirmed displaced fracture of the proximal humerus involving the surgical neck. This
should include al 2 part surgical neck fractures; 3 part (including surgical neck) and 4 part fractures of
proximal humerus (Neer Classification). It may also include displaced surgical neck fractures that do not
meet the exact displacement criteria of the Neer classification (1 cm or/and 45° angulation of displaced
parts) where this reflects an individual surgeon’s equipoise (e.g., whether or not the surgical neck fracture
should be treated surgicaly).
Exclusion criteria
l Associated dislocation of the injured shoulder joint
l Open fracture
l Mentaly incompetent patient: unable to understand trial procedure or instructions for rehabilitation;
significant mental impairment that would preclude compliance with rehabilitation and treatment advice
l Co-morbidities precluding surgery/anaesthesia
l A clear indication for surgery such as severe soft-tissue compromise requiring surgery/emergency
treatment (nerve injury/dysfunction)
l Multiple injuries: same limb fractures; other upper limb fractures
l Pathological fractures (other than osteoporotic) & terminal ilness
l Participant not resident in trauma-centre catchment area.
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Sample population
This wil be al adults (aged 16 or above) presenting within 3 weeks of injury with fracture types listed in
the inclusion criteria. Ineligible patients wil be defined as those who are excluded for reasons given in the
exclusion criteria. Al those who meet the above criteria wil be termed eligible patients. Some patients
stil may not be not included in the RCT, for instance due to lack of patient consent (patient has strong
preference for specific treatment option or refuses randomisation) or because the surgeon considers one of
the treatment options is strongly indicated for reasons other than above.
Interventions
Each centre participating in this trial has to agree to forgo the introduction of radicaly novel and
experimental interventions for these fractures during the recruitment period.
Central to the obtaining of reliable evidence is that good standard care, both surgical and non-surgical,
is provided throughout the trial. Where possible, the decisions on the actual method of surgery, when
alocated, and non-surgical treatment is left to the clinical judgement of the participating surgeon.
Participating surgeons wil be advised that they should, however, use surgical interventions and procedures
with which they are familiar. This is to avoid learning curve problems. Similarly, physiotherapists are
advised that they should use procedures with which they are familiar. The essential components of
physiotherapy at each session wil be recorded prospectively.
Surgery
For displaced (2 part) surgical neck fractures: surgical interventions with which the surgeon is familiar.
These are likely to be plate fixation or intramedulary nailing.
For 3 part (including displaced surgical neck) or 4 part fractures: surgical interventions with which the
surgeon is familiar. These are likely to include internal fixation such as nail, plate or other method which
preserves the humeral head; or humeral head replacement (hemi-arthroplasty).
Peri- and post-operative management
Peri-operative management including anaesthesia and analgesia, and antibiotic and thromboembolism
prophylaxis, dressing policies wil folow local guidelines. It is envisaged that similar rehabilitation packages,
including mobilisation protocols, should be provided for al interventions. Specificaly developed guidelines
wil be included in the materials for each centre.
Non-surgical intervention (the control group)
Brief recommendations for conservative treatment for trial participants wil be included in the materials for
each centre. Essentialy, these advise that conservatively treated patients wil be given sling immobilisation
for about 3 weeks or for as long as the treating clinician deems necessary and active early rehabilitation.
We wil stress the need for competence in conservative methods, including rehabilitation.
Rehabilitation
As far as practical, centres are required to provide writen advice on personal care during sling
immobilisation to al eligible patients. A generic document has been devised that can be adopted by the
centre if required. We wil stress that similar access to physiotherapy should be provided for surgical
and non-surgical participants. A basic treatment protocol for physiotherapy wil be provided. This wil
emphasise that while the protocol acts as a guide, variation in practice is accepted and anticipated.
Electrotherapy other than TENS wil be disalowed. We wil promote strongly the need to encourage
patients to perform home exercises and that they receive information sheets ilustrating how to do
the exercises.
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Outcome measures
The primary outcome measure is the Oxford Shoulder Score (OSS) assessed at 6, 12 and 24 months
(Dawsonet al.1996). The Oxford Shoulder Score is a condition-specific questionnaire providing a total
score based on the patient’s subjective assessment of pain and activities of daily living (ADL) impairment.
Consistent with recent developments, the range of available scores is 0 (worst) to 48 (best) (Dawsonet al.
2008). The OSS contains 12 items, each with five categories of response. It has been shown to corelate
wel with both the professionaly-endorsed Constant Score (Constantet al.1987) and the SF36 assessment
and to be sensitive to clinical change at six months after surgical intervention (Dawsonet al.2001). It has
been demonstrated to be consistent, reproducible and valid in a UK population (Dawsonet al.1996). This
questionnaire wil be administered by post for self completion by the trial participant without need for an
examination and thus avoids the requirement for folow-up visits to the clinic for assessment. To improve
compliance, reminders wil be sent and patients wil be ofered the option of completing the questionnaire
via a telephone cal. We wil also send pre-notification leters and use unconditional incentives; both have
been shown to be efective at improving response rates (Edwardset al.2002).
Secondary outcomes are:
l Surgical complications; including shoulder dislocation, failure of implant, proven wound infection
(purulent discharge plus positive bacteriology or need for revision due to infection), septicaemia (clinical
evidence of systemic infection plus positive blood cultures).
l Early medical complications, i.e. chest infection, confirmed MI or stroke (confirmed by senior clinician),
treated DVT, treated pulmonary embolism and other serious event.
l Mortality, subsequent referal for operation or substantive treatment.
l The SF12 and Euroqol (EQ-5D) to colect general health status data (at 6, 12 and 24 months).
Data for economic evaluation
Prospective cost data on trial participants include costs incured in hospital and subsequently. Thus, time
spent in theatre and hospital consumables wil be colected. Health utility data wil also be obtained from
the EQ-5D colected at 3, 6, 12 and 24 months (EuroQol Group 1990). Information for estimating NHS and
societal costs wil be colected from the trial participants at each folow-up.
We wil colect data on the actual procedures done, including anaesthesia, and interventions provided and
the experience of operators/care providers (according to grade). We wil colect these data for al
trial participants.
Data colection
We shal aim to make the trial processes as simple as possible in order to minimise the work entailed at the
participating centres. As far as possible, we hope to achieve complete folow-up of al randomised patients.
Baseline data
Basic information including key baseline characteristics wil be colected for al potentialy eligible patients
(i.e. those meeting the trial inclusion criteria) who are found not to be eligible (see Study eligibility form:
Appendix 1).
Additional data on patient preferences, surgeon’s advised treatment and the agreed treatment wil be
obtained for patients who do not consent to trial participation (see Consent status form:Appendix 2).
For consenting patients, we wil colect data on ethnicity, education, employment, previous fractures,
shoulder dominance, injury mechanism, smoking, diabetes, treatment preference, curent health status
(EQ- 5D), GP name and surgery and the patient’s contact details (see Baseline form:Appendix 4).
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Description of treatment
Surgical methods
Brief details of the actual surgery and procedures used wil be recorded by the surgeon, or assigned
deputy, folowing the operation. Also prescribed rehabilitation.
Non-surgical methods
Brief details of the prescribed non-surgical treatment wil be recorded by surgeon, or assigned deputy.
Also prescribed rehabilitation.
Colection of hospital outcome data before hospital discharge
Centres wil be required to complete data forms detailing:
l Clinical outcomes including surgical complications and early medical complications
l Resource use: the data on hospital costs wil be colected using a cost proforma designed for the trial
l Substantive deviations from prescribed treatment and rehabilitation
l Patient destination after hospital discharge.
Long term folow-up
One and two year folow-up forms from centres
Forms to notify mortality or subsequent surgery for completion and return at any time wil be made
available for the completion by centre staf.
Forms for completion wil be sent at 1 and 2 year folow-up–it is likely that al the data for these can be
gleaned from the hospital records for these patients.
Folow-up patient questionnaires: 3, 6, 12 and 24 months
post trial recruitment
A short questionnaire including the EQ-5D and brief questions on the number of consultations of NHS care
providers (GPs, physiotherapists, district nurses etc.), hospitals atendances, use of private healthcare and
days lost from work or other normal activities wil be sent by the YTU to al participants at three months.
SeeAppendix 7for a copy of the 3 month form and covering leter. Reply paid envelopes wil be included.
Reminders wil be sent after 2 and 4 weeks.
Ful questionnaires wil be sent by the YTU to al participants at six, 12 and 24 months after recruitment.
These include the Oxford Shoulder Score, EQ-5D and SF12, al of which are self completion questionnaires.
As at 3 months, brief questions on the number of consultations of NHS care providers (GPs, physiotherapists,
district nurses etc), hospitals atendances, use of private healthcare and days lost from work or other normal
activities wil also be requested. SeeAppendix 8for a copy of the 6 month folow up form and covering leter.
Reply paid envelopes wil be included. Reminders wil be sent after 2 and 4 weeks and options for completion
of the questionnaires via telephone after 6 weeks. If completed over the telephone, only the Oxford Shoulder
Score, EQ-5D and information on hospital readmissions wil be requested. An unconditional incentive
payment of £5 wil be sent for the 12 and 24 month folow-ups (Edwardset al.2002).
X-rays
Copies of al baseline X-rays for al randomised patients wil be requested for independent and blinded
assessment at the end of study recruitment. X-rays wil also be reviewed by local experts on an on-going
basis during trial recruitment to ensure the images are of suficient quality for scrutiny and classification
based on the Neer classification system by an independent panel of experts at the end of recruitment.
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Proposed sample size
The primary outcome for the trial is diferences in patients’subjective assessments of pain and activities of
daily living (ADL) as measured by the Oxford Shoulder Score (OSS). For surgery to be worthwhile, it needs
to demonstrate greater improvements in patient’s subjective assessments of pain and ADL than those for
conservative treatment to justify both its increased costs and the exposure to the hazards of surgery. In an
observational study conducted by one of us (AR) it was found that those patients who had surgery had a
5 point diferential improvement in the OSS compared with those patients treated conservatively. Given
a SD of 12 this equates to an efect size of 0.42. We propose, therefore, to design the study to observe
an efect size of 0.4 at 80% power using 5% significance level, which would require approximately
200 participants. After alowing for drop-outs of 20%, we propose to recruit and randomise 250 patients
(125 surgery and 125 controls). Our estimate of 20% loss from the RCT is purposefuly pessimistic for
sample size calculations.
Recruitment rate
We anticipate that recruitment for this trial wil be potentialy chalenging. Therefore, we have set very
conservative recruitment targets. Our recruitment period is 18 months. We aim to recruit between
18–20 centres. Each centre wil be expected to recruit only one participant per month, though encouraged
to aim higher than this. We estimate across 18 centres there wil be 6066 patients (6000 is used as a
working figure here) with a proximal humeral fracture over the 18 months of recruitment. Of these, 2391
(thus, 2400 is used as a working figure below) wil have the fracture types suitable for inclusion into the
RCT. To achieve our sample size we need to recruit only 11% of these patients.
Loss to folow-up
We anticipate that the main reason for loss to folow-up wil be mortality. We wil folow up patients
assiduously using postal questionnaires and in the event of non-response we wil contact their GP to
ascertain whether or not it is appropriate to contact the patient and, if so, their address.
Statistical analysis
Al of the analyses wil use the intention to treat principle. Consequently, any patients who cross over from
either study arm wil be analysed as per their randomisation status. The primary outcome is the Oxford
Shoulder Score (OSS). The diference between the two treatment groups wil be compared over al
folow-up assessments (i.e. 6, 12 and 24 months) using a repeated measures model. The model wil
include terms for treatment, folow-up time, and also adjust for type of fracture, age and gender (as older
people and women are more likely to sustain these fractures). Because participants are clustered by
surgical centre there is a theoretical possibility that there may be a‘surgeon’efect. We wil therefore
repeat the primary analysis using appropriate statistical techniques (robust standard erors) to account for
the clustering of patients within surgeon. The anonymity of individual surgeons and centres wil be
preserved for al analyses and there wil be no presentation or comparisons of the treatment results from
individual centres or surgeons. Subgroup analyses based on the Neer classification system are planned
to assess the efectiveness of treatment for the diferent fracture groups (2 part surgical neck; 3 part
including surgical neck and 4 part fractures; fractures not meeting the Neer classification displacement
criteria). The secondary outcomes wil be summarised for each treatment group.
Frequency of analyses
We anticipate that there wil be a single analysis at the end of the study. However, before the study starts
we wil establish an independent Trial Steering Commitee (TSC) and a Data Monitoring and Ethics
Commitee (DMEC). The chairperson of the TSC wil make the decision in conjunction with the chair of the
DMEC about the need and the number of interim analysis.
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Assessment of study recruitment and applicability
We wil report the numbers of and reasons for ineligible adults (aged 16 or above) with the study
fractures, we wil also report the numbers of and reasons for the non-inclusion of potentialy
eligible patients. We wil compare the baseline characteristics, patient preferences with those of
randomised patients.
Economic evaluation
An economic analysis wil be taken from the perspective of the UK National Health Service and Social
Services. The horizon for the baseline analysis wil be two years. However, we wil model any potential
benefits forward to 5 years and an average lifetime in a sensitivity analysis.
Health benefits for the economic analysis wil be measured in terms of quality-adjusted life-years (QALYs).
Health utility values for individuals with displaced proximal humeral fractures wil be estimated using the
Euroqol (EQ-5D) questionnaire. QALYs wil be calculated for each patient using the area under the curve
defined by her/his EQ-5D scores over the two-year folow-up period and adjusted by the Kaplan Meier
estimates of patients’survival over the same period of time. Given the horizon for the analysis is longer
than a year a discount rate of 1.5% wil be applied to health benefits (NICE 2001).
Resource use, and clinical data wil be colected for al trial participants. Information regarding total volume
of resources used in the treatment (conservative/surgical) and rehabilitation procedures wil be recorded
for each patient. Unit cost wil then be applied to estimate the total cost per patient. To account for the
censored nature of cost data, the Lin method wil be used to estimate the mean average total cost per
treatment arm (Linet al.1997). Non parametric bootstrapping techniques wil be used to estimate 95%
confidence intervals for the mean diferential cost between conservative and surgical treatment (Efronet al.
1993). Total cost wil be discounted using a 6% annual discount rate (NICE 2001).
Health benefits and mean average total costs associated with each of the trial arms wil be combined in a
cost–utility analysis, incremental costs per quality ratios wil be computed comparing the conservative and
surgical treatment interventions for adult patients with a displaced proximal humeral fracture. Multilevel
modeling wil be used to explore potential variations in treatment efect and costs between health
professionals (Roberts 1999).
Project timetable and milestones
Curently (December 2007), the anticipated start for ful-trial trial recruitment is 1st October 2008. As wel
as MREC approval, al trial materials and processes wil have been established and piloted where practical
and appropriate at Middlesbrough, the lead centre. Applications for LREC approval wil also have been
submited, and may have been approved, for several centres. Staf training for these centres wil also have
been initiated. The 10 months target date after recruitment for the feasibility study means that a robust
approach is needed for geting centres started and recruiting as soon as possible.
Trial timeline from start of ful-trial recruitment
0 months
l Start of recruitment for RCT: duration 18 months (assuming satisfactory outcome of the 10 month
feasibility study)
l Start of data colection for baseline, treatment, early complications and economic outcomes
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3 months
l Start of 3 month folow-up for RCT participants (reminders 2 & 4 weeks).
6 months
l Start of 6 month folow-up for RCT participants (reminders 2 & 4 weeks).
10 months
l Cut-of for analysis of feasibility study after 10 months of recruitment.
l Analysis and presentation of feasibility study.
12 months
l End of recruitment of feasibility study.
l Start of 12 month folow-up for RCT (reminders 2 & 4 weeks).
18 months
l End of al recruitment (RCT).
21 months
l End of 3 months RCT folow-up (reminders 2 & 4 weeks).
24 months
l End of 6 months RCT folow-up (reminders 2 & 4 weeks).
l Start 24 months RCT folow-up (reminders 2 & 4 weeks).
30 months
l End of 12 months RCT folow-up (reminders 2 & 4 weeks).
42 months
l End 24 months RCT folow-up (reminders 2 & 4 weeks).
l Analyses.
l Preparation of HTA report.
l Preparation of study publications.
Complete project: 48 months inclusive
If recruitment is stopped at the conclusion of the 12 months feasibility study, the study wil complete at
42 months.
Dissemination of trial findings
We shal disseminate our findings through relevant local, national and international conferences and
peer-reviewed publications. Reflecting the colaborative basis of this research, al active contributors wil be
named and credited in the main report.
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Trial management
The day to day management of the project is the responsibility of the Trial Management Group:
l Clinical co-ordination: Amar Rangan (Chief Investigator)
l Trial management: Stephen Brealey (Trial Manager, University of York) and Laura Dennis
(Trial Co-ordinator, University of Teesside)
l Methodological support: Helen Handol (University of Teesside), David Torgerson (University of York).
Clinical queries should be directed to any of the listed clinical co-ordinators, and any other issues may be
discussed with any member of the Trial Management Group.
The trial co-ordinating centre is York Trials Unit. Specificaly assigned to the ProFHER trial are a Statistician
(Mrs Gil Worthy, replaced by Dr Catherine Hewit (April 2009), a Health Economist (Dr Jo Dumvile,
replaced by Miss Ling-Hsiang Chuang (May 2009), Data Managers (Mr Ben Cross and Mrs Valerie Wadsworth),
and a Trial Secretary (Mrs Sarah Gardner).
Research governance
The University of Teesside, of which the Chief Investigator holds an honorary lecturership position,
is the sponsor.
Independent supervision
A Trial Steering Commitee (TSC) wil be established upon acceptance by the HTA of our nominees for
an independent chairperson and two other independent members. Other members wil be those key to
trial management and function. Accrual, whole population and‘housekeeping’statistics wil be calculated
and disseminated to members on a monthly basis to monitor the progress of the RCT. The TSC wil meet
at the discretion of the independent chairperson, however, we anticipate that it wil meet approximately a
total of nine times throughout the study.
A separate DMEC wil be established that is independent of the applicants and the TSC. The names of
three nominees, a trial statistician, a shoulder specialist and a consultant rheumatologist, who have
accepted our invitation to fulfil this role have been submited to the HTA. We anticipate that the DMEC
wil meet a total of six times, approximately every 6 months, or at any other time if any issues were to arise
that required urgent atention. An analysis of major complications wil be provided for the DMEC every
three months folowing the commencement of the recruitment phase of the trial.
Trial funding
The PROFHER trial is funded by the NHS R&D Health Technology Assessment Programme (HTA).
Reimbursement for centres
Centres wil be advised to consider employing dedicated clinical staf, such as a research nurse, to act as
the contact person for recruitment and data colection for each centre. This could involve increasing
someone’s hours.
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The HTA has agreed to a reimbursement scheme that recognises the additional eforts and resources
required for recruitment into this trial. The folowing payments have been proposed:
(a) Receipt of eligibility form for non-eligible patients (seeAppendix 1): £10
(b) Receipt of eligibility and consent status forms where patient consent has been sought: £30
(c) For each randomised patient. Provisional scheme: upon receipt of baseline materials and description of
treatment received (£500); receipt of pre-discharge information and copies of X- rays (£250); al
remaining information at 1 and 2 year folow-up (£250).
The folowing activities are covered by these reimbursement payments
l Distribution of trial materials in appropriate locations
l Seting up the trial processes
l Screening of patients’notes for eligibility
l Contacting patients or alerting appropriate clinicians for this activity
l Discussing the trial with patients and providing documentation for consideration
l Completion of trial eligibility and consent status forms
l Obtaining consent
l Randomisation of individual patients and completion of baseline form
l Completion of forms for treatment, costs and in-hospital outcome and complications for
randomised patients.
l Completion of forms for randomised patients at one and two years.
l Copying and cariage of baseline X-rays for independent review.
Health service costs
We anticipate that there wil be no excess treatment costs overal. Whilst this is likely to be the case in the
majority of centres, this may not necessarily apply to certain hospitals, even in the context of a potentialy
low recruitment rate, that have a below average rate of surgery. It wil be up to the individual providers to
consider this aspect in giving their approval for the trial. Some check at randomisation to prevent excess
surgery (especialy in smal centres) is being considered at present.
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Appendix 4Changes to the protocol
This appendix describes changes to the protocol; the final protocol is presented inAppendix 3.
Recruitment period
Cancelation of the feasibility study
In the protocol, as wel as stipulating a recruitment period of 18 months with contributions from at least
‘18 NHS trauma centres’, there was an assessment point after 10 months of recruitment (1 August 2009)
to determine whether or not recruitment into the RCT was suficient (set at 88 patients) to justify its
continuation after 12 months. It soon became clear that we would not make this target (31 participants
were recruited after 10 months). With the support of the TSC, however, we successfuly put forward a
case for canceling this feasibility study and associated stopping rule for cessation of recruitment at
12 months. Our case was based on evidence that patient consent was higher than expected–at that
stage, of 32 patients approached, 20 had consented–and that the serious delays in acquiring R&D
approval for seting up sites to recruit had significantly restricted the potential of the trial to meet this
preliminary target.
Extension
Subsequently, we applied for a funding and time extension (for 18 months). Our proposal included a
revised forecast based on doubling the original number of centres but reducing the anticipated recruitment
to one patient every 2 months per centre. Additionaly, we tightened up our approach towards potential
centres by establishing criteria for whether or not to expend resources, primarily trial manager time, on
seting up a new centre. We remain grateful to our funders for‘keeping faith’with this trial at this critical
time and for the practical support of the independent members of the TSC and DMEC.
Terminology
Reconfiguration of trauma care in the UK subsequent to the end of the trial resulted in designated‘trauma
centres’. We thus changed the description of‘trauma centres’to hospitals, to avoid confusion.
Randomisation
Originaly, we planned to start with simple randomisation, stratified by the presence or not of a tuberosity
fracture and with a prespecified block size, folowed by a prespecified period switch to randomisation
using a computer-generated minimisation programme. The intended minimisation factors were centre
and fractures involving either tuberosity. From the start, random block sizes were selected to prevent
predictability of the sequence. Minimisation was also not implemented because, with fewer patients
being recruited at centres than originaly anticipated, the rationale for minimisation by centre became
questionable. There was a potential for predictability of the sequence, and the low recruitment rate and
lower rate of recruitment at individual centres meant that there were not the anticipated logistical and cost
problems stemming from an excess of patients needing an operation at individual centres.
Study inclusion/exclusion criteria
We decided, with approval from the TSC, that the displacement of the surgical neck did not have to meet
the exact Neer displacement criteria (1 cm and/or 45° angulation of displaced parts) for inclusion of a
fracture in the trial. This is because of the arbitrary thresholds for defining displacement and the advice
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from the TSC to be more pragmatic about the exact displacement. Instead, there needed to be surgical
neck‘involvement’; however, there was emphasis on displacement of the surgical neck throughout the
trial documentation and this was implicit also in the continual reference made to Neer two- and three-part
fractures involving the surgical neck.
Interventions
Non-surgical treatment
As indicated in the final version of our protocol, we decided against the development and provision of
consensus guidelines for non-surgical treatment. Instead, we emphasised the provision of good standard
care and indicated both verbaly and in the trial manual that we anticipated that initial care would
comprise sling immobilisation for about 3 weeks or for as long as the treating clinician deemed necessary
and active early rehabilitation.
Home exercises
Throughout the trial we planned to promote home exercises. However, as stated in the final version of
our protocol, we realised that our original intention to produce generic information leaflets ilustrating
exercises for home use by patients was misguided given the expected variation in patient ability and
changes to requirements over time. Instead, we indicated that physiotherapists would either provide these
or access standard web-based facilities to generate‘bespoke’exercise sheets. However, feedback from the
lead physiotherapy contact for the trial (LG) after discussions with the physiotherapists acting as the named
contacts for physiotherapy at the participating hospitals indicated that advice on this aspect was often
adjusted to accommodate home exercises that were predominantly based on daily functional tasks, for
which writen instructions were considered unhelpful. Instead, the emphasis was on the monitoring and
reinforcement of these and related functional activities at subsequent physiotherapy.
Outcomes
The secondary outcomes listed in the protocol were as folows:
l surgical complications, including shoulder dislocation, failure of implant, proven wound infection
(purulent discharge plus positive bacteriology or need for revision because of infection) and septicaemia
(clinical evidence of systemic infection plus positive blood cultures)
l early medical complications, that is, chest infection, confirmed MI or stroke (confirmed by senior
clinician), treated DVT, treated pulmonary embolism and other serious event
l mortality, subsequent referal for operation or substantive treatment
l general health status assessed using the SF-12 and EQ-5D (at 6, 12 and 24 months).
The folowing adjustments were made to the secondary outcomes, which were reordered to give higher
precedence to health status data as reported by the patient:
l it was decided to present SF-12 data as PCS and MCS scores
l EQ-5D data are presented as part of the economic evaluation
l it was clarified that other shoulder fracture-related complications would be colected, thus removing
the unintended emphasis on complications solely related to surgery
l reflecting the wording on the data colection forms,‘subsequent referal for operation or substantive
treatment’was modified to‘secondary surgery to the shoulder or increased/new shoulder-
related therapy’
l reflecting the data colection process, it was clarified that we were focusing on medical complications
experienced during the inpatient stay
l mortality was presented as a separate outcome.
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Data for the economic evaluation
For the colection of data on hospital consumables and costs it was clarified that these were data relating
to surgery, the inpatient stay and hospital physiotherapy.
Decisions on the selection of the sources of data, from those reported in the hospital forms and patient
questionnaires, for the base-case analysis were not stipulated in the protocol but were prespecified in the
economic analysis plan. These were based on the perceived reliability and comprehensiveness, in terms of
cost information and data completeness, of the source data and relationships with similar data categories.
As planned, data for estimating societal costs were colected from the trial participants at each folow-up.
Radiological assessment to determine study eligibility
The initial intention to require hospitals to use the ful shoulder trauma series (thus, three perpendicular
views)59was adjusted, after consultation with the independent members of the TSC, to promote the need
to adhere to local guidelines (always two views). This was more in keeping with the pragmatic intention of
the ProFHER trial and addressed the need to seek local approvals for additional views, which was causing
delays in the seting up of sites.
Ongoing review of baseline radiographs
For practical reasons, including the greater than anticipated dificulties in obtaining copies of images that
could be accessed independently of the PACS at various individual hospitals, the original intention of
carying out ongoing monitoring and quality review of baseline radiographs during trial recruitment was
revised. The audit of al 250 radiograph sets was completed after the end of recruitment. Additionaly, the
Chief Investigator was assisted in the review of the quality of the copies of the radiographic images for
each trial participant by one orthopaedic surgeon (Mr Jaime Candal-Couto) instead of the two originaly
planned. In the final stage of the quality audit, the independent orthopaedic surgeon member of the TSC
(Professor Andy Car) acted as a third rater for resolving disagreements.
Classification of the radiographs
Independent classification of the radiographs according to the Neer classification system was performed,
after training, by two orthopaedic specialist shoulder surgeons experienced in assessing and operating on
proximal humeral fractures. Both surgeons, who had previous experience with the Neer classification
system, were not involved in the trial but were representative of surgeons who would have recruited
patients in a participating site. This replaced our original intention for classification to be caried out by
three‘experts’forming an independent panel of musculoskeletal radiologists or orthopaedic surgeons who
had experience with the Neer classification. To address the known problem of poor inter-rater agreement
we developed a proforma to colect data and undertook a pilot classification and training exercise with
two senior registrars in the final year of their training at the lead site (James Cook University Hospital)
using a sample of radiographs. Based on the findings of this pilot, the two independent surgeons
underwent systematic training before performing a two-staged and fuly documented process, involving
independent classification of the radiographs and discussion to reach a final verdict.
Clinical effectiveness analysis
Subgroup analyses
We added in an a priori subgroup analysis based on age (<65 years,≥65 years) and revised our subgroup
analysis of fracture classification. The later was based on recorded tuberosity involvement at baseline
(yes/no) and replaced our original intention to split the fractures into three groups (two-part fractures
involving the surgical neck; three-part fractures involving the surgical neck and four-part fractures;
and fractures not meeting the Neer classification displacement criteria). We revised this for consistency of
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reporting (tuberosity involvement being reported on the study eligibility form for al eligible patients) and to
keep to the original subgrouping in terms of study design (two-part fractures vs. three- and four-part fractures).
We conducted a supplementary sensitivity analysis comparing Neer one- and two-part fractures with Neer
three- and four-part fractures based on the results of the independent classification of baseline fractures.
Cluster analysis by surgeon
In the protocol we indicated that we would repeat the primary analysis using appropriate statistical
techniques to account for the clustering of patients within surgeons, thus testing for a potential‘surgeon’
efect. As surgeons at some hospitals operated on very few patients, we conducted the analysis at a
centre level; this quantified the performance of the surgical team(s) at the hospital rather than
individual surgeons.
Additional sensitivity analysis
After recruitment to the trial had finished, an imbalance in smoking status was observed. Baseline
imbalance in itself is not considered an appropriate reason to include a baseline measure as a covariate.
However, smoking is associated with a number of complications including prolonged fracture and
wound healing (including surgical site infection), impaired new bone formation and development of
osteoporosis.105–107Hence, as endorsed by the DMEC, a sensitivity analysis was undertaken in which
smoking status was included in the primary outcome model to explore whether or not the conclusions
drawn from the primary analysis are robust.
Economic analysis
Missing data and censoring issues
We used multiple imputation56,57rather than Lin’s methods,58as proposed in the protocol, for dealing with
missing data and censoring issues relating to cost data. This is because, although dealing with censoring
issues, Lin’s methods58,108do not take‘inter-missing’data, which are missing observations occuring before
any last observation, into account. Consider, for instance, a participant with observations at 3 and
12 months’folow-up only. In this case, apart from censoring after 12 months, the missing observations
at 6 months are caled inter-missing. Furthermore, Lin’s methods do not alow for exploration after the
folow-up of the trial; this became relevant because of a subsequent decision to perform a 5-year
long-term folow-up. Lastly, the multilevel modeling approach used for the statistical analysis could not
be implemented using Lin’s methods.
Despite the fact that we did not expect any substantial diferences between estimates based on multiple
imputation and those based on Lin’s methods, we considered that there were several advantages of multiple
imputation over Lin’s methods. First, both issues of censoring and inter-missing could be addressed. Second,
both multiple imputation and multilevel analysis alow for extrapolation. Therefore, multiple imputation
using chained equations109was adopted to address the missing data in the final economic analysis.
Discount rates
We used updated discounting rates according to the latest NICE guidance,55which difered from the rates
based on 2001 figures stated in the protocol (1.5% for health outcomes and 6% for total costs). Discount
rates were set at 3.5% for both costs and benefits.
Long-term sensitivity analysis
In the protocol we indicated that we would model any potential benefits forward to 5 years (from 2 years)
and an average lifetime in a sensitivity analysis. Because of the subsequent set-up of a long-term folow-up
study aiming to colect patient outcomes up to 5 years, we decided that, in the curent economic analysis,
we would not conduct any exploration beyond the length of the 2-year folow-up. Instead, we intend to
produce a separate paper discussing the forecast and observed outcomes once the long-term folow-up
study is completed.
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Appendix 5Study eligibility form
/ /
!
ProFHER TRIAL: STUDY ELIGIBILITY FORM
Version 5.0 (19/05/09)
Participant identification number:
This form is fororthopaedic specialiststo complete when assessing patient's eligibility to enter the trial.
Please complete this form for any patient aged 16 or above, presenting within three weeks of their injury with a
radiologicaly confirmed displaced fracture of the proximal humerus with involvement of the surgical neck. 
This includes al Neer 2, 3 part fractures involving the surgical neck and 4 part fractures.
Name of Orthopaedic 
Specialist:
Date today: / /
Patient's Hospital 
Number:
Date of injury
to shoulder:
Patient's sex:
Day Month Year Day Month Year
(please cross one box)
Affected shoulder:
Male Female Date of birth: / /
Day Month Year
(please cross one box) Left Right
The displaced fracture MUST involve the surgical neck for inclusion in the trial. In addition, does the fracture
involve:
(please cross al boxes that apply) Greatertuberosity
Lesser
tuberosity
What series of X-rays were used?
(please cross al boxes that apply)
Anteroposterior 
view
Axilary (or modified 
axilary) view
Scapular 
Y-Lateral
Exclusion criteria:(please cross al boxes that apply)
a.Associated dislocation of the injured shoulder joint: f.Pathological fracture (but not osteoporotic):
b.Open fracture: g.Terminal ilness:
h.Patient not resident in trauma-centre
c.Other upper limb fractures:
d.Clear indication for surgery such as severe soft
tissue compromise requiring surgery or emergency
treatment (e.g. neurovascular injury or dysfunction):
catchment area:
i.Mentaly incompetent (unable to understand
the trial or instructions for rehabilitation):
e.Co-morbidities that preclude surgery or anaesthesia: j.Other reason to exclude the patient:
If you crossed the box forj.please record your reason in the box below:
Is the patient eligible?(please cross one box) Yes No
If the patient iseligiblethen the designated person(s) in your hospital should obtain patient consent.
If the patient isnot eligiblethen what treatment would you advise for this patient?
(please cross one box) Surgery Not Surgery
Thank you for completing this form.Could you now please give this form to the designated person so that the form can 
becheckedfor completenessandpostedtoYorkTrialsUnit.
P
R
O PROximal Fracture of Humerus: Evaluation by Randomisation (ProFHER) TrialF A multi-centre randomised controled trial funded by NHS R&D Health Technology Assessment ProgrammeH (International Standardised Randomised Controled Trial Number 50850043)E
R 0177445626
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Appendix 6Sample population estimates
The folowing section, reporting work undertaken in 2007, explains the basis for our estimates of thenumber of sites and recruitment period needed to achieve the recruitment target prior to seting up of
the trial.
A key reference by Court-Brownet al.7supplies the incidence of proximal humeral fractures in a known
population in Edinburgh and a breakdown by fracture type (displaced 51%; two part involving the surgical
neck 28%; three part involving the greater tuberosity and surgical neck 9%; and four part without fracture
dislocation 2%). Apart from this study there was a lack of reliable data on the annual incidence of people
being treated for proximal humeral fractures in other hospitals in the UK. Indeed, the lack of information
on patient numbers found early on from putative principal investigators continued subsequently when
atempting to obtain estimates when recruiting centres into the trial. There was also a lack of catchment
population data for individual hospitals. Using publicly available HES data appeared to ofer a solution.
The 2004–5 HES data showed that there were 9378 FCEs relating to the care of proximal humeral
fractures out of a total of 13,706,765 FCEs in that period (seeAppendix 1). Assuming that a similar
proportion of proximal humeral fractures were treated each year compared with the total number of FCEs
in each of the six original centres (principal investigators were grant applicants), the folowing table was
constructed. The first estimate was based on al FCEs and the second on actual admissions (there were
7600 listed at the time according to HES 2004–5 data).
Centrea Hospital provider Al FCEs
Estimate 1: proximal
humerus fracture FCEsb
Estimate 1: proximal
humerus fracture FCEsc
Coventry and
Warwick
University Hospitals Coventry
and Warwickshire NHS Trust
105,119 72 58
Leicester United Hospitals of Leicester
NHS Trust
237,813 162 132
Newcastle Newcastle upon Tyne Hospitals
NHS Foundation Trust
175,356 119 96
Notingham Queen’s Medical Centre 119,323 82 66
Stoke-on-Trent North Stafordshire Hospital
NHS Trust
152,638 104 84
Teesside South Tees Hospitals NHS
Foundation Trust
146,356 100 81
a Al six centres participated in the trial. Three centre names were changed subsequently:‘Coventry and Warwick’was
refered to as‘Coventry’;‘Stoke-on-Trent’was refered to as‘North Stafs’; and‘Teesside’was refered to as
‘James Cook’.
b Based on 9378 (number of FCEs relating to fracture of the upper end of the humerus)/13,706,765 (total number of
FCEs) × FCEs at hospital provider.
c Estimate 1 × 0.81 to reflect the fact that 7600 (81%) of the 9378 FCEs relating to fracture of the upper end of the
humerus were admission FCEs.
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The folowing estimates were based on‘estimate 1’, thus on al FCEs. We assumed that al hospital
admissions would be displaced fractures and that these would represent 51% of the total proximal
humeral fractures7that would present to the hospital. The‘exclusion’of undisplaced fractures from the
HES data related to the perception that patients with these fractures would not be admited. Therefore, in
the six hospitals, 639 fractures would be displaced proximal humerus fractures and there would be 1253
fractures in total, of which 350 would be two-part fractures involving the surgical neck and 138 would be
three- or four-part fractures.
Based on the average for five hospitals (excluding Leicester, an outlier), 382 displaced fractures were
added for four extra hospitals; it was considered that the addition of four extra hospitals would be enough
at that time. Therefore, for nine hospitals, 1021 fractures would be displaced fractures and there would be
2044 fractures in total, of which 572 would be two-part fractures involving the surgical neck and 225
would be three- or four-part fractures.
The uncertainty in these annual estimates was emphasised. Although there was good corespondence
between the prospective data received from the principal investigator in Teesside (100 fractures annualy
in the orthopaedic department) and estimate 1 for Teeside, a much lower estimate of 100 was received
from the principal investigator at Leicester than estimate 1 for this centre (n=162).
In 2007 we took the decision to double the number of centres to 18 and to recruit for a period of
18 months. We therefore estimated that there would be 6132 patients from these centres with a proximal
humeral fracture, of whom 2391 would have the fracture types suitable for inclusion into the trial. This
would mean that only 11% of the patients identified would need to be enroled into the study to meet
our recruitment target of 250 patients, which we judged to be feasible.
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Appendix 7Table of amendments sent to the
Multicentre Research Ethics Commitee
Multicentre Research Ethics Commitee approval was obtained from the York Research EthicsCommitee (reference number 08/H1311/12)–date of favourable ethical opinion 11 March 2008
(protocol version 1, 13 December 2007).
Amendment Date
Description of main items in the request for approval [including version (v) of
protocol if revised]
Minor 1 8 April 2008 Changes, mainly relating to wording, to several forms: study eligibility form changed
to clarify that al Neer two- and three-part fractures involving the surgical neck and
four-part fractures should be considered, and‘terminal ilness’made a separate
exclusion criterion
Minor 2 10 June 2008 Protocol v2 (4 June 2008)
Changes to the protocol and study eligibility form. Additional exclusion criterion:
associated dislocation of the injured shoulder joint. Adjustment of the protocol to
reflect the revised scoring scheme for the OSS (high=best health) and the plan for an
interim review of the radiographs early in the recruitment period to monitor the
eligibility of patients entering the trial
Minor 3 22 July 2008 Protocol v3 (30 June 2008)
Changes to several forms (mainly for ease of data colection and processing), leters
and the protocol. Submission of the sling immobilisation leaflet. Copies also provided
of al leters for contacting patients at folow-up. Key changes to the protocol were
clarification of the consensus guidelines for non-surgical treatment; addition of
the information leaflet on care during sling immobilisation; and clarification of the
consensus guidelines and data colection for physiotherapy treatment, including advice
regarding home exercise
01 Substantial 28 August
2008
Protocol v4 (22 August 2008)
Measurement of EQ-5D at baseline, reflected in changes in the baseline information
form and protocol
02 Substantial 6 November
2008
Protocol v5 (6 November 2008)
Randomisation sequence changed from‘Stratified randomisation wil be performed by
displaced surgical neck fractures without versus with involvement of either tuberosity’
to‘After an initial, prespecified period of randomisation, stratified by the presence or
not of a tuberosity fracture and with a prespecified block size, randomisation wil then
be performed using a computer-generated minimisation programme. The minimisation
factors wil be fractures involving either tuberosity and centre’. Change informed by
Professor Martin Bland and endorsed by the trial statistician (Dr Brian Faragher),
an independent member of the TSC. Note: minimisation was never employed
03 Substantial 6 April 2009 Protocol v6 (6 April 2009)
Changes to the protocol to clarify that a minimum of two radiographic views/
projections are required for the assessment of trial eligibility and to amend the interim
assessment of radiographs used to determine study eligibility of trial participants to
include the assessment of the quality of al radiographs on an ongoing basis during
the recruitment period
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Amendment Date
Description of main items in the request for approval [including version (v) of
protocol if revised]
Minor 4 19 May 2009 Protocol v7 (19 May 2009)
Changes to the study eligibility form and the protocol to clarify that al Neer two-part
surgical neck fractures, three-part fractures (including the surgical neck) and four-part
fractures of the proximal humerus were eligible for inclusion
04 Substantial 1 July 2009 Trial poster to publicise the trial for display on the wards or in fracture clinics as a
reminder about the trial and who to contact when a potentialy eligible patient is
identified. There was no change to the study screening or recruitment processes
Minor 5 23 September
2009
Consent status form amended to alow for clinicians to have continued uncertainty
over what treatment they would advise for a non-consenting patient
05 Substantial 28 July 2010 Three new questions included on the last page of the 24-month patient questionnaire.
These asked (a) how the participant’s shoulder was compared with 1 year ago
(transition question for assessing minimaly important change in the primary outcome: OSS);
(b) the participant’s treatment preferences at the end of the trial; and (c) whether
or not the participant would like to be informed about the results of the study
06 Substantial 9 September
2010
Protocol for long term folow-up study v1 (9 September 2010)
Extended folow-up of trial participants, with questionnaires sent at 3, 4 and 5 years
for key outcomes. Support confirmed from the trial sponsor, independent members,
including the service users, of the TSC and the members of the trial’s DMEC
07 Substantial 14 July 2011 Protocol for long-term folow-up study v2 (30 June 2011)
For sending participants approached to take part in the folow-up study reminder
leters at 2 and, if necessary, 4 weeks to enhance the consent rate
Minor 6 4 September
2012
Protocol for long-term folow-up study v3 (9 August 2012)
Mortality dropped as a secondary outcome for the long-term folow-up study
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Appendix 8The Trial Management Group and
membership of the Trial Steering Commitee and Data
Monitoring and Ethics Commitee
Trial management
The day-to-day management of the project was the responsibility of the TMG:
l clinical co-ordination: Amar Rangan (chief investigator) and Lorna Goodchild (specialist physiotherapist)
l trial management: Stephen Brealey (trial manager, University of York) and Laura Jeferson, née Dennis
[Trial Co-ordinator, Teesside University (up to September 2011)]
l methodological support: Helen Handol (Teesside University) and David Torgerson (University of York).
The trial co-ordinating centre was the YTU. Specificaly assigned to the ProFHER trial were a statistician
(Mrs Gil Worthy, replaced by Dr Catherine Hewit April 2009, Mr Arthur Kang’ombe January 2011 and
Ms Ada Keding October 2012); a health economist (Dr Jo Dumvile, replaced by Miss Ling-Hsiang Chuang
May 2009 and Mrs Belen Corbacho January 2012), data managers (Mr Ben Cross and Mrs Valerie Wadsworth)
and a trial secretary (Mrs Sarah Gardner, replaced by Mrs Sue Colins March 2011 and Mrs Angela Rogers
May 2012).
Trial Steering Committee
Independent members:
l Professor Sarah Purdy (chairperson and independent member), Professor of Primary Care, University of Bristol
l Professor Andrew Car (independent member), Nufield Professor of Orthopaedic Surgery, University
of Oxford
l Professor Brian Faragher (independent member), Professor in Medical Statistics, Liverpool School of
Tropical Medicine
l patient representatives: Mrs Dorothy Anderson and Mrs Margaret Newlands
l sponsor representative: Dr Alasdair MacSween, Principal Lecturer in Research Governance,
Teesside University.
Data Monitoring and Ethics Committee
Independent members:
l Professor Marion Campbel (chairperson), Director of the Health Services Research Unit, University
of Aberdeen
l Professor Roger Francis, Consultant Physician, Freeman Hospital, Newcastle upon Tyne
l Mr David Limb, Consultant Orthopaedic Surgeon, St James’University Hospital, Leeds.
DOI: 10.3310/hta19240 HEALTH TECHNOLOGY ASSESSMENT 2015VOL. 19 NO. 24
© Queen’s Printer and Controler of HMSO 2015. This work was produced by Handolet al.under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the ful report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
187

Appendix 9Patient information sheet
Appendix 9Patient Information Sheet
Hospital logo                                         Version 3.0 (08/04/2008)
Patient Information Sheet
PROximal Fractures of the Humerus: Evaluation by Randomisation
The PROFHER trial
A UK multi-centre study of surgery for displaced fractures
at the top end of the upper arm bone
(Reference number: 08/H1311/12)
We would like to invite you to take part in thisresearch study. Before you decide, it is
important for you to understand why this research is being done and what it would involve for 
you. Please take time to read the folowing information carefuly and discuss it with others if
you wish. Ask us if there is anything that is not clear or if you would like more information.
Take time to decide whether or not you wish to take part.
Thank you for reading this
What is the purpose of the study?
Your doctor wil have told you that the top end of your upper arm bone (humerus) has broken
(fractured) near the shoulder joint. These fractures are common injuries, particularly in older
people. The less serious fractures are treated by supporting the arm in a sling to help the
bone to heal enough to alow movement. This is folowed by exercises.
About half of these fractures are more serious because the parts of the bone are displaced
from each other. Such fractures are more dificult to treat and the surgeon may consider that
an operation would be helpful. Surgery often involves puting the fractured parts together
again and fixing them in place with various devices such as nails or plates. Sometimes the 
top end or head of the humerus is replaced by an artificial joint. However, for the majority of 
serious fractures surgeons are not sure whether an operation is beter than supporting the 
arm in a sling and leaving the bone to heal. This is because there is no strong evidence that
surgery gives a beter result.
The aim of this UK multi-centre trial is to find out whether people with these more serious
fractures do beter if they have an operation within a few days of their injury. Surgeons and
others, including people who have had these injuries, have agreed that the best way to find
this out is to conduct a randomised trial. This means that the surgeon and patient agree to
use whatever treatment (surgery or no surgery) is selected at random (or by chance). This is
the best way to ensure that the two treatment groups are similar at the start. The results of
this trial are likely to influence how these fractures are treated in this hospital and more 
generaly in the future.
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You have been invited to enter this trial because you have a serious break (fracture) at the 
top end of your upper arm bone. Your surgeon feels that you are fit enough for an operation
but does not know if you would have just as good a result if you didn’t have surgery.
Do I have to take part?
No. It is up to you to decide. You are free to withdraw at any time, without giving a reason.
This would not afect the standard of care you receive.
What wil happen to me if I take part?
After signing the consent form, you wil be asked a few further questions. Then you wil find
out whether you have been alocated to surgery or not. In this trial there is an equal (or
50:50) chance of being alocated to surgery or no surgery.
You wil then receive the alocated procedures delivered with the same standard of care that
you would receive if you were not in the trial.
Thus, if you are alocated surgery, your surgeon wil discuss with you the type of surgery he
or she recommends for you. Your operation wil be carried out by an orthopaedic surgeon
experienced in treating shoulder fractures. Your surgeon wil advise about the best care of
your arm after your operation. Usualy you wil keep your arm in a sling for about three 
weeks. This wil be folowed by exercises.
If you are alocated to no surgery, your surgeon wil again advise about the best non-
operative treatment for you. Usualy you wil keep your arm in a sling for about three weeks, 
folowed by exercises.
The only other thing that we ask of you is to complete a short questionnaire at three months 
and a longer one at six months, one year and two years after your injury. These 
questionnaires are very important and should not take longer than fifteen minutes to 
complete. You can ask a friend or relative to help you with these. A pre-paid envelope wil be 
included. The information you give wil be treated as confidential and only used for the trial.
You wil need to tel us if you are happy for us to text you via your mobile number, if you
have one. This would only be used to inform you of when to expect a questionnaire.
With your permission, we wil inform your family doctor that you are taking part in the trial.
Again with your permission, if we have dificulties contacting you we would like to ask your
family doctor about whether it is appropriate to contact you and for your address.
We wil also colect data from the hospital. Initialy, this wil be what treatment you received in
hospital for your fracture and whether you have any complications. We wil also ask the 
hospital to check their records after one and two years in case you had any later problems.
When we contact you at two years we wil also ask if you would like to know the results of
the trial when these become available.
What are the alternatives to taking part?
If you choose not to take part then your surgeon wil discuss with you the options available
for your treatment. It is possible that your surgeon may advise you to have surgery.
Whatever you decide about taking part in the study it wil not afect the standard of care you
receive.
Why am I being asked to take part?
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What are the possible disadvantages of taking part?
While the selection of treatment, surgery or no surgery, is left to chance you wil receive the 
same standard of care as you would normaly. The surgeon and other people providing your
care are experienced in the treatments provided. There are no new treatments being tested 
in this study.
However, because al surgery involves extra risks, such as infection, it is very important that
you consider whether you would be prepared to have surgery. You should also consider
though that surgery may give you beter shoulder function and may mean that you can be
more independent. Sometimes too, surgerymay be needed to correct problems later on.
Such surgery is often more dificult to do and you may have a long wait.
If you receive an operation, you wil usualy be given a general anaesthetic. Although general 
anaesthesia is very safe with modern techniques, there are stil very smal risks involved.
You may experience nausea, vomiting and / or dizziness. These are reduced with modern 
drugs. It is important that you tel the research team, medical staf and anaesthetist about
any medical problems you have.
There is also a smal chance of developing a wound infection. The exact risk is not known
but most resolve with antibiotics. Occasionaly, the metal implant may need to be removed.
This wil involve another operation. Another operation may also be needed if the fixation
fails. For example, movement of the metal implant or parts of the implant may cause 
problems such as restricted movement and pain. Again, the exact risk of this happening is
not known. You can be assured though that your surgeon wil use devices with low
complication rates and with which they are familiar.
It is important to realise that there are risks and problems for non-operative treatment too. If
youdon’thavesurgery,itmaytakelongerforyoutorecover.Itwil meanthatthefragments
of bone wil not be put back in place. This means that while the bone may heal, it wil not be
as it was before. This may give problems such as restricted movement and pain. You may 
start geting other shoulder problems too. Sometimes, these dificulties are bad enough to 
make you more dependent on the help of others. If this occurs, an operation may sometimes
help. But because it is not a fresh fracture and other damage may have occurred, the
surgery involved is usualy more complex.
For both operative and non-operative treatment, some  problems  take a while to show
themselves. This is why we ask people to tel us how they and their shoulder are at two
years.
What are the possible benefits of taking part?
Because we do not know what treatment is best you might not benefit from taking part but by 
taking part you may help others in the future. We believe though this study has already 
increased awareness of injuries such as yours and recognition of the need for good quality 
care. If enough people take part in this study, the information we get should help ensure that
people with these injuries have the best treatment in the future.
What wil happen if I don't want to carry on with the study?
You are free to withdraw from the study at any time. You do not have to give a reason for 
this. Withdrawing wil not afect your future care or rights in any way. It is up to you whether
you tel us. However, if you do let us know of your decision then we wil know not to contact 
you in future. It is also up to you to tel us whether you would prefer that we didn’t contact the
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hospital for any further outcome data and whether you would like your contact details to be
deleted from the records. Al the other data colected for you up to the time of your
withdrawal from the study wil be kept.
Expenses and payments
This trial is funded by the NHS and involves you in no extra treatment or tests. Thus no
patient expenses have been alocated. However, in recognition of your help with this trial you
wil receive an unconditional payment of five pounds at one and two years after your injury 
when asked to complete questionnaires.
What wil happen to data that are colected about me?
Your data wil be held in a secure place in the co-ordinating centre in University of York. Al
data for the trial wil be held for a minimum of 20 years. We wil remove al names and other 
identifying information before the data are analysed and results of the trial presented to the 
medical community.
What happens if something goes wrong?
This trial only includes treatments that you would receive normaly. The clinicians treating
you wil take every opportunity to reduce risk. If something were to go wrong, they wil ofer
the best possible solution to resolve it. If you believe that you have been harmed in any way
by taking part in this study, you have the right to pursue a complaint through the usual NHS
procedures. Details about this wil be available localy.
Who has reviewed this study?
Before any research goes ahead it has to be checked by a Research Ethics Commitee.
They make sure that the research is fair. This project was passed through the National
Research Ethics Service as wel as the local Ethics Commitee for your hospital.
Who is organising and funding this research.
This trial is funded by the NHS R&D HealthTechnology Assessment Programme. The
sponsor is the University of Teesside, Middlesbrough. Trial management is by the York 
Trials Unit (YTU), University of York. This trial has received endorsement by the British 
Elbow and Shoulder Society.
None of surgeons involved wil receive payments for their involvement in the trial. The
hospitals receive payments for entering a patient into the trial but these only cover the extra 
expenses incurred by the hospital for helping with this trial.
Who can I contact for more information?
If you have any queries or you wish to obtain further information about this study, please 
contact [designated local contact] on [telephone]. Alternatively you may contact Dr Stephen
Brealey (PROFHER Trial Co-ordinator) on 01904      .
Thank you for reading this information sheet and for considering whether to take part in this
study.
P
R
O
F
H
PROximal Fracture of Humerus: Evaluation by Randomisation (PROFHER)Trial
A multi-centre randomised controled trial funded by NHS R&D Health Technology Assessment Programme
(International Standardised Randomised Controled Trial Number 50850043)E
R
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Appendix 10Payments for ProFHER trial-related
activities
Hospitals
Activity per patient Payment (£)
1. For patients meeting the inclusion criteria but subsequently judged non-eligible: completed study
eligibility form
10
2. For eligible but non-consenting patient: completed study eligibility form and consent
status form
30
3. For randomised patients: completed study eligibility form, consent status form, consent form, baseline
form, treatment confirmation form and surgical form
500
4. Hospital data: provision of copies of radiographs and completed physiotherapy treatment log,
physiotherapy treatment log–completion of treatment form and inpatient episode form
250
5. Hospital data: completed 1-year folow-up form and 2-year folow-up form 250
As noted in the trial protocol, the folowing activities were explicitly covered by these
reimbursement payments:
l distribution of trial materials in appropriate locations
l seting up the trial processes
l screening of patients’notes for eligibility
l contacting patients or alerting appropriate clinicians for this activity
l discussing the trial with patients and providing documentation for consideration
l completion of trial eligibility and consent status forms
l obtaining consent
l randomisation of individual patients and completion of the baseline form
l completion of forms for treatment, costs and in-hospital outcomes and complications for
randomised patients
l completion of forms for randomised patients at 1 and 2 years
l copying and cariage of baseline radiographs for independent review.
Patients participating in the trial
Patients did not receive payment for participation in the trial. An unconditional incentive payment of £5
was included in the questionnaires sent at 12 and 24 months’folow-up.
Trial Steering Committee, Data Monitoring and Ethics
Committee and Trial Management Group meetings
Travel and subsistence expenses were provided only. When appropriate, standard refreshments and meals
were provided.
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Appendix 11Recommended radiographic views
for the ProFHER trial
Trauma series
What views?
The folowing constitute the‘trauma series’:
1. anteroposterior view (perpendicular to the scapular plane)
2. scapular Y-lateral view (paralel to the scapular plane)
3. axilary view (or modified axilary view).
Why?
l recommended as good practice in the literature for evaluation of shoulder trauma
l a minimum of two radiographs in planes perpendicular to each other are required to safely
plan management.
Anteroposterior view in the scapular plane
This figure was published inSkeletal Trauma: Basic Science, Management and Reconstruction, volume 2,
Browner, BD, Jupiter JB, Levine AM, Trafton PG, editors, p. 1222, Copyright Elsevier, 1992. Reproduced
with permission.
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Scapular Y-lateral view
This figure was published inSkeletal Trauma: Basic Science, Management and Reconstruction, volume 2,
Browner, BD, Jupiter JB, Levine AM, Trafton PG, editors, p. 1222, Copyright Elsevier, 1992. Reproduced
with permission.
Axilary view
This figure was published inSkeletal Trauma: Basic Science, Management and Reconstruction, volume 2,
Browner, BD, Jupiter JB, Levine AM, Trafton PG, editors, p. 1222, Copyright Elsevier 1992. Reproduced
with permission.
If the axilary is not feasible/too uncomfortable for the patient, perform a modified axilary view (or Velpeau
view), which can be caried out with the injured arm in a sling.
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This figure was published inFrontiers in Fracture Management, Bunker TD, Colton CL, Webb JK, editors,
p. 110 (Figure 9.3), Martin Dunitz, 1989. Reproduced with permission of Taylor & Francis Books UK.
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Appendix 12The ProFHER trial sling
immobilisation leaflet
!
!
!
!
!!
!
!!
!
!!
injured 
because
Fractured Proximal Humerus
Information for patients on initial self-care
You have been given this leaflet because the
top end of your upper arm bone is broken. 
This is caled a 'proximal humerus fracture'.
This leaflet is to remind you of the advice
on self-care that you wil receive from your 
hospital staf. Members of staf wil be
happy to explain any of the maters raised in
this leaflet and you can also ask your family
doctor (GP) for further advice when you
have left hospital.
This leaflet covers the first few weeks after
your injury when your arm is in a sling.
People are usualy advised to wear their sling
for about three weeks. The sling wil ease
the pain and help the bone and soft tissues
to heal, so it is important that you wear it
both day and night. The sling should 
support the weight of your arm. In some
hospitals, depending on the consultant’s
preference, the sling is secured by a ‘swathe’.
In others, a ‘colar and cuf’ is used instead
of a sling. A wel-positioned sling and
swathe should look like diagram 1a.
Diagram 1b shows a sling without a swathe,
and diagram 1c shows a colar and cuf.
In the folowing sections we tel you things
you should DO, including some tips on pain
relief and on how you can make yourself
more comfortable, things you should NOT
DO, and things you MUST TELL YOUR
HOSPITAL STAFF OR FAMILY 
DOCTOR (GP) ABOUT.
Do
•remove rings and watches from your 
arm as soon as possible after the injury,
your hand and fingers might swel;
1a
1b
Sling
Swathe 
Sling
1c
Colar 
and cuf
•make an efort to keep your wrist and fingers moving every couple of hours whilst
you are wearing the sling, to prevent stifness and to maintain your circulation. To do
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this, open and close your fingers (diagram 2), and gently move your wrist (‘backwards
and forwards’ (diagram 3), in a circular motion. Next, turn your palm up towards the
ceiling then turn down towards the floor (diagram 4).
2.
3. 4.
•check the sling regularly to ensure that it is not too tight;
•try to keep the sling as clean and dry as possible (you should ask for a replacement 
sling if yours becomes very grubby and uncomfortable);
•wear loose fiting clothing and front-fastening tops, as this wil make it easier to 
dress and undress;
•learn to put your sling on and of by yourself, if possible;
APPENDIX 12
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•wash under your armpit (diagram 5) and in your elbow creases to help prevent 
these areas from becoming sore;
5.
•support the arm with extra pilows behind your shoulder and also under your
elbow when sleeping (diagram 6)
6.
(You may find that you are more comfortable sleeping in a more upright position at
first,gradualy lyingflater as yourpain setles.)
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•discuss medication with your hospital doctor or family doctor (GP), as you may 
require regular pain relieving tablets until the pain subsides.
•be aware of the position of your shoulders when you are geting pain. If you feel 
tense, try taking a deep breath in, and then, when you breathe out, leting your
shoulders relax. Being aware of your breathing may also help to reduce tension, as
it is easy to hold your breath and forget to breathe corectly when you are in pain. 
Once you have got yourself supported with pilows in bed try closing your eyes, 
breathing slowly and deeply, and imagining pain and tension disappearing.
Do not
•use your arm for lifting or cary objects in your hand;
•drive (you wil be advised when it wil be safe for you to start driving again);
•operate machinery while wearing the sling;
•try to lie on your injured arm in bed at night (this is likely to be very 
uncomfortable);
•wory if you start to feel ‘low’, as this is something that many people experience 
with this type of injury. You could talk your feelings through with a friend or 
relative. If this does not help, you may wish to discuss any concerns with your GP.
Important:
Things you must tel your doctor about
If you sufer from any of the folowing please contact your doctor.
•Very bad pain that seems to be geting worse.
•Loss of sensation in the arm.
•Prolonged tingling or pins and needles in the arm.
•Fingers or hand turning cold and clammy or blue
Finaly
Please do not hesitate to approach staf atyour hospital for further explanations or if
there is anything else you wish to know that has not been covered in this leaflet.
P
R
O
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H
E
R
PROximal Fracture of Humerus: Evaluation by Randomisation (PROFHER)Trial
A multi-centre randomised controled trial fundedby NHS R&D Health Technology Assessment Programme
(International Standardised Randomised Controled Trial Number 50850043)
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Appendix 13Questionnaire for physiotherapists
on physiotherapy for proximal humeral fractures
Appendix 13Questionnaire to physiotherapists on physiotherapy for proximal humeral fractures
Physiotherapy for patients with proximal humeral fractures: Questionnaire
The ProFHER trial, funded by the Department of Health’s Health Technology Assessment Programme, 
is a UK-based, pragmatic, multi-centre randomised trial comparing surgical versus non-surgical 
treatment for displaced fractures of the proximal humerus. Important to the validity of this trial is the
provision of comparable and good standard care including physiotherapy to both treatment groups. In
our preparations to achieve this objective, we have developed a 'basic' physiotherapy protocol to guide
treatment. The importance of this issue was emphasised by the Trial Steering Commitee who recently 
(May 2008) recommended that feedback on the draftprotocol and further insights into the current 
management of these injuries should be obtained from specialist shoulder physiotherapists and other
experts in the field. This is the reason for this short questionnaire.
Please complete this form ONLY if you have ever treated people with shoulder injury.
Name: Specialty:
• Do you treat people with these fractures in your current practice? Yes / No
• If "No", have you ever treated patients with these fractures? Yes / No
Please answer the folowing questions in terms of theexpected trial population: older people who are 
generaly retired but stil active and able to understand instructions for rehabilitation.
1. Physiotherapy protocol(please note this is a guide for the purposes of the trial and does not rule
out the use of other modalities)
a. Is this acceptable as a basic treatment protocol for these fractures? Yes / No 
If "No", please explain why not:
b. Would you be happy with folowing the approach given in the protocol? Yes / No 
If "No", please explain why not:
2.Please listother interventions / modalities that you applyroutinelyfor people with these fractures?
3.Please listany interventionsavailable in an NHS seting that you woulddiscouragefor people with
these fractures?
Please send your completed questionnaire by 23rdJune toDr Stephen Brealeyat @york.ac.uk
Thank you very much for your help.
P
R
O PROximal Fracture of Humerus: Evaluation by Randomisation (PROFHER) Trial
F A multi-centre randomised controled trial funded by NHS R&D Health Technology Assessment Programme
H (International Standardised Randomised Controled Trial Number 50850043)
E
R
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Appendix 14Physiotherapy protocol for the
ProFHER trial
Upper limb specialist physiotherapists developed this protocol to promote standard care for patients inthe ProFHER trial. It has received substantial endorsement from other specialist physiotherapists
experienced in treating people with these fractures.
Patients participating in the ProFHER trial wil have sustained an acute displaced fracture of the proximal
humerus. The trial compares surgical versus non-surgical treatment for these fractures and it is important
to the validity of the trial that comparable physiotherapy is provided to both groups of patients. These
guidelines are not intended to replace local treatment protocols, but you must document any substantive
diference from them in the accompanying physiotherapy treatment log.
We anticipate that home exercises wil be the core of patients’therapy and that you might use a range of
standard physiotherapy modalities/techniques to facilitate these, according to your clinical judgement. But
pleasedo notuse any experimental or new treatment modalities/techniques. Also, with the exception of
TENS, pleasedo notuse electrotherapy.
We have produced an information leaflet aimed at al patients with proximal humeral fractures. This
includes advice on self-care and pain relief and describes the symptoms that should prompt patients to
urgently seek medical advice. We envisage that this leaflet (or a localy developed leaflet covering the same
material) wil be handed out at the fracture clinic.
Treatment objective
The aims are to alow normal healing of bone and soft tissue and to aid the functional recovery of the
injured arm.
Cautions
Please discuss any concerns you may have regarding possible complications with the treating consultant.
Complications may include:
l avascular necrosis
l brachial plexus injury
l chest injury
l frozen shoulder
l malunion
l non-union and
l vascular injury.
This protocol is only a guidelineand we accept that physiotherapists wil use clinical reasoning and
professional judgement when progressing rehabilitation for individual patients.
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This protocol presents progression in phases. Their timing wil depend on various factors including
the patient’s:
l age
l stage of healing
l pain tolerance
l expectation and
l general health and activity level.
With a stable fracture, phase 3 wil probably start after removal of the sling at 3 weeks and phase 4 about
3 weeks later. It is anticipated that many patients wil have returned to their former or atainable functional
status by phase 6. If not, and a higher level of rehabilitation is required, completion may take several
months.
Al exercises must be performed within the limits of pain. Please advise patients todo their home exercises
regularly, atempting at least five repetitions three times per day, andnot to force or stretch.
Phase 1
l If the patient is seen early (i.e. on the ward) teach deep breathing exercises.
l Teach wrist and hand exercises to do whilst wearing the sling.
l Encourage maintenance of good posture for scapular stability.
l Gentle, slow, controled shoulder shrugs and cervical range of motion exercises may help to aleviate
muscle spasm.
l Teach the patient appropriate pain management techniques.
l Ensure the patient and/or his/her carer is taught sling application and axilary hygiene.
Phase 2
As for phase 1, except the sling may be removed for the patient to do elbow, wrist and hand exercises if
the consultant feels it is safe for him or her to do so. Add:
l elbow flexion/extension and
l pronation/supination.
Phase 3
The consultant wil recommend progression to this stage when radiographs show evidence of healing.
As for phase 2, except add:
l Gentle pendular exercises
l Active assisted flexion progressing from short to long lever and
l Active assisted external rotation (using a stick) in neutral with elbow flexed and supported on a pilow.
Patients usualy find this more comfortable to do in lying position.
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Phase 4
Patients usualy reach this stage in about 6 weeks. As for phase 3, except discontinue the hand and wrist
exercises when appropriate and add:
l isometric internal and external rotation exercise in mid-range, within pain tolerance
l closed kinetic chain exercises
l light functional activities
l progression of active assisted exercises to active, gradualy increasing range of motion, and
l gentlecapsular stretches within pain tolerance if these are required.
Phase 5
As for phase 4, except add:
l progressive strengthening exercises and endurance activities for the rotator cuf muscles, ensuring
optimum movement paterns and control through range of movement, and
l progression of functional activities as able.
Phase 6
Orthopaedic review is required to determine whether further progression is appropriate.
As for phase 5, except:
l progress strengthening exercises appropriate to patient’s premorbid activity level and
l return to function/work/sport.
Discharge criteria
The patient is discharged:
l when independent shoulder function is achieved or
l by consensus between the therapist and patient if there has been no improvement over
several sessions.
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Appendix 15Consent status form
! Version 4.0 (23/09/2009)
ProFHER TRIAL: CONSENT STATUS FORM
Participant identification number:
Thedesignated personshould complete the first part of this form to indicate whether aneligible
patienthas consented to take part in the trial.
Name of designated person:
Date today: /
Day Month Year
Has the patient agreed to consent?
(Please cross one box only) Yes 
No
If the patient hasconsentedthen the designated person should complete the baseline form with the
patient, perform the randomisation and then post al baseline materials to York Trials Unit.
If the patient hasnot consentedthen the orthopaedic surgeonshould complete this form and give
it to the designated person to post to York Trials Unit.
a. Which treatment do you as theclinicianadvise the patient to have?
(Please cross one box only) Uncertain
Surgery
No Surgery
b. Does thepatientexpress any treatment preference?
(Please cross one box only) No preference
Surgery
No Surgery
c. What is theagreedtreatment for this patient?
(Please cross one box only)
Surgery
No Surgery
Thank you very much for completing this form
P
R
O PROximal Fracture of Humerus: Evaluation by Randomisation (ProFHER) Trial
F A multi-centre randomised controled trial funded by NHS R&D Health Technology Assessment ProgrammeH (International Standardised Randomised Controled Trial Number 50850043)E
R 4625359981
/
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Appendix 16Patient consent form
onsent Form Version 1.0 (13/12/2007)
CONSENT FORM
Participant Identification Number:
Title of study:PROximal Fracture of Humerus: Evaluation by Randomisation
(ProFHER) Trial
Name of Person taking consent:
Please initial the boxes
1.I confirm that I have read and understand the information sheet version 3.0
dated 08/04/2008 for the above study. I have had the opportunity to consider
the information, ask questions and have had these answered satisfactorily.
2.I understand that my participation is voluntary and that I am free to withdraw at any
time without giving reason, without my medical care or legal rights being afected. I
also understand that if I withdraw, I can ask for al record of my contact details to be
deleted but it wil be impossible to withdraw any other data colected on me.
3.I understand that sections of any of my medical notes and the data colected during
the study may be looked at by responsible individuals where it is relevant to my
taking part in this research. I give permission for these individuals to have access
to my records.
4.I agree to my General Practitioner being informed that I am taking part in this study.
5.Should there be problems contacting me, I agree to my General Practitioner being
asked whether it is appropriate to contact me and for my address.
6.I agree to this consent form and other data colected as part of this research study
being kept at York Trials Unit, University of York.
7.I understand that records relating to me wil be kept confidential. No information wil
be released or printed that would identify me without my permission unless required
by law.
8.I agree to take part in the above study.
Name of patient (please print) Date Signature
Name of person taking consent Date Signature
(please print)
When completed, 1 for patient; 1 (original) to be kept in medical notes; 1 for York Trials Unit
P
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R
PROximal Fracture of Humerus: Evaluation by Randomisation (PROFHER) Trial
A multi-centre randomised controled trial funded by NHS R&D Health Technology Assessment Programme
(International Standardised Randomised Controled Trial Number 50850043)
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Appendix 17Baseline information form
!
Appendix 17 Baseline Information
CONFIDENTIAL
PROximal Fracture of Humerus:
Evaluation by Randomisation
(ProFHER) Trial
Version 5.0 (22/08/2008)
Baseline form for al patients with a radiologicaly confirmed
displaced fracture of the surgical neck
Participant ID Number:
Date when questionnaire
completed: /
day month year
P
R
O PROximal Fracture of Humerus: Evaluation by Randomisation (ProFHER) Trial
F A multi-centre randomised controled trial funded by NHS R&D Health Technology Assessment ProgrammeH (International Standardised Randomised Controled Trial Number 50850043)
E
R 9457133800
/
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BASELINE FORM FOR CONSENTING PATIENTS
This form is for the designated person to complete with eligible patients who consent to
take part in the trial.
Section 1:
This section asks about the patient's health in general.Please indicate which statement
best describes the patient's health state today.
Please cross one box in each group.
1. Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
2. Self-care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
3. Usual activities(e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
4. Pain or discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
5. Anxiety or depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
7850133805
APPENDIX 17
NIHR Journals Librarywww.journalslibrary.nihr.ac.uk
214
Section 2:
IT WOULD ALSO HELP TO KNOW MORE ABOUT YOU
1. Are you?
(Please cross one box)
White 
Black
Asian
Chinese
Other
If 'Other', please specify here:
2. Which of these best describes your highest qualification?(Please cross one box)
No formal qualifications
Some qualifications/no degree
Degree or higher
3. Are you?
(Please cross the box that describes you best)
Employed part-time 
Employed ful-time
Self-employed
Student
Retired
Not employed but seeking work
Other
If 'Other', please specify here:
7134133800
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4. Have you had any other fractures in the past ten years?
(Please cross one box)
If you have placed a cross in the 'Yes' box, please record:
What type of fracture(s)?
Was it/were any treated surgicaly?
(Please cross one box)
Yes 
No
Yes 
No
5. Do you smoke?
(Please cross one box)
Yes
No
If you have placed a cross in the 'Yes' box, please be advised that smoking has been shown to delay
bone healing and recovery and thus it would be a good time to stop smoking if at al possible.
6. How did you injure your shoulder?
(Please cross one box)
Fal/trip from standing height or less
Fal downstairs/steps or from a height
Other (please describe in box below)
7. Have you injured your dominant arm?
(Please cross one box)
Yes 
No
8. Are you diabetic?
(Please cross one box)
Yes 
No
9. Are you curently taking steroids?
(Please cross one box)
Yes 
No
10. In consenting for this trial, you have accepted that whether you get surgery or no surgery
is left to chance. However, we would like to know if you had a preference before you
agreed to this?
(Please cross one box) No preference
Surgery
Not Surgery
4521133807
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11. What is the name of your GP?(Please record below)
12. What is the name of your GP practice (include postcode if available)?
(Please record below)
13. Are you happy to receive a text about when to expect a questionnaire?
(Please cross one box)
Yes 
No
The rest of the form can be completed by the designated person without the patient.
14. Please record below the patient's contact details:
Patient's Name
Address Line 1
Address Line 2
Address Line 3
Postcode
Telephone (Day)
Telephone (Evening)
Mobile
Email:
15 . Please randomise the patient by contacting York Trials Unit on freephone 0800
or the folowing websitewww.yorkrand.com
16 . Please cross the box for which treatment the patient has been randomised to receive:
Surgery
Not Surgery
Please inform the patient about the treatment they wil receive.
Please post this baseline form to York Trials Unit with the signed consent form, consent 
status form and study eligibility form using the freepost envelope provided.
Thank you very much for completing this form.
3369133806
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Appendix 18Three-month patient questionnaire
Appendix 18 Three Month patient
CONFIDENTIAL
Version 3.0 (01/07/2008)
PROximal Fracture of Humerus:
Evaluation by Randomisation
(ProFHER) Trial
Three month questionnaire to find out how you are and
your health care needs after your shoulder fracture
Ofice use only
Participant ID Number:
Date when questionnaire
sent: /
day month year
P
R
O PROximal Fracture of Humerus: Evaluation by Randomisation (ProFHER) Trial
F A multi-centre randomised controled trial funded by NHS R&D Health Technology Assessment ProgrammeH (International Standardised Randomised Controled Trial Number 50850043)
E
R
8688648716
/
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING 
THE QUESTIONNAIRE
Thank you for agreeing to take part in this study.
The responses you give in this questionnaire wil help us to find out if the care you receive
is helpful for your shoulder fracture.
Please answeralthe questions.
If you find it dificult to answer a question, please give the best answer you can. 
Please folow the instructions for each section carefuly.
Please use a black or blue pen for al of the questions.
Please do not use a pencil or any other coloured pen.
Please read al the instructions for each section.
The responses you give wil be treated in the utmost confidence. The study team wil
not tel anyone else what you have writen.
2274648711
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Please enter today's date: / /
day month year
Section 1:
This section asks about your health in general. By placing a cross in one box in each 
group below, please indicate which statement best describes your health state today.
Please cross one box in each group.
1. Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
2. Self-care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
3. Usual activities(e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
4. Pain or discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
5. Anxiety or depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxiousor depressed
4986648713
DOI: 10.3310/hta19240 HEALTH TECHNOLOGY ASSESSMENT 2015VOL. 19 NO. 24
© Queen’s Printer and Controler of HMSO 2015. This work was produced by Handolet al.under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the ful report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
221
Thisfinal sectionis about the health care you have received, over thepast three
monthsFOR ANY REASON. If the health care you received was related to your 
shoulder injury, record this in the'about your shoulder'column. If the health care was 
for any other reason, enter this in the'other reason'column. Please answer every
question, even if the answer is "0".
Please fil in both boxes, for example: if seen three times. 03
Care from the NHS
In this part we would like you to tel usabout the care you have received from theNHS.
1. Over thepast three months, how many times have you:
About your shoulder Other reason
a. Seen your GP?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
b. Seen a physiotherapist?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
c. Seen a nurse at your GP practice?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
d. Seen a district/community nurse?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
e. Seen an occupational therapist?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
f. Visited hospital for an out-patient appointment?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
g Visited hospital as a day case (not overnight)?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
h. Stayed in hospital as an in-patient?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
i. If you have stayed in hospital, could you please 
record how many nights you were there over al
visits. If none enter '0' If none enter '0'
4584648717
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Private treatments
In this part we would like you to tel us aboutany additional medical treatments you have
received, which you have paid for.
2. Over thepast three months, how many times have you:
About your shoulder Other reason
a. Seen a non-NHS physiotherapist?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
b. Seen an osteopath?
(Please record the number of times in the boxes)
c. Seen a private hospital doctor?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
If none enter '0' If none enter '0'
d. Seen a chiropractitioner?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
e. Stayed in a private hospital?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
f. If you would like to tel us about any other medical treatments you have paid for, please 
record details below.
Usual activities
3. Are you in any form of paid employment? Yes No
If you have answered 'Yes'to being in any form of paid
employment, how many working days over thepast three months
have you missed because of your shoulder?
days
4. For how many days over thepast three monthshave you been
unable to perform your normal UNPAID activities (e.g. household 
chores, shopping, helping others) because ofyour shoulder? days
7936648711
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Please post the questionnaire back to us using the freepost envelope provided.
We wil ask you to complete a further questionnaire in three months time. Thus we would
be most grateful if you could inform us of any change in your contact details.
If you have been admited to a diferent hospital than the one you initialy atended for your
shoulder fracture, could you please tel us the name of the hospital.
Please let us know of anything that you think we have not asked that is badly afecting
your everyday activities because of your shoulder.
If you have any other comments about your shoulder problem, this study, or this
questionnaire, please write them here.
THANK YOU VERY MUCH FOR COMPLETING THIS QUESTIONNAIRE.
0717648711
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Appendix 19Two-year patient questionnaire
Appendix 19 Two Year patient Questionnaire
CONFIDENTIAL
PROximal Fracture of Humerus:
Evaluation by Randomisation
(ProFHER) Trial
Version 1.0 (28/07/2010)
Two year questionnaire to find out how you are and
your health care needs after your shoulder fracture
Ofice use only
Participant ID Number:
Date when questionnaire
sent: /
day month year
P
R
O PROximal Fracture of Humerus: Evaluation by Randomisation (ProFHER) Trial
F A multi-centre randomised controled trial funded by NHS R&D Health Technology Assessment ProgrammeH (International Standardised Randomised Controled Trial Number 50850043)
E
R
7695553965
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING
THE QUESTIONNAIRE
Thank you for agreeing to take part in this study.
The responses you give in this questionnaire wil help us to find out if the care you received was 
helpful for your shoulder fracture.
Please answeralthe questions. Although some questions may appear similar, it is stil important
that you answer every one.
If you find it dificult to answer a question, please give the best answer you can. 
Please folow the instructions for each section carefuly.
For sections where you are asked to put a cross in the box, please do this as folows. For 
example, if your answer to the folowing question isNo, you should place a cross firmly in the box
next toNo.
Do you drive a car?
Yes 
No
Please use a black or blue pen for al of the questions.
Please do not use a pencil or any other coloured pen. 
Please read al the instructions for each section.
The responses you give wil be treated in the utmost confidence. The study team wil
not tel anyone else what you have writen.
2928553969
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!
Please enter todays date: / /
day month year
YOUR SHOULDER PROBLEM
The folowing questions ask about the problems that the shoulder you had injured has 
caused youduring the past 4 weeks. Please answer every question with a cross. If
you are unsure about how to answer a question, please give the best answer you can.
Which shoulder did you injure?
(Please cross one box only) Left Right
1. During thepast 4 weeks, how would you describe the worst pain you had from your injured 
shoulder?
(please cross one box only)
None Mild Moderate Severe Unbearable
2. During thepast 4 weeks, have you had any trouble dressing yourself because of your injured
shoulder?
(please cross one box only )
No trouble
at al
Litle
trouble
Moderate
trouble
Extreme
dificulty
Impossible
to do
3. During thepast 4 weeks, have you had any trouble geting in and out of a car or using public
transport because of your injured shoulder? (whichever you tend to use)
(please cross one box only )
No trouble
at al
Very litle
trouble
Moderate 
trouble
Extreme
dificulty
Impossible
to do
4. During thepast 4 weeks, have you been able to use a knife and fork - at the same time?
(please cross one box only )
Yes, easily With litle
dificulty
With moderate
dificulty
With extreme
dificulty
No,
impossible
9063553966
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5. During thepast 4 weeks, could you do the household shopping on your own?
(Please cross one box only)
Yes, easily With litle
dificulty
With moderate
dificulty
With extreme
dificulty
No,
impossible
6. During thepast 4 weeks, could you cary a tray containing a plate of food across a room?
(Please cross one box only)
Yes, easily With litle
dificulty
With moderate
dificulty
With extreme
dificulty
No,
impossible
7. During thepast 4 weeks, could you brush/comb your hair with the afected arm?
(Please cross one box only)
Yes, easily With litle
dificulty
With moderate
dificulty
With extreme
dificulty
No,
impossible
8. During thepast 4 weeks, how would you describe the pain you usualy had from your injured
shoulder?
(Please cross one box only)
None Very mild Mild Moderate Severe
2786553961
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9. During thepast 4 weeks, could you hang your clothes up in a wardrobe, using the afected
arm?
(Please cross one box only)
Yes, easily With litle
dificulty
With moderate
dificulty
With great
dificulty
No,
impossible
10. During thepast 4 weeks, have you been able to wash and dry yourself under both arms?
(Please cross one box only)
Yes, easily With litle
dificulty
With moderate
dificulty
With extreme
dificulty
No,
impossible
11. During thepast 4 weeks, how much has pain from your injured shoulder interfered with your 
usual work (including housework)?
(Please cross one box only)
Not at al A litle bit Moderately Greatly Totaly
12. During thepast 4 weeks, have you been troubled by pain from your injured shoulder in bed at
night?
(Please cross one box only)
No nights Only 1 or 2 
nights
Some nights Most nights Every night
4253553962
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YOUR GENERAL HEALTH
The folowing questions ask for your viewsabout your health. This information wil help
us keep track of how you feel and how wel you are able to do your usual activities.
Answer each question by marking a cross in the box that best describes your answer.
1. In general, would you say your health is:
(Please cross one box only)
Excelent Very Good Good Fair Poor
2. During a typical day doesyour healthlimit you inmoderate actvities, such as moving
a table, pushing a vacuum cleaner, bowling or playing golf ? If so, how much?
(Please cross one box only)
Yes, limited a lot Yes, limited a litle No, not limited at al
3. During a typical day doesyour healthlimit you in climbingseveralflights of stairs ? If
so, how much?
(Please cross one box only)
Yes, limited a lot Yes, limited a litle No, not limited at al
4. During thepast 4 weeks, how much of the time have you accomplished less than you would
like in regular daily activitiesas a result of your physical health?
(Please cross one box only)
Al of the
time
Most of 
the time
Some of 
the time
A litle of
the time
None of 
the time
4647553969
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5. During thepast 4 weeks, how much of the time have you been limited in performing any
kind of work or other regular daily activitiesas a result of your physical health?
(Please cross one box only)
Al of the
time
Most of 
the time
Some of 
the time
A litle of
the time
None of 
the time
6. During thepast 4 weeks, how much of the time have you accomplished less than you would
have liked in your work or any other regular daily activitiesas a result of any emotional
problems(such as feeling depressed or anxious)?
(Please cross one box only)
Al of the
time
Most of
the time
Some of
the time
Alitleof
the time
None of
the time
7. During thepast 4 weeks, how much of the time have you done work or other activities 
less carefuly than usualas a result of any emotional problems(such as feeling
depressed or anxious)?
(Please cross one box only)
Al of the
time
Most of 
the time
Some of
the time
Alitleof
the time
None of
the time
8. During thepast 4 weeks, how much didpaininterfere with your normal work (both
outside the home and housework)?
(Please cross one box only)
Not at al A litle bit Moderately Quite a bit Extremely
5831553965
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9. This question is about how you feel and how things have been with you during thepast 4
weeks. Please give the one answer that comes closest to the way you have been feeling.
How much of the time during the past 4 weekshave you felt calm and peaceful?
(Please cross one box only)
Al of the
time
Most of
the time
Some of 
the time
A litle of
the time
None of 
the time
10. This question is about how you feel and how things have been with you during thepast 4
weeks. Please give the one answer that comes closest to the way you have been feeling.
How much of the time during the past 4 weeksdid you have a lot of energy ?
(Please cross one box only)
Al of the
time
Most of 
the time
Some of 
the time
A litle of
the time
None of 
the time
11. This question is about how you feel and how things have been with you during thepast 4
weeks. Please give the one answer that comes closest to the way you have been feeling.
How much of the time during the past 4 weekshave you felt downhearted and depressed?
(Please cross one box only)
Al of the
time
Most of 
the time
Some of 
the time
A litle of
the time
None of 
the time
12. During thepast 4 weekshow much of the time has yourphysical healthoremotional 
problemsinterfered with your social activities (like visiting friends, relatives etc.)?
(Please cross one box only)
Al of the
time
Most of 
the time
Some of 
the time
A litle of
the time
None of 
the time
2385553966
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This section also asks about your health in general.By placing a cross in one box
in each group below, please indicate which statement best describes your health
state today.
Please cross one box in each group.
1. Mobility
I have no problems in walking about
Ihavesomeproblemsinwalkingabout
I am confined to bed
2. Self-care
I have no problems with self-care
I have some problems washing or dressing myself
I am unable to wash or dress myself
3. Usual activities(e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
4. Pain or discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
5. Anxiety or depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed
7191553966
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This final sectionis about the health care you have received, over thepast twelve 
monthsFOR ANY REASON. If the health care you received was related to your
shoulder injury, record this in the'about your shoulder' column. If the health care
was for any other reason, enter this in the'other reason'column. Please answer 
every question, even if the answer is "0".
Please fil in both boxes: for example, if seen three times. 03
Care from the NHS
In this part we would like you to tel us about the care you have received from theNHS.
1. Over thepast twelve months, how many times have you:
About your shoulder Other reason
a. Seen your GP?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
b. Seen a physiotherapist?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
c. Seen a nurse at your GP practice?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
d. Seen a district/community nurse?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
e. Seen an occupational therapist?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
f. Visited hospital for an out-patient appointment?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
g. Visited hospital as a day case (not overnight)?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
h. Stayed in hospital as an in-patient?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
i. If you have stayed in hospital, could you please 
record how many nights you were there over al
visits. If none enter '0' If none enter '0'
0774553966
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Private treatments
In this part we would like you to tel us aboutany additional medical treatments you have
received, which you have paid for.
2. Over thepast twelve months, how many times have you:
About your shoulder Other reason
a. Seen a non-NHS physiotherapist?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
b. Seen an osteopath?
(Please record the number of times in the boxes)
c. Seen a private hospital doctor?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
If none enter '0' If none enter '0'
d. Seen a chiropractitioner?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
e. Stayed in a private hospital?
(Please record the number of times in the boxes)
If none enter '0' If none enter '0'
f. If you would like to tel us about any other medical treatments you have paid for, please 
record details below.
If you have been admited to a diferent hospital than the one you initialy atended for 
your shoulder fracture, could you please tel us the name of the hospital.
5413553961
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Other questions
1. Compared with one year agohow is your shoulder now?
(Please cross one box only)
Much beter 
now than one 
year ago
Slightly beter 
now than one 
year ago
About the
same now as
one year ago
Slightly worse
now than one
year ago
Much worse
now than one 
year ago
2. Based upon your experiences of the treatment that you received as part of this trial, if you
injured your shoulder today to the same extent as you did two years ago which treatment 
would you prefer?
(Please cross one box only)
No preference
Surgery
Not surgery
3. Would you like us to inform you about the results of this study?
(Please cross one box only) Yes
No
Please let us know of anything that you think we have not asked that is badly afecting
your everyday activities because of your shoulder.
If you have any other comments about your shoulder problem, this study, or this
questionnaire, please write them here.
THANK YOU VERY MUCH FOR COMPLETING THIS QUESTIONNAIRE.
Please post the questionnaire back to us using the freepost envelope provided.
0773553965
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Appendix 20Treatment confirmation form
Appendix 20 Treatment Confirmation Form
ProFHER TRIAL: One Month Treatment Confirmation Form
Participant identification number:
This form is for thedesignated personto complete at one month after trial entry.
1. Which treatment did the patient have?
(Please cross one box only) Surgery Not Surgery
2. If 'not surgery', please record the non-surgical treatment prescibed for this patient
(e.g. sling immobilisation):
3. If the patient had surgery, please record
date of surgery: / /
Day Month Year
Check for completion of surgical form and confirm this (please cross one box only):
Completed surgical form: available not available*
4. Whether the patient was treated surgicaly or not, please record the folowing:
a. Was the patient admited as aninpatient? Yes No(please cross one box only)
IfYes and patient has left hospital, please check for completion of inpatient episode
form or complete this(please cross one box only)
Completed inpatient episode form: available not available*
b. Please record date that patient started or 
is scheduled to startphysiotherapy: / /Day Month Year
Ifno physiotherapy planned,
please give reason:
5. X-rays (at baseline)
Copies of the X-rays used todetermine patient eligibility for the trial should be or have
been sent to the trial ofice. Please take agreed steps to organise this.
Please record if copies have been sent / are being sent to the trial ofice:
(please cross one box only) Yes No
If X-raysnotavailable, please contact trial ofice to discuss.
Please record in the box below any other imaging investigations (e.g. CT scan) used by
the orthopaedic surgeon to decide on the patient's eligibility for the trial.
*Ifaformisnotavailable, please contact trial ofice to discuss.
Thank you for completing this form. 8900062331
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Appendix 21Surgical form
Appendix 21 Surgical Form ProFHER TRIAL: SURGICAL FORM
Participant identification number:
Date of
surgery: / /Day Month Year
Name of operating 
surgeon:
Operation - Times
Into anaesthetic room
hr min
Into theatre
hr min
Out of theatre
hr min
Type of Anaesthesia:(Please cross al boxes that apply)
General 
Anaesthetic
Local 
Anaesthetic
Regional 
Anaesthesia (RA)
Other 
Anaesthesia
If 'Other Anaesthesia' please record in the box
Delivery of Regional Anaesthesia:(Please cross one box only)
a) Indweling catheter b) Injection
Type of Surgery:(Please describe type of implant and stick implant label on back of the form)
Nail Plate & Screws Hemiarthroplasty Other
Was a loan set/kit used for the surgery?
(Please cross one box only)
Use of antibiotics:
(Please cross one box only)
Yes No Yes No
Staff in theatre:(Please record number of staf)
Surgeon grade: Consultant Registrar Other IfOthergrade, please record:
Anaesthetist grade: Consultant Registrar Other IfOthergrade, please record:
Other staff:
(e.g. Nursing) Grade Number of staf
Grade Number of staf
Radiology:(Please cross al boxes that apply)
Image intensifier Films
Unexpected procedures:(Please cross one box only)
If yes, please
Radiographer grade(please record below)
Yes No describe andrecord reason:
Thank you for completing the form.The designated person shouldnow return the form to York
Trials Unit in the freepost envelope provided.
5706096485
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Appendix 22Inpatient episode form
Appendix 22 Inpatient Episode Form
!
ProFHER TRIAL: END OF ORTHOPAEDIC INPATIENT EPISODE FORM
Participant identification number:
This form is for thedesignated personto complete when an eligible patient comes to the end of their 
inpatient episode in the Orthopaedic Department.
Date of 
admission: / /Day Month Year
Date of 
discharge: / /Day Month Year
Date of death(if applicable) / /
Day Month Year
If the patient hasdied, please complete anadverse event formand return to York Trials Unit.
Discharged to:(please cross one box)
Home Another Hospital Nursing Home Othere.g. ward
IfOther, please give details:
Surgical and other shoulder fracture complications prior to discharge:
Please cross in box(es) if recorded
Surgical site infection requiring
treatment with antibiotics
Identified
organism:
Haematoma formation at 
surgical site Describe:
Nerve injury Describe:
Implant related complication Describe:
Dislocation/instability Describe:
Other Describe:
Please continue to complete the rest of this form overleaf.
3356038659
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Appendix 23Physiotherapy treatment log
Appendix23 PhysiotherapyTreatmentLog
ProFHER TRIAL: PHYSIOTHERAPY TREATMENT LOG
Participant identification number: Sheet number:
Please complete this form as soon as possible after each treatment session. Thank you.
Day Month Year
Date: / /
Day Month Year
/ /
Location:
Name of person 
completing form:
Staf grade:
Session number:
Alocated time
(mins):
Phase*:
*Please see ProFHER physiotherapy protocol. Note: phase 3 starts after sling removal.
Please record with a cross al that apply to the session:
Advice and/or education
Exercise
TENS
Soft tissue techniques
Joint mobilisations
Stretching techniques
Relaxation techniques 
Hydrotherapy
Other:
(Please specify)
Has the patient done
their home exercises? Yes No (any comments*) Yes No(any comments*)
Please record reasons below for any substantial diference from the ProFHER physiotherapy protocol.
Reasons
(or comments*)
Ifreferralto other 
speciality is 
required, please 
record speciality 
and reason
Please continue to complete the rest of this form overleaf for the next two sessions.
!
Prof_Physio_Treat_Logv2_Feb09 5166011303
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Appendix 24Physiotherapy treatment log:
completion of treatment (‘end of treatment’) form
Appendix 24 Physiotherapy treatment log - Completion of treatment ('End of treatment') form
!
ProFHER TRIAL: PHYSIOTHERAPY TREATMENT LOG - COMPLETION OF TREATMENT
Participant identification number:
Please record last used sheet number for Physiotherapy Treatment Log:
Name of person completing form:
Pleasecomplete appropriate section(s) below.
a) Was treatment completed (formal discharge)?(Please cross one box) Yes No
Date of discharge: / /
Day Month Year
Please record thereason for dischargeby crossing one of the folowing
Independent shoulder function achieved
No improvement noted over several sessions 
Other
IfOtherplease
describe in box:
b) Was treatment not completed?(Please cross one box) Yes No
Date of discharge: / /
Day Month Year
Please record thereason for dischargeby crossing one of the folowing boxes:
Patient stopped atending
Another problem intervened
IfAnother problem
intervenedplease
describe in box:
Other
IfOtherplease
describe in box:
Yes No
c) Did treatment start (i.e. patient never atended)?(Please cross one box)
Please return this and al other physiotherapy treatment log forms whether used or not to the
designated person at your hospital. Thank you verymuch for completing this form.
9204084715
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Appendix 25One-year folow-up form
Appendix25 OneYearFolow-upForm
ProFHER TRIAL: ONE YEAR FOLLOW-UP FORM
Participant identification number:
This form is for thedesignated personto complete for an eligible patient one year after they were enroled
into the trial.
If the patient has died, please complete and return anadverse event form.
Pre-Discharge:
Has the patient seen an occupational therapist?(Please cross one box)
Yes No
Date of orthopaedic discharge:
(i.e. end of orthopaedic treatment) / /Day Month Year
Discharged to:(e.g. GP) 
(Please record details)
Complications that occurred after the initial treatment and, if applicable, after inpatient episode:
Please cross in box(es) if recorded
Surgical site infection requiring
antibiotics/further surgery Describe:
Avascular necrosis of humeral 
head Describe:
Implant failure Describe:
Dislocation/instability Describe:
Metalwork problems requiring
further surgery Describe:
Non-union/Malunion requiring 
further treatment Describe:
Other Describe:
Other treatments after initial treatment and, if applicable, after inpatient episode:
Surgery to shoulder
(please cross one box) Yes No Date: / /
Day Month Year
If'Yes'describe surgery below.
Please continue to complete the rest of this form overleaf.
Number of days as 
hospital in-patient
9753135159
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/ /
Increased/new therapy for
shoulder related complication
(e.g. infection)
(please cross one box)
Yes No Datestarted
Day Month Year
If'Yes'describe treatment below. Number of days as 
hospital in-patient
Treatment for serious newly 
diagnosed medical 
complication
(please cross one box)
Yes No Datestarted: / /Day Month Year
If'Yes'describe treatment below. Number of days as 
hospital in-patient
Post-Discharge (i.e. end of orthopaedic treatment):
Has the patient visited the
orthopaedic/fracture clinic
since discharge from 
orthopaedic treatment?
(please cross one box)
Yes No Date: / /
Day Month Year
Number of visits
If'Yes'please describe the reason(s) for atendance in the box below:
Has the patient been 
admitted to hospital for
another fracture? 
(please cross one box)
Yes No
Date
admitted: / /
Day Month Year
If'Yes'please provide details in the box below:
Thank you for completing this form.
Number of days as 
hospital in-patient
1035135154
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Appendix 26Two-year folow-up form
Appendix 26 Two Year Folow-up Form
ProFHER TRIAL: TWO YEAR FOLLOW-UP FORM
Participant identification number:
This form is for thedesignated personto complete for an eligible patient between year one and two of being 
enroled into the trial.
If the patient has died, please complete and return anadverse event form.
For patients who were not discharged within one year of their original shoulder injury, please record
date of orthopaedic discharge:
Date of orthopaedic discharge:
(i.e. end of orthopaedic treatment) / /Day Month Year
Discharged to:(e.g. GP) 
(Please record details)
Complications that happened after one year:
Please cross in box(es) if recorded
Surgical site infection requiring
antibiotics/further surgery Describe:
Avascular necrosis of humeral 
head Describe:
Implant failure Describe:
Dislocation/instability Describe:
Metalwork problems requiring
further surgery Describe:
Non-union/Malunion requiring 
further treatment Describe:
Other Describe:
Other treatments that happened after one year:
Surgery to shoulder
(please cross one box) Yes No Date: / /
Day Month Year
If'Yes'describe surgery below. Number of days as
hospital in-patient
Please continue to complete the rest of the form overleaf. 2320411238
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/ /
Increased/new therapy for
shoulder related complication
infection)
(please cross one box)
Yes No Datestarted
Day Month Year
If'Yes'describe treatment below. Number of days as
hospital in-patient
Treatment for serious newly
diagnosed medical 
complication
(please cross one box)
Yes No Datestarted: / /Day Month Year
If'Yes'describe treatment below. Number of days as
hospital in-patient
Other patient admissions after one year:
Has the patient visited the
orthopaedic/fracture clinic this 
year?
(please cross one box)
Yes No Date: / /
Day Month Year
Number of visits
If'Yes'please describe the reason(s) for atendance in the box below:
Has the patient been 
admitted to hospital for a
fracture this year? 
(please cross one box)
Yes No
Date
admitted: / /
Day Month Year
If'Yes'please provide details in the box below:
Thank you for completing this form.
Number of days as 
hospital in-patient
8546411234
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Appendix 27Adverse event (reporting) form
x 27 Adverse Event [Reporting] Form
ProFHER Trial: Adverse Event Reporting Form
Participant ID number:
This form should be completed for patients who have had anadverse event:i.e. any
undesirable experience occurring to a patient, whether or not considered related to the
treatments being compared in the trial.
Date of assessment(dd/mm/yy):
Name of Principal Investigator:
Name of person reporting the adverse event:
Q1. Please recorddate of adverse event(dd/mm/yy): 
Q2.Nature of adverse event:
Please provide as much information as possible in the box below about the adverse event
including investigations and treatment given.
Please continue form overleaf
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Q3.Type of adverse event*:
Please categorisethis adverse event, crossing al appropriate options:
Yes No
a. Resulted in Death
b. Is life-threatening
c. Required hospitalisation or prolongation of existing hospitalisation
d. Resulted in persistent significant disability or incapacity
e. Consists of a congenital anomaly or birth defect
f. Is otherwise considered medicaly significant by the investigator
g. Other (please describe):
Q4a. In your opinion, is the adverse eventrelatedto the patient Yes
taking part in the ProFHER Trial?
No
Q4b. Is it anexpected orunexpected adverse event? 
Please explain your responses to 4a and 4b in the box below:
*If the answer to any parts of a-f for Question 3 is ‘Yes’, this is aserious adverse event
and must be reported to the ProFHER Trial Co-ordinatorwithin 24 hours of the local
investigator becoming aware of it.
If the only answer to Question 3 is ‘Yes’ to part g. this is anon-serious adverse eventand
must be reported to the ProFHER Trial Co-ordinatorwithin 5 daysof the local investigator
becoming aware of it.
Please fax this formto the ProFHER Trial Co-ordinator on 01904 for the atention
of Dr Stephen Brealey. Before you fax the form, please ring Stephen Brealey on 01904
to inform him that the fax is on its way. If Stephen is unavailable then please ring Ms
Sarah Gardner, ProFHER Trial Secretary, on 01904       .
Thank you for completing this form
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Appendix 28Review of adverse event form
Appendix 28 Review of A
Proximal Fracture of the Humerus: Evaluation by Randomisation
(ProFHER Trial)
REVIEW OF ADVERSE EVENT
Patient concerned
(Trial ID number)
How, when and by whom
was notification of the 
event made
Date of review / /
Day Month Year
Please record what action 
was taken to resolve
the adverse event
Please record whether
the adverse event has
been resolved
Signature of reviewer
Date reviewed by Trial / /
Management Group
Day Month Year
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Appendix 29Trial exit form
ProFHER Trial: Trial Exit Form
Please complete this form when the patient is leaving the trial and should no
longer be folowed-up
Name of person completing form
Participant identification number: 
Exit Date:
Day Month Year 
Reason(s) for patient not being folowed-up:
(Please place a cross in the appropriate box)
1. Patient wishes to leave the trial Yes No
Please state reason (if available) .
2. Patient is being withdrawn by doctor Yes No
Please state reason ..
3. Patient is lost to hospital folow-up Yes No
Please state reason ..
4. Patient is lost to postal folow-up Yes No
Please state reason ..
5. Patient has died
Date of death
Day Month Year
6. Other reason Yes No
(Please state below)
.
Please send this form to the York Trials Unit in the pre-paid envelope provided
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Appendix 30Questionnaire about sling
care information
Appendix 30 Questionnaire about sling care information
ProFHER TRIAL: QUESTIONNAIRE ABOUT
SLING CARE INFORMATION
This section asks about the use of the leaflet that provided advice on initial self-care during
sling immobilisation which was intended for al patients who were eligible for the ProFHER trial.
1a.Did you give the sling immobilisation leafletprovided in the recruitment pack to patients judged 
as beingeligible for ProFHER(whether or not they consented to take part in the trial)? 
(Please cross one box only)
Al of the time Most of the time Rarely Never
1b.If you did not respond 'Al of the time' for patients who were eligible for ProFHER, please 
give the reasons for this in the box below.
1c. If, for these patients, you routinely used another/other leaflet(s) instead of the sling
immobilisation leaflet provided in the recruitment pack could you please describe this/these
briefly below and forward a copy of each leaflet to Laura Dennis.
Leaflet type Please record the reason for having used an alternative leaflet
(e.g. a Trust approved leaflet was used)
2a.Did you provide a leaflet (either that providedfor ProFHER or an alternative) on sling care to
patients whoconsented to take partin the trial?
(Please cross one box only)
Al of the time Most of the time Rarely Never
2b.If you did not respond 'Al of the time' forconsenting patients, please give reasons for this 
in the box below.
Please continue to complete the rest of the form overleaf.
1360136358
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This section asks about the immobilisation that is used for patients who would have
been eligible for the ProFHER trial at your hospital.
1. Please describe in the boxes below the type(s) of sling or other methods of immobilisation 
routinely / typicaly used for patients who would have been eligible for the ProFHER trial.
Non-surgical
treatment:
Surgicaly 
treated:
2. Typicaly, how longin weeksis the recommended treatment period of arm immobilisation in
your hospital for patients who would have been eligible for the ProFHER trial?
Without surgery: weeks
Comment:
Surgicaly: weeks
Comment:
Please record the name of the person who completed the form:
Please record the name of the hospital:
Thank you very much for your help completing this questionnaire
P
R
O PROximal Fracture of Humerus: Evaluation by Randomisation (ProFHER) TrialF A multi-centre randomised controled trial funded by NHS R&D Health Technology Assessment ProgrammeH (International Standardised Randomised Controled Trial Number 50850043)E
R
5150136359
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Appendix 31Survey of radiography departments
Appendix 31 Survey of X-ray Departments
ProFHER TRIAL: Survey of X-ray Departments
1a. How many X-ray views are required at your hospital for a patient's first atendance 
in Accident & Emergency (A&E) with suspected fracture of the proximal humerus?
(Please record the number in the box)
1b. Which of the views below are the recommended series of X-rays for these patients?
(Please cross al boxes that apply)
Anteroposterior
View
Axilary
(or modified view)
Scapular
Y-Lateral
If you would like to add any comments, please record these in the box below.
2. The criteria that the two independent orthopaedic surgeons used to assess the quality of
X-rays taken for fractures of the proximal humerus are listed below. Can you please record 
whether you agree or not that these were appropriate criteria.
(Please cross a box for your response to each of the criteria)
Quality criteria: Agree Disagree Record reason you disagree
a. Arethereatleasttwo
projections in planes
perpendicular to each 
other?
b. Are the proximal humerus 
and glenohumeral joint
seen on each projection?
c. Is it possible on the two
views to clearly identify the
shaft, greater tuberosity, 
lesser tuberosity, head of
humerus and 
glenohumeral joint?
0182045415
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Please record in the boxes below any other criteria you think should be used for assessing
the quality of X-rays for these fractures:
Other quality criteria: Reason for choosing this:
3. At your hospital, are specialist reports, such as those prepared by a radiologist /
radiographer, of the X-rays of the proximal humerus fracture taken in A&E routinely
provided to the orthopaedic surgeon for use at the fracture clinic?
(Please cross one box)
Al of the time Most of the time Rarely Never
If you would like to add any comments, please record these in the box below.
4. In your opinion, are there any aspects of the interpretation of X-rays of the proximal humerus 
fractures that are dificult to report on? Please add any comments to this question in the box 
below:
5480045411
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5. In relation to the Neer's classification, which uses both linear displacement and angulation
to categorise fracture types, how dificult is it to assess these parameters when viewing
X-rays?
(Please cross one box below for each parameter)
a. Displacement
Al of the
time
Most of the 
time
Rarely Never
b. Angulation
Al of the 
time
Most of the 
time
Rarely Never
If you would like to add any comments, please record these in the box below.
6. At your hospital, is CT scanning routinely/frequently used for these fractures?
(Please cross one box) Yes
No
If you would like to add any comments, please record these in the box below.
Please record the name of the person who completed the form:
Please record the name of the hospital:
Thank you very much for your help completing this questionnaire.
P
R
O PROximal Fracture of Humerus: Evaluation by Randomisation (ProFHER) TrialF A multi-centre randomised controled trial funded by NHS R&D Health Technology Assessment ProgrammeH (International Standardised Randomised Controled Trial Number 50850043)E
R
6328045413
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Appendix 32Post-recruitment survey of
hospital radiographers
Completed surveys on issues relating to imaging and radiograph quality for people with proximalhumeral fractures were received from radiographers from 26 participating centres. Eleven (42%) of
these were from the trial-designated radiographer listed in the staf delegation log for that centre.
Recommended views
The first two questions of the survey (seeAppendix 31) asked about the recommended radiographic views
for patients atending an A&E department with a suspected fracture of the proximal humerus. Two views
wererequiredat 25 hospitals and three at one hospital (answers to question 1).Table 91shows the
responses for the recommended series of radiographs for these patients. Comments on their selection
were received from 18 radiographers. The fifth category [anteroposterior view and (axilary vieworscapular
Y-lateral view)] was based on the selection of the views (crossed boxes) and comments from the
radiographers on the alternative use of the view (axilary vieworscapular Y-lateral view) not selected as a
recommended view. Of the 13 in this group, nine indicated that the axilary or modified axilary view was
the prefered view and one stated that the scapular Y-lateral view was performed more often. Twelve of
the 13 in this group and three of the other six radiographers providing feedback commented on the choice
of view being dependent on the patient’s condition, such as mobility, and related practicalities. Two of
these advised that the choice of view would also depend on the presentation of the fracture and two
others gave insights on what views were best for dislocation and other fracture types. One refered to
additional training being needed for A&E staf and orthopaedic surgeons for interpreting the modified
axilary view. One comment refered only to the choice being radiographer dependent.
TABLE 91Views recommended by hospital radiographers for patients with a proximal humeral fracture (n=26)
Radiographic views n %
Anteroposterior and axilary views 6 23
Anteroposterior and scapular Y-lateral views 5 19
Axilary and scapular Y-lateral views 0 0
Anteroposterior, axilary and scapular Y-lateral views 2 8
Anteroposterior view and (axilary vieworscapular Y-lateral view) 13 50
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Quality criteria
As shown inTable 92, the majority of radiographers indicated that they agreed with al three quality
criteria used in our interim assessment of baseline radiographs. In al, eight radiographers recorded a
disagreement with these criteria, with six disagreeing with one criterion, one disagreeing with two criteria
and one disagreeing with al three criteria.
Two of the five comments received on the first criterion pointed out that the modified axial was oblique
(45°) to the anteroposterior view; one also noted that the scapular Y-lateral view was oblique to the
anteroposterior view. The other three comments related to choice of view, which was covered in
the preceding question.
Al five comments received on the second criterion refered to potential dificulties in viewing the
structures, mainly the glenohumeral joint in the scapular Y-lateral view. These dificulties were restated or
implied in five of the six comments on the third criterion. The remaining comment questioned the wording
of the criterion, suggesting that it‘should be between the two views that this is shown, not on the
two views’.
Eleven radiographers proposed other criteria for assessing the quality of radiographs for proximal humeral
fractures. These mainly related to (1) image exposure and contrast and (2) patient positioning.
Provision of specialist reports for use at the fracture clinic
Seventeen radiographers reported that specialist reports, prepared by the radiographer/radiologist,
were routinely provided to the surgeon for use at the fracture clinic‘al of the time’. A further seven
reported that such provision was‘most of the time’and the remaining two reported that it was‘rarely’.
Pertinent comments on this issue related to the timing of the fracture clinic and availability of personnel.
One radiographer considered that‘The question is a nonsense with PACS’. (These responses and responses
to later questions implied that, although the specialist report may have been available it was unlikely that
it informed the interpretation of the radiographs by the surgeon in terms of patient eligibility for the
ProFHER trial.)
Perceived difficulties in interpretation of radiographs of the
proximal humerus
The survey asked about dificulties in interpretation in a general way and then specificaly in relation to
Neer’s linear displacement and angulation criteria. Of the 20 responses to the general question, eight
implied that there were dificulties resulting from poor-quality images, relating, according to six
radiographers, to one or al of the folowing: patient positioning/condition, inadequate exposure and poor
technique. Four responses refered to limitations of or chalenges of interpreting specific radiographic
views, specificaly scapular Y-lateral and the modified axilary views. One response observed that A&E
TABLE 92Radiographer agreement with quality criteria (n=26)
Radiographic views
Agree with
criterion,n %
1. Are there at least two projections in planes perpendicular to each other? 24 92
2. Are the proximal humerus and glenohumeral joint seen on each projection? 22 85
3. Is it possible on the two views to clearly identify the shaft, greater tuberosity, lesser
tuberosity, head of the humerus and glenohumeral joint?
21 81
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referal often resulted in the selection of the less useful anteroposterior image (presumably in the coronal
rather than the scapular plane) for interpreting proximal humeral fractures. Six radiographers refered to
limitations or chalenges in relation to the fracture itself. These related to more complex and severe
fractures in four responses and to‘subtle’or undisplaced fractures in the other two responses. As captured
in the final pithy response (‘Generaly not’), there was no indication that there were problems in
interpretation that made reporting of these fractures routinely dificult for radiographers.
Of the 17 responses on dificulties in interpretation relating to Neer’s linear displacement and angulation
criteria, nine indicated that it was dificult most of the time and eight indicated that it was rarely dificult.
Of the 12 comments on this aspect, six emphasised that they did not use the Neer classification and one
other commented on the known problems regarding inter-rater agreement for this classification. Two
radiographers remarked that the question was dificult to understand; one of these though suggested that
it was usualy possible to assess both linear displacement and angulation. One radiographer’s response
gave this impression too but in the context of image quality, whereas another radiographer suggested that
reporting of these was‘sometimes dificult’. The final response refered to the need for a scapular Y-lateral
view to check for displacement.
On review of these responses, which gave no real insights into the quantification of fracture displacement,
we realised that our emphasis on the Neer classification had been unhelpful.
Routine use of computerised tomography scans
One radiographer reported that CT scanning was‘routinely/frequently used for these fractures’in her
centre and 24 reported that it was not (the answer was missing for one centre). Comments received from
10 radiographers reinforced this picture, with some reference made by four radiographers to the use of CT
to augment diagnosis subsequently in the case of poor-quality radiographs and/or complex fractures.
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Appendix 33The Neer classification of
radiographs pro forma
Appendix 33 Neer s classification of X-rays proforma
ProFHER TRIAL: Neer's X-ray Classification Proforma
Trial Participant ID : Rater :
1. Please record a cross in the box(es) below that apply:
X-ray ID
Anteroposterior 
(Scapular plane)
Anteroposterior 
(Coronal plane)
Axilary (or
modified axilary)
Scapular 
Y-lateral Other - please describe
2. Are there at least two projections in planes perpendicular to each other? 
(Please cross one box only) Yes No
3. For each X-ray projection is the:
X-ray ID
Proximal humerus
visible?
Yes / No
Glenohumeral
joint visible?
Yes  / No
Clip on Left / Right
marker available? *
Yes  / No
Clear / gross
distortion in size?
Yes  / No
* This applies to a clip that was added to the cassete at the time of image acquisition
4. Are proximal humerus and glenohumeral joint seen on each projection
[of at least two diferent views?] (Please cross one box only) Yes No
5. For each X-ray, can you clearly identify the folowing:
X-ray ID
Humeral
shaft?
Yes  / No
Greater 
tuberosity?
Yes  / No
Lesser 
tuberosity?
Yes / No
Head of
humerus?
Yes  / No
Glenohumeral
joint?
Yes  / No
6. Considering al the available views together, can you visualise the location of al five
structures (the humeral shaft, greater tuberosity, lesser tuberosity, head of humerus 
and glenohumeral joint) suficiently to determine the position and displacement of the
fractured segments? (Please cross one box only)
Yes No
7. Please give your overal assessment of quality for this set of images (i.e. in terms of exposure and patient
positioning) based on the three grades: (Please cross one box only)
a) Good: Optimal image definition & content, good for classification
b) Fair: Suboptimal image definition & content, but adequate for classification
c) Poor: Suboptimal image definition & content, inadequate for classification
4291527808
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of a fracture for that anatomical structure
learly insuficient to meet Neer's criteria
arginal cases: some uncertainty that displacement meets Neer's 
ity image may be reasons)
lete displacement), clearly meets Neer's criteria (45 ; 1cm - linear 
x-rays)
) - the shaft has displaced fuly in relation to the head and these 
tion of the humeral head from the glenoid.
8. hat apply: (N.B. If you do record that an anatomical structure is
(undisplaced, displaced (unclear if Neer), displaced (Neer)) 
Displacement
Criteria / terms for displacement:
- "involved" - this includes any indication o
- "undisplaced" - either not displaced or c
- "displaced (unclear if Neer)" - indicates m
criteria (lack of scale marker or poor qual
- "displaced (Neer)" - gross (including comp
measurement may not be possible for some
"No contact fracture" (of the surgical neck
segments have no contact with each other
Fracture dislocation applies to the disloca
Please record a cross in the box(es) below t
'involved' then choose one ofthe three other descriptors
to indicate the extent of displacement according to Neer's criteria.
X-ray ID X-ray ID X-ray ID X-ray ID Verdict
Anatomical neck
- involved
- undisplaced
- displaced (unclear if Neer)
- displaced (Neer)
Surgical neck
- involved
- undisplaced
- displaced (unclear if Neer)
- displaced (Neer)
- no contact fracture
- impacted
Greater tuberosity
- involved
- undisplaced
- displaced (unclear if Neer)
- displaced (Neer)
Lesser tuberosity
- involved
- undisplaced
- displaced (unclear if Neer)
- displaced (Neer)
Fracture dislocation
-anterior
- posterior
Head splitting #
Isthereanarticular
surface fracture?
Head position
Head segment in varus
Head segment invalgus
9. Using the separate sheet provided of Neer's classification 1 to 16 and your verdicts above
("displaced (Neer)" only), please record Neer's category:
9049527804
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Appendix 34List of hospitals contributing to the
ProFHER trial and primary care trusts for which
research and development approval was obtained for
folow-up
Sitea Hospital name and/or trust (if applicable)
Basildon Basildon Hospital, Basildon and Thurock University Hospitals NHS Foundation Trust
Basingstoke Basingstoke and North Hampshire Hospital
Birmingham Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
Blackburn Royal Blackburn Hospital, East Lancashire Hospitals NHS Trust
Blackpool Blackpool Victoria Hospital, Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust
Coventry University Hospitals Coventry and Warwickshire NHS Trust
Fife Queen Margaret Hospital (Dunfermline), NHS Fife
Frenchay Frenchay Hospital, North Bristol NHS Trust
Glan Clwyd Ysbyty Glan Clwyd Hospital (Rhyl), North Wales NHS Trust
Ipswich Ipswich Hospital NHS Trust
James Cook James Cook University Hospital (Middlesbrough), South Tees Hospitals NHS Foundation Trust
Kings King’s Colege Hospital NHS Foundation Trust (London)
Leeds Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust
Leicester Leicester General Hospital, University Hospitals of Leicester NHS Trust
Lincoln Lincoln County Hospital, United Lincolnshire Hospitals NHS Trust
Liverpool Royal Liverpool University Hospital, Royal Liverpool and Broadgreen University Hospitals NHS
Trust
Manchester Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust
Newcastle upon Tyne Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust
Norfolk Norfolk and Norwich University Hospitals NHS Foundation Trust
North Stafordshire University Hospital of North Stafordshire NHS Trust (Stoke-on-Trent)
North Tees University Hospital of North Tees (Stockton-on-Tees), North Tees and Hartlepool Hospitals NHS
Foundation Trust
North Tyneside North Tyneside General Hospital (North Shields)
Northampton Northampton General Hospital NHS Trust
Notingham Queen’s Medical Centre, Notingham University Hospitals NHS Trust
Oldham Royal Oldham Hospital, Pennine Acute Hospitals NHS Trust
Oxford John Radclife Hospital, Oxford Radclife Hospitals NHS Trust
Royal London Royal London Hospital (London), Barts and the London NHS Trust
Salford Salford Royal Hospital, Salford Royal NHS Foundation Trust
Scunthorpe Scunthorpe General Hospital, North Lincolnshire and Goole Hospitals NHS Foundation Trust
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Sitea Hospital name and/or trust (if applicable)
Southport Southport and Ormskirk District General Hospital, Southport and Ormskirk Hospital NHS Trust
Sunderland Sunderland Royal Hospital, City Hospitals Sunderland NHS Foundation Trust
Torquay Torbay Hospital, South Devon Healthcare NHS Foundation Trust
Traford Traford General Hospital (Manchester), Traford Healthcare NHS Trust
Wansbeck Wansbeck General Hospital (Ashington), Northumbria Healthcare NHS Foundation Trust
Yeovil Yeovil District Hospital, Yeovil District Hospital NHS Foundation Trust
a These were the names used in the trial for the individual sites. With some notable exceptions, most corespond to the
location of the hospital. When there are exceptions, the hospital location has been stated in the next column.
Primary care trusts
Site Primary care trust
Basingstoke Hampshire Community Health Care
Blackburn NHS East Lancashire
NHS Blackburn with Darwen
Leicester NHS Leicestershire County and Rutland
NHS Leicester City
Newcastle upon Tyne NHS Newcastle and North Tyneside Community Health
Norfolk NHS Norfolk
NHS Great Yarmouth and Waveney
Notingham NHS Notinghamshire County
Oxford Thames Valey Primary Care Research Partnership
Royal London NHS Tower Hamlets
Salford NHS Salford
Torbay NHS Devon
NHS Torbay Care Trust
Yeovil NHS Dorset Primary Care Trust
Taunton & Somerset R&D Consortium
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Appendix 35Health-care colaborators at
participating acute trust centres
Health-care colaborators have been identified from delegation logs and site-specificinformation documents.
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Appendix 36Report of the processing of
complications and associated treatment including
‘discards’
With interim feedback and checks from the statistician (AK) to ensure consistency, two raters screenedand coded data from a file with 273 entries for complications and treatments drawn from the
relevant fields for each trial patient from three forms (end of orthopaedic inpatient episode form, 1-year
folow-up form and 2-year folow- up form) (seeChapter 3). One rater (HH) coded the‘discards’into eight
categories, which were honed down to four categories for reporting purposes by AK: repeat information,
subsequent/additional information to treatment for a complication, irelevant content and, for further
fracture data, routine folow-ups. Additionaly, incorectly reported categories were reclassified and
information from another source (these were surgery forms received for two non-surgical patients who
received surgery because of an early complication–these data were handled as if they had been reported
at the 1-year folow-up; coding was by the two raters) was identified and added to the definitive data set.
Entries were also added for surgical and shoulder fracture-related complications that were implied only
from descriptions of treatment.
The folowing gives an account of the‘discards’and adjustments for the various categories
of complications.
Surgical and shoulder fracture-related complications
A total of 81 surgical and shoulder fracture-related complications were reported over the 2-year folow-up
period. In total, 34 of these reports were discarded (23 contained repeat information, six were subsequent/
additional information to treatment for a complication and five contained irelevant content). Of the
remaining 47 complications, two had been assigned a wrong category on the hospital form and were
recategorised. A total of 14 complications were added (one recategorisation from a diferent section on a
form and 13 additional complications derived from other available information). The final data therefore
consisted of 59 surgical and shoulder fracture-related complications reported for 53 patients.
Of the 48 treatment reports (including the two reported in surgery forms only) for these complication, 13 were
discarded (five contained repeat information, sevenwere subsequent/additional information to treatment
for a complication and one contained irelevant content). Of the remaining 35 treatments, two had been
assigned a wrong category and were recategorised, leaving 33 valid entries reported for 33 patients.
Medical complications during the inpatient stay
A total of eight medical complications were reported, to which a further two were added that had been
entered under the wrong category on other forms, resulting in a total of 10 valid medical complications for
10 patients.
Treatment for serious newly diagnosed medical complication
A total of 64 treatments for medical complications were reported over the 2 year folow-up period. In
total, 12 of these reports were discarded (11 contained repeat information and one contained irelevant
content). Of the remaining 52 treatments, one had been assigned a wrong category and was
recategorised, leaving 51 valid treatments for 46 patients.
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Further fractures
Of a total of 23 reported hospital admissions for another fracture, five were discarded (repeat information),
resulting in 18 valid entries for 18 patients.
Of a total of 51 reported visits to orthopaedic/fracture clinics, 27 were discarded (seven contained repeat
information, nine were subsequent/additional information to treatment for a complication, eight related to
routine folow-ups and three contained irelevant content). To the remaining 24 visits, two were added
that had been assigned the wrong category in other sections of the form, resulting in a total of 26 valid
visits for 25 patients.
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Appendix 37Additional sensitivity analysis
exploring the efect of clustering at centre level
Feedback obtained subsequent to the preparation of this report prompted a formal analysis to examinethe efect of clustering at centre level. This is in addition to our descriptive analysis of centre variability
presented inChapter 5.
We conducted an extra sensitivity analysis whereby centres were added as a random efect to the primary
model to explore the efect of clustering at the centre level. Adjusted OSS means and group diferences for
this model are presented inTable 93. Similar to the primary analysis, there was no significant overal efect
of treatment group over the 2-year folow-up period and no significant efect of treatment group at
individual time points. Therefore, the results of the primary analysis are robust to the efects of clustering
by centre. As with the primary and al subgroup and sensitivity analyses, al 95% CIs for the treatment
efect excluded the prespecified diference of 5 OSS points, representing‘clinical significance’.
TABLE 93Difference in mean OSS scores over time by treatment group: sensitivity analysis–adjusted for clustering
by centrea
Folow-up
Surgery (n=125)
(n=114 in analysis),
mean (95% CI)
Not surgery (n=125)
(n=117 in analysis),
mean (95% CI) Difference (95% CI) p-value
Overal 39.06 (37.18 to 40.86) 38.27 (35.81 to 40.03) 0.79 (–1.30 to 2.88) 0.460
6 months 37.83 (35.81 to 39.75) 35.54 (33.48 to 37.49) 2.29 (–0.03 to 4.61) 0.053
12 months 39.22 (37.26 to 41.08) 38.76 (36.86 to 40.57) 0.46 (–1.75 to 2.66) 0.686
24 months 40.10 (38.13 to 41.99) 40.36 (38.48 to 42.16) –0.26 (–2.51 to 1.99) 0.821
a Multilevel model accounting for centre as a random efect, adjusted for treatment group, time (6, 12 and 24 months),
group × time interaction, baseline EQ-5D index, gender, age group (<65 years/≥65 years) and tuberosity involvement at
baseline (yes/no).
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